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Abstract 
Background: Adverse drug reactions are responsible for a significant proportion of  
hospitalisations. This PhD aimed to develop and optimise methods for detecting 
serious adverse drug reactions in databases of electronic health records for use in 
pharmacoepidemiology and genetic epidemiology, with a focus on cholestatic liver 
injury.  
Methods: A systematic review was performed before developing a multiple database 
source (“multisource”) algorithm for identifying cholestatic liver injury. Multisource 
algorithm case status was used to guide the development of another algorithm using 
data from a standard UK Clinical Practice Research Datalink (CPRD) record only (the 
CPRD algorithm). Testing of the CPRD algorithm was performed within a cohort 
analysis of an established cause of the injury (flucloxacillin), before carrying out a case-
control study investigating a number of putative associations (drug exposures 
carbamazepine, celecoxib, duloxetine, ramipril and risperidone).   
Results: The majority of reviewed studies lacked a reproducible case definition, and 
case assignment generally required information external to database records. 
Secondary care (HES) data provided little additional information than that found in 
primary care (CPRD), meaning that the CPRD algorithm had a very good ability to 
discriminate between multisource algorithm cases statuses (ROC area under the curve 
0.95). The flucloxacillin 45-day risk estimate obtained from the cohort study using the 
highest specificity CPRD algorithm (6.15 per 100 000 users, 95% CI 4.61 – 8.04) was 
very similar to previous studies. Celecoxib and risperidone were associated with 
cholestatic liver injury (celecoxib multivariablemultivariable RR recent vs. current users 
low specificity CPRD algorithm 1.89, 95% CI 1.11 – 3.22, risperidone 
multivariablemultivariable RR high specificity CPRD algorithm 2.59, 95% CI 1.41 – 
4.75). 
Conclusions: The CPRD algorithm detected similar flucloxacillin effects as (1) the 
multisource algorithm and (2) previous studies. Associations with risperidone and 
celecoxib were also detected. Algorithm characteristics that could facilitate (1) 
pharmacovigilance and (2) recruitment to genetic association studies include the ability 
to (a) detect cases without using information external to the EHR and (b) apply varying 
levels of specificity and sensitivity. 
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1 Background 
1.1 Introduction 
In this chapter, the definition and epidemiology of adverse drug reactions are provided, 
along with an overview of drug safety and pharmacoepidemiological approaches 
adopted for their detection, analysis and prevention. Particular emphasis is provided on 
(1) the current use of databases of routinely collected electronic health records and (2) 
cholestatic liver injury caused by flucloxacillin and other drugs (two areas of focus of 
this Ph.D.). Finally, the aims and objectives of the thesis are described. 
1.2 Adverse drug reactions 
1.2.1 Definition, epidemiology and public health impact 
The World Health Organisation defines adverse drug reactions (ADRs) as “Any 
response to a drug which is noxious and unintended and that occurs at doses used in 
man for prophylaxis, diagnosis or therapy” [1]. More common adverse reactions are 
classified as Type A reactions; serious (Type B or “idiosyncratic”) adverse reactions are 
less common, and may not be well predicted by pharmacology [2].  Type A reactions 
are normally due to the presence of drug levels within the body that are too high, which 
can be due to (1) the patient having been administered more of the drug than is 
advised or (2) the patient receiving a correct dose but then either metabolizing or 
excreting the drug slower than is normal, or being overly sensitive to the drug [3]. 
Reduction of dose can therefore normally be used as a treatment for Type A reactions. 
In contrast, Type B reactions usually require treatment to be stopped completely, and 
have a range of underlying causes which may be immunological (hypersensitivity 
reactions), inherited susceptibility, or unknown [3].  
Examples of both types of reaction with an indication of the frequency at which they 
occur are provided by two of the known side-effects of the anti-epileptic 
carbamazepine. Greater than 1 in 10 users of carbamazepine experience drowsiness, 
which can often be alleviated by dose-reduction (a Type A reaction), while fewer than 1 
in 10,000 users experience the life-threatening skin reaction Stevens-Johnson 
syndrome (a Type B reaction) [4] .  
It has been estimated that adverse drug reactions are responsible for over 5% of 
hospital admissions in the EU and US [5, 6]. An additional important public health 
impact relates to the availability of medicines. If a marketed drug is discovered to cause 
serious adverse reactions, drug regulatory authorities can enforce changes to the 
labeling in order to restrict its use in certain populations, introduce specific risk 
 16 
 
minimisation measures and in extreme cases they may revoke the marketing 
authorisation. Approximately 150 drugs have been withdrawn from the market since 
1960 due to safety issues [7], in some cases many years after initial approval [8].  
1.2.2 The genetics of adverse drug reactions 
Evidence is increasing for a genetic predisposition to a number of adverse reactions, 
with genes related to enzymes involved in drug metabolism, drug receptor proteins, 
immune response and mitochondrial functions all having been investigated in recent 
years  [9]. A number of genetic variants that effect susceptibility to various different 
drugs have been successfully identified (e.g. the HLA-B*5701 allele and Abacavir 
hypersensitivity, see section 1.3.4), and the magnitude of association between gene 
mutation and reaction phenotype has generally been substantially greater than those 
observed during investigations into the genetic basis of complex diseases. Genetic 
associations for adverse reactions also have a tendency to involve far fewer genes 
than those for complex diseases, suggesting the potential for relatively rapid 
developments in this area [9, 10].  
1.3 Drug safety, pharmacoepidemiology and databases of stored 
electronic health records 
1.3.1 Detection of adverse drug reactions during drug development  
International regulations related to medicinal products require that the quality, 
effectiveness and safety of a newly developed medicine should be demonstrated 
before sale [11, 12].  Three phases of clinical testing in humans are required [3, 13]. 
Phase 1 studies are “first-in-human” and typically include 20 – 100 healthy volunteers, 
with an aim to determine a safe dosage range and exclude any common toxic 
reactions. In Phase 2 studies, the medicine’s efficacy is evaluated for the first time in 
approximately 100 – 200 patients with the target disease, to assess first information on 
efficacy and also to try and detect more common adverse reactions. Finally, Phase 3 
studies generally include 1000 – 5000 patients exposed to the drug and obtain further 
detailed information related to the drug’s efficacy (through randomised controlled trials) 
and any less common adverse reactions. 
There are a number of challenges associated with identifying and characterising 
adverse reactions during drug development (Figure 1.1). Firstly, the number of people 
exposed to the drug by the end of Phase 3 is likely to be no more than around 5000, 
which would mean only those reactions that occur at a frequency of approximately 1-2 
per 1000 users would be detected. This would exclude many of the rarer, more serious 
(Type B) reactions. Secondly, the duration of use of the drug during randomised clinical 
 17 
 
trials in Phase 3 may well be shorter than its post-approval use. Finally, the individuals 
exposed to the drug during the carefully controlled experimental settings of randomised 
controlled trials are likely to be a very restricted subset of the actual underlying 
population. In particular, patients in drug trials are unlikely to include the very old, very 
young or pregnant women, are unlikely to be taking medications other than the one 
under study, and are unlikely to be suffering from more than one disease [14].   
 
Figure 1.1: Drug development versus post-approval patient exposures – challenges for 
drug safety  
Approx number of patients exposed to drug pre-approval: 3000 – 5000 (allowing detection of adverse events at 
frequencies of 1-2 per 1000 users). Post-approval exposure can involve millions of patients over the first few years of 
approval, meaning that adverse events occurring at frequencies less than 1 per 1000 occur and can have a substantial 
public health impact (in terms of direct patient impact but also due to the possibility of reduced availability of therapies 
due to restrictions on marketing authorisations) 
1.3.2 Adverse event reporting and signal detection  
An existing approach used for the detection of adverse drug reactions is the use of 
adverse event reporting and signal detection methods (also known as 
pharmacovigilance). Suspected adverse drug reactions are reported by clinicians or 
patients to national regulatory authorities, who enter the information into national and 
international databases of adverse drug reactions, such as the WHO VigiBase [15]. 
These databases can then be screened in order to allow potential drug adverse 
reaction associations that may require further analysis to be identified. The UK system 
for the reporting of suspected adverse drug reactions is known as the Yellow Card 
Phase 1 Phase 2 Phase 3 Drug launch
TIME
= Drug development (controlled trials, 
restricted homogenous population)
= Post‐approval (“real‐world”, uncontrolled setting,
unrestricted heterogenouspopulation)
= Serious rare adverse event
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Scheme, with information obtained via standardised forms entered into the UK 
Medicine and Healthcare products Regulatory Agency (MHRA) ADR database for 
signal detection [16].    
Although spontaneous reporting systems such as this may enable early detection of 
previously unidentified serious adverse events, the information gathered is crude and 
subject to various types of error and bias. Outcome definition is non-standardised, 
information on the characteristics of the patient is often incomplete, an accurate 
measure of the frequency of the event cannot be obtained as the denominator is 
unknown and the numerator is unlikely to reflect the actual number outcomes, some 
outcome events are more likely to be reported than others (e.g. only more serious 
occurrences of a particular reaction) and there may be many external factors that 
influence whether the report is filed for a particular drug (e.g. reporting in the scientific 
literature or media).  
1.3.3 Pharmacoepidemiological studies of adverse events and databases 
of stored electronic health records  
In order to quantify and characterise the risk of an adverse reaction associated with a 
new (or currently marketed) medicine, large epidemiological studies of the adverse 
drug reaction are typically performed, also known as pharmacoepidemiological studies. 
The requirement for such a study may originate from a variety of sources: increased 
case reports in the scientific literature, detection of signals at regulatory authorities or 
by the WHO, clinicians noticing increased incidence or in some cases media reports. 
Studies may be performed by a variety of stakeholders, including pharmaceutical 
companies (at the request of regulatory agencies), universities working on drug 
epidemiology and public health, regulatory agencies themselves, not-for-profit 
organisations, clinical research organisations or charities.  
Randomised controlled trials designed to study the adverse effect of drugs are often 
not feasible; the low frequency of events for any particular drug would likely mean a 
very large trial at very high cost and possibly for a long duration. There may also be 
ethical issues in assigning patients to treatment groups for the purpose of measuring 
harmful effects. Therefore, pharmacoepidemiological studies tend to be very large 
observational studies (such as cohort, case control or self-controlled case series) 
performed using routinely collected health records. There are a number of 
characteristics of (particularly Type B) adverse reactions that present challenges for 
epidemiology, including: their relatively low incidence, their clinical presentation, their 
time of onset, the characteristics of the patients in which they may occur, and the 
possibility of similarity of symptoms to the indication being treated. These factors mean 
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that study sizes often have to be very large, classification of outcome is often difficult, 
and confounding by concomitantly administrated medicines or indication can be 
problematic (see Table 1-1). 
Table 1-1: Characteristics of (Type B) adverse drug reactions and associated challenges 
for epidemiological studies 
# Adverse drug reaction characteristic Challenge for pharmacoepidemiological 
studies 
1.  Low incidence for any specific drug Very large sample sizes required 
2.  Symptoms similar to other diseases Risk of measurement error (outcome 
misclassification) 
3.  Delayed symptoms Risk of measurement error (outcome 
misclassification) 
4.  Patients likely to be prescribed multiple 
drugs 
Confounding by other medications likely 
5.  Indication for treatment may be related to 
likelihood of experiencing future health 
outcomes 
Confounding by indication likely 
 
1.3.3.1 Databases of routinely collected electronic health records 
Over the past 25 years, routinely collected health records stored in very large 
databases from primary and secondary care have become the predominant setting for 
pharmacoepidemiological studies. These electronic records are typically longitudinal 
records of health care for patients, capturing information routinely, and not for the 
purpose of a predesigned research study or survey [17]. A typical set of information in 
an electronic health record will include (anonymised) demographic information, drug 
prescription and diagnostic information and information on subsequent referrals. 
Databases are increasingly being linked, providing the potential for detailed patient 
profiles to be created.  
Major advantages of electronic health record databases include the ability to perform 
very large studies at relatively low cost, a relatively complete record of drug 
prescriptions and prior or subsequent clinical diagnoses, the presence of lifestyle 
information to allow assessment of the role of confounders, minimisation of observer or 
participant bias, and the ability to assess the effect of drugs in the settings, populations 
and for the duration that they are actually being used (the “real-world”). Conversely, 
one major challenge is being able to accurately classify and measure exposures and 
outcomes in relation to any particular study question. Due to the routine nature of the 
data, substantial data management and development of complex algorithms using 
multiple variables is often required in order to allow assignment of exposure and 
outcome status, in addition to careful review of electronic records by medically qualified 
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professionals [18-20]. Furthermore, studies performed within these databases have 
been particularly susceptible to time-related biases [21, 22].  
Three important databases for pharmacoepidemiology include the US Kaiser 
Permanente database, the Spanish BIFAP database and the UK Clinical Practice 
Research Datalink (CPRD).  
Kaiser Permanente medical care programs is a U.S. private health insurance scheme 
covering approximately 8 million members  [23]. Multiple databases covering drug 
prescriptions, hospital discharge information, outpatient diagnoses and laboratory test 
results are linked by a unique id for each patient [24]. Recent pharmacoepidemiological 
studies using the data have included the effectiveness and safety of Spironolactone for 
systolic heart failure and [25] and the cardiovascular risk associated with different 
rheumatoid arthritis therapies [26].  
The Spanish BIFAP (Base de datos para la Investigación Farmacoepidemiológica en 
Atención Primaria) is a major project to evaluate the feasibility of a computerised 
database aggregating information provided by general practitioners and paediatricians 
in the Spanish National Health Service, with a particular focus on data provision for 
pharmacoepidemiological studies, which currently has aggregated information from 
around 2.2 million patients [27]. Inspiration for the project came from the UK Clinical 
Practice Research Datalink (CPRD, formally The General Practice Research 
Database), which contains anonymised data on patients from over 625 primary care 
practices across the UK (approximately 12 million total patients). The electronic record 
of every patient in the database includes a unique CPRD patient id, the date the patient 
first contributed data up to research-level standard (start UTS), the date the patient 
transferred out of the database (if applicable) and patient demographics (such as 
gender and date of birth).  Information for each patient is then added to the electronic 
record by general practitioners as part of routine clinical care and includes all 
consultations, diagnoses, prescribed drugs, out-patient referrals and some lifestyle 
information [28]. Links to other databases (such as hospital records) are possible, and 
examples of recent pharmacoepidemiological studies on drug safety include the use of 
metformin and the risk of lung cancer [29] and the risk of fracture associated with 
bisphosphonates [30]. 
1.3.4 Predictive genetic testing for drug safety 
The discovery of a genetic basis for many adverse drug reactions (see section 1.2.2) 
has enabled the possibility of predictive genetic tests to be developed for drug safety. 
Such tests can be performed on people who have been identified as candidates for 
receipt of a particular drug, in order to assess the likelihood of them having a reaction 
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and directing subsequent treatment accordingly. This provides the potential for the risk-
benefit profile of drugs that cause serious adverse events to be improved.  
One high-profile success in this area is Abacavir, an antiretroviral launched in 1998 that 
was found to be associated with a severe hypersensitivity reaction in approximately 8% 
of patients [31]. Genetic association studies were able to demonstrate the critical role 
of the HLA-B*5701 allele in susceptibility to the reaction [32, 33], and following 
development of a genetic test, randomised controlled trials were able to demonstrate 
the test efficacy [32].   Abacavir remains available and testing is now routinely 
performed.  
Despite this example, the development and use of predictive genetic tests for drug 
safety in clinical practice is limited. The FDA currently only mandates genetic testing for 
four drugs (the oncology drugs cetuximab, trastuzumab and dasatinib and the 
antiretroviral maraviroc [34]), and these are tests for the identification of responders, 
rather than for drug safety. Due to that fact that drugs that cause serious adverse 
reactions for which there is no predictive genetic test may be removed from the market 
(or have their development program stopped), the public health impact of not 
developing predictive genetic tests is potentially very large. The unfortunate cessation 
of the development program of the anti-malarial Lapdap due to safety issues 
associated with G6PD deficiency (a testable genetic trait) is one such example [35].  
Possible reasons for the lack of development and use of predictive genetic tests 
include the difficulty/expense associated with accurately identifying true cases for 
inclusion in genetic association studies, the inadequate size of these studies, the 
prohibitively high cost of setting up randomised controlled trials of predictive genetic 
test effectiveness, and the inadequate assessment of co-existing clinical and 
environmental determinants of the reaction [36], [37].  
1.3.5 Adaptive licensing 
The current drug approval process is effectively a “binary” decision system: (0) pre-
approval the drug is not considered safe and effective and is therefore not available for 
use to the general public (1) post-approval there is a presumption of effectiveness and 
safety that allows use by the general public. Pharmacoepidemiological studies of drug 
safety are likely to be performed some time after approval of the drug, or may not be 
performed at all. Algorithms as described in section 1.3.4 have typically been applied to 
database study populations at a single time-point following drug registration, in order to 
retrospectively identify sufficient cases for inclusion in well-powered epidemiological 
studies [36].   
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Adaptive drug licensing is a proposal to move away from such binary regulatory 
categorisation to a model involving iterative data-gathering and regulatory assessment, 
with corresponding phased approvals (or restrictions) [38]. Observational studies of 
drug-safety would be likely to fit more formally into regulatory requirements associated 
with an adaptive licensing framework. Furthermore, approaches that could allow early 
identification of people who have suffered a serious reaction associated with the drug 
of interest from within electronic health record databases could mean that updated 
safety information is available much earlier than is typical within the current non-
adaptive models.  
1.4 Serious drug-induced liver injury 
Serious (idiosyncratic, Type B) drug-induced liver injury (DILI) is the leading cause of 
withdrawal of drugs from the market [39, 40], and has been estimated in one study to 
cause hospitalisations at a frequency of 13.9 per 100,000 inhabitants [41]. Over 50 
drugs are known to have some potential for causing DILI, and these include 
analgesics, anti-hypertensives, antipsychotics and many antimicrobials [39, 42]. Two 
recent important examples include troglitazone for Type 2 diabetes and the antibiotic 
trovafloxacin. Troglitazone was approved by the FDA for the treatment of Type 2 
diabetes in 1997 and withdrawn in 2000 due to the occurrence of liver failure at a 
frequency of around 1 per 10,000 users  [43], while trovafloxacin was approved in 1998 
and its use severely restricted after two years due to the occurrence of  serious hepatic 
events (including liver transplantation and deaths) at a frequency of around 6 per 
100,000 users [44]. 
A number of articles have been published for assisting with the identification and 
classification of drug-induced liver injury, including a widely-cited paper published 
under the auspices of the Council for International Organizations of Medical Sciences 
(CIOMS) [45]. A subsequent update and consolidation article was prepared by the DILI 
Expert Working Group of the Phenotype Standardization Project [46], a project aiming 
to improve and standardize phenotype definitions to facilitate the development of 
predictive genetic tests for drug safety [47].  Both articles classify liver injury into three 
types based on the underlying cellular mechanism: cholestatic, hepatocellular or mixed. 
Classification relies on the results of biochemical analysis of liver enzymes (liver tests), 
as shown in Table 1-2. Liver biopsy or ultrasound investigations can help in 
determining the type of injury, but are secondary evidence to liver test results [46]. 
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Table 1-2: Classification of DILI using liver test results 
# Type of liver injury Liver test result 
1.  Any DILI ALT ≥ 5 x ULN or 
ALP ≥ 2 x ULN or 
ALT ≥ 3 x ULN and Bil > 2 x ULN 
2.  Hepatocellular type of DILI R* ≥ 5 
3.  Mixed type of DILI (=cholestatic hepatitis) R > 2 and < 5 
4.  Cholestatic type of DILI R ≤ 2 
*R=(ALT/ULN)/(ALP/ULN), where ALT=alanine aminotransferase, ALP=alkaline phosphatase, Bil=bilirubin and 
ULN=upper limit of normal  
1.4.1 Drug-induced cholestatic liver injury 
Drug-induced cholestatic liver injury can be defined as liver injury caused by drug 
therapy in which all or some of the pathology is due to impairment of the flow of bile, 
known as cholestasis [48]. Injury can be purely cholestatic in nature, or include a 
hepatocellular component and be classified as mixed (also known as cholestatic 
hepatitis, see Table 1-2). Common non-drug causes of cholestasis include pregnancy, 
alcoholism, and some cancers (with bile duct cancer commonly mistaken for drug-
induced cholestasis [48]). Up to half of all hepatic drug toxicity may be accounted for by 
a cholestatic type of adverse reaction, although prevalence estimates for population 
subgroups that are likely to be more susceptible (such as the elderly) are lacking [49].  
Classes of drugs that have been linked to cholestatic liver injury include non-steroidal 
anti-inflammatory drugs, antihypertensives, antidiabetics, anticonvulsants, lipid-
lowering agents and psychotropic drugs [49]. Cholestatic reactions have a tendency to 
be prolonged after discontinuation of treatment, and clinical symptoms vary by whether 
the reaction is pure or mixed, and by the specific drug [48, 49]. Pure cholestasis is 
typical of synthetic steroids, and patients are likely to present with debilitating pruritus, 
with severe cases exhibiting jaundice.  Symptoms appear 2 – 3 months after starting 
therapy, but may be delayed for up to 9 months. Cholestatic hepatitis is typical of 
numerous drugs, including: chlorpromazine, tricyclic ant-depressants, erythromycins, 
oxy-penicillins, amoxicillin-clavulanate, flouroquinolones and some neuroleptic agents 
[48]. Clinical symptoms usually occur 1 – 6 weeks after starting treatment, and can 
include jaundice, pruritus, fever, anorexia, upper abdominal pain, nausea, pale stools 
and dark urine. In most patients, symptoms normally resolve within 1 month of 
cessation of therapy, although complications include bile duct injury and a “vanishing 
bile duct syndrome” that can persist and may be fatal [48]. 
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1.4.1.1 Flucloxacillin 
Flucloxacillin is an antibiotic of the penicillin class, that has a broad range of uses in the 
treatment of gram-positive bacterial infections, including the treatment of skin and soft 
tissue infections, respiratory tract infections, urinary-tract infections and meningitis in 
addition to prophylaxis during some major surgical procedures [50]. First available in 
1960, case reports appeared in the 1980’s of a serious adverse drug reaction in which 
the patient developed cholestatic hepatitis, which in some cases could be fatal [51]. 
The vast majority of reports of the reaction were from Australia, a type of “mini-
epidemic” caused by a rapid increase in use and increase in publicity of the adverse 
reaction leading to a large increase in spontaneous report [48, 52]. Intense promotion 
of alternative therapies has decreased the use of flucloxacillin in Australia, while in the 
UK it remains heavily prescribed [53]. In the U.S., and some European countries, 
flucloxacillin is not marketed, but alternative therapies that are perceived to have a 
better safety profile are used (such as dicloxacillin).  
Studies have shown that flucloxacillin causes cholestatic hepatitis at a frequency of 
around eight per 100,000 users, and is characterised by cholestatic liver test results, 
pruritus and jaundice, which may occur up to 45 days from initiation of treatment (and 
in some cases after discontinuation of therapy) [52-54]. Age, duration of use and 
gender may be related to susceptibility [53, 55, 56]. A genetic association study 
demonstrated a very strong association between the flucloxacillin-induced adverse 
reaction phenotype and the HLA-B*5701 allele, suggesting the reaction has an 
immune-related mechanism [57, 58]. Despite the strong association, the numbers 
needed to screen to prevent one case (upwards of 13,000) mean that a predictive 
genetic test is not yet feasible, and further work on the characterisation of 
environmental and genetic susceptibility is required [59].  
1.5 Thesis aim, rationale and objectives 
1.5.1 Aim 
The aim of this thesis is to develop new methods for the measurement and detection of 
serious adverse drug reactions in databases of stored electronic health records, with a 
focus on cholestatic liver injury caused by (1) flucloxacillin (2) other drugs. 
1.5.2 Rationale 
Methods developed during the work on this thesis should facilitate 
pharmacoepidemiological studies in databases of routinely collected electronic health 
records, the development of predictive genetic tests and adaptive licensing. 
 25 
 
1.5.3 Objectives 
(1) To perform a systematic literature review on the identification of individuals with 
cholestatic liver injury in epidemiological studies utilising databases of routinely 
collected electronic health records 
(2) To develop a “multi-source” algorithm using the UK clinical practice research 
datalink (CPRD) and other sources to identify cases that are potentially drug-
induced cholestatic liver injury 
(3) To develop a CPRD algorithm that uses data only within the CPRD database 
for the identification of cases of potential drug-induced cholestatic liver injury, 
and to validate this against the “multi-source” algorithm from (2) 
(4) To test the CPRD algorithm within an epidemiological study on a known drug 
cause of cholestatic liver injury (flucloxacillin) and improve the understanding of 
the epidemiology of this reaction 
(5) To use the CPRD algorithm to study drugs that are putatively associated with 
drug-induced cholestatic liver injury 
1.5.4 Organisation of the thesis 
Chapter 2 describes a systematic review performed to understand (i) how studies on 
cholestatic liver injury have been performed in databases of electronic health records. 
Chapter 3 describes the data sources used and overall methods for research. Chapter 
4 provides results related to development of the new algorithm for identifying 
cholestatic liver injury within the CPRD. Chapters 5 and 6 provide detailed results for 
the epidemiological studies performed using the new methods. Chapter 7 summarizes 
and discusses the overall findings in relation to the background, rationale and context 
of the work. 
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1.6 Chapter 1 Summary 
• This chapter provided the background to the project, including discussion of: 
adverse drug reactions, drug safety and pharmacoepidemiology, databases of 
stored electronic health records and cholestatic liver injury 
 
• Adverse drug reactions are responsible for a significant proportion of all 
hospitalisations and can impact the availability of medicines 
 
• Databases of stored electronic health records are used to study the 
epidemiology of adverse drug reactions and predictive genetic tests for drug 
safety have been developed for a limited number of drugs 
 
• Serious drug-induced liver injury is the most common type of serious adverse 
drug reaction, with cholestatic liver injury caused by the antibiotic flucloxacillin 
an important example   
 
• This PhD will develop new methods for detecting serious adverse drug 
reactions in the UK clinical practice research database that can improve 
pharmacoepidemiological studies, facilitate predictive genetic test development 
and be used in an adaptive drug licensing model, with a focus on cholestatic 
liver injury caused by flucloxacillin and other drugs 
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2 Systematic review on the identification of individuals with 
cholestatic liver injury for epidemiological studies utilising 
databases of stored electronic patient health records 
2.1 Introduction and Aims 
The primary objective of this review was to provide an overview and understanding of 
how cholestatic liver injury has been defined as an outcome and how individuals have 
been assigned as having cholestatic liver injury in epidemiological studies that utilise 
pre-existing population-based databases of patient health records. The specific 
questions of interest were: 
1. What are the diagnostic codes, laboratory test cut-offs and clinical descriptions 
that have been used to define cholestatic liver injury in the study? 
2. Which data sources were used to obtain information related to the diagnosis of 
cholestatic liver injury? 
3. How were the diagnostic criteria in (1) applied to the data sources in (2), and 
how reproducible was the case-definition? 
2.2 Methods 
2.2.1 Search strategy 
2.2.1.1   Databases and sources 
Two very large medical journal databases, MEDLINE (1946 to present) and EMBASE 
(1947 to present) were searched electronically on the 30th June 2014 for studies that 
were performed within databases of stored (routinely collected) electronic health 
records and had cholestatic liver injury (or a synonym) mentioned as the main or one of 
a number of outcomes. In order to obtain any potential “grey literature” the websites of 
the electronic health record databases or electronic health record database research 
groups were manually searched for publications: The General Practice Research 
Database, The Health Improvement Network Database, The Hospital Episode 
Statistics database, The Base de datos para la Investigación Farmacoepidemiológica 
en Atención Primaria (BIFAP), The PHARMO institute for Drug Outcomes Research 
and The Boston Collaborative Drug Surveillance Program. The reference list of 
selected publications found using the above methods were also searched for relevant 
articles, and any found were used to amend the search terms as necessary and update 
the search. Reference lists of any review articles obtained were also searched. 
 28 
 
2.2.1.2 Search keywords and terms 
In designing the search strategy, the research question was divided into two main 
categories of terms: (1) terms related to cholestatic liver injury and (2) terms related to 
databases of stored electronic health records. Terms within each category were 
combined by “or” statements while the two categories were combined by an “and” 
statement. 
Within Medline (indexed according to the MeSH terms), the following MeSH keywords 
were identified and used: 
CHOLESTASIS or DRUG-INDUCED LIVER INJURY or CHOLESTASIS, 
INTRAHEPATIC and DATABASE MANAGEMENT SYSTEMS or DATA COLLECTION 
or INFORMATION STORAGE AND RETRIEVAL 
Within EMBASE (indexed according to its own hierarchy of terms), the following 
EMBASE terms were identified and used: 
CHOLESTATIC LIVER INJURY and DATA BASE  
A number of terms were then identified as being relevant to the search, but not 
available for selection as headings in either of the databases’ indexes. These were 
therefore included as search terms of article title, abstract or keywords in both of the 
databases,  and were as follows (with “*” indicating that any subsequent ending is 
acceptable, “adj” specifying the number of permissible separating words before or after 
the terms and “#” meaning any letter is permissible at this position): 
CHOLESTAT* adj1 HEPAT* or CHOLANGIOL#TIC adj1 HEPAT* or CHOLESTAT* 
LIVER adj1(FAIL* or DISEASE* or DAMAGE*, INJUR*) or CHOLANGIOL#TIC* LIVER 
ADJ1(FAIL* or DISEASE* or DAMAGE*, INJUR*) and ADMINISTRATIVE or DATAB* 
or PRACTICE MANAG* adj1(SYSTEM or SOFTWARE) or AUTOMAT* 
adj1(RECORD*) or COMPUTER* adj7(GENERAL PRACT*) or RECORD* 
adj5(COMPUTER*) or ARIANNA or BIFAP or BASE DE DATOS PARA LA 
INVESTIGACION FARMACOEPEDEMIOLOGICA ATENCION PRIMARIA or BOSTON 
COLLABORATIVE DRUG SURVEILLANCE PROGRAM or BRIDGE DATABASE OF 
DATABASES or CALLIOPE or CCEP or CPRD or DAPI or DANISH MEDICAL 
REGISTRIES or EFEMERIS or ELECTRONIC MEDICAL RECORDS DATA or GECEM 
INVENTORY or GEPARD or GPRD or GROUP HEALTH COOPERATIVE or 
HOSPITAL CDM-US or HOSPITAL EPISODE STATISTICS or HES or HARVARD 
PILGRIM HEALTH CARE or HEALTHCORE or HENRY FORD HEALTH SYSTEMS or 
HEIS or HCUP or HMORN or IMS or INDIANA HEALTH INFORMATION EXCHANGE 
or IMPCI or INTERACTION DATABASE or IADB or INTEGRATED PRIMARY CARE 
INFORMATION DATABASE or KAISER PERMENENTE NORTHWEST or KAISER 
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PERMANENTE MEDICAL CARE PROGRAM or LIFELINK or MANITOBA HEALTH 
RESEARCH or MEDICAID or MEDICARE or MEDICINES MONITORING UNIT or MIS 
or ODENSE UNIVERSITY PHARMACOEPIDEMIOLOGICAL DATABASE or OPED or 
PCCIU-R or PEDIANET or PEM or PHARM or PHARMO RECORD LINKAGE 
SYSTEM or PHARMACOEPIDEMIOLOGICAL PRESCRIPTION DATABASES OF 
NORTH JUTLAND or PDNJ or POPULATION DATA BC or POPULATION HEALTH 
RESEARCH UNIT or PRESCRIPTION CLAIMS DATA or PRESCRIPTION EVENT 
MONITORING DATABASE or QRESEARCH or SASKATCHEWAN HEALTH 
SERVICES or SEER-MEDICARE LINKED DATABASE or SIDIAP or SWEDISH 
CENTRE FOR EPIDEMIOLOGY or UNITED HEALTH GROUP or TAYSIDE 
MEDICINES MONITORING UNIT or THE HEALTH IMPROVEMENT NETWORK or 
THIN adj7(DATA*) or THIN adj7(COMPUTER*) or VALUE ADDED MEDICAL 
PRODUCTS or VACCINE SAFETY DATALINK or VETERANS ADMINISTRATIVE 
DATABASES. 
Note that the terms “COMPUTER* adj7 GENERAL PRACT*” and “RECORD* adj5 
COMPUTER*” were added to the search terms after a number of documents had been 
found through searching database websites/reference lists of the retrieved articles that 
had not been retrieved by the database searches. Updating the search terms 
accordingly for each database allowed these documents (and additional ones using 
similar terms) to be retrieved. 
2.2.1.3   Inclusion and exclusion criteria 
Inclusion criteria 
The following inclusion criteria were applied: 
Any type of study design. 
Outcome (primary or otherwise) of the study is cholestatic liver injury (or 
a synonym). 
Study population and outcome/exposure information have been 
obtained from a database of stored electronic health records that were 
collected prior to the design of the study. 
Exclusion criteria 
The electronic search strategy was designed with a high sensitivity but low specificity, 
in order to ensure that all relevant articles would be retrieved. The following exclusion 
criteria were applied by manually reviewing the title, abstract (and full document where 
necessary) of retrieved articles in order to increase the specificity of the search 
method.  
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Studies involving: (1) pharmacovigilance (signal-detection or 
spontaneous reporting) databases or (2) databases that were not 
population-based, for example databases: 
• containing records related to a specific disease (or diseases) 
only  
• holding records on a single or selected hospital departments 
only (such as a hepatology clinic) 
• relating to a specific procedure (for example, liver transplants) 
• holding information only on medical inpatients 
• created specifically for a clinical trial. 
2.2.1.4   Procedure  
Titles and abstracts of all retrieved articles were screened for an initial assessment of 
eligibility for inclusion. For the articles that fulfilled the inclusion criteria defined in 
section 2.2.1.3  (or articles for which eligibility was still unclear), the full text was 
obtained for review. Eligibility decisions were finalised based on the full-text review as 
necessary. The list of information extracted from each included article is provided in 
Table 2-1, along with a rationale for why the information was considered important. 
Reference was made to existing standards for the reporting of observational studies 
[60] when deciding what information to extract, with a particular focus on case-
identification methods and their reproducibility [61, 62].   
Table 2-1: Information extracted from reviewed studies, with rationale 
Description of information extracted Rationale 
1. First author and year of publication Descriptive information about the study 
2. Database(s) Descriptive information about the study 
3. Study design Descriptive information about the study 
4. Outcome(s) Descriptive information about the study 
5. Exposure(s) Descriptive information about the study 
6. Main study results (for cholestatic 
injury type) including number in 
exposure groups, frequency of 
cholestatic liver injury and risk, rate or 
odds ratio (where possible) 
Allows the impact of different case identification 
approaches on the study results to be assessed. 
7. Age range criteria Descriptive information about the study and allows 
understanding of how comparable results are across 
studies 
8. Database diagnostic terms/codes 
used 
Use of different diagnostic codes across studies for 
outcome definition is likely to influence the number 
of cases identified. Providing lists of terms allows 
comparisons to be made across studies and 
facilitates reuse of an electronic health record case 
 31 
 
Description of information extracted Rationale 
identification method. 
9. Any liver test criteria used Liver test results that may be recorded in databases 
of electronic health records provide a way of 
assessing the presence of liver injury (including 
cholestatic injury). Publication of the biochemical 
criteria used to define liver injury facilitates the 
comparison of results obtained across studies and 
the reuse of the case identification method by other 
research groups. 
10. Whether external standards were 
referenced 
Use of external standards for case identification can 
reduce measurement error and increase 
reproducibility of methods by other research groups. 
For example, external standards for defining type of 
liver injury. 
11. Time interval between diagnostic 
code and liver test 
Due to the routine nature of the data used, the time 
interval that defines that a diagnostic code and a 
subsequent (or preceding) liver test are part of the 
same clinical episode is applied at the discretion of 
the researchers. Varying time intervals could 
influence whether somebody is assigned as a case 
or not by one case identification method compared 
to another.  
12. How the data were used (e.g. 
diagnostic codes, full computer record, 
external sources) 
Sources of data used in studies of electronic health 
records might include diagnostic codes/liver test 
results, other information in the electronic record 
and information requested directly from clinicians 
(e.g. paper records external to the database). Case 
identification methods within a study may rely on 
specific combinations of these sources, and the data 
quality and availability associated with each source 
is likely to lead to different results across studies. 
13. Whether blinding to exposure status 
was performed 
A lack of blinding to exposure status can lead to 
observer bias, where case status assignment may 
become subjective rather than objective. This could 
undermine the case identification process. 
14. Response rate for external note 
requests and comment on impact of low 
response rate 
If a case-identification process relies heavily on 
external (paper) notes requested directly from 
clinicians and there is a very low response rate, this 
could be a factor in the number of cases that were 
identified in the study. 
15. Whether appropriate reviewers were 
clearly identified (e.g. medical 
qualifications, speciality) 
Provides an indication as to whether appropriate 
steps of case identification involved people with 
expertise in the disease area being studied (i.e. 
liver-related conditions) 
16. Whether exclusions were applied 
appropriately  
Applying exclusions inappropriately can lead to bias 
in cohort studies (if follow-up time is not correctly 
assigned) and in case-control studies (if different 
criteria are applied to the potential case and control 
populations). Clear descriptions of how exclusions 
were handled facilitates comparison of results 
obtained across studies that may have used similar 
case-identification methods.  
17. Whether there was an attempt to 
measure method validity 
A comparison of the case identification method used 
with another standard can help demonstrate how 
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Description of information extracted Rationale 
well a case-identification method has performed. 
18. Whether more than one case level 
was defined 
Where there is clinical uncertainty around case 
identification (often due to a lack of information in 
routinely collected data for all patients), using 
multiple defined case levels can assist in 
interpretation of results obtained and facilitate 
comparisons across different studies. 
 
The search was initially conducted in October 2011. An auto-update was setup so that 
the search then ran automatically (monthly) during the preparation of the other sections 
of this project. The final update/run of the search was performed in July 2014.  
2.3 Results 
The automated searches of the Medline and EMBASE databases retrieved 412 
articles, 36 of which were duplicated between databases, leaving 376 unique articles. 
Manual searching of the websites specified in section 2.2.1.1 retrieved a further 5 
articles, giving a combined search result of 381 articles. Based upon title and abstract 
review, 277 articles were excluded because they either did not meet one or both of the 
inclusion criteria (271) or met the exclusion criteria (6). The full text of the remaining 
104 documents was then obtained for further review. Review of full text led to the 
exclusion of a further 90 articles, 79 that did not meet either or both of the inclusion 
criteria, 10 that met the exclusion criteria and 1 that was a duplicated report 
(conference proceedings) of the results of another included article. 
During the search, 2 eligible studies were obtained from a review of the reference lists 
and included in the final number of articles for review (updating of the search terms 
based on these two studies was not possible due to the vague terms used for 
electronic health record databases in the abstract and title of these articles). An 
overview of these results is provided in Figure 2.1.
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Figure 2.1: Flow diagram of search strategy used   
 
Flow diagram format adapted from PRISMA guidelines for systematic review and meta-analyses [63] 
Did not meet inclusion criteria (n=271)
Cholestatic hepatitis (CH) was not an outcome and study was not performed in
database (DB) of stored electronic health records (EHR) (n=151)
CH was not an outcome (n=26)
Study was not performed in DB of EHR (n=93)
Article full‐text obtained and reviewed for further analysis of eligibility
Studies included in final review (n=16)
Literature search
Databases: PubMed, Embase
Websites: GPRD, THIN, HES
Combined search results (n=381)
Articles screened on basis of title and abstract
Included (n=104)
Did not meet inclusion criteria (n=79)
CH was not an outcome and study was not performed in DB of EHR (n=9)
CH was not an outcome (n=27)
Study was not performed in DB of EHR (n=43)
Reference lists of review articles and retrieved studies searched
Included (n=14)
Extra studies identified for inclusion (n=2)
Articles found in reference lists but title and abstract terms too
vague to allow updating of database search terms (n=2)
Met exclusion criteria (n=6)
Study performed using :
Pharmacovigilance DB (n=1)
Specific disease DB (n=1)
Specific procedure DB (n=2)
Clinical trial DB (n=2)
Met exclusion criteria (n=10)
Study performed using :
Pharmacovigilance DB (n=3)
Specific disease DB (n=3)
Specific procedure DB (n=2)
Inpatient DB (n=1)
Hospital dept DB (n=1)
Excluded due to duplicated content (n=1)
Conference abstract reporting already included article (n=1)
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2.3.1 Description of studies included in the final review 
A total of sixteen studies performed between 1992 and 2014 were included in the final 
review [53, 55, 64-77]. Table 2-2 contains a description of the studies. The earliest was 
performed in 1992 [64] and the most recent in 2014 [77]. Of these sixteen studies, one 
was performed using records from the Saskatchewan Health Plan Database, Canada 
[64], two in the Kaiser Permanente Southern California (KPSC) electronic medical 
record system, USA [76, 77]  and the remaining thirteen were performed using either 
the General Practice Research Database (GPRD) in the UK [53, 69-75] or its 
predecessor (the Value Added Information Medical Products Ltd, VAMP) [55, 65-68]. 
Twelve of the sixteen studies utilised a cohort design only. Of the four that used other 
designs, three cohort studies that included a secondary nested case control analysis 
[66, 68, 71], while the other was a case-control study only [74].  
Five studies had cholestatic liver injury as the main outcome [53, 55, 65, 67, 75] while 
in the remaining studies, cholestatic liver injury was one of a number of outcomes 
under a broader aim of the whole study (looking at acute liver injury, for example).  The 
drug exposures under study included non-steroidal anti-inflammatory drugs, 
flucloxacillin, oxytetracycline, erythromycin, chlorpromazine, isoniazid, trimethoprim-
sulfamethoxazole, amoxicillin, cimetidine, ketoconazole, macrolides, tetracyclines, 
metoclopramide, betahistine, sulphasalizine, azathioprine, diclofenac and 
antiepileptics. Three specific drug-exposures were studied multiple times: the 
antibiotics flucloxacillin and amoxicillin & clavulanic acid, and the antipsychotic 
chlorpromazine.  
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Table 2-2: Description of studies performed in databases of electronic health records that have cholestatic liver injury as an outcome 
First author and 
year of 
publication 
Electronic 
health 
record 
database 
Study 
design 
Outcome(s) Exposure(s) Number of people in 
exposure group (number of 
cases of cholestatic liver 
injury)1 
Frequency of cholestatic liver 
injury (by exposure)2 
 
Risk, rate or 
odds ratio3 
García Rodríguez 
1992 [64] 
Saskatchew
an Health 
Plan 
Database, 
Canada 
Cohort 
 
Acute liver injury 
(including 
cholestatic 
injury) 
NSAIDs  5  different NSAIDs 
177 550 (11) 
No NSAIDs 
467 906 (9) 
5 different NSAIDs 
6.2 per 100 000 (95% CI 3.1 – 
11.1) 
No NSAIDs 
1.9 per 100 000 (0.9 – 3.7) 
3.2 (1.3 - 7.8) 
Derby 1993a [55] VAMP, UK Cohort 
 
Cholestatic 
hepatitis (2 case 
definitions: 
“characteristic” 
and  
“consistent”)  
Flucloxacillin compared 
with oxytetracycline 
“characteristic”  
Flucloxacillin 
132 087 (6) 
Oxytetracycline 
145 844 (3) 
“characteristic” + “consistent” 
Flucloxacillin 
132 087 (10) 
Oxytetracycline 
145 844 (3) 
“characteristic”  
Flucloxacillin 
4.5 per 100 000 (1.7 – 9.9) 
Oxytetracycline 
2.1 per 100 000 (0.4 – 6.0) 
“characteristic” + “consistent” 
Flucloxacillin 
7.6 per 100 000 (3.6 – 13.9) 
Oxytetracycline 
2.1 per 100 000 (0.4 – 6.0) 
“characteristic”  
2.2 (0.6 – 8.8) 
 
 
 
“characteristic” + 
“consistent” 
3.3 (0.9 – 12.2) 
Derby 1993b [65] VAMP, UK Cohort 
 
Cholestatic 
hepatitis 
(2 case 
definitions: 
“characteristic” 
Erythromycin “characteristic”  
Erythromycin 
366 064 (10) 
“characteristic” + “consistent” 
Erythromycin 
“characteristic”  
Erythromycin 
2.7 per 100 000 (1.3 – 5.0) 
“characteristic” + “consistent” 
Erythromycin 
No comparator 
group 
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First author and 
year of 
publication 
Electronic 
health 
record 
database 
Study 
design 
Outcome(s) Exposure(s) Number of people in 
exposure group (number of 
cases of cholestatic liver 
injury)1 
Frequency of cholestatic liver 
injury (by exposure)2 
 
Risk, rate or 
odds ratio3 
and  
“consistent”) 
366 064 (13) 3.6 per 100 000 (1.9 – 6.1) 
Derby 1993c [66] VAMP, UK Cohort & 
nested 
case 
control 
 
Liver toxicity 
(including 
cholestatic 
jaundice) 
(2 case 
definitions: 
“probable” and  
“possible”) 
Chlorpromazine,  
isoniazid 
 
“probable” 
Chlorpromazine 
10 502 (3) 
Isoniazid 
921 (3)  
“probable” + “possible” 
Chlorpromazine 
10 502 (3) 
Isoniazid 
921 (4) 
“probable” 
Chlorpromazine 
28.6 per 100 000 (5.9 – 83.5)  
Isoniazid 
325.7  per 100 000 (67.2 – 951.9) 
“probable” + “possible” 
Chlorpromazine 
28.6 per 100 000 (5.9 – 83.5)  
Isoniazid 
434.3 per 100 000 (118.3 – 
1112.0) 
 
No comparator 
group 
Jick 1994 [67] VAMP, UK Cohort 
 
Cholestatic 
hepatitis 
Flucloxacillin compared 
with oxytetracycline 
Flucloxacillin 
77 552 (5) 
Flucloxacillin 
6.4 per 100 000 (2.1 – 15.0) 
No comparator 
group 
García Rodríguez 
1994 [68] 
 
VAMP, UK Cohort & 
nested 
case 
control 
Acute liver injury 
(including 
cholestatic 
injury) 
NSAIDs 12 different NSAIDs  
625 307 (17) 
12 different NSAIDs  
2.7 per 100 000 (1.6 - 4.4)* 
No comparator 
group 
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First author and 
year of 
publication 
Electronic 
health 
record 
database 
Study 
design 
Outcome(s) Exposure(s) Number of people in 
exposure group (number of 
cases of cholestatic liver 
injury)1 
Frequency of cholestatic liver 
injury (by exposure)2 
 
Risk, rate or 
odds ratio3 
Jick 1995 [69] GPRD, UK Cohort 
 
Serious drug 
toxicity 
(including 
cholestatic 
hepatitis)  
Trimethoprim-
sulfamethoxazole, 
trimethoprim, cephalexin 
 
TMP-SMZ 
232 390 (5)  
Trimethoprim 
266 951 (4) 
Cephalexin 
196 397 (3) 
TMP-SMZ 
2.2 per 100 000 (0.7 - 5.0) 
Trimethoprim 
1.5 per 100 000 (0.4 - 3.8) 
Cephalexin 
1.5 per 100 000 (0.3 - 4.5) 
No comparator 
group 
García Rodríguez 
1996 [70] 
GPRD, UK Cohort 
 
Acute liver injury 
(including 
cholestatic liver 
injury) 
Amoxicillin and clavulanic 
acid (combination) 
compared with amoxicillin 
Amoxicillin & clavulanic acid 
93 433 (19) 
Amoxicillin 
329 213 (7) 
Amoxicillin & clavulanic acid 
20.3 per 100 000 (12.2 – 31.8) 
Amoxicillin 
2.1 per 100 000 (0.9 – 4.4) 
9.6 (4.0 – 22.7) 
García Rodríguez 
1997 [71] 
GPRD, UK Cohort & 
nested 
case 
control 
Acute liver injury 
(including 
cholestatic liver 
injury) 
Cimetidine and other acid-
suppressing anti-ulcer 
Anti-ulcer drugs 
108 981 (18) 
Anti-ulcer drugs 
16.5 per 100 000 (9.8 – 26.1) 
No comparator 
group5 
García Rodríguez 
1999 [72] 
GPRD, UK Cohort Acute liver injury 
(including 
cholestatic liver 
injury) 
Ketoconazole and other 
antifungal drugs 
Fluconazole 
35 833 (0) 
 
Griseofulvin 
6 731 (0) 
Itraconazole 
19 488 (2) 
Fluconazole 
0.0 per 100 000 (0.0 – 10.3) 
 
Griseofulvin 
0.0 per 100 000 (0.0 – 54.8) 
Itraconazole 
10.3 per 100 000 (1.2 – 37.1) 
No comparator 
group5 
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First author and 
year of 
publication 
Electronic 
health 
record 
database 
Study 
design 
Outcome(s) Exposure(s) Number of people in 
exposure group (number of 
cases of cholestatic liver 
injury)1 
Frequency of cholestatic liver 
injury (by exposure)2 
 
Risk, rate or 
odds ratio3 
Ketoconazole 
1 052 (2) 
Terbinafine 
13 430 (1) 
Ketoconazole 
190.1 per 100 000 (23.0 – 686.8) 
Terbinafine 
7.4 per 100 000 (0.2 – 41.5) 
Huerta 2002 [73] GPRD, UK Cohort 
 
Acute liver injury 
(including 
cholestatic 
injury) 
Diabetes and antidiabetic 
[70, 74, 77]drugs 
Diabetes 
98 726 (8) 
No diabetes 
148 028 (5) 
Sulfonylureas 
17 151 (5) 
Metformin 
10 471 (3) 
Arcabose 
1 550 (1) 
Insulin 
8 880 (2) 
Diabetes 
8.1 per 100 000 (3.5 - 16.0) 
No diabetes 
3.4 per 100 000 (1.1 - 7.9) 
Sulfonylureas 
29.1 per 100 000 (9.5 – 68.0) 
Metformin 
28.7 per 100 000 (5.9 – 83.7) 
Arcabose 
64.5 per 100 000 (1.6 – 359.5) 
Insulin 
22.5 per 100 000 (2.7 – 81.4) 
Diabetes vs. no 
diabetes: 
1.6 (0.8 – 3.4) 
Adjusted for age, 
sex, calendar year 
and antidiabetic 
drug use. 
De Abajo 2004 
[74] 
GPRD, UK Case-
control 
 
Drug-induced 
liver injury 
(including 
cholestatic 
injury) 
Wide range of drugs Amoxicillin & clavulanic acid 
151 942 (8) 
Flucloxacillin 
155 185 (3) 
Tetracyclines 
Amoxicillin & clavulanic acid 
5.3 per 100 000 (2.3 – 10.4) 
Flucloxacillin 
1.9 per 100 000 (0.4 – 5.6) 
Tetracyclines 
No comparator 
group 
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First author and 
year of 
publication 
Electronic 
health 
record 
database 
Study 
design 
Outcome(s) Exposure(s) Number of people in 
exposure group (number of 
cases of cholestatic liver 
injury)1 
Frequency of cholestatic liver 
injury (by exposure)2 
 
Risk, rate or 
odds ratio3 
162 417 (4) 
Macrolides 
243 832 (3) 
Sulpiride 
1 241 (2) 
Chlorpromazine 
4 432 (6) 
 
Sulfasalazine 
5 335 (3) 
Azathioprine 
2 204 (2) 
Metoclopramide 
41 689 (3) 
Chlorpheniramine 
43 137 (2) 
Betahistine 
15 780 (2) 
Diclofenac 
157 721 (7) 
2.5 per 100 000 (0.7 – 6.3) 
Macrolides 
1.2 per 100 000  (0.3 – 3.6) 
Sulpiride 
161.2 per 100 000  (19.5 – 582.2) 
Chlorpromazine 
135.4 per 100 000 (49.7 – 294.7) 
 
Sulfasalazine 
56.2 per 100 000  (11.6 – 164.3) 
Azathioprine 
90.7 per 100 000  (10.9 – 327.8) 
Metoclopramide 
7.2 per 100 000  (1.5 – 21.0) 
Chlorpheniramine 
4.6 per 100 000  (0.6 – 16.7) 
Betahistine 
12.7 per 100 000  (1.5 – 45.8) 
Diclofenac 
4.4 per 100 000  (1.8 – 9.1) 
Russman 2005 GPRD, UK Cohort Cholestatic liver Flucloxacillin compared Flucloxacillin Flucloxacillin 11.1 (1.5 – 82.2) 
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First author and 
year of 
publication 
Electronic 
health 
record 
database 
Study 
design 
Outcome(s) Exposure(s) Number of people in 
exposure group (number of 
cases of cholestatic liver 
injury)1 
Frequency of cholestatic liver 
injury (by exposure)2 
 
Risk, rate or 
odds ratio3 
[53]   disease 
 
with oxytetracycline 283 097 (24) 
Oxytetracycline 
131 189 (1) 
8.5 per 100 000 (5.4 – 12.6) 
Oxytetracycline 
0.8 per 100 000 (0.02 – 4.3) 
Li 2009 [75] GPRD, UK Same as 
Derby 
1993a 
Same as Derby 
1993a 
Same as Derby 1993a Flucloxacillin 
346 072 (21) 
Penicillin 
1 179 360 (4) 
Co-fluampicil 
159 215 (6) 
Flucloxacillin 
6.1 per 100 000 (3.8 – 9.3) 
Penicillin 
0.3 per 100 000 (0.1 – 0.9) 
Co-fluampicil 
3.8 per 100 000 (1.4 – 8.2) 
Flucloxacillin 
compared with 
penicillin 
17.9 (6.1 – 52.1) 
Shin 2013 [76] KPSC, USA Cohort Drug-induced 
liver injury 
(including 
cholestatic 
injury) 
14 drugs frequently 
associated with 
hepatotoxicity 
14 different drug exposures6 
601 125 (68) 
14 different drug exposures 
11.3 per 100 000 (8.9 – 14.3) 
No comparator 
group 
Cheetham 2014 
[77] 
KPSC, USA Cohort Drug-induced 
liver injury 
(including 
cholestatic 
injury) 
(2 case 
definitions: 
15 drugs frequently 
associated with 
hepatotoxicity 
“probable or highly probable” 
15 different drug exposures6 
1 239 071 (1 222) 
 “possible” + “probable or 
highly probable” 
15 different drug exposures6 
1 239 071 (5 923) 
“probable or highly probable” 
15 different drug exposures 
98.6 per 100 000 (93.2 – 104.3) 
 “possible” + “probable or highly 
probable” 
15 different drug exposures 
478.0 per 100 000 (465.9 – 490.4) 
No comparator 
group 
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First author and 
year of 
publication 
Electronic 
health 
record 
database 
Study 
design 
Outcome(s) Exposure(s) Number of people in 
exposure group (number of 
cases of cholestatic liver 
injury)1 
Frequency of cholestatic liver 
injury (by exposure)2 
 
Risk, rate or 
odds ratio3 
“possible” and  
“probable or 
highly 
probable”) 
 
 
 
1Cholestatic liver injury: Cholestatic liver injury includes any liver injury with a cholestatic component i.e. pure cholestatic and/or cholestatic hepatitis (mixed).  
2Frequency of cholestatic liver injury All bracketed figures are 95% Confidence Intervals. Frequency estimates extracted from those in each article or if not present for cholestatic liver injury, calculated from 
the number of cases of cholestatic liver injury reported in each exposure group. 95% confidence intervals were calculated assuming a Poisson distribution. All denominators are number of people exposed, apart 
from García Rodríguez 1992/1999 and Huerta 2002 which are person-years (choice of denominator used in this table dependent on the information provided in the article). 
3Risk, rate or odds ratio: Unadjusted unless specified otherwise. Where these figures were not included in the article, they were calculated from the published or calculated frequencies in each exposure group. 
4Jick 1994: This study was an extension of the Derby 1993b study 
5No comparator group (García Rodríguez 1997/1999, De Abajo 2004): Comparator groups of non-drug-use are discussed in García Rodríguez 1997/1999 but cases within this exposure group are not broken 
down by liver injury type.  Furthermore, in the García Rodríguez 1997  and the De Abajo 2004 articles, odds ratios for separate drugs estimated by case control analysis are presented, but the case-control 
analysis includes any liver injury type (not just cholestatic).  
6Multiple different drug exposures (Shin 2013, Cheetham 2014): Incidence of cholestatic injury only presented for the entire cohort in the article, not broken down by drug
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2.3.2 Overall approach to identification of individuals with cholestatic 
liver injury 
The general methods used for defining and obtaining cases of cholestatic liver injury 
were similar across the majority of studies. An overview is provided in Figure 2.2, and 
may be described as follows: 
Step 1: Definition of diagnostic criteria: authors identified (1) a broad 
list of relatively non-specific database diagnostic codes and (2) more 
specific laboratory test result parameters and/or descriptive clinical 
information (other than database codes) to use as criteria for selecting 
individuals with cholestatic liver injury.  
Step 2: Identification of database records of potential cases: the 
patient id and full (anonymised) electronic records of patients with any of 
the computer database codes in the codelist were obtained. Additional 
processing of the computer records of potential cases may have been 
performed to exclude patients with certain conditions, and some 
exclusions may also have been applied to the entire study population, 
based on the presence of specific codes prior to start of follow-up. 
Step 3: Finalisation of cases status based on information external 
to the database: general practices (or hospitals) were contacted by 
post (or in person) to request additional information for the patients with 
the patient ids identified by the broad computer diagnostic code search. 
The information provided by GPs was reviewed, and this information 
considered with the full database record in order to assign individuals 
identified as possible cases in the computer search as (definite) cases 
or non-cases. Analysis could then be performed using the designated 
case status and information on (e.g. drug) exposures contained in the 
full database record.  
For the two studies that applied a slightly different method, cases were identified solely 
on the basis of liver test results (without the use of diagnostic codes) [77, 78]. 
All of the steps applied across all studies will be considered in greater detail in the 
following sections. 
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Figure 2.2: Overview of methodology employed for identifying individuals with 
cholestatic liver injury in 14 of the 16 included studies 
 
Step 1: Definition of diagnostic criteria 
 A broad list of database disease codes and more specific laboratory/clinical criteria are identified as 
diagnostic criteria for cholestatic liver injury.  
Step 2: Identification of database (DB) records of potential cases 
The list of database disease codes is used to identify indiviudals with records in the database who 
potentially have the outcome and their full electronic record is retrieved. Exclusion criteria may also be 
applied to potential cases at this stage (e.g. by excluding those with specific codes).  
Step 3: Finalisation of case status based on information external to the DB  
Additional information (e.g. medical notes) for the patients with patient ids identified in step (2) are 
requested and obtained from GP practices or hospitals, and the the laboratory/clinical diagnostic criteria 
are applied during a review of medical notes and computer record in order to provide a definite 
classification of cholestatic liver injury. Analysis using e.g. drug exposure information held within the 
electronic record is then performed to obtain frequency and effect measures in relation to cholestatic 
liver injury. 
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2.3.3 Step 1: Definition of diagnostic criteria 
2.3.3.1   Database codelists 
Fourteen of the sixteen studies initially used a list of database disease codes to select 
patients that could potentially have acute liver injury. Providing the actual list of codes 
used in the published studies provides benefit by (1) allowing readers to assess how 
accurate/biased the studies might be and (2) allowing the studies to be reproduced in 
order to support development of an evidence base. Within the fourteen studies, the 
specific type of code used depended upon the design of the database in which the 
study was performed. The study performed by García Rodríguez et al in the 
Saskatchewan Health Plan database [64] therefore used International Disease 
Classification (ICD) codes (version 9), while all GPRD/VAMP based studies relied on 
the OXMIS coding system [53, 55, 65-75], with one GPRD study additionally including 
READ codes [53]. Only three of the fourteen studies did not either (1) include a list of 
all codes used or (2) clearly reference another study which contained the codes used. 
The codelists for these studies were therefore obtained from the authors by contacting 
them personally [53, 70, 74]. A complete list of all codes and their frequency of use 
(across all studies and across those analysing only cholestatic liver injury) is provided 
in Table 2-3, while the list of database codes used by each of the studies can be found 
in Table 2-5 (Step 1 column). Chapter 2 Appendix (Table A1) contains all the 
diagnostic codes used listed alphabetically. 
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Table 2-3: Frequency of database codes used by all (14) studies that applied a code search and 
by the (5) studies that analysed only cholestatic liver injury 
Database code  
(OXMIS unless specified) 
Diagnosis (OXMIS terms) Frequency 
across all studies 
(OXMIS, other) 
Frequency 
across 
cholestatic 
liver injury 
studies  
570XX*, J633.00 (READ), 573.3 (ICD-9)  Hepatitis/liver necrosisa 14 (12, 1, 1) 5 (4,1) 
7852XX, R024111 (READ), 782.4 (ICD-9) Jaundiceb 14 (12, 1, 1) 5 (4,1) 
576A, J66y600 (READ) Obstructive jaundicec 12 (11, 1) 5 (4, 1) 
L3264AB Abnormal hepatic function 12 4 
L3263AB Abnormal liver enzymes 12 4 
L3260AB Abnormal liver function test 12 4 
L3262AB Biochemical liver dysfunction 12 4 
070F Fulminant hepatitis 12 4 
L3263H Liver enzymes raised 12 4 
573XX Other liver disorders 12 4 
785CP Pale stools 11 4 
5730D Hepatocellular damage 9 4 
5719CH Chronic hepatitis 7 4 
070 Infectious hepatitis 7 4 
K501 Liver biopsy 7 4 
L3260 Liver function test 7 4 
575XX Other gallbladder disorders 
(cholangitis/cholecystisis) 
7 4 
5710HA Alcoholic  hepatitis 6 4 
7516JA Familial intrahepatic cholestasis 6 4 
574XX Gallbladder disorders 6 4 
K5091 Hepatostomy 6 4 
070N Non-A non-B hepatitis 6 4 
L109H ALT raised 5 0 
L1002CR Aspartate aminotransferase 
level raised 
5 0 
L110H AST raised 5 0 
L1151NA Bilirubin serum level abnormal 5 0 
9779PN Drug-induced jaundice 5 0 
7851XX Enlarged liver 5 0 
K501XX Liver biopsy 5 0 
9669XX Abnormal drug reactions/effects 1 0 
L4720N Alkaline phosphatase level 1 0 
L1151 Bilirubin serum level normal 1 0 
574AL Cholelithiasis 1 0 
57300 Hepatocellular damage 1 0 
All  249 91 
*XX = category including a range of diagnoses 
aHepatitis/liver necrosis: García Rodríguez et al 1992 [64]specified ICD-9 codes  (570: Necrosis of the liver and 573.3: 
Unspecified hepatitis) which are counted as a single code search for Hepatitis/liver necrosis in this table. The READ code of 
J633.00 specified by Russman et al [53] has been considered as appropriate for the OXMIS heading of Hepatitis/liver necrosis in 
this table 
bJaundice: Russman et al [53] specified five diagnostic codes for jaundice. These are counted as a single code search for 
Jaundice in this table and the READ code for Jaundice (R024111) is included.  
cObstructive jaundice: Russman et al [53] specified codes for obstructive jaundice(/obstructive jaundice nos) using both OXMIS 
and READ codes, this is counted as a single code search for obstructive jaundice in this table and the READ code is included. 
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The most common codes selected by all studies were those for hepatitis/liver necrosis 
and for jaundice (Table 2-3), which were included in every study. These two codes 
were also used most frequently among those studies that only included cholestatic liver 
injury as an outcome, in addition to the code for obstructive jaundice. The next most 
frequent group of codes across all studies included those indicating results for 
laboratory tests for liver functions, the code for fulminant hepatitis and the code for 
other liver disorders (used by 12/14 studies).  Codes of note that were used by studies 
that were looking at acute liver injury but not by those assessing only cholestatic liver 
injury included drug-induced jaundice and liver biopsy. 
As four of the five articles in which cholestatic liver injury was studied as the only 
outcome used the same codelist, the difference in frequency of codes across these 
studies was attributable only to the study that utilised a different codelist (Russman et 
al, 2009 [53]). This article included a much more restricted list than the other four 
cholestatic liver injury studies (Table 2-5), and the list provided was described as “the 
codelists of included cases”[53]. In a personal communication with the author, he 
stated that he thought this was also the list used to search for cases although could not 
be “100% sure” if additional codes weren’t used for searching. 
2.3.3.2   Liver test results 
For disease outcomes that can be measured by laboratory analysis of (e.g.) blood 
samples, the use and reporting of such standards can help minimise bias caused by 
measurement error. Use of the same standards across studies may also allow meta-
analyses to obtain reliable pooled point estimates of effect across homogenous studies 
(facilitating evidence-based medicine). Standard criteria were published for defining 
cholestatic liver injury in 1990, in a paper reporting on an international consensus 
meeting on the criteria of drug-induced liver disorders published under the auspices of 
CIOMS [45], and again in 2011 (by an international DILI working group [46]). Table 2-5 
lists the laboratory standards used for each study (step 1 column) and Table 2-6 
displays which of the studies referenced diagnostic standards. Of the sixteen included 
studies, nine referenced the CIOMS paper [64, 68, 70-74] or the working group paper 
[76, 77] .  Of those that didn’t reference these articles, six described (or referenced 
another study describing) laboratory test parameters as “predominant elevation of 
bilurubin and alkaline phosphatase” [53, 55, 65, 67, 69, 75], while the remaining study 
described using laboratory test results but did not include details of the parameters 
used [66]. 
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2.3.3.3   Other test results, clinical descriptions and exclusions 
Biopsy and ultrasound examination are two other tests that may be used to strengthen 
the diagnosis of cholestatic liver injury [46]. Only two of the fourteen studies that used 
information other than just liver test results did not specify anywhere that biopsy results 
had been considered [53, 64]. In the case of Russman et al [53], it is possible it was 
included as an initial code search (see comment from author in section 2.3.3.1). Six of 
the fourteen studies described consideration of ultrasound results somewhere during 
review of computer records or complete medical notes [55, 65, 67, 69, 74, 75]. 
Six of the studies provided (or referenced a study who had provided) some additional 
descriptive information that was used to define a case in their study (in addition to the 
diagnostic codelists and laboratory test results), specifying that an individual was 
considered to be suffering drug-induced cholestatic liver injury if they had “painless 
jaundice” with positive lab test results (and no history of other causes of cholestasis)  
[53, 55, 65, 67, 69, 75]. 
Details of the exclusions applied were provided by all the studies, although of note was 
that none of the studies included a list of database diagnostic codes that were 
considered exclusions but instead included more general descriptions of 
conditions/diseases without identifying any specific database codes. A complete list of 
the exclusion criteria used across all studies is provided in Table 2-4, which also shows 
frequency of use, and an alphabetical list is provided in Chapter 2 Appendix (Table A2). 
Table 2-5 illustrates which exclusion criteria were applied at the database records (step 
2 column of the table) or during the review of notes external to the database (step 3 
column of the table) for each of the studies. For the five studies in which cholestatic 
liver injury was the only outcome, there were only two exclusions described: normal 
liver function test results and other liver disorders (Table 2-4) [53, 55, 65, 67, 75]. The 
other studies provided more extensive lists of exclusions, with alcoholism, congestive 
heart failure, and other well defined pathology or disease the three exclusions cited 
most frequently (Table 2-4).  Four of the studies stated that patients who were not 
referred to a specialist or admitted to hospital would be excluded [64, 71-73].  
  
 48 
 
Table 2-4: Frequency of exclusions used by all (16) studies and by the (5) studies that 
analysed only cholestatic liver injury 
Exclusion description 
 
Frequency 
across all 
studies 
 
Frequency across 
cholestatic liver injury 
studies  
Alcoholism 9 0 
Congestive heart failure 9 0 
Other well defined pathology or disease 9 0 
Other liver disorders 8 5 
Normal liver function test results 7 5 
Malignant neoplasm 7 0 
Cholelithiasis 7 0 
Viral hepatitis (based on serology) 6 0 
Gallbladder or pancreatic disease 5 0 
Chronic liver disease 4 0 
Rheumatoid arthritis 3 0 
Not referred to a specialist or admitted to hospital 3 0 
Cirrhosis 2 0 
Hepatitis after blood transfusion 2 0 
Sarcoidosis 2 0 
Systemic lupus 2 0 
Viral infection (serologically confirmed) 2 0 
Cancer of the liver 2 0 
Cancer of the gallbladder 1 0 
Cancer of the pancreas 1 0 
Cholecystitis 1 0 
Crohn's disease 1 0 
HIV infection 1 0 
Inflammatory bowel disease 1 0 
Pancreatic disease 1 0 
Ulcerative colitis 1 0 
Well-defined systemic condition affecting the liver 1 0 
Liver disease 1 0 
Other co-morbidity associated with liver chemistry elevations 1 0 
ALT or AST elevations above normal levels during 1 year prior 1 0 
Concomitant use of medications associated with hepatotoxicity 1 0 
All 102 8 
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Table 2-5: Summary of overall methodology used by each study for the identification of individuals with cholestatic liver injury, including diagnostic 
criteria/exclusions applied and data sources used 
First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
García 
Rodríguez 
1992 [64] 
ICD-9 codes (3) 
570: necrosis of the liver 
573.3: unspecified hepatitis 
782.4: jaundice 
 
Increase of over twice 
the upper limit of the 
normal range in 
alkaline phosphatise 
(AP) alone or when the 
ratio (R) of serum 
activity of alanine 
aminotransferase  to 
serum activity of 
alkaline phosphatase 
was ≤ 2 
Outcome definition included 
admission to hospital. Unclear what 
aspects of computer record were 
used and what criteria were applied 
– only exclusions mentioned are 
those for step 3, results say that 
“patients were excluded based on 
computer and hospital records”.  
Excluded those with no liver disease or 
the following other causes for liver 
disease: alcoholism, malignant 
neoplasm, cholelithiasis, viral hepatitis 
based on serology, chronic liver 
disease, cirrhosis, congestive heart 
failure, hepatitis after blood 
transfusion, other well defined 
pathology and then used laboratory 
test results of those remaining to 
assign final cholestatic liver injury 
status. 
Derby 1993a 
[55] 
OXMIS codes (22) 
070: Infectious hepatitis 
070F: Fulminant hepatitis 
070N: Non-A non-B hepatitis 
K501: Liver biopsy 
570XX: Hepatitis/liver necrosis 
573XX: Other liver disorders 
574XX: Gallbladder disorders 
575XX: Other gallbladder disorders 
576A: Obstructive jaundice 
785CP: Pale stools 
L3260: Liver function test 
L3260AB: Abnormal liver function 
test 
L3262AB: Biochemical liver 
Elevation of bilirubin 
and alkaline 
phosphatase levels or 
biopsy showing 
cholestatic jaundice 
 
Identified those “with a first-time 
diagnosis of a liver disorder that 
might represent intrahepatic 
cholestatic jaundice” and requested 
their GP records, but no specifics 
on exactly how identification was 
achieved.  
Excluded individuals if other causes of 
liver injury were well defined, the 
history and lab findings were not 
suggestive of chol-hep or the disorder 
appeared before drug use and 
considered the remaining as cases if 
they presented with painless jaundice 
and positive lab results.  
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
dysfunction 
L3263AB: Abnormal liver enzymes 
L3263H: Raised liver enzymes 
L3264AB: Abnormal hepatic function 
K5091: Hepatostomy 
5710HA: Alcoholic  hepatitis 
5730D: Hepatocellular damage 
7516JA: Familial intrahepatic 
cholestasis 
7852XX: Jaundice 
5719CH: Drug-induced jaundice 
 
XX=category including a range of 
diagnoses 
Derby 1993b 
[65] 
Same as Derby 1993a (22) Same as Derby 1993a Same as Derby 1993a Same as Derby 1993a 
Derby 1993c 
[66] 
Same as Derby 1993a (22) Laboratory results 
used but no laboratory 
parameters provided. 
 
Based on “review of available 
computer data”, excluded 
individuals who had an illness that 
was likely to account for the liver 
disorder (“conditions such as 
cancer of the pancreas, pre-existing 
liver disease”) and requested GP 
records for those that remained.  
Applied unspecified exclusions, 
although results state that those 
excluded based on notes review had: 
gallbladder disease, serology-
confirmed hepatitis A, alcoholic liver 
disease or jaundice secondary to 
cardiac failure.  Then categorised as 
having probable or possible drug-
induced liver disease based on lab 
results, biopsy, timing and 
“extensiveness of documentation”.  
Jick 1994 [67] Same as Derby 1993a (22) Same as Derby 1993a Same as Derby 1993a Same as Derby 1993a 
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
García 
Rodríguez 
1994 [68] 
OXMIS codes (15) 
L3263AB: Abnormal liver enzymes 
L3260AB: Abnormal liver function 
test 
L3264AB: Abnormal hepatic function 
070F: Fulminant hepatitis 
5719CH: Chronic hepatitis 
070: Infectious hepatitis 
L3262AB: Biochemical liver 
dysfunction 
K501: Liver biopsy 
L3263H: Liver enzymes raised 
570XX: Hepatitis/liver necrosis 
574AL: Cholelithiasis 
575XX: Cholangitis/cholecystisis 
573XX: Other liver disorders 
7852XX: Jaundice 
9669XX: Abnormal drug 
reactions/effects 
Increase of more than 
twice the upper limit of 
the normal range in AP 
alone or R≤2. 
 
Used “computerized patient profile” 
(specifics unclear) to “eliminate” 
those with clear causes for their 
liver injury (“such as viral infection, 
cholelithiasis, cancer of the liver, 
and cancer of the gall bladder”) and 
requested GP notes for the 
remaining individuals.  
Excluded patients with cholelithiasis, 
malignant neoplasm, viral hepatitis 
(serologically confirmed), chronic liver 
disease, congestive heart failure, 
alcoholism, or other well defined 
disease and then used laboratory test 
results to define outcome status.  
Jick 1995 [69] Same as Derby 1993a (22) 
 
 
 
“Strong consideration” 
applied to lab findings 
but no parameters 
provided. 
 
Identified those with a “first-time 
diagnosis of one of the study 
outcomes for which no apparent 
cause was noted” (specifics of 
which data used not provided) and 
requested GP notes for these 
individuals.  
Authors gave “strong consideration to 
the details of all clinical and laboratory 
findings as well as the clinical 
diagnoses made by the attending 
physicians” in order to assign final 
outcome status. Exclusions specified 
only in results but included: “no 
referral/hospitalisation and other 
clinical diagnosis present”.  
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
García 
Rodríguez 
1996 [70] 
OXMIS codes (19)  
(obtained from authors) 
070F: Fulminant hepatitis 
570XX: Hepatitis/liver necrosis 
573XX: Other liver disorders 
5730D: Hepatocellular damage 
576A: Obstructive jaundice 
785CP: Pale stools 
7851XX: Enlarged liver 
7852XX: Jaundice 
9779PN: Drug-induced jaundice 
K501XX: Liver biopsy 
L1151NA: Bilirubin serum level 
abnormal 
L3260AB: Abnormal liver function 
test 
L3262AB: Biochemical liver 
dysfunction 
L3263AB: Abnormal liver enzymes 
L3263H: Liver enzymes raised 
L3264AB: Abnormal hepatic function 
L109H: ALT raised 
L110H: AST raised 
L1002CR: Aspartate 
aminotransferase level raised 
Alkaline phosphatase 
over twice the limit of 
normal or R>2*. 
 
*R>2 likely to be a 
typo, as CIOMS paper 
is referenced which 
states R≤2. 
 
 
Excluded individuals from the total 
study population (prior to start of 
study follow-up) who had codes for 
neoplasm of the liver, diseases of 
the liver, jaundice, or RA and 
specified age range requirement of 
10 - 79 years. 
Excluded potential cases with DB 
codes for neoplasm, cholecystitis, 
alcohol-related conditions or 
alcohol mentioned in the free-text. 
Then assigned individuals as non-
cases based on presence of normal 
liver function test results (or minor 
elevations), viral hepatitis, 
cholelithiasis, congestive heart 
failure, or other well defined 
pathological findings found during 
“manual review of complete 
computerized patient profile”. Notes 
for the remaining (“undetermined”) 
individuals were requested from 
GPs. 
Based on information within medical 
records, excluded patients with 
cholelithiasis, malignant neoplasm, 
viral hepatitis (serologically confirmed), 
chronic liver disease, congestive heart 
failure, alcoholism, or other well 
defined disease then used lab test 
results to identify cases from the 
remaining individuals. 
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
García 
Rodríguez 
1997 [71] 
OXMIS codes (21) 
070F: Fulminant hepatitis 
570XX: Hepatitis/liver necrosis 
573XX: Other liver disorders 
576A: Obstructive jaundice 
785CP: Pale stools 
7851XX: Enlarged liver 
7852XX: Jaundice 
9779PN: Drug-induced jaundice 
K501XX: Liver biopsy 
L1151: Bilirubin serum level 
L1151NA: Bilirubin serum level 
abnormal 
L3260: Liver function test 
L3260AB: Abnormal liver function 
test 
L3262AB: Biochemical liver 
dysfunction 
L3263AB: Abnormal liver enzymes 
L3263H: Liver enzymes raised 
L3264AB: Abnormal hepatic function 
L4720N: Alkaline phosphatase level 
L109H: ALT raised 
L110H: AST raised 
L1002CR: Aspartate 
aminotransferase level raised 
Increase of over twice 
the upper limit of the 
normal range of 
Alkaline Phosphatase 
alone or the ratio of 
serum activity of 
Alanine 
AminoTransferase 
(ALT) over AP (R) ≤2. 
 
Excluded individuals from the total 
study population (prior to start of 
study follow-up) who had any of the 
codes listed in step 1 and 
additionally: cancer, other liver 
disease, jaundice, gallbladder or 
pancreatic disease, congestive 
heart failure, alcoholism, 
rheumatoid arthritis, sarcoidosis, 
systemic lupus, Crohn's disease or 
ulcerative colitis and specified age 
range requirement of 20 - 74 years 
Excluded potential cases not 
referred to a specialist or admitted 
to hospital. Then “manually 
reviewed the patients computerized 
profile” to select those for whom 
medical records should be 
requested from GPs, based on 
absence of alcoholism, malignant 
neoplasm, cholelithiasis, viral 
hepatitis based on serology, 
chronic liver disease, cirrhosis, 
congestive heart failure, hepatitis 
after blood transfusion or other well 
defined pathology. 
Based on medical records, excluded 
patients with other well defined causes 
for liver injury (other liver disorders, 
cancer, cholelithiasis, serologically 
confirmed viral hepatitis, congestive 
heart failure, alcoholism or a well-
defined systemic condition affecting 
the liver) and then used laboratory test 
results to define outcome status. 
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
García 
Rodríguez 
1999 [72] 
OXMIS codes (19) 
070F: Fulminant hepatitis 
570XX: Hepatitis/liver necrosis 
573XX: Other liver disorders 
5730D: Hepatocellular damage 
576A: Obstructive jaundice 
785CP: Pale stools 
7851XX: Enlarged liver 
7852XX: Jaundice 
9779PN: Drug-induced jaundice 
K501XX: Liver biopsy 
L1151NA: Bilirubin serum level 
abnormal 
L3260AB: Abnormal liver function 
test 
L3262AB: Biochemical liver 
dysfunction 
L3263AB: Abnormal liver enzymes 
L3263H: Liver enzymes raised 
L3264AB: Abnormal hepatic function 
L109H: ALT raised 
L110H: AST raised 
L1002CR: Aspartate 
aminotransferase level raised 
Increase of more than 
twice the upper limit of 
the normal range in 
APh alone or R≤2. 
 
Excluded individuals from the total 
study population (prior to the start 
of study follow-up) who had a 
history of liver injury in the 
preceding 5 years and any of the 
following: cancer, liver disease, 
gallbladder disease, pancreatic 
disease, heart failure, alcohol 
abuse, HIV infection, rheumatoid 
arthritis, sarcoidosis, systemic 
lupus or inflammatory bowel 
disease (likely to be DB codes but 
this is not specified) and had an 
age inclusion criteria of 20-79 
years. 
 
Assigned definite case status to those 
presenting with symptoms suggestive 
of liver disorder, referred to a specialist 
or admitted to hospital, free of 
exclusion criteria mentioned in step 2 
and with lab test results showing 
cholestatic injury. 
 
Huerta 2002 
[73] 
OXMIS codes (19) 
070F: Fulminant hepatitis 
570XX: Hepatitis/liver necrosis 
573XX: Other liver disorders 
57300: Hepatocellular damage 
An increase of more 
than 2 times the upper 
limit of normal in 
alkaline phosphatase 
alone or the ratio of 
Excluded individuals from the total 
study population (prior to start of 
study follow-up) who had any of the 
codes listed in step 1 and any of 
the following: other liver diseases, 
Questionnaire used to “validate the 
diagnosis”, same exclusion criteria 
applied as in step 2, laboratory results 
then used to assign final case status. 
 
 55 
 
First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
576A: Obstructive jaundice 
785CP: Pale stools 
7851XX: Enlarged liver 
7852XX: Jaundice. excluding 
7852PF 
9779PN:   Drug-induced jaundice 
K501XX: Liver biopsy 
L1151NA: Bilirubin serum level 
abnormal 
L3260AB: Abnormal liver function 
test 
L3262AB: Biochemical liver 
dysfunction 
L3263AB: Abnormal liver enzymes 
L3263H: Liver enzymes raised 
L3264AB: Abnormal hepatic function 
L109H: ALT raised 
L110H: AST raised 
L1002CR: Aspartate 
aminotransferase level raised 
the serum activities of 
ALT was 2 or less. 
 
gallbladder or pancreatic disease, 
alcoholism, or congestive heart 
failure (time window not-specified, 
also doesn’t specify codes, 
although likely to be these). 
Included only those between 20 - 
79 years. 
Reviewed “computerised patient 
profiles” manually to exclude all 
patients not referred to a specialist 
or hospital, patients with a recorded 
liver function test result of normal, 
or with minor elevations, patients 
with serologically confirmed viral 
infection, cancer, cholelithiasis, 
congestive heart failure, and/or 
alcoholism and requested notes on 
those remaining. 
 
De Abajo 2004 
[74] 
Same as García Rodríguez 1996 
(19)  
Increase of over twice 
the upper limit of the 
range in AP alone or 
R≤2. 
 
Excluded individuals from the total 
study population (prior to start of 
study follow-up) who had any of: 
liver-related diagnosis, cancer, 
gallbladder or pancreatic disease, 
alcohol-related disorders (no time 
window provided). Included only 
those aged 5-75 years. 
Reclassified potential cases as 
noncases if they had minor 
Excluded patients with no confirmed 
liver injury, antecedents of liver 
disease, or presented primary causes 
then used laboratory values to identify 
cases of cholestatic liver injury. 
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
elevations in serum enzymes, a 
primary cause was identified 
(chronic liver disease, malignant 
neoplasm, viral hepatitis, 
cholelithiasis, alcoholism, 
congestive heart failure or other 
well-defined pathology of the liver) 
or the patient was not referred to a 
consultant or hospital or had died.  
Medical notes from GPs were 
requested for the remaining 
potential cases. 
 
Russman 
2005 [53] 
OXMIS codes (3) 
7852: Jaundice 
576A: Obstructive jaundice 
7852JC: Cholestatic jaundice 
READ codes (5) 
J66y600: Obstructive jaundice nos 
1675.11: Jaundice – symptom 
J633.00: Hepatitis unspecified 
R024.00: Jaundice (not of newborn) 
R024111: Jaundice 
 
 
Predominant elevation 
of alkaline 
phosphatase and 
bilurubin 
concentrations. 
 
Requested GP notes for those who 
had “computer-recorded data  
consistent with idiopathic 
cholestatic liver disease” (unclear 
specifically what this was based 
upon). If notes unavailable, used 
computer record to assign final 
case status.  
Excluded all subjects where a causal 
relationship was unlikely and classified 
remaining individuals as cases of drug-
induced cholestatic liver disease when 
they showed painless jaundice with 
predominant elevations of alkaline 
phosphatase and bilirubin 
concentrations.  
 
Li 2009 [75] Same as Derby 1993a (22) Same as Derby 1993a Same as Derby 1993a Same as Derby 1993a 
Shin 2013 [76] None (used laboratory test criteria AP ≥2 x ULN and Identified cases as people over the Step not performed (case status 
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
only) R≤2[76] age of 18 without underlying non-
drug causes of liver injury who had 
clinically significant elevations in 
liver chemistry tests (ALT, AST, 
and alkaline phosphatase (AP)) that 
were temporally associated with 
drug use. Liver chemistry 
elevations were required to meet 
laboratory threshold criteria within 
clearly defined (drug-specific) high-
risk period s. Exclusions were 
people with (i) an ICD-9 diagnosis 
code for liver disease or other co-
morbidity associated with liver 
chemistry elevations starting from 
the year prior to the index date until 
the liver injury date (or until the end 
of the drug exposure if liver injury 
was not identified); (ii) ALT or 
aspartate aminotransferase (AST) 
elevations above normal levels 
anytime during the year prior to the 
index date; or (iii) concomitant use 
of medications, besides the 14 
selected drugs, that were 
associated with hepatotoxicity. 
finalised in step 2 using database 
records only) 
Cheetham 
2014 [77] 
None (used laboratory test criteria 
only) 
AP ≥2 x ULN and R≤2 Identified cases (probable or 
possible) based solely on screening 
for elevated liver enzyme levels 
temporally associated with drug 
Step not performed (case status 
finalised in step 2 using database 
records only) 
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First author 
and year of 
publication 
Step 1: Definition of diagnostic criteria Step 2: Identification of database 
records of potential cases (see 
note1) 
Step 3: Finalisation of case status 
based on information external to the 
database 
 Database diagnostic codes  Laboratory test criteria   
initiation. Then applied 7 criterion 
based on the RUCAM method [45] 
to determine case status. Excluded 
patients with a diagnosis of liver 
disease or co-morbidity that could 
cause liver enzyme elevations in 
the 12 months prior to the index 
date or patients with concomitant 
medications [other than the 14 
study drugs] potentially associated 
with liver injury. 
1Note for Step 2: A common step for all studies was to use the list of DB diagnostic codes from step 1 to retrieve computer records of potential cases (i.e. individuals for further analysis in case identification 
process). The Step 2 column contains methods that were applied in addition to this common method.  
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2.3.4 Step 2: Identifying database records of potential cases 
For each of the studies, a single database of stored electronic health records was 
used for the retrieval of records, application of exclusions and initial review of 
disease information in order to identify potential cases. Two of these studies then 
finalised case status using information within the database only [76, 77].  An 
overview of the differing approaches adopted in (1) the use of diagnostic codes 
prior to start of study follow-up and (2) the use of diagnostic codes/full database 
electronic health record from the beginning of study follow-up can be found in 
Table 2-5 (Step 2 column), and is discussed in the following section. 
2.3.4.1 Exclusions of electronic records prior to start of follow-up 
The use of diagnostic codes within electronic health record databases allows 
individuals with a history of specific diseases to be excluded from a study 
population prior to the start of follow-up using quick automated searches. 
Application of exclusions prior to start of follow-up allows individuals who may have 
conditions other than the one under study to be removed, therefore reducing 
misclassification of outcomes. In studies looking at (for example) drug-induced 
cholestatic liver injury, this could therefore include other conditions that are likely to 
cause or be mistaken for cholestatic liver injury (such as alcoholism or some 
cancers). 
Only seven of the sixteen studies describe using the database diagnostic codes for 
the application of exclusions from the total study population prior to start of follow-
up [70-74, 76, 77]  (see Table 2-5 and Table 2-6). Although those that do not apply 
such exclusions do subsequently apply exclusions based upon information in the 
full computer record and/or medical notes obtained from the general practitioner, 
this means that exclusions are applied only to a subset of the study population 
(those that have been selected as possibly having the outcome based upon 
diagnostic codes, as described in section 2.3.4.2). This represents a particular 
problem for the two case control studies where this occurs [66, 68], because it 
could have introduced a selection bias, where the controls are being selected from 
a group that is not representative of the population from which the cases were 
selected, as the same exclusions have not been applied.  
An additional point of note that varied between studies was whether an age-range 
criteria was applied when selecting patients for inclusion in the study. Only seven 
of the sixteen specified an age-range inclusion criteria (Table 2-6), with age ranges 
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of 10 – 79 [70], 20 – 74 [71], 20 – 79 [72, 73], 5 – 75 [74] and over 18 [76, 77] 
(Table 2-5, Step 2 column).  
2.3.4.2 Use of computer records from start of follow-up 
For the two studies that relied only on liver test results to define case status [76, 
77], only information within the database was used to assign case status (the liver 
test result values). One of the methods in these studies then applies detailed steps 
based on the RUCAM methodology  [45] focusing on assigning causality to a 
specific drug cause.  
For all of the remaining studies,  the single source of stored electronic health 
records was queried using the broad disease codelist described in section 2.3.3.1 
to obtain the full anonymised electronic health record of each patient (identifiable 
by a unique patient identifier). The study performed by García Rodríguez et al 
using the Saskatchewan Health Plan database [64] utilised electronic records 
created at hospitals (from the hospital plan services database component of this 
database), while all the other (GPRD based) studies utilised electronic health 
records routinely entered by personnel at general practices in the UK. The studies 
describe various different ways of utilising the electronic records in assisting with 
case definition (Table 2-5, Step 2 column). 
In the studies performed by García Rodríguez et al in 1992 [64] and 1999 [72] the 
authors  used the broad list of diagnostic codes only to obtain full computer 
records for individuals that represented possible cases of acute liver injury. Limited 
information is provided on whether information in the computer record was used to 
remove those unlikely to be cases (either of cholestatic or of any liver injury) prior 
to obtaining notes from hospital/general practice.  
Studies performed by Derby et al [55, 65, 66], Jick et al [67], Jick and Derby [69], 
García Rodríguez et al in 1994 [68], Russman et al [53] and Li et al [75] describe 
some further use of the computer record. In the first two Derby et al studies in 
1993 [55, 65] and the study by Li et al [75], for example, the authors reviewed the 
electronic health record medical information to “identify those with a first-time 
diagnosis of a liver disorder that might represent intrahepatic cholestatic jaundice”, 
although further information on what criteria were applied in doing this are not 
provided. Russman et al describe a similar approach [53]. When performing a 
cohort study using stored electronic health records in which groups with (e.g.) 
differing drug exposures are being compared, ensuring that reviewers are blinded 
to exposure status during record review can minimise observer bias (where a 
reviewer may be influenced by knowledge of exposure to assign somebody to a 
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particular outcome). This is particularly the case if the information being reviewed 
is of a subjective nature. In the first study performed by Derby et al [55] and the 
study performed by Russman et al [53] two drug exposures were compared 
(flucloxacillin, suspected of causing cholestatic liver injury and oxytetracycline, a 
comparator drug not known to cause cholestatic liver injury) and blinding of 
reviewers to exposure status during the review of the electronic records was not 
specified (Table 2-6). 
The most recent of the studies performed by Derby et al [66] describes using “the 
available computer data to exclude subjects who had an illness that was likely to 
account for the liver disorder (e.g. cancer of the pancreas, pre-existing chronic liver 
disease)”; the studies performed by García Rodríguez et al in 1994 [68] and Jick 
and Derby [69] describe similar approaches. Of these three studies, only García 
Rodríguez et al 1994) [68]  specify that reviewers were blinded to medication 
exposure status during review of electronic health records. The study by Jick and 
Derby [69] was one of the four studies who excluded patients not referred to a 
specialist or hospitalized (see section 2.3.3.3), and this criteria was applied based 
upon review of the electronic computer record.   
A final group of studies [70, 71, 73, 74] include the most detail on how the 
electronic health records were used to assist with outcome identification. In these 
studies, there is clear definition that exclusion criteria were applied based on 
information in the database prior to study start date and during the study period, 
and detail is provided on how computer records allowed identification of potential 
cases, for which additional information was required from other sources. García 
Rodríguez et al (1996) [70] firstly used the computer search to identify all study 
members who had a code of liver disorder recorded for the first time within 45 days 
after a study drug prescription was written, they then applied exclusions, which 
included use of free-text comments (for identifying alcoholics). The complete 
computerized patient profile without information on drug use was then manually 
reviewed to categorize the individual into either a non-case or an undetermined 
case (for which further information from GPs was needed to assign case status). 
Liver function test (LFT) results were used at this stage (normal LFT result = non-
case). García Rodríguez et al (1997) [71], Huerta et al [73] and de Abajo et al [74]  
described very similar approaches to this, although without the use of GPRD 
freetext. Blinding of drug exposure status in the computer record was emphasised 
in each of these studies (Table 2-6).  
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2.3.5 Step 3: Finalisation of case status based on information 
external to the database 
2.3.5.1 Request for additional information from general practices 
The percentage of notes received that provide adequate information to allow a final 
outcome status to be assigned is useful information in a case identification 
approach which relies heavily upon feedback or additional information from GPs 
(or other health centres) to assign case status. If notes or additional information 
sufficient to designate case status were received for a low percentage of the total 
number of individuals for which notes were requested, this would result in a large 
proportion of individuals for whom the data for classifying as a case is either not 
available or is being obtained from a single source (the database alone), rather 
than from two sources (the database and the external source). This could increase 
the likelihood that the individual’s outcome status is being incorrectly assigned and 
introduce bias in the subsequent epidemiological study.  The direction and 
magnitude of the bias could be small and more likely towards the null if it occurs 
completely independent of exposure status or, alternatively, larger and in either 
direction if it does not. This is likely to be dependent upon the drug exposure being 
studied -  if the drug caused or was indicated for a condition with high mortality and 
extended morbidity, for example, the chances of receiving the notes could be 
reduced due to death of the patient or the requirement for photocopying a large set 
of notes at the GP surgery [79]. If exposure was related to the likelihood of notes 
being received in this way, for case control studies a selection bias could be 
introduced (where unexposed individuals could be more likely to be included in the 
study as cases due to availability of notes) and in cohort studies a differential 
information bias could occur, where those exposed to the drug of interest would be 
more likely to have their disease status wrongly assigned, leading to under-
ascertainment of exposed cases. 
Of the fourteen studies that used data external to the database, all of the studies 
except the Canadian study performed in the Saskatchewan Health Plan database 
requested and received information by post from GP surgeries in the UK. In the 
Canadian study (performed by García Rodríguez et al [64]), no response rate is 
included, but the method of collection of notes involved nurses travelling to the 
hospital themselves, which may have meant that the response rate was effectively 
100%. For the other studies, two (both updates to a previous study sent as letters 
to the editor of a journal) do not publish a response rate [67, 75]. Of the remaining 
eleven, six studies obtained response rates over 90% [55, 65, 68, 69, 71-73], three 
others obtained response rates over 80% [66, 69, 70] while there were two with 
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response rates lower than 80% [53, 74]. The study by Russman et al [53] obtained 
the lowest response rate (64%). Of those writing to GPs, all requested existing 
notes apart from Huerta et al [73], who sent out a questionnaire for completion.  
Only four of the fourteen studies that used external data included some discussion, 
comment or analysis related to the % of missing or/inadequate notes (Table 2-6). 
Derby et al 1993c [66] and Russman et al [53] both stated that for those individuals 
for whom notes were not received, they used information available in the computer 
record to assign a status (with Derby et al providing crude risk figures both with 
and without the inclusion of these individuals). García Rodríguez et al (1994 and 
1996) assumed that those not-received would be likely to have the same risk of 
outcome as those received, but do not provide any further discussion as to 
whether the non-receipt could be related to exposure or outcome, as discussed 
above.  
2.3.5.2 Review of medical notes to assign final outcome status  
All studies that used data external to the database effectively relied on review of 
the notes to confirm the status of potential cases identified from information in the 
computer record. In contrast to database diagnostic codes, the information in 
medical notes is not categorical, meaning that clear identification of which aspects 
of the notes were used to facilitate decision-making can be helpful, as can a clear 
definition of who performed the review and of any exclusion criteria that were 
applied. Blinding of the reviewers to the exposure status of the individuals can 
decrease the likelihood of bias, as described previously (section 2.3.4.2). Including 
a check of the validity of the method used can provide confidence in the method, 
such as having somebody perform a new review of a set of notes that include a 
selection of those designated as cases and non-cases by the method used in the 
study, and comparing the results. Finally, the use of multiple case status levels 
such as (e.g.) possible or probable, can increase the transparency and 
interpretability of the results obtained in the study (and the impact on risks or rates 
of including/excluding possible cases can be assessed). Table 2-5 contains a 
description of how the medical notes were utilised by each study (step 3 column), 
while Table 2-6 describes whether reviewers and blinding were clearly described, 
whether validation of individuals not designated as potential cases was performed 
and whether multiple case-status levels were applied.   
Three of the studies provided minimal information on which of the authors 
reviewed the notes, whether blinding to exposure status was performed during the 
review and on any attempt to test validity [64, 66, 70]. García Rodríguez et al 
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(1992 [64]) reviewed the hospital notes together with the computer record, and 
applied exclusions considering both sets of records. The same author adopted a 
different approach in his study performed in 1996 [70], with the computer records 
having already been used to remove potential cases before review of the notes 
took place.  Despite not identifying reviewers clearly or specifying blinding, both 
studies provide clear descriptions of how the notes were used to define cases, 
stating that after application of exclusions, laboratory results were used to define 
outcome status (and the CIOMS international standard was clearly referenced). 
Although the 1993 study by Derby et al [66] lacked information on blinding, who 
performed review and validation of non-cases, the authors did include a 
probable/possible notation to indicate the availability/extensiveness of supporting 
documentation for assigning case status to an individual.  
A further eight studies provided additional detail on the notes review methodology 
applied [53, 55, 65, 67, 69, 72-75]. Derby et al (1993a [55]), Jick et al [67] and Li et 
al [75] specified that at least three of the authors reviewed the notes and one was 
blinded. They also described how disagreements between blinded and unblinded 
reviewers were resolved and provided a clear definition of what they were looking 
for (“painless jaundice with predominant elevations of bilirubin and alkaline 
phosphatase levels with no history of alcoholism or other cause of cholestasis 
identified clinically”).  A check of the validity of the method as described above was 
not performed, however.  Jick and Derby [69] also described blinded review of the 
notes, and highlighted that clinical, laboratory and the diagnosis made by the 
attending physician were all used in identifying cases. García Rodríguez et al 1999 
[72], Huerta et al [73], De Abajo et al [74] and Russman et al [53] all provided very 
clear definitions of what would be considered a case based on review of 
notes/questionnaires (for example García Rodríguez et al 1999 [72] described a 
case of acute liver injury as “a person presenting with symptoms suggestive of liver 
disorder (nausea, vomiting, abdominal pain and/or jaundice) referred to a specialist 
or admitted to hospital, and who was free of exclusion criteria” and then further 
assigned cholestatic status based upon laboratory test results). All four studies 
clearly identified who reviewed the notes, although only García Rodríguez et al 
1999 [72] described blinding to drug exposure status at this stage. None of the four 
studies attempted to validate the method. 
The two studies with the greatest level of detail on how the medical notes were 
used for case definition were two of the four case-control studies [68, 71]. García 
Rodríguez et al 1994 [68] applied additional exclusions (having applied exclusions 
already at the computer record stage) and gave a detailed description of what was 
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being considered a case and how the laboratory tests were used to help with the 
case definition at this stage. Blinding to drug exposure status was performed and 
the reviewers were clearly identified, and a random sample of non-cases was 
reviewed separately by a third party in an attempt to provide some indication of 
validity of the method. García Rodríguez et al 1997 [71]  were also very clear with 
the criteria being used on notes review to decide how a case is identified, and on 
reviewers/blinding, although did not describe any attempt at measuring validity.  
2.3.5.3 Note on appropriate application of exclusions according to study design 
For the four case-control studies included in the review, a subsequent step 
following identification of cases (those with the outcome) was to select controls. As 
discussed previously (section 2.3.4.1), selection bias can be minimised by applying 
the same exclusion criteria to controls as has been applied to cases. Of the four 
studies including a case control component [66, 68, 71, 74], only De Abajo et al 
[74] specify that they applied the same exclusion criteria to the controls as had 
been applied to the cases (Table 2-6), meaning the results obtained for the case 
control analyses of the other studies are potentially biased. In addition, of the four 
studies, only De Abajo et al [74] specify that potential cases designated as not 
having the outcome during the case identification process were “classified as non-
cases” (as opposed to excluded completely from the analysis). A final aspect of the 
case control studies that is of particular importance when considering database 
studies is that all of them describe detailed review of potential case records in 
order to identify final cases (and remove those considered non-cases due to other 
underlying conditions), but do not describe applying a similar review to the 
(potential) control population. This therefore creates a risk of bias due to the 
exposure distribution among controls being different to that in the source case 
population [80].  
For the cohort studies, where potential cases are discounted as cases during the 
review of their computer records/notes due to the presence of an exclusion criteria 
(such as a code for congestive heart failure) that has occurred after the start of 
study follow-up, the person time from the start of follow-up until the occurrence of 
the exclusion event should be included in the analysis [78], as this represents time 
when these people should be considered at risk of the event. Only four of the 
thirteen studies that included a cohort analysis described clearly that this person-
time was included in the analysis [70-73], with the remaining eleven either 
specifying only that these individuals were excluded, or not providing sufficient 
detail to understand if the pre-exclusion event person time had been included [53, 
55, 64-69, 75]. 
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Table 2-6: Summary of methodological characteristics for case identification and ratio of potential cases:final cases selected for each study  
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range inclusion 
criteria? 
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2. Provided list of 
diagnostic codes used 
to identify cases 
included in study? 
3 3 3 3 3 3 3 3 3 3 3 3 3 3 NA NA 
3. Liver test parameters 
described? 
3 3 3  3 3 3 3 3 3 3 3 3 3 3 3 
4. External diagnostic 
standards for liver tests 
referenced? 
3     3  3 3 3 3 3   3 3 
5. Time interval 
between diagnostic 
code and liver test 
described? 
              3  
6. Excluded individuals 
based on DB codes 
prior to start of study? 
       3 3 3 3 3   3 3 
47. Blinding to 
exposure status at 
electronic record 
review? 
3  NA1   3  3 3  3 3   2 2 
8. GP/hospital notes 
response rate (%) 
NP3 98 97 86 NP3 95 86 83 94 90 95 76 64 NP
3 
NA1 NA1 
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9. Analysis or comment 
on % of notes received?
   3  3 3 3     3  NA1 NA1 
10. Reviewers of notes 
clearly defined? 
 3 3  3 3 3  3 3 3 3 3 3 NA1 3 
11. Blinding to 
exposure status at 
notes review? 
 3 NA1  3 3 3  3 3    3 NA1 NA1 
12. Exclusions 
appropriate for study 
design?4 
 3 3  3  3 3  3 3 3 3 3   
13. Attempt to measure 
validity? 
     3          3 
14. Use of >1 case 
status level? 
 3 3 3            3 
Cases identified 
(potential cases:final 
cases, (%))5 
127:20 
(16%) 
 
143:1
3 
(10%) 
 
28:3 
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199:14 
(7%) 
 
166:1
7 
(10%) 
 
6 330:12 
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177:26 
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185:18 
(10%) 
 
73:9 
(12%) 
 
165:1
3 
(8%) 
 
1022:77 
(8%) 
 
36:30 
(83%) 
 
6 
 
NA1 NA1 
1NA: Garcia Rodriguez 1992 , Derby 1993b - not applicable as entire study population was exposed (there was no baseline exposure studied); Shin 2013, Cheetham 2014 – neither study relied on notes 
obtained from sources external to the database so no response rate or analysis. Shin 2013 did not perform any notes review, while Cheetham 2014 did review charts as part of validation (and reviewer was 
clearly identified). Blinding to exposure status not applicable to Cheetham 2014 because knowledge of the prescribed drug was part of the algorithm being assessed. Finally, as case identification did not 
involve identifying potential cases (but only final cases using liver test results), there was no potential case:final case ratio for either study. 
2: Blinding not specified, but may not have been necessary as case identification procedure may have been completely automated (i.e. no manual record review) 
3NP: No information provided on % of notes received or could not otherwise be calculated from results 
4Exclusion criteria appropriately for study design: Cohort study – where a time-to-event analysis was being applied, for individuals with one of the exclusion criteria, the person-time contributed prior to the 
exclusion criteria event for that individual was included in the analysis; Case control study – any exclusion criteria applied to individuals during the case identification process was also applied to the controls 
(including whether the same detailed review of records was applied to the potential control set if it was also applied to the potential case set).  
5Cases identified: Cases are the numbers of individuals identified at each stage in the format number found by code search:number confirmed by full computer/notes review (also shown as a %).  
6Jick 1994, Li 2009 cases: Provided no information on numbers of cases identified at each stage.
 68 
 
 
2.4 Discussion 
This systematic review has identified sixteen studies that were performed in databases 
of stored electronic health records in which cholestatic liver injury (or a synonym) was 
one of the outcomes of the study, and considered the, diagnostic criteria, data sources 
and methodology used in order to identify individuals with cholestatic liver injury.  
The overall method was similar in fourteen of the sixteen studies, involving 
identification of potential cases with (generally) a broad search using a set of database 
diagnostic codes, retrieval and review of the database computer record of these 
potential cases in order to narrow the search, and then retrieval and review of the 
actual medical notes (or completed questionnaires) from GP/hospitals for remaining 
individuals in order to allow a final decision on case status to be made. The two 
remaining studies (performed most recently) used only data within the database with a 
particular focus on liver test results. 
Two recent reviews of studies that have performed validation of General Practice 
Research Database diagnostic codes [81, 82] include some overlap of the 
considerations applied in this review (and retrieved four of the same studies [68, 72-
74]). However, in contrast to those reviews, this one focused specifically on cholestatic 
liver injury as an outcome, and was not restricted to the GPRD. A second important 
difference was that the GPRD validation reviews were investigating the range of 
methods used to validate the coded diagnoses in the database record against other 
data sources identified as the “gold standard” (such as GP notes). In contrast, this 
review has focused on how any of a number of data sources (e.g. diagnostic codes, 
computer record, GP notes) have been utilised in order to identify cases, and was not 
considering whether a particular source might be a “gold standard” that was validating 
any of the other sources.  
It is of note that one of the other reviews [82] compared the positive predictive value 
(PPV) for studies of a wide range of diseases/conditions, and the three with the lowest 
PPVs were those related to acute liver injury, also included in this review [72-74]. The 
relatively low PPVs obtained  are very likely a reflection of (1) the fact that the authors 
of these three studies have deliberately used broad diagnostic codes as detection of 
cholestatic liver injury (and acute liver injury) based on diagnostic code alone is very 
difficult (requiring additional verification, such as LFT test results and application of a 
number of exclusions, as discussed previously in this review) and (2) the fact that PPV 
varies with prevalence, each disease will have a different prevalence, and acute liver 
injury is typified by a low prevalence compared to other conditions such as, e.g. 
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diabetes (which has the highest PPV in the review). In fact, although these three 
studies use codelists with a very low PPV, this is not the most suitable measure for the 
quality of the overall methodology for identifying cases of cholestatic liver injury when 
using multiple data sources, because a powerful method would likely have a highly 
sensitive codelist search (and codelist PPV is of less importance). 
There were a number of strengths in the methodologies used for identifying cases of 
cholestatic liver injury that were consistently demonstrated across the studies in this 
review.  
In general, studies used a codelist that would be able to identify all cases of cholestatic 
liver injury (or other acute liver injury outcomes) but would also return individuals who 
were unlikely to have cholestatic liver injury (i.e. a sensitive non- specific search). At 
the early stage of case identification, this approach may be sensible for a condition 
such as cholestatic liver injury, where LFTs and consideration of other conditions 
causing symptoms similar to cholestatic liver injury are likely to be needed to designate 
a final case status [46].  There was uncertainty on the exact codes used for only one of 
the studies [53]. All the remaining studies provided codelists, which increases method 
transparency and reproducibility, and may be in contrast to the majority of studies that 
use diagnostic codes to identify cases [81]. In the study using the most restricted list of 
codes (Russman et al [53]), 83% of the potential cases were eventually classified as 
final cases based on notes review (over six times more than the study with the next 
highest % of potential cases classified as final cases) (Table 2-6). Using a more 
restricted set of codes would reduce the resource required to perform the study due to 
lower total potential cases retrieved, but could increase the risk of true cases being 
missed.  
The majority of studies describe review of/application of exclusions to both the full 
GPRD computer record and the information obtained from hospitals/GPs. This means 
that a total of at least three different sources were used to assist with case definition 
(database codes, full database computer record and medical notes or questionnaire) in 
these studies. Today, linkages between databases of electronic health records provide 
the potential for information contained in other databases to be used for assisting in 
case identification. Of those studies that did not just rely on liver test results, the most 
recent was performed in 2009 (and the earliest in 1992). The authors of these studies 
can be seen to have made good use of multiple available data sources in order to 
minimise misclassification.  
Other positive characteristics of the methods utilised across all the studies included the 
citation of external standards for laboratory tests indicating cholestatic liver injury. The 
majority of the studies either referenced the CIOMS standard [45] or provided a clear 
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description of the laboratory criteria considered, minimising the likelihood of 
measurement error and maximising reproducibility. In general, the studies clearly 
identified reviewers of the data, allowing the reader to assess whether the review 
process was carried out by a sufficient number of appropriately qualified people in 
order to minimise measurement error. Clear descriptions of the exclusion criteria that 
were being applied at each stage of the review (for example computer record versus 
medical notes) were also present for the majority of studies.  The majority of studies 
provided response rates for medical notes/questionnaires from GPs, providing an initial 
indication of how biased the results could be due to non-receipt of notes. 
In a number of other areas, this review found that there were less consistent 
approaches applied across the studies, and some ambiguities/weaknesses could be 
observed. 
Although the studies used multiple data sources (diagnostic codes, database computer 
records, information from GPs or hospital records), in each case there was only one 
database of electronic health records that was used. Thirteen of the sixteen studies 
were performed using primary care electronic health records stored in the UK GPRD 
(or its predecessor, VAMP), which contains a patient’s medical history (prescriptions 
and diagnoses) as recorded at the General Practice that the person has attended. 
Other databases of electronic health records exist in the UK, and the information in 
these databases could be used to assist with case identification. The Hospital Episode 
Statistics (HES) database, for example, contains information on every NHS hospital 
admission in England, with metadata on patient demographics, hospital administrative 
information and clinical information related to diagnoses and operations or procedures 
performed. There is likely to be additional useful information in the HES record that 
could assist with identification of cholestatic liver injury when performing a study within 
the GPRD. During the time-period that the studies performed within the UK GPRD that 
were included in this review were performed, linkage of the information held within 
GPRD to HES data was not possible, which explains why this additional source of data 
was not utilised. From 2011 linkages between the GPRD database and the HES 
database have been possible (linking via the unique patient id), and could be utilised in 
future studies requiring the identification of cases of cholestatic liver injury.  
There was likely to have been additional information that could have been used within 
the computer records for the studies reviewed. For example, the GPRD record contains 
a freetext component that is available for analysis, and only García Rodríguez et al 
(1996)  [70] specify searching the freetext of the computer record during the process of 
identification of those with cholestatic liver injury (specifically, for identifying alcoholics 
who should be excluded). Obtaining freetext is expensive, which may have prohibited 
 71 
 
use of this as a source of data within the computer record. In addition, none of the 
studies described assigning a hierarchy within the codelists (i.e. designating some 
codes as representing a stronger weight of evidence for the individual to be an actual 
case). Reviewers may well have done this implicitly (for example, considering 
somebody with a diagnosis of obstructive jaundice to be more likely to be a case than 
somebody with abnormal hepatic function). Including this level of detail could improve 
the reproducibility of the study. 
Although the majority of the studies specified criteria for laboratory test results for 
confirmation of cholestatic liver injury and exclusions were clearly defined, a clear 
case-definition for cholestatic liver injury that was used to select cases at the final stage 
of reviewing all the information gathered was lacking in many of the studies. If this 
omission is due to the lack of a clear protocol, there is a risk of information bias having 
caused spurious results (incorrect measurement of outcome due to lack of clear 
definitions in a protocol). The reproducibility of the study (or the ability to assess 
heterogeneity in reviews of the work) is also limited. 
There were a number of issues related to how exclusions were applied. The majority of 
the studies did not apply exclusions based on historical diagnostic codes, but applied 
them only to groups of individuals who had already been designated as potential cases 
due to the presence of specific diagnostic codes.  As discussed, this approach is 
problematic for the case-control studies where this occurred, because if the same 
exclusion criteria are not applied to controls after selection, then the controls are being 
selected from a population that is systematically different from the population from 
which the cases were selected. For the cohort studies, omitting this step is unlikely to 
have biased the results, providing that when the exclusions were applied to the 
“potential case” subset, reviewers were blinded to exposure status.  Blinding of 
reviewers to exposure status was not described in half the studies, however. This 
would create a risk of misclassification of outcome based on reviewer’s knowledge of 
exposure for all these studies, and the two studies particularly susceptible to bias were 
those in which there was a lack of both reviewer blinding and no application of 
exclusion criteria to the whole study population based on historical codes [64] [53].  
Exclusion criteria were inconsistently defined across studies, with no studies choosing 
to present a list of database diagnostic exclusion codes, as the majority did with their 
database diagnostic inclusion codes. A standardised approach with respect to 
provision of both inclusion and exclusion codes across studies utilising databases of 
stored electronic health records would be very helpful.  
A number of studies excluded individuals that were not referred to a specialist or a 
hospital. Although it is unlikely that patients with cholestatic liver injury would not be 
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referred to a specialist or to hospital, using this criteria in an “all or nothing” fashion 
does risk omission of some cases of cholestatic liver injury who may actually be true 
cases (possibly meaning only severe cases would be included in the study).  A 
preferable option might be to include this criteria as one of a number that would 
contribute to the weight of evidence for assigning the individual as one of a number of 
different case statuses. It should be noted, however, that a recent expert working group 
on drug-induced liver injury advised that including hospitalisation as a criteria for 
applying judgements of the severity of liver injury was not advisable, as whether or not 
people are hospitalised for a particular indication varies worldwide [46].   
Finally, only a minority of studies described applying exclusions appropriately to fit the 
study design (section 2.3.5.3 and Table 2-6). One key point to emphasise that could be 
a particular issue for case-control studies performed in large databases of stored 
electronic health data is that where a case-identification/verification process requires 
detailed case review, it may not be possible to apply the same review steps to the 
potential control pool. This is due to (1) comparable information not being available for 
review (e.g. free text related to underlying issues with the liver may be more likely to be 
populated for potential cases) and (2) the large number of controls in a case control 
study. This further increases the risk that the controls will not be representative of the 
source case population, introducing a bias that is dependent upon case-status  [80]. 
The potential for bias is difficult to predict as it will be related to the prevalence of 
exclusion events/conditions in the control population, and the degree to which they are 
associated with the medication being studied. Therefore, when estimating relative 
frequency in a case control study within an EHR database, a case definition based on a 
set of well-populated data elements may be advisable. If the aim of an analysis is to 
estimate an absolute rather than a relative effect (i.e. risk or rate rather than a ratio for 
liver injury), then detailed review of any and all additional case information can be 
performed to verify case status, rule out other causes of liver injury and allow accurate 
risk estimates. 
The majority of studies described a sequential approach to definition of cases, where a 
group of individuals are selected based on diagnostic codes, computer records for this 
group are then reviewed in order to exclude those with/without certain criteria and 
reduce the size of the group before finally medical notes are reviewed in order to apply 
further exclusions and identify those who are considered to be true cases of cholestatic 
liver injury. There may be a number of potential issue with this approach. 
Firstly, it may be removing possible cases from the study inappropriately. For example, 
if a patient is identified as not having cholestatic liver injury based upon criteria applied 
by the reviewers following review of the full computer record, additional information 
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would not be requested from the (e.g.) general practice. If the general practice notes 
contain additional information that was not present in the full database record that in 
fact provides strong evidence for cholestatic liver injury (such as a biopsy result), then 
this individual would have been classified as not having cholestatic liver injury because 
insufficient data was reviewed to classify him or her as such, and not because the true 
situation was that he or she did not have cholestatic liver injury. For an approach that 
relies on external information from GPs/hospitals, a less risky method could have been 
to request GP/hospital records for all of those obtained from the initial code search, and 
then consider the full computer record and the notes received from the GP 
concomitantly, considering the information from both data sources as being responsible 
for contributing to the weight of evidence, rather than removing individuals (possibly) 
based on lack of information in the computer record. In fact, two of the studies by 
García Rodríguez et al (1992 and 1999) [64, 72] do follow this method somewhat, as 
notes are requested for all individuals identified as having the codes of interest, and all 
the available information for the individual is considered in order to assign a case 
status.    
Secondly, the reliance on medical notes/completed questionnaires from GP/hospitals 
for case ascertainment introduces possible limitations in the form of financial and time 
costs. At present, the approximate cost of obtaining a set of notes for a patient is £70, 
which could well effect the methodology applied. If there is a tight budget constraint for 
the study, then a researcher may be less likely to request a large number of sets of 
notes (e.g. for those individuals returned by an initial codelist search) but could instead 
use the full computer record to exclude some potential cases before requesting notes, 
resulting in possible cases being missed due to lack of data as described above.  For 
epidemiological studies performed for publishing in peer-reviewed journals, the 
additional time required to obtain records from GPs or hospitals is unlikely to represent 
a serious problem. If the method for the identification of cholestatic liver injury is part of 
an algorithm that is to be used for the “real-time” identification of cases of (e.g. drug 
induced) cholestatic liver injury during upload of information into databases of stored 
electronic health records, however, then it would not be possible to rely on external 
records in the way that all studies in this review have done.  
Thirdly, relying heavily on GP notes to ascertain case status means that there is always 
a risk of a low % response, which (as discussed in section 2.3.5) could potentially be 
associated with exposure and therefore introduce a selection bias. Although measures 
could be taken to minimise or account for this (such as paying practices more for larger 
patient files or checking the prescription frequency for the drug of interest between 
participating and non-participating practices), the risk remains, effectively negating 
 74 
 
some of the benefits of using stored electronic information in the first place. It is also of 
note that some GP practices never provide notes, as they have not agreed to take part 
in this aspect of GPRD research, which could result in a general under-ascertainment 
of cases. It is possible that participation could be associated with drug exposure, as 
practices who participate in provision of notes for research purposes may (for example) 
have a differing level of interest in evidence-based medicine than those who do not 
provide notes, which could also mean that prescribing practices differ. 
Finally, it is also possible that clinicians asked for information may simply refer to the 
same electronic record already accessed by the researchers. Of note is that one of the 
studies utilising only the electronic record obtained a similar risk for any (i.e. not just 
cholestatic) amoxicillin-clavulanate induced liver injury (33.8 per 100 000 people, 95% 
CI 19.2 – 48.4) [76] as one of the other studies that relied on external note review (22.5 
per 100 000 people 95% CI 13.9 – 34.4) [70] (frequency calculated from data 
presented in this study i.e. 21 cases of any type of liver injury in 93433 exposed 
people). In future studies, it would be of interest to assess the need for external note 
review.  
The two studies that did not utilise data external to the database relied only on liver test 
results recorded within the database. Although this handles many of the problems 
detailed above associated with using external data, other challenges are created. 
Firstly, not all databases have liver function tests recorded, so this may limit how widely 
such a method could be applied across different databases. An additional issue relates 
to whether or not this approach will always be identifying clinically important liver injury 
– in one of the studies that used liver test results only, 59% of test results reaching the 
threshold for DILI did not have corresponding liver injury-type codes [76]. In addition to 
highlighting a challenge with this method, this interesting finding also raises questions 
about the current method for classification of DILI based on liver function test results.  
Eight of the sixteen studies chose to illustrate the suitability of the database in which 
they are performing their study (GPRD in all cases) by citing three previous studies that 
have been performed relating to the validity of the database [83-85], which have shown 
the positive predictive value (PPV) of a GPRD coded diagnoses to be in the region of 
90%. As highlighted in a recent review of validation studies within the GPRD [81] and 
discussed earlier in this section, presenting this figure as a way of supporting the 
validity of a subsequent study is ambiguous as PPV is only one measure of validity 
(indicating the likelihood that a person with a particular diagnostic code actually has the 
disease in question based on the “gold standard” of medical notes obtained from GPs). 
PPV tells the reader nothing about the sensitivity (the % of true cases that the method 
will identify as cases), specificity (the % of true non-cases that the method will identify 
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correctly as non-cases) or negative predictive value (NPV, the likelihood that a person 
without a particular diagnostic code does not actually have the disease in question). 
PPV also varies with disease prevalence, which is likely to differ based upon time of 
the original validation studies (due to actual difference in disease prevalence and 
knowledge/experience with the disease of GPs at that time, although whether 
cholestatic liver injury prevalence has actually changed over time is unclear, and 
further work could be performed in relation to this).  In all of these studies, diagnostic 
codes, information in the computer records and the medical notes were being used as 
a method of identifying cases. Therefore, the PPV of diagnostic codes is of limited use 
in assessing the validity of these methods. Preferable would be to choose a completely 
new “standard” against which to validate the method, sampling those designated as 
cases but also non cases, so that all of the measures of validity specified above can be 
assessed, as described elsewhere [81]. Only one of the studies attempted to measure 
validity in this way, by selecting one reviewer to review all the information on the cases 
and a sample of potential cases designated as non-cases by the complete method [68]. 
Where methods for outcome identification are using what is acknowledged elsewhere 
as the “gold standard” (notes from GPs) as part of the outcome identification method, 
using one or a number of other data sources that could allow measures of validity to be 
assessed could be considered. 
Although the use of standards and clear definition of criteria can minimise differing 
results across studies that are due to differing opinions of those reviewing data, in 
studies where outcome information collected for a purpose other than the study in 
question is being reviewed, there will always be an element of the decision on outcome 
that is subjective. One way of handling this variability is to use levels of case 
designation, where two (or more) categories of case definition are created, indicating 
(for example) definite and probable case definition status, with the reasoning for the 
difference in case status clearly identified. The analysis can then be repeated with 
different scenarios in which, for example, the probable cases are included or excluded. 
If the reasoning for the difference in case status is clearly defined, then this allows an 
understanding of some of the clinical uncertainty to be assessed. The impact of 
decisions on case definition to be clearly assessed by those reading the study and can 
improve transparency and standardisation across studies. Of the studies assessed in 
this review, only the three studies by Derby et al ([55, 65, 66]) included levels of case-
definition, which included consideration of whether the outcome was drug-induced or 
not. 
A final point relates to reusability of the method used for case identification. All of the 
studies relied on a review team to assess information held within a variety of sources in 
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order to assign cholestatic liver injury case status. If another research group wanted to 
perform a similar study at a later date, their ability to apply the same criteria would be 
maximised by many of the steps considered in this review, but because the review of 
information relied ultimately on review teams specific to the original study, application 
of the same criteria to outcome definition is not guaranteed. Development of a data-
driven algorithm, that uses specific characteristics of the database record to assign an 
individual as having cholestatic liver injury (or to varying levels of evidence for 
cholestatic liver injury), as was done in a recent study looking at Rheumatoid Arthritis 
within the GPRD [79], could allow standardised case identification methods to be 
reused between groups. Database owners could also facilitate collaboration by storing 
and providing such algorithm program files for reuse. 
2.4.1  Limitations of review 
In a systematic review of the literature such as this one, there is always the possibility 
that references have been missed. However, the search was performed on multiple 
databases, and a number of other sources were searched as were selected reference 
lists in order to minimise the chances of missing references in this area. The search 
criteria for the database search were deliberately designed to be sensitive, with 
specificity increased by manual review, in order not to miss any articles. In addition, 
setting up a weekly automatic update of the database search allowed the search to be 
as up-to-date as possible during this project. Publication bias should be considered 
when performing a systematic review. However as this review was focusing on 
methodologies for identifying cholestatic liver injury as an outcome and not the results 
of the studies, the impact on the range of methods found is likely to be minimal. Of note 
is that the database search did not include any language limitations (although only 
English-language papers were found). A final limitation that relates to the analysis of 
methodologies is that the analysis relies on what was described in a scientific paper, 
and may not reflect actually what was done. Where possible, authors were contacted in 
order to clarify points of uncertainty, although it remains that issues were picked up as 
(e.g.) being omitted that were in fact performed but not explained clearly (for example, 
blinding at one stage of review but not another). 
2.4.2 Conclusions 
In conclusion, although there was not a single study that might be used as a model for 
future studies of cholestatic liver injury in databases of stored electronic health records, 
across all of the studies there were approaches that should certainly be applied, in 
terms of use of multiple data sources, use of database codelists for identifying potential 
cases/exclusions, external standards for defining cholestatic liver injury, clear definition 
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of reviewers, blinding of reviewers, measurement of validity, use of levels of evidence 
for cases (probable versus possible versus definite) and publication of response rates 
related to use of external sources.  
Important areas for further work include investigating (1) the use of new linkages 
between databases to improve identification (such as links between primary and 
secondary care databases) (2) assessing the benefit provided by obtaining notes from 
health centres to verify case status (3) development of methods that could facilitate 
“real-time” identification of cases and (4) development of reusable methods that could 
allow a departure from binary case-designation based on often opaque clinical 
reasoning.   
One novel approach that could be applied to address some of these issues while 
maintaining the rigour of the studies assessed in this review could be to use a 
modification of the data-driven algorithm approach used recently in other disease areas 
[79]. The modified approach could improve upon the range of data sources used by the 
studies in this review by utilising linkages that now exist between multiple data 
repositories (such as the UK GPRD and HES), and develop the methodology used by 
Thomas et al [79] to create an algorithm that could be used entirely within a single 
database, enabling real-time analysis of data as it is uploaded to a repository 
(facilitating screening of patients for recruitment in e.g. studies looking at the molecular 
genetics of cholestatic liver injury as a drug reaction).  
One way of approaching this could be to firstly develop a “multisource” algorithm that 
uses multiple data sources (including multiple databases) to assign a cholestatic liver 
injury case status to individuals. The case definitions (e.g. possible, probable and 
definite) from this (multisource) algorithm could then be considered as the outcome, 
information within the database record could be considered as exposures, and logistic 
regression could be used to assess the characteristics of the database record that are 
associated with a case of cholestatic liver injury as defined by the multisource 
algorithm. If the log Odds Ratios (OR) for exposures in the final model were then used 
to obtain a cholestatic-liver injury diagnosis score for each patient classified (by the 
cholestatic liver injury multisource algorithm) as having cholestatic liver injury by 
assigning the value of the log OR for each of the exposures present in their GPRD 
record and then summing these values to produce an overall score for the individual, 
one or more score values could be chosen as case “cut-offs” for defining case status 
(with the specific score used dependent upon the setting). This would allow real-time 
identification of cases being uploaded to the database (for example, in relation to a 
particular drug exposure such as flucloxacillin), and would be reusable in other studies. 
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Having said this, one should be careful in creating methods that are leaning too far 
towards reliance on purely algorithmic methods, compared to the input of experienced 
physicians who can pick up nuances of diagnoses from hospital notes or freetext 
review that could not be picked up by pre-programmed pattern recognition. This 
becomes particularly important when estimating absolute effects from population-level 
data.  
A final point should be made in relation to the sensitivity/specificity of a real-time 
algorithmic method. This could depend on the specific application that the algorithm is 
being used for. For example, if it were to be used for obtaining individuals that are 
definitely cases of cholestatic liver injury, for example for further genetic analysis in 
studying the genetics of drug-induced cholestatic liver injury, then a highly specific non-
sensitive method could be appropriate (e.g. only retrieving definite cases). If the 
algorithm were not specific enough in this case, many individuals could be ascertained 
incorrectly as having the cholestatic liver injury phenotype, which would make 
identifying the genotype very difficult. The balance between specificity and sensitivity in 
this situation is likely to depend on the associated resource available for review of 
further information to assign case status. 
If the algorithm was to be used for identifying cases related to a specific drug for which 
there were emerging case reports that it was causing cholestatic liver injury, it is likely 
to be more suitable to use the algorithm with a higher sensitivity but lower specificity, 
enabling probable as well as definite cases to be obtained for further review with 
consideration of the drug of interest. Using an algorithm that was too specific in this 
case, may result in people who have suffered cholestatic liver injury due to this drug 
being missed, which could mean the reported adverse effect of the drug in relation to 
cholestatic liver injury was lower than the actual effect. 
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2.5 Summary 
• A systematic review was performed focusing on methods of identifying 
cholestatic liver injury as an outcome in studies performed within databases of 
stored electronic health records. 
 
• 16 studies were identified, 13 of which were performed within the GPRD (or its 
predecessor, VAMP). 
 
• Only one study did not provide a clear description of the diagnostic codes and 
laboratory test cut-off used, however a completely reproducible case-definition 
was lacking in the majority of studies  
 
• Strengths of the studies included the use of multiple data sources in order to 
designate case status, clear definition of database diagnostic codes used, the 
use of external standards for defining cholestatic liver injury, clear identification 
of reviewers, and publication of response rates for information requested 
external to the database. 
 
• Areas identified in this review that would be desirable in a case identification 
algorithm and will be focused on during algorithm development within this 
project include: the provision of clear descriptions related to what is considered 
a case, ensuring that reviewers are blinded to exposure status, a reduction in 
reliance on non-database sources (such as external notes from GP surgeries), 
provision of validity measurements for the methods used, the use of more than 
one database source in a single study, careful consideration of how to apply 
exclusions in relation to study design,  the use of multiple levels of evidence for 
case status and the creation of methods that can be reused by other research 
groups.  
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3 Methods 
3.1 Introduction 
In this chapter, the data sources used in this study are described (section 3.2), followed 
by the methods used for the development of the algorithms for detection of cholestatic 
liver injury (section 3.3) before finally the methods of two epidemiological studies using 
the CPRD cholestatic liver injury algorithm (section 3.4) are provided.  
3.2 Data sources 
3.2.1 The Clinical Practice Research Datalink 
The main data source utilised was the primary care database of the UK Clinical 
Practice Research Datalink (CPRD Gold, hereafter referred to as CPRD), which 
contains anonymised data on patients from over 625 NHS primary care practices from 
across the UK (approximately 12 million total patients). Information is recorded by 
general practitioners or other health centre staff as part of routine clinical care, and 
data quality checks at the database headquarters ensure that each practice 
contributing data maintains “up-to-standard” data [81]. In addition to the routinely 
collected data from primary care consultations, information from some secondary 
sources that has been provided to primary care clinicians (such as major diagnoses 
made in hospital) may also be recorded.  The database has been collecting data since 
1987, and has recently been shown to be broadly representative of the UK population 
[86]. Epidemiological research has been performed using the database for over 20 
years (generating over 1000 publications) [87], and the validity of many diagnoses 
recorded in the database has been shown to be high [81].   
Patient records for study cohorts are extracted from the database based upon the 
presence of standardised diagnostic codes (Read codes) or, if defining a cohort by 
drug exposure, British National Formulary (BNF) drug product or substance codes. 
Searchable dictionaries of all diagnostic and drug prescription terms used in the 
database are provided, with each record including a specific code and the 
corresponding descriptive term. Based on the diagnostic or prescription codes selected 
from the dictionaries, electronic health records can be obtained for all patients who 
have any of the codes of interest during a period of interest. Data are extracted from 
the database as a number of separate data files, each containing a different type of 
data, with the information relevant to any particular patient identified via a unique 
patient identifier (patient id). Table 3-1 provides details of the CPRD data files used in 
this thesis.  
 81 
 
Table 3-1: Description of CPRD extracted data files 
Data file Data organisation Data description 
Index list One  record per patient Master list for cohort, contains unique patient id1 
and date of clinical diagnosis or drug 
prescription of interest (the “index date”) 
Patient One  record per patient Contains demographic data such as gender, 
date of birth, death date (if applicable) 
Clinical Multiple records per patient All clinical diagnoses for the patient, including 
diagnostic codes, terms and dates 
Therapy Multiple records per patient All drug prescriptions for the patient, including 
therapy code, term, dates, strength and 
formulation 
Test Multiple records per patient All test records for the patient, including test 
type, date and result 
Referral Multiple records per patient All referral records for the patient, including 
referral date and diagnosis associated with 
referral 
Additional Multiple records per patient Contains additional information that can be used 
to derive smoking, BMI and alcohol status 
1Unique patient id is present in all data files and allows multiple clinical, therapy, test, referral and additional records to 
be linked to a single patient 
3.2.2 The Hospital Episodes Statistics Database 
A secondary data source used was the UK Hospital Episodes Statistics Database 
(HES). A subset of CPRD-contributing practices (those in England only) have had their 
patient records linked to HES, which is an administrative data source that contains 
patient demographics, clinical diagnoses and a record of procedures performed while 
in hospital for every NHS hospital admission in England. Linked CPRD-HES records 
exist from April 1997 onwards. The coding system used for diagnoses is a slight 
modification of the (WHO) ICD-10 standard, while procedures are identified by 
standard codes for hospital procedures (OPCS4 codes). Lists of all of the HES 
diagnostic and procedural terms (and codes) are provided as searchable text dictionary 
files. 
HES data is organised into hospitalisations (a single stay in hospital) which can be 
made up of one or more episodes (the period of care under a single consultant). Within 
each episode, a patient can have one or multiple diagnoses and one or more 
procedures. Data from the HES database is extracted as separate files for patients, 
hospitalisations, episodes, clinical diagnoses and procedures. By linking a CPRD 
cohort containing patients from practices in England to their HES records (via the 
unique patient id) and searching on specific dates, it is possible to obtain primary care 
and secondary care information for a patient in temporal relation to an index diagnosis 
or prescription of interest.    
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3.2.3 The UK Office of National Statistics (ONS) mortality data 
The final data source used was the Office of National Statistics (ONS) mortality 
database, which is linked to CPRD (and HES) via the unique patient id. A list of the 
causes of death (as coded on the individual’s death certificate) for people who have 
died can be obtained from the database by providing CPRD headquarters with a list of 
patient ids. Cause of death is coded according to the WHO ICD-10 standard.  
3.3 Cholestatic liver injury algorithm development 
As detailed in section 1.5.3 Objectives, two algorithms were developed for the 
identification of cholestatic liver injury; one “multisource” algorithm using CPRD, HES 
and ONS data and a second CPRD algorithm using data only from within the CPRD 
database. Development of the CPRD algorithm was facilitated by using the multisource 
algorithm as a validation tool. The multisource algorithm was designed to be a suitable 
validation tool because it used both primary and secondary health care records. It was 
considered that the involvement of liver specialists working within specialist liver clinics 
in secondary care  would likely mean that a diagnosis that included information from 
secondary care would be more accurate and/or reliable than one made using primary 
care data alone. The results of this algorithm development work are presented in 
Chapter 4. 
3.3.1 The multisource cholestatic liver injury algorithm 
Figure 3.1 provides an overview of steps performed by the multisource cholestatic liver 
injury algorithm in order to assign a cholestatic liver injury case status, which are then 
described in more detail in the following sections. 
 Figure 3.2 provides an overview in a diagrammatic form of all the data sources and 
time periods searched in obtaining data for  a multisource algorithm cholestatic liver 
injury health record. 
 83 
 
Figure 3.1: Overview of steps performed by the multisource cholestatic liver injury 
algorithm 
3. All CPRD liver test results for alkaline phosphatase (ALP), alanine 
aminotransferase (ALT) and Bilirubin (Bil) obtained for each potential case
4. Any missing upper limit of normal (ULNs) for liver enzymes assigned 
(based on Mosby’s manual of Diagnostic & Lab Tests, 4th Edition)
Liver test result day 
allows calculation of 
R*?
5. Data management 
performed in order to obtain 
liver test data suitable for 
calculating R (see C4 Table 4)
6. Test days further than 90 days away from index date removed, and 
calculation performed to obtain R
7. Liver test day closest to index date kept (or closest indicating any DILI), 
leaving record with index diagnosis and liver test result
Day marked as 
characteristic of
cholestatic injury 
(pure)
R≤2? 2<R<5? R≥5?
Day marked as 
characteristic of
cholestatic injury 
(mixed)
Day marked as
characteristic of 
hepato‐
‐cellular injury
1. Potential cases identified from CPRD based upon the first occurrence (= 
index date) of the liver‐related diagnoses listed in C3 Appendix Table 1
11. Multisource algorithm cholestatic liver injury status assigned to record 
based on: CPRD index diagnosis, CPRD liver test result, HES liver‐related 
diagnosis, HES liver‐related procedure, ONS mortality data
Yes
Yes Yes Yes
8. Record updated with HES clinical diagnosis data
9. Record updated with HES procedure data  (e.g. biopsy, scan)
Any HES liver‐related 
diagnoses (C4 Appendix Table 
2) within 1 year of CPRD index 
date
Any HES liver‐related 
procedures (C4 Appendix Table 
3) from same hospitalisation as 
liver‐related diagnosis
10. Record updated with ONS mortality data (cause of death)
Any ONS mortality records 
after index date with cause of 
death as “Toxic liver disease 
with cholestasis”
No
Individual from a 
HES‐linked practice?
Yes
2. Individual removedNo
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3.3.1.1 Identification of CPRD clinical diagnostic codes indicating possible cholestatic 
liver injury 
A list of clinical diagnostic terms that could represent cholestatic liver injury was 
developed following review of the studies included in Chapter 2 of this thesis. These 
search terms (and additional terms used to increase the specificity of the search) are 
detailed in Table 3-2, and were used to search the CPRD medical diagnosis 
dictionaries (clinical, test and referral files).  
Table 3-2: Search terms used for the identification of CPRD clinical diagnostic terms that 
could represent possible cholestatic liver injury 
Inclusion terms 
Search based on the word “liver” 
*liver* AND (*biopsy* OR *necrosis* OR *disease* OR * enlarged* OR *disorder*)  
Search based on the word “hepatic” 
*hepatic* AND (*failure* OR *coma* OR encephalopathy*) 
Other search terms 
*cholesta*, *jaundice*, *icterus*, *cholangitis*, *other gall bladder disorders*, *cholaemia*, 
*yellow atrophy*, *hepatitis* 
Terms excluded during search to increase specificity 
*fetal*, *hepatitis a*, *hepatitis b*, *hepatitis c*, *hepatitis e*, *hepatitis g*, *delive*, *pregn*, 
*neonat*, *perinatal*, *viral*, *virus*, *congenital*, *autoimmune* 
Note 1: * represents a wildcard, which means that any text can be present in this position 
Note 2: the search was set to look for words after the word “AND” on either side of the main search term (e.g. both “liver 
biopsy” and “biopsy liver” would be searched for) 
 
Terms identified by the search and considered relevant were included in a final code 
list, and categorised into three evidence groups as follows (Group 1=strongest 
evidence for cholestatic liver injury, Group 3=weakest evidence): 
• Group 1: included only the term for “Toxic liver disease with cholestasis” 
• Group 2: terms for jaundice or unspecified hepatitis 
• Group 3: other terms for liver-related diagnoses that could possibly be 
cholestatic liver injury 
Chapter 3 Appendix Table 1 contains the full list of diagnostic terms with their codes 
and evidence groupings indicated. 
3.3.1.2 Selection of participants from CPRD (primary care) records based on liver 
diagnosis codes 
The CPRD database was searched for individuals over the age of 18 years with a first 
occurrence of any of the liver- related codes listed in Chapter 3 Appendix Table 1 
between the dates of January 1, 2000 and January 31, 2013. The date of the liver 
diagnosis was termed the index diagnosis date (or index date), and a restriction that 
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individuals have to be in the database for at least 12 months before the index date was 
applied, in order to try and ensure that the index date was the actual date of liver 
diagnosis (new CPRD registrants often have legacy diagnoses entered within the first 
few months of their registration [88]). 
The relevant CPRD data files (see Table 3-1) were extracted for this cohort, and 
manipulated in order to obtain a dataset with one record per patient, including unique 
patient ID, index date and relevant medical diagnosis code and term. Any individuals 
from practices that were not linked to HES were then removed (see section 3.2.2).  
3.3.1.3 Management of CPRD liver test data 
All test results for the liver enzymes Bilirubin (Bil), Alkaline Phosphatase (ALP) and 
Alanine Aminotransferase (ALT) were then selected from the extracted test file. Blood 
levels of these enzymes are standard biochemical parameters for indicating serious 
liver injury that could be caused by drugs (DILI) and for the classification of that injury 
based on the R value (=the ratio of (ALT/ULN)/(ALP/ULN), where the ULN is the upper 
limit of the normal blood level for the enzyme) [46]. Any results with missing ULN’s had 
ULN values inserted based upon standard definitions of these values [89] while any 
identical repeated results for the same enzyme on the same day were considered as 
data entry errors and removed . 
In order for valid assessment of liver injury based on calculation of the R value, 
measurement of the enzyme levels should ideally be performed using the same blood 
sample [46]. Within the CPRD test records, blood enzyme levels recorded on the same 
day were considered to have been measured using the same blood sample. For days 
where calculation of a single R value was not possible (due to an arrangement of 
recorded enzyme levels other than a single ALT level and a single ALP level), data 
management was performed in order to obtain clean data suitable for calculation of R 
(see Table 3-3). Any individual whose test records required data management in this 
way was marked with a “data issue” variable in order to assess the impact on 
subsequent case status assignment.  
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Table 3-3: Data management performed to ensure days with liver enzyme levels recorded 
(“test days”) contained sufficient and appropriate data for calculation of R (i.e. exactly 
one ALT result and exactly one ALP result) 
# Scenario Problem Data management 
performed1 
Example illustration of 
change made to an 
individual’s test record 
1. Liver enzyme level 
record exists but 
result value is 
empty (missing) 
Cannot 
calculate R if no 
result value is 
present 
Liver enzyme level 
record removed 
 
2. Test day only has 
a single liver 
enzyme level 
recorded (e.g. ALT 
level only) 
R cannot be 
calculated from 
levels for only a 
single enzyme 
type 
Enzyme levels 
recorded <7 days of 
this day considered to 
be from the same 
blood sample, and 
record date amended 
accordingly2 
 
3. Test day has ≥3 
enzyme levels 
recorded on it, 2 of 
which are for the 
same enzyme (e.g. 
(1) Bil, ALP, and 
ALT x 2 or (2) ALP 
x 2 and ALT) 
If there is (e.g.) 
2 x ALP 
measurements 
on the same 
day with 
different values, 
then two 
possible R 
values can be 
calculated 
Keep only the highest 
result for any 
duplicated enzyme 
level  
 
4. Test day has 2 or 3 
enzyme level 
records on it, and 
all are for the same 
enzyme (e.g. ALP 
x 2) or has 2 
enzyme level 
records and one is 
Bil (e.g. Bil, ALT) 
R cannot be 
calculated from 
results for a 
single enzyme, 
or from results 
for Bil and one 
other enzyme 
Remove test day 
 
Note 1: All individuals who had test records that required any of the data management steps described 
here had a “data issue” variable set to “1”, enabling the record to be checked during subsequent analysis if 
necessary 
Note 2: For enzyme levels measured using the same blood sample, 7 days was considered to be the 
longest time that could elapse between recording the result for the first enzyme and the second enzyme in 
CPRD. Such a delay could be caused by administrative delay at the general practice or at the laboratory 
performing the tests. 
ALT: ‐‐
ALP: 220
May 19
ALP: 220
May 19
ALP: 220
May 19
ALP: 220
ALT: 95
May 25
ALT: 95
May 25
ALT: 95
ALT: 160
ALP: 35
Bil: 74
June 24
ALT: 160
ALP: 35
Bil: 74
June 24
Bil: 74
ALP: 220
Sep 27
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The resulting dataset was then formatted so that each record represented a single test 
day, with variables indicating the type of test performed (i.e. ALP or ALT or Bil), its ULN 
and its result.  
Classification of potential liver injury based on pattern of liver test results  
The liver test result dates were then classified as not characteristic of drug-induced 
liver injury, characteristic of hepatic drug-induced liver injury or characteristic of 
cholestatic drug-induced liver injury (with the difference between pure or mixed 
cholestatic injury also indicated) by calculating the R value and categorising according 
to the standard criteria presented in Table 3-4 [46].   
Table 3-4: Classification of type of liver injury using liver test results 
# Type of liver injury Liver test result 
1.  Characteristic of any DILI ALT ≥ 5 x ULN or 
ALP ≥ 2 x ULN or 
ALT ≥ 3 x ULN and Bil > 2 x 
ULN 
2.  Characteristic of hepatocellular type of DILI R* ≥ 5 
3.  Characteristic of mixed type of DILI (=cholestatic hepatitis) R > 2 and < 5 
4.  Characteristic of pure cholestatic type of DILI R ≤ 2 
*R=(ALT/ULN)/(ALP/ULN), where ALT=alanine aminotransferase, ALP=alkaline phosphatase, Bil=bilirubin 
and ULN=upper limit of normal  
In order to only consider those test results that had been performed either as a result of 
(or as part of the steps leading up to) the index diagnosis, only test dates that occurred 
within 90 days before or after the index date were considered relevant. Liver test dates 
falling outside of this period were removed, and the liver test results dataset was then 
finalised by restricting to either (1) the test date closest to the index date (for those 
people who only had test results that were not characteristic of any DILI) or (2) the 
closest test date indicating potential injury of any type (for those people who had at 
least one liver test date with results characteristic of DILI).   
3.3.1.4 Management of hospital diagnostic and liver-related procedure information  
Identification of HES diagnostic codes indicating possible cholestatic liver injury 
The same search terms used to search the CPRD diagnostic terms dictionary were 
applied to the HES diagnostic terms dictionary (see Table 3-2). Only two that were 
considered relatively specific were selected (Chapter 3 Appendix Table 2) because in a 
hospital setting the diagnoses made are likely to be more accurate than in primary 
care, as outcome assessment is being performed in a liver clinic with specialised 
clinicians and additional procedures available.  
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Identification of HES codes for liver-related procedures 
Liver-related procedures occurring in hospital were considered relevant because data 
from a liver-related procedure in hospital (such as a biopsy or a scan) can support the 
classification of the type of liver injury [46]. Terms used to search the HES procedural 
dictionary were developed based upon review of an international meeting on case 
definition and phenotype standardisation of drug-induced liver injury [46] and are 
provided in Table 3-5.  The final codelist created after reviewing the terms returned by 
the search is provided in Chapter 3 Appendix Table 3.  
Table 3-5: Search terms used for the identification of HES procedure codes that are likely 
to assist in the identification of cholestatic liver injury 
Inclusion terms 
*liver* OR *abdomen* AND (*biopsy* OR *endoscopic* OR *imaging* OR  *tomography* OR 
*ultrasound*)  
Note 1: * represents a wildcard, which means that any text can be present in this position 
Selection of HES diagnostic and procedure information for the cohort 
The raw HES data for the cohort was obtained by searching the HES database for the 
patient ids of those in the cohort. The HES episode diagnoses file was then searched 
for the liver-related codes of interest (Chapter 3 Appendix Table 2), in order to identify 
people with a liver-related diagnosis of interest during any hospitalisation within one 
year before or after the CPRD index diagnosis date or test result indicating cholestatic 
liver injury (if this was recorded first and within 90 days of the index diagnosis in the 
patient’s CPRD record). Including the prior 365 days (in addition to the subsequent 365 
days) covers situations where the individual may have presented initially at hospital 
with (e.g.) jaundice, with the CPRD record being updated based upon the hospital 
report. If a person had a code for Jaundice and a code for Toxic Liver Disease with 
Cholestasis in the period of interest, the Toxic Liver Disease code was considered as 
the diagnosis of interest. The procedure codelist (Chapter 3 Appendix Table 3) was 
then used to identify patients who had had a liver-related procedure of interest 
performed during the same hospitalisation as any of the liver-related diagnoses of 
interest. 
3.3.1.5 Management of ONS mortality data   
The ONS mortality data for the cohort was searched for the presence of the code 
“Toxic Liver Disease with Cholestasis” (=a Group 1 code) as any cause at any time 
after the index date (or test result indicating cholestatic liver injury, if this preceded the 
index date).   
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Figure 3.2: Data sources and time-periods searched in obtaining data for a multisource algorithm cholestatic liver injury health record
CPRD clinical records
CPRD liver test records
HES clinical  records
HES procedure records
(e.g. scan or biopsy)
ONS mortality records
Final multisource
algorithm record
Jan 2000 Jan 2013
90 days90 days
365 days 365 days
Period 
of hospitalisation
Index date
Example data
Electronic data source Time periods searched (with example records retrieved for one person)
RIP
RIP
Cholestatic Toxic liver
Disease with
cholestasis
UltrasoundJaundice Toxic liver
Disease with
cholestasis
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3.3.1.6 Multisource algorithm status assignment 
The multisource cholestatic liver injury algorithm case status was then assigned based 
upon the following: 
1. the CPRD index diagnosis group (group 1, 2 or 3) 
2. the diagnostic code group for any HES liver diagnosis of interest within one year 
either side of the CPRD index diagnosis date (group 1 or 2 or “no HES diagnoses 
of interest” i.e. person attended hospital within one year of CPRD index diagnosis 
date but no liver-related diagnoses of interest were recorded or “no HES record” i.e. 
person did not attend hospital within one year of CPRD index diagnosis date) 
3. the presence of any HES liver procedure (e.g. a liver-related biopsy or a scan) in 
the same hospitalisation as a liver HES code 
4. whether any death was recorded within ONS mortality data as “Toxic liver disease 
with cholestasis”. 
Table 3-6 shows how each of these elements contributed to case assignment. Anyone 
with a CPRD liver test result that qualified as cholestatic was considered to be a 
“definite” case, based on internationally agreed consensus of the importance of 
biochemical criteria in the classification of liver injury [45, 46]. Individuals who had died 
and had an ONS ICD code that indicated a death certificate coded with “Toxic liver 
disease with cholestasis”  (group 1) were also considered to be definite cases, in 
addition to individuals who were assigned this code in hospital after a biopsy or scan. 
Subsequent case statuses (from very likely through probable, possible, least likely and 
non-case) were then assigned. Very likely cases were those who did not have any liver 
test results (so no biochemical data to show that they either were or were not a definite 
case), but had a code for “Toxic liver disease with cholestasis” (i.e. group 1) in both 
their CPRD and HES records. Probable cases also had no liver test result data, but 
had a code for “Toxic liver disease with cholestasis” in either their CPRD or their HES 
record. Possible cases were those who had a liver test result that showed no 
cholestatic injury or had no liver injury test results, but who had “Toxic liver disease 
with cholestasis” (group 1) indicated within CPRD or HES, or those with no liver test 
results to reference but both CPRD and HES codes indicating some kind of jaundice 
(group 2 codes).  
Those classified as “least likely” were people with either (1) test results that did not 
indicate cholestasis who had a CPRD diagnosis of “Toxic liver disease with 
cholestasis”  but either no HES record or no liver code in the HES record or (2) a test 
result not indicating cholestasis with a group 3 CPRD code (i.e. a relatively non-specific 
liver diagnosis) and a HES code of “Toxic liver disease with cholestasis” or (3) no LFT 
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results but a CPRD code indicating jaundice (group 2) and either no HES codes of 
interest or not admitted to hospital. All individuals with other arrangements of data from 
each of the sources were considered to be non-cases. 
Table 3-6: Assignment of the multisource algorithm case status using CPRD, HES, & 
ONS data 
# CPRD 
(READ) 
diagnostic 
code 
HES diagnostic (ICD-10) 
code (plus HES procedural 
code and ONS mortality 
code, where considered)  
CPRD liver test 
result 
Multisource 
algorithm case 
status 
1.  Group 1|2|31 Not considered Cholestatic Definite 
2.  Group 1|2|3 ONS (death): Group 1 Not considered Definite 
3.  Group 1|2|3  Biopsy/Scan + Group 1 Not considered Definite 
 
4.  Group 1 Group 1 None2 Very likely 
 
5.  Group 1 Group 2 or No HES record3 None Probable 
6.  Group 2|3 Group 1 None Probable 
 
7.  Group 1 Group 1|2 Not cholestatic4 Possible 
8.  Group 1 HES record has no codes of 
interest5 
None Possible 
9.  Group 2 Group 1 Not cholestatic  Possible 
10.  Group 2 Group 2 None Possible 
 
11.  Group 1  No HES record | HES 
record has no codes of 
interest 
Not cholestatic Least likely 
12.  Group 2 No HES record | HES 
record has no codes of 
interest 
None Least likely 
13.  Group 3 Group 1 Not cholestatic Least likely 
 
14.  Group 2 Group 2 | No HES record | 
HES record has no codes of 
interest 
Not cholestatic Non-case 
15.  Group 3 Group 2 None | Not 
cholestatic 
Non-case 
16.  Group 3 No HES record None | Not 
cholestatic 
Non-case 
17.  Group 3 HES record has no codes of 
interest 
None | Not 
cholestatic 
Non-case 
Note 1: Group 1=highest evidence for cholestatic liver injury, Group 3=lowest evidence (see Chapter 3 Appendix Tables 
1 and 2). Note 2: No liver test result recorded within 90 days of index diagnosis. Note 3: No HES record indicates 
person did not attend hospital < 1 year either side of index diagnosis. Note 4: Liver test result was recorded within 90 
days of index diagnosis but results indicate either no injury or pure hepatic injury. Note 5: Person attended hospital < 
1year from index diagnosis but no liver diagnoses of interest 
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3.3.2 The CPRD cholestatic liver injury algorithm 
This section details how a CPRD algorithm for assigning cholestatic liver injury case 
status was developed by using the multisource algorithm case status as a validation 
tool.  
An overview of the CPRD algorithm design is provided in Figure 3.3. Potential cases 
are selected from extracted CPRD data files based upon the presence of specific 
CPRD diagnostic codes. CPRD characteristic variables required for calculation of a 
CPRD cholestatic liver injury cut-off score are then created and each patient record has 
a score assigned to it based on whether they have a “1” assigned for each variable. 
There is then a two-stage procedure of case-status assignment: 
(a) Stage 1 -  individuals with a value of “1” for variables that perfectly predict 
cholestatic liver injury case status are assigned as cases 
(b) Stage 2 -  individuals who have not been already assigned as cases (during 
stage 1) with a CPRD algorithm score above a specific cut-off are assigned as 
cases, with anyone remaining unassigned considered a non-case   
The remainder of this chapter describes the cohort that was used to develop this 
algorithm (section 3.3.2.1), the identification of CPRD characteristic used as potential 
explanatory variables for the multisource algorithm response variable (3.3.2.2), the 
multisource algorithm response variable (3.3.2.3), the statistical analysis performed to 
identify true CPRD explanatory variables (including those that perfectly predicted the 
multisource response variable) (3.3.2.4), and finally the use of ROC analysis to assess 
the validity of the CPRD algorithm and allow consideration of appropriate cut-off scores 
for further studies. 
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Figure 3.3: Overview of steps performed by the CPRD cholestatic liver injury algorithm 
3.3.2.1 Selection of participants from CPRD based on liver diagnosis codes 
The CPRD database was searched for individuals over the age of 18 years with a first 
occurrence of any of the liver-related codes used in the multisource algorithm 
development (Chapter 3 Appendix Table 1) between the dates of January 1, 2000 and 
January 31, 2013. The search was performed within the clinical, referral and test 
records. The date of the liver diagnosis was termed the index diagnosis date (or “index 
date”), and a restriction that individuals had to be in the database for at least 12 months 
before the index date was applied. 
3.3.2.2 CPRD algorithm exposure: potential explanatory variables 
For the individuals selected from CPRD based upon the presence of one of the liver 
codes of interest (Chapter 3 Appendix Table 1) there were four main characteristics 
considered to be potential predictors of the multisource algorithm cholestatic liver injury 
case status: liver test result information, referral information around the index date, the 
2.CPRD exlanatory variables necessary for calculation of cut‐off score 
created (related to CPRD liver test results, specific liver‐related diagnosis, 
other liver‐related diagnoses  and referrals) 
 Individual has  a “1” 
for any variable 
shown to be a perfect 
predictor?
4. CPRD algorithm score calculated for an individual based upon those 
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type of liver-related index diagnosis and information on any other liver-related 
diagnosis apart from the index diagnosis. Binary variables were created for 
characteristics of interest, with 0 meaning that the person did not have the 
characteristic and 1 meaning that they did have the characteristic. Variables created in 
relation to the index diagnosis terms coded for whether the person had a specific type 
of diagnosis or not, and the type of diagnosis was defined by grouping together 
clinically similar diagnoses (for example “hepatic failure related” or “jaundice or similar 
terms”). A full list of the explanatory variables considered is provided in Chapter 3 
Appendix Table 4. 
3.3.2.3 CPRD algorithm outcome: multisource case status 
The outcome (response variable) used in development of the CPRD cholestatic liver 
injury algorithm was the multisource case status, categorised so that a value of 1 was a 
multi-source case status of definite through to possible, while 0 was a multi-source 
case status of least likely or non-case.  
3.3.2.4 Statistical analysis 
Prior to statistical analysis, the cohort was randomly split into two separate datasets of 
equal size, one for statistical model building (the training dataset) and the other for 
testing of the model (the validation dataset).  
Using the training dataset, each of the potential CPRD explanatory variables was 
tabulated against case status, before univariable analysis was performed in order to 
obtain a crude odds ratio for the association between the potential explanatory variable 
(CPRD characteristic) and the response variable (multisource algorithm case status). 
Any potential explanatory variables that perfectly predicted multisource definite-
possible case status (i.e. 100% of the individuals in one of the binary categories of the 
potential explanatory variable were cases) were noted and removed from consideration 
as potential explanatory variables.  
Multivariable analysis was then performed on those potential explanatory variables that 
had shown an association with the outcome in univariable analysis (with association in 
univariable analysis indicated by an odds ratio of association less than or greater than 
1.0, and a 95% confidence interval that did not include 1.0). A multivariable logistic 
regression model was constructed, and used to assess if each variable of interest was 
associated with the outcome after adjustment for all the other variables in the model. In 
order to be able to cope with strata containing a lack of data in the multivariable model, 
Firth’s logistic regression methodology was used for this multivariable analysis, which 
can handle strata with sparse data by using penalised maximum likelihood estimation 
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[90].   Evidence for an association was assessed by performing likelihood ratio tests 
(LRT). Variables with LRT p-values of less than 0.05 were considered to be associated 
with the outcome and kept in the model. Variables considered not to be associated 
after adjustments were removed from the model, and the analysis for the other 
variables repeated as necessary with the reduced model. 
3.3.2.5 CPRD algorithm score generation and assignment 
Variables for storing explanatory variable “scores” were added to the validation dataset, 
and if an individual had a value of 1 for any of the CPRD explanatory variables, the 
corresponding score variable for that variable was populated with the log odds value 
obtained from the multivariable regression analysis. A total score variable was created 
and this was populated with the sum of all the explanatory variable scores, in order to 
generate a final CPRD cholestatic liver injury score for the individual equal to the 
overall predicted log odds for the individual, given their covariate values. 
3.3.2.6  ROC analysis of CPRD cholestatic liver injury algorithm and consideration of 
cut-off scores 
The ability of the CPRD cholestatic liver injury algorithm to discriminate between the 
two multisource cases statuses (definite to possible vs. least likely to non) was 
assessed by plotting a Receiver Operator Characteristic (ROC) graph (sensitivity vs. 1-
specificity) across the range of CPRD algorithm cut-off scores. As detailed in Figure 
3.3, the CPRD algorithm follows a two stage case identification procedure, where firstly 
those who have a “1” for any variables that perfectly predict multisource case status 
are assigned as cases, before the cut-off score is applied to the remainder of the 
cohort in order to identify any remaining cases. The following ROC analyses were 
therefore performed: 
(1) The complete CPRD algorithm i.e. assessing the ability of the complete 
algorithm (both stage 1 and stage 2 from Figure 3.3) to discriminate between 
the two multisource case statuses. For this analysis, those individuals who had 
a “1” for any of the variables shown to be perfect predictors of multisource case 
status were included in the cohort, and were assigned a “perfect prediction” 
CPRD algorithm score (a score that was manually inputted as higher than the 
highest combined CPRD algorithm score of all those individuals in the cohort 
who did not have a “1” for any perfect predictor variables). This allowed the 
performance of the complete algorithm to be assessed. 
(2) The CPRD algorithm cut-off score i.e. assessing the ability of the cut-off 
score only (stage 2 from Figure 3.3) to discriminate between the two 
multisource case statuses. For this analysis, those individuals who had a “1” for 
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any of the variables shown to be perfect predictors of multisource case status 
were removed from the cohort, meaning the performance of the algorithm score 
on its own could be assessed in the conditions that it would be applied (i.e. 
identifying cases in the subset of people who did not have a “1” for variables 
shown to be perfect predictors of multisource case status) 
For each ROC analysis, the sensitivity and specificity for a range of CPRD algorithm 
score cut-offs was considered, using the ROC graph and tabulations of the full range of 
CPRD algorithm cut-off scores versus sensitivity and specificity.   
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3.4 Pharmacoepidemiological studies of drug-induced cholestatic 
liver injury 
3.4.1 Applying the algorithm to a well established association: a cohort 
study of the association between flucloxacillin and cholestatic liver 
injury 
This section describes a study that compares different CPRD cholestatic liver injury 
algorithm cut-off scores with varying specificity and sensitivity with (1) each other and 
(2) the multisource algorithm for outcome identification in a pharmacoepidemiological 
study. 
3.4.1.1 Study design 
A cohort analysis of the association between flucloxacillin and cholestatic liver injury, 
with oxytetracyline as a comparator drug.   
3.4.1.2 Setting and participants (incl. exclusions) 
Setting 
The study was performed within the UK CPRD (see section 3.2.1) and included 
patients actively registered in the database between the dates of 1st January 2000 and 
1st January 2012. Additional information required for applying the multisource algorithm 
was obtained from information within HES that is linked to patients within the CPRD 
(see section 3.2.2). 
Exposed group – inclusion criteria 
People over the age of 18 with at least one prescription for flucloxacillin and at least 12 
months of computerised prescription history in CPRD prior to their first prescription. 
The 12 month period was used to ensure that the date of flucloxacillin or 
oxytetracycline prescription (index date) was as accurate as possible (people who have 
recently registered may have all legacy diagnoses and prescriptions entered into the 
system on one date, that represents only the date at which the person was first 
registered into the system). 
Exposed group – exclusion criteria 
In order to remove patients with diseases or conditions that were likely to cause 
cholestatic liver injury, patients who had any of the following in their CPRD record 12 
months prior to their flucloxacillin prescription were excluded: any documented liver 
disease, alcoholism, malignant neoplasm of the liver/gallbladder/pancreas, 
cholelithiasis, viral hepatitis, chronic liver disease, cirrhosis, congestive heart failure, 
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hepatitis following blood transfusion, HIV, rheumatoid arthritis, sarcoidosis, systemic 
lupus or inflammatory bowel disease (see Chapter 3 Appendix Table 5 for full list of 
diagnostic codes) and any liver test results that met the criteria for drug-induced-liver 
injury (see Table 3-4). In addition, any woman with a code indicating pregnancy within 
40 weeks prior to their index date who did not have a subsequent code indicating 
delivery (or termination of pregnancy in any other way) was excluded, due to the fact 
that the incidence of cholestasis in pregnant women is approximately 1 in 100 women 
[91].   Individuals with any previous prescription for flucloxacillin were also excluded. 
Comparison group – inclusion criteria 
The comparison group was chosen to be people prescribed another antibiotic with a 
similar range of indications to flucloxacillin but that was not considered to be a cause of 
cholestatic liver injury. Users of such antibiotics are likely to be more comparable to the 
exposed group with respect to exposures (in terms of e.g. health-seeking behaviour, 
illnesses) than non-users but not the outcome. Oxytetracycline was selected as one 
such comparator, as it is an antibiotic with a similar range of indications that has been 
used by researchers performing comparable studies in the past [53]. Figure 3.4 
provides details of the exposed and comparator groups. 
Comparison group – exclusion criteria 
Same criteria as for the exposed group, in relation to oxytetracycline. 
3.4.1.3 Sample size/power calculations 
A recent CPRD cohort study estimated the risk of cholestatic liver disease to be 8.5 per 
100 000 first time users for flucloxacillin (95% CI 5.4 – 12.6) and 0.8 per 100 000 first 
time users for oxytetracycline (95% CI 0.02 – 4.3), a risk ratio of 8.5/0.8 = 10.63 [53] . A 
power calculation using STATA version 13 was performed and in order to detect a 
difference of this size with 95% precision and 90% power, calculated that a sample size 
of 164,806 in each exposure group would be required.  
A feasibility count in CPRD was performed by obtaining the number of people who had 
a first time prescription for flucloxacillin and for oxytetracycline in a sample of 1 million 
people (extracted from the database October 2011) between the start and end of the 
study period (01/01/2000 – 01/01/2012) and multiplying this appropriately to reflect the 
total number of patient records in CPRD in October 2011 (11.6 million). There were 
1,793,267 people with a first time prescription for flucloxacillin with records in the 
database in October 2011 and 297,795 people with a first time prescription for 
oxytetracycline, meaning that the study would be adequately powered to detect the 
likely difference, even after applying exclusion criteria. 
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3.4.1.4 Standard Protocol Approvals, Registrations, or Patient Consents 
The study was approved by the Independent Scientific Advisory Committee for MHRA 
database research and the internal ethics committee of the London School of Hygiene 
and Tropical Medicine (see Chapter 3 Appendix Table 7). 
3.4.1.5 Exposures, outcomes and co-variates 
Exposures 
Exposures were determined from prescription records within the CPRD therapy data 
files for these antibiotics. A person was considered exposed up to 45 days after the 
start of a first prescription for flucloxacillin or oxytetracycline, as flucloxacillin-induced 
cholestatic liver injury may occur up to approximately 6 weeks after first administration 
of the drug (see Chapter 1, Section 1.4.1.1 and Figure 3.4). The date of prescription of 
the drug under study was termed the index date, and people who were prescribed 
flucloxacillin on the same date as oxytetracycline were included in the flucloxacillin 
group only. Any person who received oxytetracycline on their index date but then 
received a prescription for flucloxacillin (before their end of follow-up) was assigned to 
the flucloxacillin group, and their index date updated appropriately (see section 3.4.1.6 
for a description of end of follow-up). 
Whether a person was prescribed the flucloxacillin plus ampicillin (co-fluamp) 
formulation or flucloxacillin alone was also recorded, as it has previously been shown 
that there are differing risks associated with pure flucloxacillin vs. the formulation which 
includes ampicillin. Duration of flucloxacillin use was considered in order to assess any 
duration-response effects, and was assessed by using prescriptions recorded in CPRD 
therapy records. The dates of the first, second and third flucloxacillin prescriptions 
within 90 days after the index date (but before the end of follow-up) were identified and 
used to create a time-updated variable called number of flucloxacillin prescriptions. 
This allowed events and follow-up time after each person’s first, second (if present) and 
third (if present) prescriptions to be identified and a corresponding rate and rate ratios 
to be calculated. A time between first flucloxacillin prescription and case assignment 
date was also created.    
Outcomes 
The main outcome under study was the CPRD cholestatic liver injury algorithm (see 
section 3.3.2 for details). CPRD algorithm scores of “High” specificity (100% specificity, 
81% sensitivity, against a gold standard of the multisource algorithm probable to 
definite case - cut off score of 5.0), “Medium” specificity: 86% specificity, 87% 
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sensitivity (cut of score 2.29) and “Low” specificity: 48% specificity, 100% sensitivity 
(cut off score 1.63) were compared with each other and the following:  
1. Each other (within the full dataset) 
2. The multisource algorithm as described in section 3.3.1.6 (within the dataset 
restricted to HES-linked participants only) 
3. Published studies on the association between flucloxacillin and cholestatic liver 
injury [53, 55, 67, 75]  
Details on how the CPRD algorithm outcome definitions were compared with each 
other and the multisource and published outcome definitions are provided in section 
3.4.1.6.  
The CPRD and multisource algorithms were used to identify cases of cholestatic liver 
injury as described in sections 3.3.1 and 3.3.2, with an additional check applied to 
ensure none of the clinical, test or referral dates used by the algorithms occurred 
before the index date of this study (i.e. before the prescription for either of the drugs of 
interest). A further slight amendment to the multisource algorithm was made to avoid 
potential time-related bias in this cohort setting: in contrast to the method for selecting 
HES diagnostic information described in section 3.3.1.4, if a code for Jaundice 
occurred before a code for Toxic Liver Disease with Cholestasis, the code for Jaundice 
was considered as the diagnosis of interest. 
All cases of cholestatic liver injury identified by each outcome definition were 
considered as potentially caused by one of the drugs under study. The full electronic 
record within 12 months prior to the outcome event was extracted for all these 
cholestatic liver injury cases and reviewed in order to make a final case status 
assignment (with consideration as to whether there was any other more likely 
pathological/therapeutic cause for the detected injury). This review was performed by 
two reviewers (blinded to drug exposure) one of whom was clinically trained (Dr Adrian 
Root, LSHTM and General Practitioner). In case of disagreements, the final decision 
was made by the clinically trained reviewer. 
Co-variates 
Results of previous studies, a-priori knowledge and causal diagrams were used to 
assist with the identification of co-variates. A causal diagram was prepared using the 
DAGitty graphical tool for analyzing causal diagrams [92], and is included in Chapter 3 
Appendix Table 6a.  Age, gender, smoking, ethnicity, BMI, alcohol intake, SES, use of 
other drugs known to cause cholestatic liver injury and calendar period were all 
considered as potential measurable confounders or effect modifiers.  
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Age and gender have been suggested as risk factors for flucloxacillin-induced liver 
injury [53, 55, 56], and are included as part of the CPRD patient (demographic) data 
file. A categorical age variable was created with ten year categories.  
The role of ethnicity has not been previously studied, and was considered important 
due to a likely genetic susceptibility to flucloxacillin-induced liver injury [57, 58]. 
Ethnicity codes based on the 2001 UK census data were used to search the CPRD 
additional files [93], in order to assign ethnicity to the cohort, as a 5-category variable. If 
no ethnicity records were found in CPRD for a patient, the HES records of any patients 
that were HES-linked were also searched for ethnicity information. Any patients who 
did not have ethnicity information in CPRD or HES were assigned to an “Unknown” 
category.    
BMI, alcohol intake and SES are likely to be associated with indications requiring 
flucloxacillin (such as cellulitis) and with susceptibility to liver-related conditions. CPRD 
smoking status is recorded as non-, ex-, current and unknown. CPRD alcohol status is 
recorded as never, ex-, current (not-otherwise-specified), ≤2 or less units/day, 3-6 
units/day, >6 units per day, and unknown. A categorical BMI status variable was 
created with categories of <20, 20-25, 25+, and unknown. Smoking, alcohol and BMI 
status were assigned according to the classification of the nearest date prior to the 
index date (if no prior status, the status from the nearest post-index date was used). 
SES information is not part of the standard CPRD database, and was obtained 
separately as linked data. This was provided by CPRD as an Index of Multiple 
Deprivation score based upon individual patient postcode, and as a practice level score 
based upon practice postcode (both variables consisting of 5 categories representing 
quintiles of score). A dedicated SES variable was created for the study and populated 
with the patient-level score, unless this was missing, in which case the practice-level 
score was used. This linked SES data was only available for practices in England. 
Calendar period was included in order to assess if changes in prescribing habits or 
recording of outcomes occurred over time (for example, improved automation of the 
system for capturing liver test results within CPRD over time). A calendar time-period 
variable was created with categories spanning 3-year periods. 
The possible impact of the use of other drugs associated with cholestatic liver injury 
was assessed by looking for prescriptions for other drugs that occurred before the end 
of follow-up for the patient and up to 1 month before the index date. A variable was 
created with three categories: 0=no use of other drugs, 1=use of drugs thought to 
cause cholestatic liver injury at a frequency lower than flucloxacillin, 2=use of drugs 
thought to cause cholestatic liver injury at a frequency higher than flucloxacillin. The list 
of drugs and categorisation was based upon review of results of studies included in 
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Chapter 2 of this thesis, combined with a number of additional sources [48, 49, 94, 95], 
and included non-steroidal anti-inflammatory drugs, other antibiotics, antidepressants 
and antifungals. A full list of therapies included is provided in Chapter 3 Appendix Table 
7.   
Patients exposed to both oxytetracycline and flucloxacillin during their follow-up were 
included in the flucloxacillin group only, and a sensitivity analysis performed to assess 
the impact of excluding these patients. 
3.4.1.6 Data management, statistical analysis and bias 
CPRD data file extraction 
Drug substance names and BNF codes were used to identify a list of codes used to 
search prescription records in CPRD. Patient ids and first prescription dates from 
CPRD for people over 18 years of age receiving a first prescription for flucloxacillin or 
oxytetracycline between 1st January 2000 and 1st January 2012 (latest prescription date 
22 December 2011) were extracted as a single (index) file from CPRD, along with 
additional separate data files containing information on all patient demographic 
information, clinical diagnoses, therapies and test results (all linked by unique patient 
id). Any patient with clinical codes for the exclusions listed in Chapter 3 Appendix Table 
5 within 12 months prior to the date of their first prescription for one of the study drugs 
was excluded. For the comparison of the CPRD algorithm with the multisource 
algorithm, any individuals from practices that were not linked to HES were then 
removed (as described previously - see section 3.3.1.2). 
A list of potential cases was then prepared by searching patient clinical records for the 
diagnostic codes applicable to the outcome being assessed, and either the specific 
CPRD algorithm cut-off score or multisource algorithm was used to assign a cholestatic 
liver injury case status for each of the outcome definitions (performed blinded to drug 
exposure status). Due to the different criteria applied by each of the outcomes, it was 
possible for one individual to be classified as a cholestatic liver injury case according to 
one outcome definition but not another.  The cholestatic liver injury case status 
information was then applied to the cohort, and the resulting dataset was searched for 
the presence (and date) of the exclusions listed in Chapter 3 Appendix Table 5. All 
patients with an exclusion event during their follow-up had the date of that event added 
to their record, their case status changed to non-case. The co-variate information was 
then added to the dataset before the record review described in section 3.4.1.5 
(Outcomes section) was performed. This allowed case status to be finalised based 
upon the presence or absence of any more likely cause of cholestatic liver injury than a 
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prescription with either of the drugs under study. The final step was the addition of the 
drug exposure status to the cohort.  
Statistical analysis 
The initial step was to perform a descriptive analysis of the cohort, including tabulation 
of characteristics of participants by exposure to the drug of interest. A comparison of 
the 3 CPRD algorithm outcomes and the multisource algorithm outcome was then 
performed by performing the analyses detailed below, which were considered to be 
typical of pharmacoepidemiological studies.  
1. Number and characteristics of identified cases 
The number of cases of cholestatic liver injury identified by each of the outcome 
definitions was tabulated, along with the number and % that were considered as final 
cases of cholestatic liver injury caused by one of the drugs under study. The time 
between first prescription and injury and characteristics of the cases were also 
tabulated.  
2. Risk of cholestatic liver injury  
The risk of cholestatic liver injury for each drug was calculated by dividing the total 
number of events by the number of patients in each exposure group (see Figure 3.4). 
95% confidence intervals were calculated on the basis of a Poisson distribution of 
injury events within each exposure group and the risk of cholestatic liver injury 
occurring per 100,000 users within each of the exposure groups was tabulated.  The 
risk of cholestatic liver injury in the 46 – 90 day period after exposure to flucloxacillin 
was also calculated, in order to assess whether this differed from the 1 – 45 day period 
after an exposure to flucloxacillin. 
3. Association between flucloxacillin and cholestatic liver injury 
For the analysis of the association between flucloxacillin and cholestatic liver injury, all 
relative effects were calculated using rates of injury (to obtain rate ratios). The rate of 
injury was calculated by dividing the number of events by the total person-time at risk. 
For all rate calculations, individuals were followed up until the first of death, end of the 
study period (45 days after the index date), drug-induced cholestatic liver injury as 
defined by the outcome being tested and clinical expert review, any of the exclusion 
criteria, or transfer out date.  
The three CPRD algorithm cut-off scores required multiple sequential pieces of 
information from the CPRD record (e.g. an index diagnosis followed by an associated 
liver function test or a hospital referral), and follow-up was until the latest date of the 
entries that qualified that person as a case for the particular outcome definition. So, for 
example, if the case cut-off score was 2.29, and the individual was considered a case 
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due to having a score of 2.29 that was the total of an index diagnosis of obstructive 
jaundice (contributing a score of 1.89) and another liver-related diagnosis within one 
month (contributing a score of 0.40), then the person was followed up until the latest of 
either of these events. Note that it was possible for the same person to have a different 
case date if they also qualified as a case according to one of the other cut-off score 
definitions. For example, the patient described here could also have had a cholestatic 
liver test result, meaning they would qualify as a case according to the CPRD algorithm 
cut-off score definition of 5. If the cholestatic result appeared later in their record than 
their additional liver-related diagnosis, they would have a different case date for the 
algorithm cut-off score of 5. For the multisource algorithm, follow-up was until the 
earliest date at which they had accumulated the multisource (possible to definite) cut-
off score.  
Associations between each co-variate and drug exposure were assessed by tabulating 
and looking for differences in % for exposed vs. unexposed groups. Associations 
between co-variates and the outcome under test were assessed by looking at rate 
ratios, their 95% confidence intervals, and Likelihood Ratio Tests for the overall 
association of the co-variate. Classical (Mantel Haenzel) analysis was performed on 
each co-variate considered a potential confounder or effect modifier. 
Crude rate ratios for the association between flucloxacillin and cholestatic liver injury 
were then obtained by comparing the rate of cholestatic liver injury during the 1 - 45 
day period after a first prescription of flucloxacillin to the rate during the 1 - 45 day after 
a first prescription of oxytetracycline. 
Figure 3.4 provides an example of the exposure groups and follow-up timelines applied 
in this study.  
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Figure 3.4: Exposed and comparator groups of the flucloxacillin and cholestatic liver 
injury cohort study 
Risk calculations were performed within the following two exposure groups (1) Exposed to flucloxacillin = all 
people who are prescribed flucloxacillin at day 0 (2) Comparator group = all people who are prescribed 
oxytetracycline at day 0 (and not also flucloxacillin before their end of follow-up) The risk of injury was 
calculated by dividing the total number of events that occur within 45 days of the first day of each group by 
the total number of people in each group. 
For rate calculations, patients in the exposed to flucloxacillin group were followed up from their first 
prescription for flucloxacillin (the index date) for a maximum of 45 days. Patients in the comparator group 
(exposed to oxytetracycline) were followed up from their first prescription of oxytetracycline (the index date), 
also for a maximum of 45 days. The rate of cholestatic liver injury in the exposed to flucloxacillin group was 
compared to the rate in the oxytetracycline group to obtain the rate ratios used in this study. In this 
example, the person exposed to flucloxacillin experiences an event within the 45 day period, and is therefore 
not followed up beyond this point. The person exposed to oxytetracycline does not experience a cholestatic 
liver injury event (or exclusion event or death), so follow-up for this patient ends after 45 days. 
A Poisson regression model was then constructed, with potential confounders or effect-
modifiers included as informed by the DAG analysis. Statistical tests (Likelihood Ratio 
Tests or LRT tests) for interaction were used to investigate effect modification for those 
co-variates identified as potential effect modifiers in classical analysis, and if confirmed, 
stratum specific rate ratios were presented. If no effect modifiers were identified, a 
single multivariable adjusted rate ratio was presented. Multivariable analysis was then 
performed using two separate approaches: (1) a stepwise approach, adding co-
variates to the Poisson regression model one-by-one, and keeping those that were 
associated with a substantial (>5%) relative change in rate ratio and (2) a fully adjusted 
approach, including all available variables identified by the DAG analysis. Both results 
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were presented in the results tables (with the fully adjusted figures included as 
footnotes).  
4. Analysis of risk factors for flucloxacillin-induced cholestatic liver injury 
A risk-factor based analysis was performed, in order to look at characteristics within 
those in the exposed to flucloxacillin group only that were associated with an increased 
rate of cholestatic liver injury (i.e. identifying variables that interacted with the exposure 
to flucloxacillin). Risk factors were selected based upon (1) evidence of association in 
univariable analysis (2) identification in published literature as potential risk factors. 
Risks, rates, and crude rate ratios were calculated and tabulated, along with 
multivariable adjusted rate ratios (allowing the impact of adjusting for other potential 
risk factors to be assessed). 
Bias 
Observer bias was limited by blinding to drug exposure status and to outcome status 
during preparation of the cohort for analysis, which was achieved by managing this 
information separately from the main cohort, and combining only immediately prior to 
analysis. Review of the electronic record was also performed blinded to initial and any 
subsequent exposure to the drugs of interest. Attempts to reduce measurement error 
(related to main exposure) were made by ensuring that people prescribed 
oxytetracycline but then flucloxacillin before their end of follow-up were assigned to the 
flucloxacillin group. Misclassification of outcome was considered throughout the study, 
by careful consideration of the results obtained using the case identification algorithms 
of varying sensitivity and specificity. 
Handling low numbers of events and missing values 
For numerical-categorical variables that had a lack of events within one or more 
categories, where possible these were combined in order to allow analysis of the 
variable to be performed. The design of the study ensured that the final dataset for 
analyses had no missing values for the main exposure (flucloxacillin or oxytetracycline) 
or for the outcome (cholestatic liver injury as determined by different algorithms).  For 
co-variates with missing values, the use of three approaches was compared: 
(1) including all individuals in the analyses and assigning individuals with missing data 
for a particular co-variate to an “unknown” category for that co-variate (allowing the 
extent of the missing data for that variable to be clearly presented) 
(2) restricting the analysis only to those individuals with complete records (complete 
records analysis) 
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(3) imputing any missing data for co-variates included in the final substantive models 
of association using multiple imputation (assuming missing at random and 
performing sensitivity analyses for missing not at random).   
Sensitivity analyses 
The following sensitivity analyses were performed: 
1. An analysis of the effect of excluding patients exposed to both oxytetracycline 
and flucloxacillin, compared with assigning them to the flucloxacillin group (as 
done in this study) 
2. An analysis of the effect of assigning people identified as cases of cholestatic 
liver injury who had an exclusion code between their index date and injury date 
as cases of drug-induced cholestatic liver injury, compared with considering 
them as non-cases (as done in this study) 
3. The effect of excluding cases who were in the heaviest drinking category was 
assessed (i.e. considering their liver injury to be caused by drinking) 
4. The effect of excluding people who had been prescribed co-fluamp was 
assessed. 
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3.4.2 Applying the algorithm to putative but unknown associations: a 
case-control study of the association between five drug exposures 
and cholestatic liver injury 
This section describes a study that uses two of the cholestatic liver injury CPRD 
algorithm case definitions (1:highest sensitivity, lowest specificity, 2: highest specificity, 
lowest sensitivity) to analyse the association between cholestatic liver injury and five 
possible drug causes of cholestatic liver injury. The drugs of interest were selected 
because they were considered to be prescribed relatively frequently in the UK and had 
a lack of large epidemiological studies of their effect on cholestatic liver injury. 
Furthermore, all the drugs had (a) been included in recent or multiple cholestatic liver 
injury case reports published in the literature and/or (b) had statements in their 
prescribing information suggesting that they caused liver injury at an unknown 
frequency (or at a frequency estimated using adverse event reporting figures). An 
overview of the five drugs is provided in Table 3-7. 
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Table 3-7: An overview of the five drugs in the cholestatic liver injury case control study 
Drug Type or class Indications Current information on 
drug as a cause of liver 
injury 
Carbamazepine Anticonvulsant Epilepsy, pain association 
with trigeminal neuralgia 
and prevention of manic-
depressive psychosis 
Prescribing information: 
rare cause of jaundice 
(≥1/10,000 to <1/1,000) 
[96] 
Published literature: case 
reports (examples [97, 98]) 
Celecoxib NSAID (selective 
COX-2 inhibitor) 
Relief of symptoms of 
osteoarthritis, rheumatoid 
arthritis and ankylosing 
spondylitis 
Prescribing information: 
hepatitis and jaundice 
occur at an unknown 
frequency [99] 
  
Duloxetine Serotonin-
norepinephrine 
reuptake inhibitor 
(SNRI) 
Depression, anxiety and 
diabetic neuropathic pain 
Prescribing information: 
jaundice caused at a 
frequency of ≥1/10,000 to 
<1/1,000 users based on 
adverse event reporting 
from post-marketing 
surveillance [100] 
Published literature: case 
reports (examples [101, 
102]) 
Ramipril Angiotensin-
converting 
enzyme inhibitor 
Hypertension, renal 
disease, symptomatic 
heart failure. 
Prescribing information: a 
rare (≥1/10,000 to 
<1/1,000) cause of 
jaundice and causes 
cholestatic hepatitis at an 
unknown frequency [103] 
Published literature: case 
report plus review of 
adverse event reporting 
[104]  
Risperidone Antipsychotic Schizophrenia, manic 
episodes of bipolar 
disorders and persistent 
aggression associated with 
Alzheimer’s dementia and 
childhood conduct 
disorder. 
Prescribing information: a 
rare (≥1/10,000 to 
<1/1,000) cause of 
jaundice [105] 
Published literature: case  
reports (examples [106, 
107]) 
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3.4.3 Study design 
A case-control analysis of the association between five drug exposures and cholestatic 
liver injury in the UK CPRD (described in detail in section 3.2.1). The study also 
included estimation of the incidence of cholestatic liver injury caused by any of the 
drugs under study that were (1) shown to be strongly associated with cholestatic liver 
injury by the case control analysis (with strongly associated considered to be a rate 
ratio >1.5 and 95% CI not crossing the null value) and (2) have consistent results for 
the high and low specificity algorithms. 
3.4.3.1 Setting and participants (incl exclusions) 
Setting 
The study was performed within the UK CPRD (see section 3.2.1) and included 
patients actively registered in the database between the dates of 1st January 1992 and 
31st July 2014. 
Cases – inclusion criteria 
People identified as having cholestatic liver injury by the CPRD cholestatic liver injury 
algorithm (see section 3.3.2) who have at least 12 months of computerised clinical 
diagnostic history in CPRD prior to their injury date (see section 3.4.1.2). The date at 
which the person is identified as a case by the CPRD cholestatic liver injury algorithm 
will be considered the index date. 
Cases – exclusion criteria 
In order to remove patients with recently diagnosed diseases or conditions that were 
likely to cause symptoms of cholestatic liver injury, patients who had any of the 
following in their CPRD record 12 months prior to their case date (or matched case 
date for controls) were excluded: any documented liver disease, alcoholism, malignant 
neoplasm of the liver/gallbladder/pancreas, cholelithiasis, viral hepatitis, chronic liver 
disease, cirrhosis, congestive heart failure, hepatitis following blood transfusion, HIV, 
rheumatoid arthritis, sarcoidosis, systemic lupus or inflammatory bowel disease (see 
Chapter 3 Appendix Table 5 for a full list of diagnostic codes) and any liver test results 
that met the criteria for drug-induced-liver injury (see Table 3-4). In addition, any 
woman with a code indicating pregnancy within 40 weeks prior to their index date who 
did not have a subsequent code indicating delivery (or termination of pregnancy in any 
other way) was excluded, due to the fact that the incidence of cholestasis in pregnant 
women is approximately 1 in 100 women [91].    
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Selection of controls 
Controls were selected from the total CPRD population over the age of 18 by a density 
sampling method, meaning that control subjects were selected from the same point in 
time when each case occurred [108]. Up to 4 controls were selected for each case, 
matched on age (+ or – 1 year), sex and practice. Controls were people in the 
database who were being followed on the index date of their matched case (i.e. did not 
have any exclusion criteria in the preceding 12 months), did not have a designation as 
a case of cholestatic liver injury on the index date of their matched case, and also had 
at least 12 months of computerised clinical diagnostic history in CPRD prior to their 
(matched) injury date. If no matches were identified for a particular case, the reasons 
for the no matches being found were considered and presented in the results, before 
dropping the case. The matching program used was an adaptation of a program 
created by Tim Collier (LSHTM), 2012. 
Controls -exclusion criteria 
Identical to that applied to the cases. 
3.4.3.2 Sample size/power calculations 
Power calculations were performed for a matched case control study for each drug 
exposure as described in the literature, using proportion of exposed controls, likely 
number of cases, odds ratio to be detected, number of matched cases and required 
significance as inputs [109]. The proportion of exposed controls was estimated for each 
drug by obtaining a 1 million random sample of people in the database who had an end 
of registration period that was after the start of the study period (1st January 1992), 
searching for the number of people with at least one prescription for the drug of 
interest, and dividing by 1 million. The minimum number of likely cases identified by the 
CPRD cholestatic liver injury algorithm was estimated as 6000, based upon the number 
of (likely to probable) cases identified by the multisource algorithm for a study period 
that was ten years shorter (5014 likely to probable cases, see Chapter 4 Table 4-2).  
The analysis of carbamazepine, celecoxib and ramipril was estimated to have over 
80% power to detect an odds ratio of 1.5 or higher, at a significance of 0.05 (see Table 
3-8). For risperidone and duloxetine, due to the lower number of (estimated) exposed 
controls, the analysis was estimated to have over 80% power to detect an odds ratio of 
2.0. 
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Table 3-8: Power of study to detect cholestatic liver injury for each drug exposure 
Drug Detectable 
odds ratio 
Estimated 
proportion of 
exposed 
controls 
Estimated 
number of 
cases 
Number of 
matched 
controls 
Significance Calculated 
power of 
study 
Carbamazepine 1.5 0.01 6000 4 0.05 83% 
Celecoxib 1.5 0.01 6000 4 0.05 83% 
Duloxetine 1.5 0.003 6000 4 0.05 39% 
 2.0 0.003 6000 4 0.05 84% 
Ramipril 1.5 0.04 6000 4 0.05 99% 
Risperidone 1.5 0.005 6000 4 0.05 57% 
 2.0 0.005 6000 4 0.05 96% 
 
3.4.3.3 Outcome, exposure and co-variates 
Outcomes 
Two of the CPRD cholestatic liver injury algorithm definitions (see section 3.3.2 for 
details) were used as outcomes in the study: (1) the “High” specificity definition (100% 
specificity, 81% sensitivity compared against a gold standard of the multisource 
algorithm probable to definite case - cut off score of 5.0) and (2) the “Low” specificity 
definition (48% specificity, 100% sensitivity, cut off score 1.63). The two CPRD 
algorithm definitions were used to identify cases of cholestatic liver injury as described 
in sections 3.3.1 and 3.3.2.  
For estimations of the relative effect via the case-control analysis (looking at the 
association between the drug exposure and cholestatic liver injury), selection of 
outcomes was performed entirely using the CPRD cholestatic liver injury algorithm. 
Detailed/clinician review of the electronic record of potential cases within a set time 
period prior to the case date (as performed in the previous study in this chapter) was 
not performed, because this was not feasible for the potential control population. 
Furthermore, performing detailed review of only the potential cases and not the 
potential controls would risk biasing the study, because it may have resulted in final 
controls being selected from a population that was not representative of the source 
population from which the final cases were selected [80].  For the analysis of the 
absolute effect of each drug exposure on the incidence of cholestatic liver injury, 
however, the full electronic record of those identified as cases of cholestatic liver injury 
by the CPRD algorithm within 12 months prior to the outcome event was extracted and 
reviewed in order to make a final case status assignment (with consideration as to 
whether there was any other more likely pathological/therapeutic cause for the 
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detected injury). This review was performed by two reviewers (blinded to drug 
exposure) one of whom was clinically trained (Dr Adrian Root, LSHTM and General 
Practitioner), the other being myself. In case of disagreements, the final decision was 
made by the clinically trained reviewer. 
Exposures 
Exposures were determined by searching prescription records within the CPRD 
therapy data files for the drugs under study prior to the index date (searching based on 
drug substance keyword). A person was considered to be exposed to the drug for the 
period that the drug prescription covered (calculated from dosage and pack size 
information in CPRD) plus an additional “grace period” which was dependent upon the 
specific drug, and allowed for the possibility of an additional full prescription. This grace 
period was particularly designed to accommodate drugs that were likely to have been 
prescribed repeatedly over a long period (such as risperidone), where it would have 
been possible that the individual continued to use the drug after the end of their last 
prescription (due to, for example, having a repeat prescription already at home).  The 
exposure variable was split into four categories, defining the following user groups: 
1. current users: people who are exposed to the drug on their index date (i.e. the 
dosage and pack size information plus grace period indicate that the person 
was taking the drug on their index date) 
2. recent users: people who are not current users, but received a prescription that 
ends 1 to 30 days prior to the index date (after taking into account the grace 
period) 
3. past users: people who are not current or recent users, but received a 
prescription that ends earlier than 30 days prior to the index date (after taking 
into account the grace period)  
4. non-users: people who had no prescriptions for the drug of interest prior to their 
index date.  
Where dosage pack and size information was missing and duration could not be 
calculated, a median population pack duration was imputed.  In addition to the five 
drugs under study, flucloxacillin was also analysed as an exposure. This was to allow 
the results obtained in the case control analysis to be verified against those obtained in 
the previous cohort study,(as described in section 3.4.1). 
Co-variates 
Results of previous studies, a-priori knowledge and causal diagrams were used to 
assist with the identification of co-variates. A causal diagram was prepared using the 
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DAGittty graphical tool for analyzing causal diagrams [92], and is included in Chapter 3 
Appendix Table 6b.  Age, gender, smoking, ethnicity, BMI, alcohol intake, SES, use of 
other drugs known to cause cholestatic liver injury and calendar period were all 
considered as potential measurable confounders or effect modifiers. Existing variables 
in the CPRD dataset were created or new ones setup as described for the previous 
study in this chapter (section 3.4.1.5),  
3.4.3.4 Data management, statistical analysis and bias 
CPRD data file extraction 
Patient ids and date of first potential cholestatic liver injury codes (see Chapter 3 
Appendix Table 1) from CPRD for people over 18 years of age with one of the liver-
injury codes of interest between 1st January 1992 and 31st July 2014 were extracted as 
a single (index) file from CPRD, along with additional separate data files containing 
information on all patient demographic information, clinical diagnoses, therapies and 
test results (all linked by unique patient id). This list comprised potential cases. The 
necessary variables for running the CPRD algorithm were then created (see section 
3.3.2), and the CPRD algorithm was applied in order to select actual cases from the list 
of potential cases. Two separate potential case files were created: one containing the 
cases identified by the high specificity version of the algorithm and the other containing 
cases identified by the low specificity version. In both files, all cases had a case date 
variable populated with the date at which they qualified as a case for the specific case 
type (e.g. date of the CPRD record that qualified them as a case according to the 
specific algorithm definition).  Any potential case with clinical codes corresponding to 
the exclusions described in Chapter 3 Appendix Table 5 or liver test results indicative 
of drug-induced liver injury within one year prior to the date of their case assignment 
date was then removed from the two cohorts of cases.  Matched controls from anyone 
in CPRD over the age of 18 with at least 12 months of clinical diagnostic history prior to 
their matched case date were then identified for the cases, and identical exclusion 
criteria applied (searching within one year prior to the matched case date). The two 
case cohorts were then combined with their controls in order to form complete analysis 
cohorts for the two case definitions. All co-variate information was then added to each 
cohort. Finally, drug substance name was used to prepare codelists for each of the 
study drugs (with an additional check using BNF code), which were used to search for 
prescription records for the 5 drugs under study and allowed the (current, recent, past 
and non- user) drug exposure variable to be created.  
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For calculating incidence, the drug codelists were used to identify the total number of 
people over the age of 18 who had at least one prescription for the drug of interest in 
CPRD during the study period.  
Statistical analysis 
Relative effect estimates (rate ratio) 
As density sampling was used to select controls (meaning that controls were selected 
longitudinally through the course of the study as each case was found), the calculated 
odds ratio in this study estimates the rate ratio [108]. All subsequent effect measures 
will therefore be described as rate ratios.  Initial descriptive analysis involved tabulating 
demographic characteristics and co-variates by case and control status. Conditional 
logistic regression was then used to assess the association of the co-variates with the 
outcome, by looking at the estimated rate ratios, their 95% confidence intervals and 
Likelihood Ratio Tests for the overall association of the co-variate.  
A conditional logistic regression model was then prepared, comparing each use 
category with having never used the drug of interest, in order to obtain a crude 
estimated rate ratio for the association between being a current, recent or past user of 
one of the drugs of interest and experiencing a subsequent cholestatic liver injury.  
Figure 3.5 illustrates index dates and drug user classification periods for a sample case 
and a matched control. 
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Figure 3.5: Example patient outcome and exposure timelines for the cholestatic liver injury 
and multiple drug exposures matched cases control study 
Index date for the case is the cholestatic liver injury date, while for the control, it is the cholestatic liver injury 
date for the case it was matched to. In this example, the case has three consecutive prescriptions for the 
drug under study, with the final prescription occurring within 30 days of the index date. Based on 
dosage/pack size information and the addition of any “grace period”, the prescription is estimated to cover a 
period that ends after the index date, meaning that this case would be classified as a “current user”. In 
contrast, the matched control has two prescriptions, the second of which begins more than 30 days before 
the matched index date. The period this prescription is estimated to cover (again based on dosage/pack size 
and “grace period”) ends within 30 days of the matched index date, meaning that this control would be 
classified as a “recent user”. 
Multivariable analysis was then performed by creating a model that included the drug 
exposure of interest and all of the co-variates identified in the causal analysis (age, 
gender, smoking, ethnicity, BMI, alcohol intake, SES, use of other drugs known to 
cause cholestatic liver injury and calendar period).  Statistical tests (LRT) for interaction 
were used to investigate effect modification for each co-variate, and if confirmed, 
stratum specific rate ratios were presented. If no effect modifiers were identified, only a 
single multivariable adjusted rate ratio was presented.  
Absolute effect measures (risk) 
Absolute effect measures were estimated for the drugs under study if the results 
produced by the case control analysis met the following criteria: 
1. There was good evidence that being a current or recent user of the drug was 
shown to be strongly associated with cholestatic liver injury (with a RR of >1.5 
selected as representing a strong association and a 95% CI that did not cross 
the null value of 1.0 selected to indicate good evidence) 
2. The results obtained by the low and high specificity algorithms were 
consistent. This meant that if an association that met the criteria in “1.” above 
day ‐30 day 0
Case
(current user)
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(index date)
Study start
Prescription for
drug of interest
x
day ‐30 day 0
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Study start
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x
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was detected by either the high or low specificity algorithm, the effect estimated 
by the other algorithm was in the same direction and/or the 95% CI included the 
original effect estimate. 
The risk of cholestatic liver injury was calculated by dividing (1) the total number of 
cases identified for the drug (by the low and the high specificity algorithms separately) 
by (2) the total number of people in CPRD with at least one prescription during the 
study period. 95% confidence intervals were calculated on the basis of a Poisson 
distribution of injury events and the risk of cholestatic liver injury per 100 000 current 
and recent users was presented.   
Bias 
Attempts to minimize selection bias were made by selecting controls from the total 
underlying source population that the cases were selected from, and applying exactly 
the same exclusion criteria to controls as cases. Care was taken not to perform review 
of case information that could not also be applied to control information (for example, 
detailed review of potential case records that could not also be applied to potential 
control records was not performed).  Observer bias was minimised by defining set 
periods when people were considered exposed to the drugs of interest and assigning 
exposure status without consideration of case status. Considering consistency of 
results across algorithms carefully (as detailed in the section on absolute effect 
measures above) was performed in order to separate real results from those that may 
have been caused by (for example) unmeasured confounders. 
Handling missing values and low numbers of events 
For numerical-categorical variables that had a lack of events within one or more 
categories, where possible these were combined in order to allow analysis of the 
variable to be performed. The way of defining exposure ensured that the final dataset 
for analyses had no missing values for the main exposure (any of the drugs under 
study) or for the outcome (cholestatic liver injury as determined by different algorithms).  
For co-variates with missing values, the use of two approaches was compared (see 
Chapter 6 for full discussion): 
(1) including all individuals in the analyses and assigning individuals with missing data 
for a particular co-variate to an “unknown” category for that co-variate (allowing the 
extent of the missing data for that variable to be clearly presented) 
(2) restricting the analysis only to those individuals with complete records (complete 
records analysis) 
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3.5 Chapter 3 Summary 
• This chapter described the overall methodology used in the thesis, including 
data sources, methods for algorithm development and methods for two 
epidemiological studies 
 
• The methodology for the following steps was described in detail: 
 
o The use of multiple linked electronic health record sources (CPRD, 
HES, and ONS mortality databases) to construct a multisource algorithm 
for detection of cholestatic liver injury 
 
o The use of the multisource algorithm case status to aid development 
and validation of a CPRD cholestatic liver injury algorithm, using data 
only from a standard CPRD record 
 
o Assessment of the performance of the CPRD algorithm via a cohort 
study on the association between flucloxacillin and cholestatic liver 
injury 
 
o Investigation of a number of putative drug causes of cholestatic liver 
injury via a case control study 
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4 Results – multisource and CPRD cholestatic liver injury 
algorithm development  
4.1 Introduction 
In this chapter, the results of the development of the multisource and CPRD cholestatic 
liver injury algorithms are presented. Details of the number of participants included and 
cohort descriptions are provided for the cohorts used to develop both algorithms. For 
the multisource algorithm, additional results are provided related to the number of 
individuals assigned to each case status (according to the methods described in 
Chapter 3 section 3.3.1.6). For the CPRD algorithm regression analyses results for the 
association between the CPRD explanatory variables and the multisource outcome 
(according to Chapter 3 section 3.3.2.4) are provided, followed by the results of ROC 
analyses to assess how well the CPRD algorithm discriminates the multisource case 
status (according to Chapter 3 section 3.3.2.6).  
4.2 Multisource algorithm development 
4.2.1 Participants 
Between the dates of January 1st 2000 and December 31st 2012 37,520 people were 
identified in CPRD with any of the codes indicative of possible liver injury (as detailed in 
Chapter 3, Appendix Table 1). 7,056 people were then removed as they did not meet 
the necessary eligibility criteria (see Figure 4.1), and removal of a further 14,424 
individuals from practices in Scotland, Wales or Northern Ireland (not part of the HES-
linkage process, as detailed in Chapter 3 section 3.2.2) left a total of 16,040 individuals 
in the cohort used for the development of the multisource algorithm. 
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Figure 4.1: Flow of number of individuals included in the multisource algorithm and the 
CPRD algorithm cohorts 
 
1Ineligible: <18 years of age or registered in CPRD for <12 months prior to liver-related diagnosis 
2No HES-linkage: individual was registered with a primary care practice that was not part of the HES-
linkage process (i.e. practices in Scotland, Wales or Northern Ireland; English practices that have not 
agreed to participate and patients within participating practices that have opted out) 
4.2.2 Descriptive data 
Table 4-1 provides an overview of the characteristics of the people included in the 
multisource algorithm cohort. The median age of the cohort was 62 years, and 52% 
were male. There was a slight increase in the number of diagnoses for the codes of 
interests (see Chapter 3 Appendix Table 1) over the recruitment period of 2000 - 2012 
(with 30% of codes diagnosed between 2009 and 2012), but only in accordance with 
the increase in size of the database between 2009 - 2012 compared to the other 
(shorter) time periods (Chapter 4 Appendix Table 1). The most common index 
diagnosis codes in CPRD were jaundice, obstructive jaundice and cholangitis. Over 
54% of people had a CPRD liver test result recorded within 90 days of their index 
diagnosis date, with the majority of these occurring on or after the index diagnosis date. 
79% of people had been admitted to hospital for any reason within 1 year either side of 
the index diagnosis date (or date of liver test indicating any type of liver injury, if the 
test date was within 90 days prior to the index diagnosis), and for the majority of these, 
the closest hospital admission date to the index date was either on or after the 
diagnosis date. 37% of the cohort had any ONS mortality record at any time after index 
diagnosis.
Individuals in CPRD with at least one of the liver codes of interest between 
01/01/2000 and 31/01/2013 (N=37,520)
Total eligible individuals in CPRD (N=30,464)
Total individuals  included in multisource algorithm cohort (N=16,040)
Ineligible (n=7,056)1
No HES‐linkage (n=14,424)2
CPRD algorithm training 
cohort (N=8,020)
CPRD algorithm validation 
cohort (N=8,020)
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Table 4-1: Characteristics of people included in the multisource algorithm cohort (data 
from CPRD record unless otherwise stated) 
   (N = 16040) 
  n (%)
Age at index diagnosis date1 18 – 29 948 (6)
30 – 39 1452 (9)
40 – 49 2164 (13)
50 – 59 2736 (17)
60 – 69 2937 (18)
70 – 79 3127 (20)
80+ 2676 (17)
median (25 ‐ 75%): 62 (47 – 75)
   
Gender  Male 8406 (52)
Female 7634 (48)
   
Date of index diagnosis  2000 – 2002 3336 (21)
  2003 – 2005 3867 (24)
  2006 – 2008 3962 (25)
2009 – 2012 4875 (30)
   
Index diagnosis   Jaundice2 6951 (43)
Obstructive jaundice nos 2531 (16)
Cholangitis 1144 (7)
Hepatitis unspecified 408 (4)
Chronic hepatitis 541 (3)
Other liver disorders 528 (3)
Biopsy of liver 412 (3)
Any other code3 3223 (20)
   
Liver test results4   No liver test result 7354 (46)
  Test results before index diagnosis 4039 (25)
Test results on or after index diagnosis  4647 (29)
   
HES record5 No HES record 3392 (21)
  HES record before index diagnosis 923 (6)
  HES record on or after index diagnosis  11725 (73)
   
ONS mortality record6  No ONS mortality record 10157 (63)
  Had ONS mortality record 5883 (37)
Note 1: Date of diagnosis with one of the potential cholestatic liver injury codes listed in Chapter 3 
Appendix, Table 1 
Note 2: Includes codes “Jaundice – symptom”, “[d]jaundice”, “O/e – jaundiced”, “[d]jaundice (not of 
newborn)” 
Note 3: People in this group had an index diagnosis of any of the other codes listed in Chapter 3 
Appendix, Table 1 
Note 4: No liver test results=none within 90 days either side of index diagnosis date; test results 
before/after=closest liver test result was before/after the index and within 90 days  
Note 5: No HES record=no HES record ever (n=1080) or no record within 365 days either side of index 
diagnosis date (n=2312); HES record before/after index diagnosis:=closest HES record was before/after 
the index & within 365 days 
Note 6: ONS mortality record at any time (after index diagnosis) 
  
 122 
 
4.2.3 Results 
Applying the algorithm described in Chapter 3 section 3.3.1 resulted in individuals 
being assigned the case statuses shown in Table 4-2. 4032/16040 (25%) of the cohort 
were assigned as definite cases, with almost all of these assigned due to the presence 
of a liver test result recorded in CPRD indicating cholestatic liver injury (pure or mixed, 
as defined in Chapter 3 section 3.3.1.3). None of the individuals who had ONS 
mortality records had “toxic liver disease with cholestasis” indicated on their ONS death 
certificate, and after assignment of definite case status based upon liver test results in 
CPRD, only one person remained who was classified as a definite case based upon 
having had a biopsy or scan in hospital and then being diagnosed with a HES 
diagnosis of toxic liver disease with cholestasis (Group 1). 
No individuals were assigned into the very likely case category (being people without a 
liver test result recorded in CPRD but with both CPRD and HES diagnoses of toxic liver 
disease with cholestasis), and only four individuals were assigned as probable (people 
without liver test results but with at least one database having a recorded diagnosis of 
toxic liver disease with cholestasis). 977/16040 (6%) of the cohort were assigned as 
possible cases of cholestatic liver injury, with the majority (947/977) assigned this 
status due to codes related to jaundice (Group 2) in both databases but no liver tests to 
confirm the presence or absence of a cholestatic pattern of liver injury. The remainder 
of the cohort were assigned as unlikely or non-cases, with unlikely cases being 
assigned as such primarily (3468/3492) due to having a code for jaundice in CPRD but 
no HES records of interest and no liver test results, and non-cases having a less 
specific injury code in CPRD (Group 3) without any codes of interest recorded in HES. 
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Table 4-2: Multisource cholestatic liver injury algorithm – results of case status 
assignment 
CPRD (READ) 
diagnostic 
code 
HES diagnostic (ICD‐10) 
code (plus HES procedural 
code or ONS mortality code, 
where considered)  
CPRD liver test result  Multisource 
algorithm case 
status 
(N = 
16040) 
n (%) 
Group 1|2|31  Not considered  Cholestatic Definite  4032 (25)
Group 1|2|3  ONS (mortality): Group 1 Not considered Definite  0 (0)
Group 1|2|3   HES Biopsy/Scan + Group 1 Not considered Definite  1 (0)
  Total definite  4033 (25)
 
Group 1  Group 1  None2 Very likely  0 (0)
  Total very likely  0 (0)
 
Group 1  Group 2 or No HES record3 None Probable  0 (0)
Group 2|3  Group 1  None Probable  4 (0)
  Total probable  4 (0)
 
Group 1  Group 1|2  Not cholestatic4 Possible  1 (0)
Group 1  HES no codes of interest5 None Possible  25 (0)
Group 2  Group 1  Not cholestatic  Possible  4 (0)
Group 2  Group 2  None Possible  947(6)
  Total possible  977 (6)
 
Group 1   No HES record | 
HES no codes of interest 
Not cholestatic Unlikely  22 (0)
Group 2  No HES record | 
HES no codes of interest 
None Unlikely  3468 (22)
Group 3  Group 1  Not cholestatic Unlikely  2 (0)
  Total unlikely  3492 (22)
 
Group 2  Group 2 | No HES record | 
HES no codes of interest 
Not cholestatic Non‐case  2869 (18)
Group 3  Group 2  None | Not 
cholestatic 
Non‐case  173 (1)
Group 3  No HES record  None | Not 
cholestatic 
Non‐case  340 (2)
Group 3  HES no codes of interest None | Not 
cholestatic 
Non‐case  4152 (26)
  Total non‐case  7534 (47)
Note 1: Group 1=highest evidence for cholestatic liver injury, Group 3=lowest evidence (see Chapter 3 
Appendix Tables 1 & 2) 
Note 2: No liver test result recorded within 90 days of index diagnosis 
Note 3: No HES record indicates person did not attend hospital < 1 year either side of index diagnosis 
Note 4: Liver test result was recorded <90 days from index diagnosis but results indicate either no injury or 
pure hepatic injury 
Note 5: Person attended hospital < 1year from index diagnosis but no liver diagnoses of interest 
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4.3 CPRD algorithm development 
4.3.1 Participants 
Randomly splitting the multisource algorithm cohort into equal-sized datasets (as 
described in Chapter 3 Section 3.3.2.4) left a CPRD algorithm training cohort and a 
CPRD algorithm validation cohort which each contained 8020 individuals (see Figure 
4.1). 
4.3.2 Descriptive data 
The CPRD algorithm training and validation cohorts had a similar distribution of gender, 
age and date of diagnosis characteristics to the (parent) multisource algorithm cohort 
described in section 4.2.2 (see Chapter 4 Appendix Table 2), which was as expected 
given that patients were divided into the two cohorts at random. 
Additional descriptive characteristics for the training cohort are presented in the first 
results column of Table 4-3. 25% of the individuals had a CPRD cholestatic liver test 
result, and just under one fifth had at least one liver-related referral recorded in CPRD 
within 30 days either side of the index date. Almost half of the CPRD index diagnoses 
(46%) were jaundice-related codes, while only 1% were for a code of toxic liver disease 
with cholestasis. 23% of people had one or more additional liver-related diagnoses in 
CPRD within 30 days of the index date, with only 5% having a referral for a liver-related 
scan (or other hospital-based test) recorded in their CPRD record within the same time 
period. 
4.3.3 Results 
4.3.3.1 Univariable and multivariable analysis (training cohort) 
As detailed in Chapter 3 Section 3.3.2, the univariable and multivariable results were 
used to identify those CPRD explanatory variables that were predictors of multisource 
algorithm definite to possible cases (subsequently referred to as “cases”, with 
multisource algorithm least-likely to non-case status referred to as “non-cases”) using 
the training cohort.  
Liver test result status was shown to perfectly predict case status i.e. all of those with 
CPRD cholestatic liver test results were classified as cases, This variable was 
therefore not considered subsequently in the multivariable model, but was included in 
the final design of the CPRD algorithm as described in Chapter 3 section 3.3.2 (Figure 
3.3).  
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The two CPRD explanatory variables that were the strongest predictors of being a case 
in univariable analysis were having an index diagnosis of “Toxic liver disease with 
cholestasis” (OR 5.53, 95% CI 2.54 – 12.03) or having an index diagnosis of 
“Obstructive jaundice” (OR 2.29, 95% CI 2.02 – 2.59).  For both these index diagnoses, 
the association with case status was strengthened after adjustments for all other 
variables, with multivariable odds ratios of 20.59 (95% CI 9.41 – 45.08) for “Toxic liver 
disease with cholestasis” and 6.64 (95% CI 5.42 - 8.13) for “Obstructive jaundice”.    
Having a code for “Jaundice” (or similar) was also strongly associated with being a 
case (multivariable OR 5.10, 95% CI 4.25 – 6.11). Multivariable analysis showed 
weaker positive associations for “Cholangitis” (or similar) (OR 1.89, 95% CI 1.47 – 
2.44) and “Liver enlargement” (or related) (OR 1.98, 95% CI 1.12 – 3.49).  Of the 
remaining index-diagnosis related variables, two were demonstrated to be negative 
predictors for outcome status after multivariable adjustments: “Other or non-specific 
diagnoses” (OR 0.63, 95% CI 0.42 – 0.95) and “Chronic hepatitis” (OR 0.20, 95% CI 
0.09 – 0.45). 
Of the CPRD explanatory variables related to referrals or to additional liver-related 
diagnoses, three showed strong evidence of small associations with multisource 
algorithm case status. People who had any referral recorded in CPRD within 30 days 
before or after the index diagnosis date were more likely to be cases (multivariable OR 
1.48, 95% CI 1.33 – 1.65), as were people referred for a liver-related scan or test 
(multivariable OR 1.51, 95% CI 1.18 – 1.94).  Having an additional liver-related 
diagnosis within 30 days of the index diagnosis date was also a weak predictor for 
being a case (multivariable OR 1.49, 95% CI 1.33 – 1.67). 
The univariable and multivariable results therefore meant that the CPRD variables 
included in the final CPRD cholestatic liver injury algorithm were as listed below. The 
stages refer to the two case-assignment stages of the algorithm as described in 
Chapter 3 section 3.3.2, Figure 3.3 (stage 1=variable perfectly predicts outcome status, 
so anyone with a “1” for this variable is assigned as a case first; stage 2=variable is 
used when obtaining a score for each individual not assigned as a case by stage 1, so 
that total score for the individual can be compared against a specified cut-off score in 
order to assign case status). 
1. CPRD liver test result of cholestatic: algorithm stage 1  
2. Had any referrals: algorithm stage 2  
3. Jaundice (or similar) as index diagnosis: stage 2 
4. Cholangitis-related index diagnosis: stage 2 
5. Chronic hepatitis index diagnosis: stage 2 
6. Obstructive jaundice index diagnosis: stage 2 
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7. Toxic liver disease with cholestasis index diagnosis: stage 2 
8. Liver-enlargement related index diagnosis: stage 2 
9. Other or non-specific liver-related index diagnosis: stage 2 
10. Number of liver related diagnoses <30 days from index diagnosis: stage 2 
11. Referral for liver-related scan <30 days from index diagnosis: stage 2 
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Table 4-3: Descriptive, univariable and multivariable analysis of the association between being a multisource algorithm (definite to possible) case and 
potential CPRD explanatory variables (using the training cohort) 
CPRD explanatory variable   Total
N = 8020 
Cases
N = 2468 
Crude OR1
(95% CI2) 
Multivariable3 OR (95% 
CI) 
p‐value4 
    n (%) n (%)  
CPRD liver test result None |not 
cholestatic 
  6044 (75)    492 (20) ‐ ‐  
Had any referrals5 None    4650 (58)   1132 (46) 1 1  
  1 or more 
referrals 
  3370 (42)   1338 (54) 2.04 (1.86 ‐ 2.25) 1.48 (1.33 ‐ 1.65) <0.001 
Had liver referrals5 None    6513 (81)   1812 (73) 1 1  
  1 or more    1507 (19)    658 (27) 2.01 (1.79 ‐ 2.26) 0.99 (0.84 ‐ 1.15) 0.858 
Top liver referral code5 None | Group 3   6936 (86)   1973 (80) 1 1  
  Group 1 or 
Group 2 
  1084 (14)    497 (20) 2.13 (1.87 ‐ 2.43) 0.98 (0.84 ‐ 1.15) 0.840 
Hepatitis (or similar) index6 No    7442 (93)   2403 (97) 1 1  
  Yes    578 (7)     67 (3) 0.27 (0.21 ‐ 0.36) 1.07 (0.76 ‐ 1.50) 0.701 
Jaundice (or similar) index No    4301 (54)    944 (38) 1 1  
  Yes    3719 (46)   1526 (62) 2.47 (2.24 ‐ 2.73) 5.10 (4.25 ‐ 6.11) <0.001 
Hepatic failure‐related index No  7951 (99)   2464 (100) 1 1  
  Yes      69 (1)      6 (0) 0.21 (0.09 ‐ 0.49) 0.88 (0.38 ‐ 2.01) 0.752 
Cholangitis‐related index No    7262 (91)   2337 (95) 1 1  
  Yes     758 (9)    133 (5) 0.45 (0.37 ‐ 0.54) 1.89 (1.47 ‐ 2.44) <0.001 
Chronic hepatitis index No    7720 (96)   2464 (100) 1 1  
  Yes     300 (4)      6 (0) 0.04 (0.02 ‐ 0.10) 0.20 (0.09 ‐ 0.45) <0.001 
Hepatic enceph or coma index No    7932 (99)   2462 (100) 1 1  
  Yes      88 (1)      8 (0) 0.22 (0.11 ‐ 0.46) 0.96 (0.46 ‐ 1.98) 0.904 
Alcohol‐related index No    7659 (96)   2423 (98) 1 1  
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CPRD explanatory variable   Total
N = 8020 
Cases
N = 2468 
Crude OR1
(95% CI2) 
Multivariable3 OR (95% 
CI) 
p‐value4 
    n (%) n (%)  
  Yes     361 (5)     47 (2) 0.32 (0.24 ‐ 0.44) 1.42 (0.99 ‐ 2.05) 0.065 
Liver necrosis‐related index No    8014 (100)   2469 (100) 1 1  
  Yes       6 (0)      1 (0) 0.45 (0.05 ‐ 3.85) 2.12 (0.34 ‐ 13.24) 0.455 
Obstructive jaundice index No    6774 (84)   1886 (76) 1 1  
  Yes    1246 (16)    584 (24) 2.29 (2.02 ‐ 2.59) 6.64 (5.42 ‐ 8.13) <0.001 
Toxic liver w cholestasis index No    7989 (99)   2448 (99) 1 1  
  Yes      31 (1)     22 (1) 5.53 (2.54 ‐ 12.03) 20.59 (9.41 ‐ 45.08) <0.001 
Toxic liver disease (non‐chol) index  No    7994 (100)   2468 (100) 1 1  
  Yes      26 (0)      2 (0) 0.19 (0.04 ‐ 0.79) 0.88 (0.24 ‐ 3.31) 0.851 
Liver‐enlargement related index  No    7939 (99)   2454 (99) 1 1  
  Yes      81 (1)     16 (1) 0.55 (0.32 ‐ 0.95) 1.98 (1.12 ‐ 3.49) 0.027 
Liver biopsy‐related index No    7689 (96)   2447 (99) 1 1  
  Yes     331 (4)     23 (1) 0.16 (0.10 ‐ 0.25) 0.66 (0.41 ‐ 1.04) 0.060 
Cholaemia index  No    8016 (100)   2470 (100) ‐ ‐  
  Yes       4 (0)      0 (0) ‐ ‐  
Other|non‐specific liver‐related 
index  
No    7598 (95)   2439 (99) 1 1  
  Yes     422 (5)     29 (1) 0.16 (0.11 ‐ 0.23) 0.63 (0.42 ‐ 0.95) 0.020 
No. of liver‐related diag on index5  One     7734 (96)   2350 (95) 1 1  
  More than one    286 (4)    120 (5) 1.66 (1.30 ‐ 2.10) 1.16 (0.90 ‐ 1.49) 0.256 
No. of liver‐related diag5 None    6165 (77)   1652 (67) 1 1  
  One | more   1855 (23)    818 (33) 2.15 (1.94 ‐ 2.40) 1.49 (1.33 ‐ 1.67) <0.001 
Top‐ranked addtl liver diag5 None or Group 
3 
  6693 (83)   1842 (75) 1 1  
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CPRD explanatory variable   Total
N = 8020 
Cases
N = 2468 
Crude OR1
(95% CI2) 
Multivariable3 OR (95% 
CI) 
p‐value4 
    n (%) n (%)  
  Group 1 | 
Group 2 
  1327 (17)    628 (25) 2.15 (1.93 ‐ 2.39) 1.00 (0.82 ‐ 1.22) 0.950 
Referral for liver‐related scan|test5  No referral   7719 (96)   2312 (94) 1 1  
  Had a referral    301 (4)    158 (6) 2.58 (2.05 – 3.26) 1.51 (1.18 ‐ 1.94) <0.001 
1OR: Odds ratio,  2CI: Confidence interval, 3Multivariable OR: Frith method (see Chapter 3), adjusted for all other variables in the table, 4p‐value: result of the Likelihood Ratio Test of the assoc. of the 
variable with the outcome after adjustments for all other variables in the table , 5multiple variables:+‐30 days from index date (see Chapter 3 Appendix Table 4), 6index: index diagnosis
 130 
 
4.3.3.2 ROC analyses of cholestatic liver injury algorithm and consideration of cut-off 
scores (validation cohort) 
ROC analysis of the complete CPRD cholestatic algorithm (stage 1 and stage 2 case 
assignment) 
The variables shown to be predictors of multisource algorithm case status in the 
training cohort were added to the validation cohort. A CPRD algorithm score was then 
generated for each person and a “perfect prediction” score was assigned to those 
individuals with a “1” for any of the variables shown to be perfect predictors of 
multisource case status (as described in Chapter 3 section 3.3.2.6). The sensitivity and 
specificity of the full 2-stage algorithm was then calculated by applying the algorithm to 
the validation cohort data, using a range of cut-off scores to define case status. A ROC 
(receiver operating graph) of these results is provided in Figure 4.2, with the full 
tabulation of results provided in Chapter 4 Appendix Table 3. 
Figure 4.2: ROC (Receiver Operating Characteristics) graph of Sensitivity against 1-
Specificity for a range of CPRD algorithm cut-off scores, comparing the complete CPRD 
cholestatic liver injury algorithm against a multisource algorithm case status of probable 
to definite 
 
Area under ROC curve: 0.95  
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The area under the ROC curve (AUC) may be used to indicate the ability of a measure 
(in this case the complete CPRD algorithm) to discriminate between individuals with 
and without a particular condition [110] (in this case discrimination is between 
individuals with a multisource algorithm case status of “definite” to “possible” and 
individuals with a multisource algorithm case status of “unlikely” to “non-“ ). An AUC of 
1.0 indicates perfect discrimination, while 0.5 indicates that the measure under test 
does not discriminate at all. The value of 0.95 obtained indicates that overall the 
complete CPRD algorithm has an excellent ability to discriminate between individuals 
with a multisource algorithm case status of “definite” to “possible” and individuals with a 
multisource algorithm case status of “unlikely” to “non-“. 
Chapter 4 Appendix Table 3 provides detail on how the sensitivity and specificity are 
related to the total CPRD algorithm (stage 1 and stage 2 case assignment) score, this 
shows that with increasing specificity, sensitivity remains high (for a specificity of 
100.0%, sensitivity is over 80.0%). 
ROC analysis of the algorithm cut-off score (stage 2 case assignment only) 
As described in Chapter 3 section 3.3.2.6, in order to assess how well the CPRD 
algorithm cut-off score can discriminate between multisource case status within the 
population that it would be applied to (i.e. all those people who do not have a 
cholestatic liver test result), the ROC analysis was repeated having removed all the 
individuals from the cohort who had a cholestatic liver enzyme test result (i.e. all people 
who would already have been assigned as cases by stage 1 of the CPRD cholestatic 
liver test result algorithm). A ROC graph of these results is provided in Figure 4.3 with 
the full tabulation of results provided in Chapter 4 Appendix Table 4. 
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Figure 4.3: ROC (Receiver Operating Characteristics) graph of Sensitivity against 1-
Specificity for a range of CPRD algorithm cut-off scores, comparing the CPRD 
cholestatic liver injury algorithm score (i.e. stage 2 case assignment only) against a 
multisource algorithm case status of probable to definite 
 
Area under ROC curve: 0.75 
 
The area under the ROC curve of 0.75 obtained indicates that overall, within the 
population that it will be applied to (i.e. people who do not have a cholestatic liver test 
result), the CPRD algorithm score has quite good ability to discriminate between 
individuals with a multisource algorithm case status of “definite” to “possible” and 
individuals with a multisource algorithm case status of “unlikely” to “non-“. 
Chapter 4 Appendix Table 4 provides detail on how the sensitivity and specificity are 
related to the CPRD algorithm score generated for stage 2 of the algorithm. For a score 
that would achieve a specificity of over 90%, sensitivity would be less than 25% 
(meaning that although one could be sure that 90% of the non-cases would be 
identified as such, less than 25% of all cases would be correctly identified = a high 
number of false negatives). Conversely, a moderately high specificity (65%) could be 
achieved while maintaining a very high sensitivity (94%), meaning that one could be 
sure that 94% of all cases and 65% of all non-cases would be correctly identified (very 
nearly all cases would be correctly classified and the majority of non-cases would be 
correctly classified). 
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4.4 Discussion 
4.4.1 Multisource algorithm 
The results for development of the multisource algorithm showed that definite case 
status is heavily influenced by the CPRD record, with almost all of the definite cases 
assigned as such based on liver enzyme level test results recorded in CPRD (Table 
4-2). HES or ONS information only allowed for the identification of one additional 
definite cases among the people not identified as definite cases by their liver test 
results in CPRD. The lack of people with an ONS cause of death of “Toxic liver disease 
with cholestasis” could be because it is a rare occurrence, or also because the actual 
cause of death is likely to be recorded as a less specific term such as acute liver failure 
(which would not be specific enough to aid with the identification of cholestatic injury as 
the cause of death).  
Table 4-1 showed that nearly half of the cohort (46%) did not have a liver test result 
recorded in CPRD within 90 days either side of their index diagnosis. Given the fact 
that the members of the cohort were identified by the presence of (mainly acute) liver-
related codes, one could expect that standard clinical procedure would be to have 
performed a test of liver enzyme levels within the period 90 days before or after the 
index diagnosis. Many of the individuals who did not have liver tests recorded in CPRD 
are therefore likely to have had tests performed elsewhere, for example in hospital. An 
important limiting factor of HES data is that while liver enzyme level tests are 
performed in UK hospitals, their results are not recorded in the HES database. If results 
from hospital liver tests were available in HES, this could result in individuals within the 
cohort being promoted from any other multisource case status to “definite”. The lack of 
liver test data within HES is a major deficiency when comparing HES to CPRD, and for 
the ability of HES to facilitate detection of patients with liver injury.  
A second reason why the proportion of people with liver tests is not higher could be 
because the standardisation and automation of transfer of laboratory test results 
between pathology labs and primary care centres was only implemented around 2007 
[111], and therefore although the tests were being performed in primary care, they 
were not being entered into the database. An analysis of the proportion of people who 
had liver test results recorded in CPRD for those with liver injury dates before 2007 
compared with after 2007 (Chapter 4 Appendix Table 5) supports this reasoning, as 
65% of people with potential liver injury after 2007 had liver test results recorded in 
CPRD (compared to 45% of those with potential liver injury dates before 2007). 
In addition to the definite case status, HES data do not help identify any very likely 
cases and only four probably cases. Apart from the lack of liver test result information, 
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this could be attributed to the fact that there are very few people without liver test 
results recorded in primary care who have diagnoses in hospital of toxic liver disease 
with cholestasis (with or without a biopsy or related procedure). Searching for these 
people within the subset who had already been identified as definite cases based upon 
liver enzyme level results retrieved an additional three people only, showing that a 
hospital diagnosis of toxic liver disease with cholestasis is rare, even within those 
people who have liver enzyme levels indicating a cholestatic pattern of liver injury. 
The HES data in this algorithm did allow possible cases to be distinguished from 
unlikely cases, within people who had a code for “Jaundice” in CPRD but did not have 
any liver test results recorded. These people make up 28% of the cohort, with around a 
fifth of these people (6% of the cohort) identified as possible cases (rather than unlikely 
cases) due to the presence of a code for “Jaundice” in the HES data.  
4.4.2 CPRD algorithm 
A liver enzyme test result of cholestatic was a perfect predictor of multisource case 
status, which is not surprising given the weight applied to this in the multisource 
algorithm (based upon international consensus on the importance of liver enzyme 
levels for classification of liver injury [46]). Strong predictors were diagnostic terms that 
clinically would be expected to be describing a cholestatic type of liver injury (toxic liver 
disease with cholestasis, obstructive jaundice and jaundice). Having other referrals was 
associated with being a multisource case, while the association between having a liver-
related referral and being a multisource case observed in univariable analysis was 
removed after multivariable adjustments. The people with one or more liver-related 
referrals are likely to also have liver diagnoses that are strong predictors for cholestatic 
injury (such as jaundice), so adjusting for these diagnoses removes the observed 
association. 
In the complete CPRD algorithm, the first stage assigns all those with liver enzyme test 
results of cholestatic as cases, before the second stage assigns a case status to the 
remaining individuals based upon the algorithm score obtained from the regression 
analysis. The ROC analysis showed that this complete CPRD algorithm had very good 
ability to discriminate between the two multisource algorithm case statuses (definite to 
probable compared to unlikely to non-). This is not an unexpected result, because the 
CPRD liver test results included in stage 1 of the CPRD liver test results are a strong 
driver of the multisource case status (81% of the definite to possible multisource cases 
have a cholestatic liver test result). Individuals without cholestatic liver test results who 
are multisource cases may then be assigned as cases by the CPRD algorithm score 
developed by the regression analysis. The second ROC analysis showed that within 
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those people who did not have cholestatic liver test results, the regression score had 
quite good ability to identify the remaining multisource cases. 
As discussed in the results section, there is a trade-off of sensitivity and specificity. A 
very specific application of the algorithm and one that is comparable with legacy 
approaches (although it is difficult to accurately compare with legacy approaches due 
to generally vague descriptions of exactly how cases have been identified in the past - 
see Chapter 2) would be to use the score of 5 from Chapter 4 Appendix Table 3 (100% 
specificity, 81% sensitivity), which corresponds to only assigning those people who 
have cholestatic liver test results as cases. A more sensitive and less specific method 
could use a cut-off score set to 2.29 (86% sensitivity and 86% specificity), which would 
still include all those people with cholestatic liver test results, but in addition would 
include people who (for example) did not have cholestatic liver test results but had 
index diagnosis of “obstructive jaundice” and multiple liver-related diagnoses within one 
month, or people who had an index diagnosis of “jaundice” (or similar), multiple liver-
related diagnoses within one month and one or more referrals to hospital within a 
month. 
In terms of applying the score for pharmacoepidemiological studies, it is important to 
note that the CPRD algorithm (and multisource algorithm) developed here only detects 
people who have biochemical, clinical and administrative characteristics that are 
suggestive of a cholestatic type of liver injury. For estimating absolute effects, further 
review of the records of people selected by the algorithm by medically trained 
professionals would be needed in order to rule out non-drug causes, and assist in the 
decision as to whether the injury is caused by the drug under study.  Nevertheless, it is 
worthwhile to consider what type of score could be used for different scenarios. The 
score used to identify people is likely to depend on the type of study being performed, 
financial resources available, time that the drug has been on the market, and frequency 
of liver injury events associated with the drug. For performing a 
pharmacoepidemiological study to quantify frequency and risk of cholestatic liver injury 
for a drug that has been marketed for some time and/or is associated with a relatively 
high rate of event, a highly specific method could be applied (for example, based only 
on liver test results), because power is unlikely to be an issue. In contrast, if the study 
is being performed shortly after drug launch, when exposure has been limited and/or 
the drug does not cause many events, a more sensitive score could be needed in order 
to increase numbers. When considering the results obtained, one might expect that if 
performing a cohort study, using a more sensitive less-specific score may not be 
expected to influence the relative risk or rate ratios (assuming that the loss of specificity 
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is non-differential with respect to exposure status), but would influence the absolute 
rate estimates, which could be critical for making risk/benefit decisions about a drug. 
For active recruitment to studies required for developing predictive genetic tests, the 
proximity to market launch, severity of injury and how much of the reaction can be 
attributed to genetic factors are all aspects that could influence which score to use. For 
drugs that have been marketed for some time and are not at risk of being withdrawn 
from the market due to the adverse reaction, a specific score could be used. In 
contrast, if fast recruitment is required in order to try and develop a predictive genetic 
test to ensure that a drug causing more serious liver injury can be used as an effective 
therapy and not removed from the market, a more sensitive method could be adopted, 
but really only if additional resources are available for thorough clinical review of 
records and/or obtaining data that could confirm the individual as a definite cases (e.g. 
liver test results that were performed but not recorded in CPRD, possibly via new 
linkages to liver clinics). 
4.4.3 Comparison with previous work 
A systematic review of the studies that included a number of algorithms for identifying 
cholestatic liver injury was performed as Chapter 2 of this thesis. None of these studies 
used multiple databases in the development of their algorithms. One study looking at 
acute liver injury published in 2014 did develop algorithms involving more than one 
database (one in the UK and one in Spain), but in contrast to the work performed here, 
was looking at the application of separate algorithms to each database, rather than 
using multiple database sources to validate a single-source database algorithm [112]. 
A validation step was performed, but this was not part of the development of the 
algorithm, but instead was to assess performance of the computer algorithm against 
expert review of the records.  A similar exercise is described within a U.S. study 
involving the application of 4 different algorithms across 7 databases [113]. While this 
study does discuss the fact that the recording of liver test results was found to be 
variable across databases, liver test results were available in each database, and 
differences in measurement are discussed as being due to differences in the evaluation 
and handling of acute liver injury within each database population. 
4.4.4 Limitations 
In the development of the CPRD algorithm, the response variable “case” included 
multisource case statuses of “definite” to “possible”, with possible cases including 
people who had been diagnosed with jaundice in both CPRD and HES, but with no 
additional supporting information to guide case status assignment (such as liver 
enzyme level test results or biopsies/scans). There is therefore a potential for people to 
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have been incorrectly classified as cases of cholestatic liver injury in this scenario, and 
development of a CPRD algorithm based upon this potentially non-specific case 
definition could negatively affect the ability of the resultant CPRD algorithm to detect 
true cases of cholestatic liver injury. Including these people in the response variable 
“case” was considered preferable to not including them, however, because it is likely 
that many of them did have liver tests performed that indicated cholestasis, but this 
information was not available. The uncertainty is due to the (lack of) availability of data, 
therefore. Including them as cases means that they at the very least have the 
opportunity to be considered as cases subsequently, and ensures that the CPRD 
algorithm developed using the multisource algorithm also has the ability to identify 
these people as cases. Their inclusion in epidemiological studies can then be 
considered based upon some of the factors detailed previously in this section. 
A second limitation that should be considered relates to the similarity of data that the 
multisource and CPRD algorithms relied on for assigning case status, meaning that the 
comparison of the two algorithms performed in this chapter was a slightly circular 
exercise. As discussed earlier, this is partly due to the lack of liver test result records in 
HES data, and also because the number of liver-related procedures recorded in HES 
was low. Despite this effective negative result, the finding that combined (linked) CPRD 
and HES data does not increase the ability to detect acute liver injury when compared 
to CPRD alone is an important one. Publication of the results of this method 
development will allow other researchers considering similar approaches to benefit. 
Furthermore, publication will allow emphasis to be placed on the fact that while new 
linkages are being created between databases that could facilitate 
pharmacoepidemiology, the quality of the underlying data needs to be improved in 
order to realise the full potential of such linkages. 
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4.5 Chapter 4 Summary 
• In this chapter, the results of the development of the multisource and CPRD 
cholestatic liver injury algorithms were presented.  
 
• Within the multisource algorithm, data from CPRD (particularly liver test results) 
enabled definite cases of cholestatic liver injury to be identified.  
 
• HES data allowed possible cases to be discriminated from unlikely cases (6% 
of total cases were considered to be possible due to the presence of HES data), 
but a lack of liver test result data limited the use of HES data for the 
identification of definite cases of cholestatic liver injury. 
 
• CPRD variables that were shown to be predictors of multisource algorithm case 
status during development of the CPRD algorithm included liver test results, 
diagnostic terms related to cholestasis and jaundice, and being referred to 
hospital.  
 
• ROC analysis showed that the CPRD algorithm had a very good ability to 
discriminate between multisource case statuses of definite to possible vs. 
unlikely to non- (area under the curve 0.95), and that highly specific CPRD 
algorithm cut-off scores had a lower sensitivity than those with lower specificity 
 
• The use of either a highly specific or highly sensitive CPRD algorithm score for 
identifying cases of cholestatic liver injury could depend on the setting 
(pharmacoepidemiological studies versus recruitment for genetic association 
studies; newly marketed drug versus older drug; poorly resourced study versus 
well-resourced study) 
 
  
 139 
 
5 Results: applying the algorithm to a well-established 
association – a cohort study of the association between 
flucloxacillin and cholestatic liver injury  
5.1 Introduction 
In this chapter, the results are presented for the cohort study of the association 
between flucloxacillin (compared with oxytetracycline) and cholestatic liver injury, 
performed in order to compare CPRD cholestatic liver injury algorithm cut-off scores 
with varying specificity and sensitivity with (1) each other (2) the multisource algorithm 
and (3) published literature. Details of the number of participants included and a cohort 
description are provided, before the results of the following analyses are presented for 
each outcome definition: 
(1) Number and characteristics of identified cases 
(2) Frequency (risk) of cholestatic liver injury 
(3) Association between flucloxacillin (compared with oxytetracycline) and 
cholestatic liver injury 
(4) Risk factors for flucloxacillin-induced liver injury 
Finally, a discussion of the results is provided, in which the outcome definitions are 
compared with each other and with previously published results. 
Throughout this chapter, the CPRD algorithm cut-off scores will be described in terms 
of their specificity (as compared to the multisource case status of definite to probable), 
with cut-off score 5 being “high” specificity (specificity 100%, sensitivity 81%), score 
2.29 “medium” specificity (86%, 87%) and score 1.63 “low” specificity (48%, 100%). 
5.2 Participants 
Between the dates of 1st January 2000 and 1st January 2012 1 073 894 people aged 18 
years and over were identified in CPRD who received a first prescription for either 
flucloxacillin or oxytetracycline and had been registered in the database for at least 12 
months.  27 156 people were subsequently removed as they did not meet the 
necessary eligibility criteria, leaving 1 046 738 patients in the cohort. An additional 42 
were found to have reasons for exclusion during case review (i.e. assessment of 
whether one of the study drugs had caused the detected injury), leaving a final cohort 
of 1 046 696 people for analysis.  Of these, 861 959 were in the flucloxacillin exposure 
group. For analyses performed with the multisource algorithm outcome, restricting the 
cohort to only those from HES-linked practices left 621 476, 517 803 of whom were in 
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the exposed to flucloxacillin group. Full details of exclusions, numbers of individuals in 
each analysis and their exposure status are provided in Figure 5.1. 
 
Figure 5.1: Flow of number of individuals included in the cohort study of the association 
between flucloxacillin (compared with oxytetracycline) and cholestatic liver injury  
1Ineligible: had a diagnostic exclusion code or test result within 1 year prior to their index date, made up 
of: (i) 11089 individuals with pregnancy codes but no subsequent end of pregnancy code before index date 
(ii) 13139 individuals with liver pathology codes as defined in Chapter 3 Appendix Table 5 and (iii) 2928 
individuals with liver test results that qualified as DILI as defined in Chapter 3 Table 5 
2Excluded: individuals identified as cases of cholestatic liver injury, but on clinician review of record from 2 
years prior to index date, an underlying cause other than a prescription with either of the drugs of interest 
was identified (and the date was prior to the index date) 
3Flucloxacillin: Number of people prescribed flucloxacillin on their index date. 47370/861959 were 
prescribed the flucloxacillin-ampicillin combination (co-fluampicil). 
4Oxytetracycline: Number of individuals prescribed oxytetracycline on their index date who were not also 
prescribed flucloxacillin before their end of follow-up. Individuals who were also prescribed flucloxacillin 
before their end of follow-up were assigned to the flucloxacillin group. 
  
Individuals in CPRD over the age of 18 prescribed one of the drugs under study 
between 01/01/2000 and 01/01/2012 with at least 6 months registration in CPRD 
prior to drug prescription (N=1,073,894)
Ineligible (n=27,156)1
Complete cohort analysis 
(N=1,046,696)
Flucloxacillin3: n=861,959
Oxytetracycline4: n=184,737
Total eligible individuals (N=1,046,738)
Excluded (n=42)2
Complete cohort (N=1,046,696)
No HES‐linkage 
(n=425,220)
HES‐linked cohort analysis
(N=621,476)
Flucloxacillin: n=517,803
Oxytetracycline: n=103,673
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5.3 Descriptive data 
The cohort consisted of 1 046 696 people, 861 959 first-time users of flucloxacillin and     
184 737 first time users of oxytetracycline (who were not also prescribed flucloxacillin 
during follow-up).  Between the earliest prescription for a drug of interest (1st January 
2000) and the latest end of follow-up (22 December 2011), the cohort contributed a 
total of 3 026 080 person months at risk (2 490 320 person months of exposure to 
flucloxacillin). The median follow-up was 90 days. Table 5-1 provides an overview of 
the characteristics of the people included in the cohort, by therapy exposure group. 
There was a suggestion that people prescribed flucloxacillin were slightly younger than 
those prescribed oxytetracycline (median age of 48 compared to median age 50). 56% 
of those prescribed oxytetracycline were female, compared with 54% of those 
prescribed flucloxacillin, and a higher proportion of those in the oxytetracycline group 
(55%) had an index date prior to 2006 than in the flucloxacillin group (48%). 
Oxytetracycline included a higher proportion of people on other drugs likely to cause 
cholestatic liver injury than flucloxacillin users (81% vs. 52%). There was no difference 
in recorded ethnicity between the groups, with 51% of people recorded as “White”, and 
there were minimal differences in alcohol intake, SES, smoking and BMI between 
exposure groups. 
For the HES-linked cohort used for all analyses involving the multisource algorithm, 
there was a total of 621 476 people (517 803 of whom were in the exposed to 
flucloxacillin group), contributing a total of 1 796 270 person months at risk. Distribution 
of co-variates by exposure status was comparable to the main cohort (Chapter 5 
Appendix Table 1).  
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Table 5-1: Characteristics of participants included in the cohort analysis of the association 
between flucloxacillin (compared with oxytetracycline) and cholestatic liver injury, by exposure 
status  
  Oxytetracycline 
(N = 184,737) 
Flucloxacillin
(N = 861,959) 
  n (%)  n (%)
Age at index date  18 – 29 31067 (17)  147656 (17)
  30 – 39 30594 (17)  159177 (18)
  40 – 49 30678 (17)  146803 (17)
  50 – 59 30269 (16)  129179 (15)
  60 – 69 28229 (15)  111368 (13)
  70 – 79 21214 (11)  91441 (11)
  80+ 12686 (7)  76335 (9)
  median (25 ‐ 75%): 50 (35 – 65)  48 (34 – 65)
   
Gender  Male 81316 (44)  394125 (46)
  Female 103421 (56)  467834 (54)
   
Date of index prescription  2000 – 2001 32439 (17)  112188 (13)
  2002 ‐ 2003 34830 (19)  143752 (17)
  2004 ‐ 2005 32615 (18)  156808 (18)
  2006 ‐ 2007 30090 (16)  159304 (18)
  2008 ‐ 2009 29217 (16)  153679 (18)
  2010 ‐ 2011 25546 (14)  136228 (16)
   
Prescriptions for other causes   None 34529 (19)  415687 (48)
of cholestatic injury1 Less common cause 143164 (77)  399846 (47)
  More common cause 7044 (4)  46426 (5)
   
Smoking status   Non‐smoker 84864 (46)  382320 (44)
  Ex‐smoker 40979 (22)  219122 (25)
  Current smoker 55343 (30)  242314 (29)
  Unknown 3551 (2)  18203 (2)
   
BMI   <20 10923 (6)  48451 (6)
  20 ‐ 25 55689 (30)  247583 (29)
  25+ 95215 (52)  447203 (52)
  Unknown 22910 (12)  118722 (13)
   
Alcohol intake  Non‐drinker 20831 (11)  97065 (11)
  Ex‐drinker 5581 (3)  28277 (3)
  Current NOS 5852 (3)  27452 (3)
  2 or less u/d 30424 (16)  139300 (16)
  3/6 u/d 84057 (46)  381539 (44)
  >6 u/d 13232 (7)  66576 (8)
  Unknown 24760 (14)  121750 (15)
   
Socioeconomic status2  1 (Highest SES) 33239 (18)  153552 (18)
  2  29919 (16)  145586 (17)
  3  27753 (15)  140223 (16)
  4  27541 (15)  131425 (15)
  5 (Lowest SES) 19122 (10)  102723 (12)
  Unknown 47163 (26)  188450 (22)
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  Oxytetracycline 
(N = 184,737) 
Flucloxacillin
(N = 861,959) 
  n (%)  n (%)
 
Ethnicity3  White 93400 (51)  440740 (51)
  South Asian 3010 (2)  14487 (2)
  Black 1445 (1)  8566 (1)
  Other 1470 (1)  6202 (1)
  Mixed 392 (0)  2238 (0)
  Not Stated 14390 (8)  70946 (8)
  Unknown 70630 (37)  318780 (37)
Note 1: Prescription counted if it occurred anytime from 1 month prior to index date or between index date and before end of 
follow‐up (see  Chapter 3 section 3.4.1.5). Less or more common in relation to flucloxacillin, as reported in the literature (see 
Chapter 3 section 3.4.1.5) 
Note 2: Linked data, only available for practices in England, based on index of Multiple Deprivation (individual patient 
postcode) or otherwise practice level score based upon practice postcode (if no individual‐level data) (see Chapter 3 section 
3.4.1.5). 
Note 3: Obtained from CPRD, unless none found, in which case from HES if patient from a linked practice (see Chapter 3 
section 3.4.1.5). 
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5.4 Number and characteristics of identified cases 
393 people had one of the liver-related codes used as the first identification step in all 
of the algorithms (as detailed in Chapter 3 Appendix Table 1).  Of these, 277 (70%) 
were identified as being cholestatic liver injury cases by any of the CPRD algorithms (3 
cut-off scores of high to low specificity) within 90 days of the index prescription. The % 
of cholestatic liver injury cases identified as being due to flucloxacillin or oxytetracycline 
was similar for the high and low specificity CPRD algorithms (72% and 68% 
respectively), and slightly higher for the medium specificity CPRD algorithm (78%) 
(Table 5-2). When the CPRD algorithms were applied to the HES-linked cohort, the 
proportions of cholestatic liver injury cases considered to be caused by flucloxacillin or 
oxytetracycline following record review were higher than in the complete cohort. The 
proportion detected by the multisource algorithm in the HES-linked cohort was 74%, 
which was lower than any of the CPRD algorithms when applied to this population 
(lowest figure: 82%). 
The median time between the index prescription and date of liver injury was between 
32 and 36 days across all four algorithms. Cases selected by the high specificity CPRD 
algorithm were characterised by the broadest range of diagnoses, but all had 
cholestatic liver injury results. The medium-specificity algorithm included all 75 of the 
individuals identified by the high specificity algorithm, along with an additional 43 
people identified due to having a diagnoses for jaundice/obstructive jaundice or toxic 
liver disease with cholestasis and either a hospital referral or another liver-related 
diagnoses. An additional 71 people identified by the low specificity algorithm were 
included due to having had one of the afore-mentioned diagnoses only. All of the 70 
individuals identified as cases of flucloxacillin or oxytetracycline-induced liver injury by 
review of the multisource algorithm individuals had these diagnoses, with 40 also 
having cholestatic liver test results and the remainder having a HES diagnosis of 
jaundice or toxic liver disease with cholestasis.  
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Table 5-2: Number of cholestatic liver injury cases and number subsequently identified as flucloxacillin or oxytetracycline-induced, time between 
prescription and case assignment date, and characteristics of cases for each of the algorithms under test 
Algorithm 
(specificity1) 
Specificity, 
sensitivity 
Number identified as cholestatic liver injury cases: 
Number subsequently identified as flucl‐ or oxyt‐ 
induced (%)2 
Time from first 
prescription until case 
assignment 
Characteristics of cases3 
    Complete cohort  HES‐linked cohort  Median in days (25 ‐ 75%)   
CPRD (High)  100%, 81%  104:75 (72%) 68:56 (82%) 36 (24 – 40) From CPRD: an index diagnosis of jaundice, obstructive 
jaundice, toxic liver disease with cholestasis or liver 
disorder nos AND (2) a cholestatic liver test result (within 
90 days of index diagnosis). 
   
CPRD (Medium)  86%, 87%  151:118 (78%) 96:84 (88%) 35 (25 – 40) From CPRD: an index diagnosis of jaundice, obstructive 
jaundice or toxic liver disease with cholestasis AND 
EITHER a hospital referral OR an additional liver‐related 
diagnosis (both within 30 days of index diagnosis).  
   
CPRD (Low)  48%, 100%  277:189(68%) 149:123 (83%) 32 (22 – 38) From CPRD: an index diagnosis of jaundice, obstructive 
jaundice or toxic liver disease with cholestasis.  
   
Multisource 
(probable ‐ 
definite) 
‐ NP4 95:70 (74%) 36 (24 ‐ 40) From CPRD: an index diagnosis of jaundice, obstructive 
jaundice or toxic liver disease with cholestasis AND 
EITHER a cholestatic liver test result OR FROM HES: a 
diagnoses of jaundice or toxic liver disease with 
cholestasis (within 90 days of the index diagnosis). 
Note 1: Compared against a gold standard of the multisource algorithm (probable – definite case). High=CPRD algorithm cut‐off score of 5, medium=CPRD algorithm cut‐off score of 2.29, low=CPRD 
algorithm cut‐off score of 1.63. 
Note 2: The multisource results were obtained from a dataset that was (necessarily) smaller than that used to obtain the CPRD algorithm results, because only the subset of patients in English practices 
have HES data (which is required for the multisource algorithm). For ease of comparability with the multisource figures, the CPRD algorithm figures are presented for the HES‐linked proportion of the 
CPRD dataset (in addition to those for the full dataset). 
Note 3: CPRD algorithms 2.29 and 1.63 include patients selected with the characteristics described, in addition to all of those selected by the higher algorithm cut‐off score(s) 
Note 4: NP = analysis not performed, as multisource algorithm can only be applied to a cohort of HES‐linked CPRD patients. 
 146 
 
5.5 Frequency (risk) of cholestatic liver injury  
Within the complete cohort, there were 53 out of 861959 users of flucloxacillin who 
experienced cholestatic liver injury as defined by the high specificity algorithm in the 
45-days after prescription. This gave a 45-day risk of flucloxacillin-induced cholestatic 
liver injury of 6.15 (95% confidence interval (CI) 4.61 – 8.04) cases per 100 000 
patients prescribed the drug (Table 5-3). The risk increased with increasing algorithm 
sensitivity, up to 14.15 (95% CI 11.95 – 16.90) cases per 100 000 patients for the least 
specific algorithm. The oxytetracycline risk for the comparable period was 1.62 (95% CI 
0.33 – 4.75) for the algorithms with medium and high specificity, increasing to 3.79 
(95% CI 1.52 – 7.81) for the most sensitive algorithm (low specificity). The 45-day risk 
starting from the 46th day from first prescription with flucloxacillin was 2.02 (95% CI 
1.18 – 3.24) for the high specificity CPRD algorithm, and increased slightly by 
increasing algorithm sensitivity.  
The estimated 45-day risk from the day of first prescription with flucloxacillin using the 
multisource algorithm in the cohort restricted to HES-linked patients was 8.69 (95% CI 
6.34 – 11.63) per 100 000 users. The risk estimates for the CPRD algorithms for 
flucloxacillin in the restricted cohort were all higher than (but generally similar to) those 
obtained in the complete cohort analyses.  
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Table 5-3: Risk of cholestatic liver injury identified using the CPRD algorithm (3 different cut-off scores) and the multisource algorithm by (1) exposure to 
flucloxacillin or oxytetracycline (for the 1-45 day period after exposure) and (2) flucloxacillin exposure period (1-45 days compared to 46-90 days after 
exposure)   
      Complete cohort    Cohort restricted to HES‐linked patients only 
Algorithm 
(specificity) 
Specificity, 
sensitivity1 
Exposure group # with 
outcome 
Patients2  45‐day risk (CI3) 
(per 100 000 patients 
prescribed the drug) 
  # with 
outcome 
Patients  45‐day risk (CI) 
CPRD (High)  100%, 81% Oxytetracycline 1 ‐ 45 days <54 184737 1.62 (0.33 – 4.75) 0 103673 ‐ 
  Flucloxacillin 1 ‐ 45 days 53 861959 6.15 (4.61 – 8.04) 40 517803 7.72 (5.52 – 10.52) 
  Flucloxacillin 46 ‐ 90 days 17 840910 2.02 (1.18 – 3.24) 15 505020 2.97 (1.66 – 4.90) 
       
CPRD (Medium)  86%, 87% Oxytetracycline 1 ‐ 45 days <5 184737 1.62 (0.33 – 4.75) 0 103673 ‐ 
  Flucloxacillin 1 ‐ 45 days 77 861959 8.93 (7.05 – 11.16) 57 517803 11.01 (8.34 – 14.26) 
  Flucloxacillin 46 ‐ 90 days 32 840888 3.81 (2.60 – 5.37) 24 505020 4.75 (3.04 – 7.07) 
       
CPRD (Low)  48%, 100% Oxytetracycline 1 ‐ 45 days 7 184737 3.79 (1.52 – 7.81) <5 103673 1.93 (0.23 – 6.97) 
  Flucloxacillin 1 ‐ 45 days 122 861959 14.15 (11.75 – 16.90) 83 517803 16.03 (12.77 – 19.87) 
  Flucloxacillin 46 ‐ 90 days 48 840847 5.71 (4.21 – 7.57) 32 504997 6.34 (4.33 – 8.95) 
       
Multisource   ‐ Oxytetracycline 1 ‐ 45 days NP5 NP NP <5 103673 0.96 (0.02 – 5.37) 
  Flucloxacillin 1 ‐ 45 days NP NP NP 45 517803 8.69 (6.34 – 11.63) 
  Flucloxacillin 46 ‐ 90 days NP NP NP 22 505035 4.36 (2.73 – 6.59) 
Note 1: Compared against a gold standard of the multisource algorithm (probable – definite case). 
High=CPRD algorithm cut‐off score of 5, medium=CPRD algorithm cut‐off score of 2.29, low=CPRD 
algorithm cut‐off score of 1.63. 
Note 2: Number of patients prescribed the drug at day 1 of the specific analysis. 
Note 3: 95% confidence interval. 
Note 4: CPRD guidance stipulates that cells with under 5 events should be reported this way 
Note 5: NP = analysis not performed, as multisource algorithm can only be applied to a cohort of 
HES‐linked CPRD patients. 
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5.6 Association between flucloxacillin and cholestatic liver injury  
5.6.1 Associations between cholestatic liver injury and co-variates 
Chapter 5 Appendix Table 2 shows the association between each of the co-variates in 
the study and flucloxacillin-induced cholestatic liver injury as identified by the four 
algorithm outcomes (and subsequent record review). For each of the algorithm 
definitions, there was very good evidence that the rate of injury increased with 
increasing age (result of likelihood ratio test (LRT) of an association with age over all 
categories of the variable: p<0.001), with the association increasing in strength 
substantially over the age of 50 and over the age of 70 for each outcome definition. 
The rate ratio (RR) comparing the oldest age group (80+ yrs) to the youngest (18-49 
yrs) was estimated at over 50 for both the CPRD medium specificity algorithm and the 
multisource algorithm, and over 100 for the high specificity CPRD algorithm (although 
with wide confidence intervals in all cases).  
Being prescribed another drug that was a possible cause of cholestatic liver injury was 
also associated with drug-induced liver injury (LRT p-values <=0.002 for all outcome 
definitions), with a maximum RR of 3.69 (95% CI 1.53 – 8.89) for the medium 
specificity CPRD algorithm (comparing those people prescribed a relatively common 
cause of injury to those not prescribed any cause). Smoking status also demonstrated 
good evidence of an association across all outcome definitions (with the highest rate 
for ex-smokers) while for gender, RRs were consistent with an increased rate in 
females for all outcomes, although there was a lack of evidence to support this 
association for all outcome definitions except the least specific CPRD algorithm. There 
was a suggestion across all outcome definitions that those with a moderate BMI had a 
higher rate than those at lower or higher weights. There was a lack of evidence of an 
association between the date of index prescription and cholestatic liver injury. 
5.6.2 Stratified (classical) analysis 
Chapter 5 Appendix Table 3 shows stratified and Mantel Haenzel pooled rate ratios for 
co-variates considered to be potential confounders or effect modifiers. For all 
outcomes, the mantel haenzel pooled rate ratio suggested that having had a 
prescription for another cause of cholestatic liver injury was a strong negative 
confounder, as rate ratios increased from crude for all algorithms. Date of index 
prescription did not seem to confound the association for any of the outcome 
definitions, and there was a lack of evidence for effect modification (although only the 
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lowest specificity CPRD algorithm had sufficient numbers to allow analysis across the 
majority of categories for this variable).  
5.6.3 Crude and multivariable adjusted result of exposure to flucloxacillin 
compared to oxytetracycline analysis 
Table 5-4 shows the crude and multivariable adjusted results of the association 
between flucloxacillin and cholestatic liver injury (compared with oxytetracycline), for 
the varying specificity CPRD algorithms and the multisource algorithm. The crude rate 
ratio for the association between flucloxacillin and cholestatic liver injury for the high 
specificity CPRD algorithm was 3.79 (95% CI 1.19 – 12.13). After adjusting for date of 
index prescription and concomitant prescriptions for other causes of cholestatic liver 
injury, the rate ratio decreased slightly to 3.72 (95% CI 1.16 – 11.96). This was very 
similar to the age-adjusted rate ratio estimate for the most sensitive (low specificity) 
CPRD algorithm, which had a slightly narrower confidence interval (RR 3.70, 95% CI 
1.73 – 7.94). The estimated multivariable (age-adjusted) rate ratio for the medium 
specificity CPRD algorithm was higher than for the other two CPRD algorithms, and 
with wider confidence intervals (RR 5.46, 95% CI 1.72 – 17.30).  
For the analysis performed within the HES-linked cohort (in order to test the 
multisource algorithm), only the multisource algorithm and the most sensitive (low 
specificity) CPRD algorithm identified sufficient numbers of oxytetracycline – exposed 
cases for a rate ratio to be estimated. For the multisource algorithm, the crude rate 
ratio was 9.02 (95% CI 1.24 – 65.7), which increased to 9.26 (95% CI 1.27 – 67.35) 
after adjustment for age and concomitant prescriptions. The (age-adjusted) 
multivariable rate ratio for the low specificity CPRD algorithm in the HES-linked dataset 
was over two times more than the rate ratio estimated using the same algorithm in the 
unrestricted cohort (RR 8.86, 95% CI 2.17 – 36.11), but similar to the multisource 
estimated rate ratio (although with narrower confidence intervals), suggesting that the 
difference is due to differences in the underlying populations within each dataset.  
Classical (Mantel Haenszel) did not provide evidence that any of the co-variates were 
effect modifiers of the association between flucloxacillin and cholestatic liver injury, 
when compared with oxytetracycline (Chapter 5 Appendix Table 3). For the 
multivariable adjusted models, the RRs obtained using the fully adjusted models based 
on the DAG analysis were almost identical to the RRs obtained from models prepared 
using a stepwise approach (maximum change in relative effect <2%). 
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Table 5-4: Rates and crude/multivariable adjusted rate ratios (RR) of cholestatic liver injury identified using the CPRD algorithm (3 different cut-off scores) and 
the multisource algorithm by exposure to flucloxacillin or oxytetracycline (for the 1-45 day period after exposure) 
      Complete cohort    Cohort restricted to HES‐linked patients only 
Algorithm
 
Sp, Sns2  Drug  Cases  PM5  Rate6(CI7)  Crude RR (CI)  MV RR (CI)    Cases  PM  Rate (CI)  Crude RR (CI)  MV RR (CI) 
CPRD 
(High) 
100%, 81%  Oxyt3  <5  2.71  1.11 (0.36 – 3.44)  1  1    0  1.52  ‐9  ‐  ‐ 
    Flucl  53  12.61  4.20 (3.21 – 5.50)  3.79 (1.19 – 12.13)  3.72 (1.16 – 11.96)8    40  7.57  5.28 (3.87 – 7.20)  ‐  ‐ 
                           
CPRD 
(Med) 
86%, 87%  Oxyt  <5  2.71  1.11 (0.36 – 3.44)  1  1    0  1.52  ‐  ‐  ‐ 
    Flucl  77  12.61  6.11 (4.88 – 7.63)  5.51 (1.74 – 17.46)  5.46 (1.72 – 17.30)10    57  7.57  7.53 (5.80 – 9.76)  ‐  ‐ 
                           
CPRD 
(Low) 
48%, 100%  Oxyt  7  2.71  2.59 (1.23 – 5.3)  1  1    <5  1.52  1.32 (0.33 – 5.26)  1  1 
    Flucl  122  12.61  9.67 (8.10 – 11.55)  3.74 (1.75 – 8.01)  3.70 (1.73 – 7.94)11    83  7.57  10.96 (8.84 – 13.59)  8.32 (2.05 – 33.83)  8.86 (2.17 – 36.11) 
                           
MS1  ‐  Oxyt  NP4  NP  NP  NP  NP    <5  1.52  0.65 (0.09 – 4.67)  1  1 
    Flucl  NP  NP  NP  NP  NP    45  7.57  5.81 (4.32 – 7.81)  9.02 (1.24 – 65.47)  9.26 (1.27 – 67.35)12 
Note 1: Multisource. 
Note 2: Specificity and sensitivity compared against a gold standard of the 
multisource algorithm (probable – definite case). High=CPRD algorithm cut‐off 
score of 5, med=CPRD algorithm cut‐off score of 2.29, low=CPRD algorithm 
cut‐off score of 1.63. 
Note 3: Oxyt=Oxytetracycline, Flucl=Flucloxacillin. 
Note 4: NP = analysis not performed, as multisource algorithm can only be 
applied to a cohort of HES‐linked CPRD patients. 
Note 5: 100000 person‐months at risk. 
Note 6: Per 100000 person months.
Note 7: 95% confidence interval. 
Note 8: Adjusted for age, date of index prescr and concomitant prescriptions for other causes of cholestatic liver injury.  
Fully adjusted model: 3.71 (1.15 – 11.94). 
Note 9: All blanks (“‐“) are where there were insufficient numbers to perform the analysis in question. 
Note 10: Adjusted for age. Fully adjusted model: 5.56 (1.75 – 17.70). 
Note 11: Adjusted for age. Fully adjusted model: 3.74 (1.74 – 8.04). 
Note 12: Adjusted for age and concomitant prescriptions. Fully adjusted model: 9.12 (1.25 ‐ 64.42). 
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5.7 Risk factors for flucloxacillin-induced liver injury 
Table 5-5 shows the rate and multivariable rate ratios for cholestatic liver injury 
for a number of characteristics previously reported as being possible predictors 
for flucloxacillin-induced cholestatic liver injury (age, gender, number of 
prescriptions and concomitant therapy with other causes of cholestatic liver 
injury) [56]. All multivariable rate ratios are presented adjusted for all other 
variables in the table and date of index prescription.  
Age was the strongest predictor for flucloxacillin-induced cholestatic liver injury, 
after adjustments, particularly as measured by the most specific CPRD 
algorithm and the multisource algorithm. For all algorithms, the increase was 
particularly marked over the age of 50 and over the age of 70 (e.g. CPRD 
algorithm cut-off 5 RR for aged 70 – 79 compared to aged 18 – 49: 80.80, 95% 
CI 10.66 – 612.20). For gender, there was a suggestion across all outcomes 
except the multisource that females had a slightly higher rate of injury, although 
the 95% confidence intervals did not rule out a decreased rate (e.g. CPRD 
algorithm 1.63 RR: 1.38, 95% CI 0.92 – 2.00). Number of flucloxacillin 
prescriptions did seem to be a risk factor, with increasing numbers of 
prescriptions associated with a higher rate of injury. This was particularly 
marked for both the high specificity CPRD algorithm (RR comparing those with 
3+ prescriptions to those with 1: 5.62, 95% 2.48 – 12.74) and the multisource 
algorithm (RR 5.66, 95% CI 2.33 – 13.74). Being prescribed other drugs 
considered to be causes of cholestatic liver injury did not seem to be a strong 
predictor of flucloxacillin-induced cholestatic liver injury, although wide 95% 
confidence intervals meant that moderate increased or decreased rates 
associated with their use could not be ruled out.
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Table 5-5: Rate ratio for cholestatic liver injury within those exposed to flucloxacillin (for the 1-45 day period after exposure) using the 
three CPRD algorithm cut-off scores and the multisource algorithm by age, gender, no. of prescriptions and concomitant therapies 
Algorithm 
(specificity1) 
Specificity, 
sensitivity 
Risk factor # with 
outcome 
PMAR2  Rate3 (CI4) Multivariable RR5 (CI)
CPRD (High)  100%, 81% Age6 18 – 49 1 6.64  0.15 (0.02 – 1.07) 1
  50 – 59 9 1.90  4.75 (2.47 – 9.12) 29.55 (3.73 – 233.88)
  60 – 69 5 1.63  3.06 (1.27 – 7.36) 17.49 (2.02 – 151.21)
  70 – 79 20 1.34  14.94 (9.64 – 23.18) 80.80 (10.66 – 612.20)
  80+ 18 1.11  16.28 (10.37 – 26.96) 82.47 (10.79 – 630.16)
  Gender Male 21 5.77  3.64 (2.37 – 5.58) 1
  Female 32 6.84  4.68 (3.31 – 6.62) 1.16 (0.67 – 2.03)
  No. of prescrs 1 34 11.02  3.08 (2.20 ‐ 4.32) 1
  2 12 1.32  9.10 (5.17 ‐ 16.02) 2.33 (1.20 – 4.50)
  3+ 7 0.28  26.06 (12.42 ‐ 54.65) 5.62 (2.48 – 12.74)
  Concomitant7  None 11 6.08  1.81 (1.00 – 3.27) 1
  Common  38 5.85  6.49 (4.72 – 8.92) 1.32 (0.66 – 2.64)
  Less common  4 0.68  5.89 (2.21 – 15.70) 1.27 (0.40 – 4.03)
CPRD (Med)  86%, 87% Age 18 – 49 3 6.64  0.45 (0.15 ‐ 1.40) 1
  50 – 59 12 1.90  6.33 (3.59 ‐ 11.14) 13.25 (3.73 – 47.09)
  60 – 69 13 1.63  7.96 (4.62 ‐ 13.71) 15.55 (4.38 – 55.14)
  70 – 79 24 1.34  17.93 (12.02 ‐ 26.75) 33.06 (9.78 – 111.75)
  80+ 25 1.11  22.61 (15.28 ‐ 33.46) 39.01 (11.53 – 132.00)
  Gender Male 29 5.77  5.02 (3.49 ‐ 7.23) 1
  Female 48 6.84  7.02 (5.29 ‐ 9.31) 1.28 (0.80 – 2.04)
  No. of prescrs 1 52 11.02  4.72 (3.60 ‐ 6.19) 1
  2 18 1.32  13.64 (8.60 ‐ 1.65) 2.32 (1.35 – 3.97)
  3+ 7 0.27  26.06 (12.42 ‐ 54.65) 3.75 (1.70 – 8.29)
  Concomitant  None 17 6.08  2.80 (1.74 – 4.50) 1
  Common  53 5.85  9.05 (6.92 – 11.85) 1.30 (0.74 – 2.30)
  Less common  7 0.68  10.31 (4.92 – 21.63) 1.59 (0.65 – 3.89)
CPRD (Low)  100%, 81% Age 18 – 49 13 6.64  1.96 (1.14 ‐ 3.37) 1
  50 – 59 19 1.90  10.02 (6.39 ‐ 15.71) 5.04 (2.48 – 10.24)
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Algorithm 
(specificity1) 
Specificity, 
sensitivity 
Risk factor # with 
outcome 
PMAR2  Rate3 (CI4) Multivariable RR5 (CI)
  60 – 69 16 1.63  9.80 (6.00 ‐ 16.00) 4.80 (2.29 – 10.09)
  70 – 79 40 1.34  29.88 (21.92 ‐ 40.74) 14.09 (7.38 – 26.90)
  80+ 34 1.11  30.75 (21.97 ‐ 43.03) 13.60 (7.00 – 26.40)
  Gender Male 44 5.77  7.62 (5.67 ‐ 10.24) 1
  Female 78 6.84  11.41 (9.14 ‐ 14.24) 1.38 (0.92 – 2.00)
  No. of prescrs 1 87 11.02  7.89 (6.40 ‐ 9.74) 1
  2 27 1.32  20.46 (14.03 ‐ 29.84) 2.16 (1.40 – 3.33)
  3+ 8 0.27  29.78 (14.89 ‐ 59.54) 2.74 (1.33 – 5.68)
  Concomitant  None 35 6.08  5.76 (4.13 – 8.02) 1
  Common  77 5.85  13.15 (10.52 – 16.45) 1.04 (0.68 – 1.58)
  Less common  10 0.68  14.73 (7.93 – 27.38) 1.25 (0.61 – 2.55)
Multisource  ‐  Age 18 – 49 1 3.99  0.25 (0.04 ‐ 1.78) 1
  50 – 59 6 1.13  5.30 (2.38 – 12.56) 19.45 (2.33 – 162.20)
  60 – 69 4 0.97  4.12 (1.55 – 11.63) 13.85 (1.53 – 125.50)
  70 – 79 16 0.80  20.68 (12.52 – 32.22) 63.31 (8.23 – 487.76)
  80+ 18 0.68  26.57 (17.01 – 42.29) 81.81 (10.65 – 628.38)
  Gender Male 20 3.45  5.79 (3.74 ‐ 8.98) 1
  Female 25 4.12  6.06 (4.09 ‐ 8.98) 0.91 (0.50 – 1.65)
  No. of prescrs 1 28 6.62  4.23 (2.92 – 6.13) 1
  2 11 0.79  13.87 (7.68 – 25.05) 2.55 (1.27 – 5.13)
  3+ 6 0.16  37.03 (16.64 – 82.43) 5.66 (2.33 – 13.74)
  Concomitant  None 9 3.72  2.42 (1.26 – 4.66) 1
  Common  33 3.47  9.50 (6.75 – 13.36) 1.37 (0.64 – 2.93)
  Less common  3 0.39  7.79 (2.51 – 24.15) 1.20 (0.32 – 4.49)
Note 1: Compared against a gold standard of the multisource algorithm (probable – definite 
case). High=CPRD algorithm cut‐off score of 5, med=CPRD algorithm cut‐off score of 2.29, 
low=CPRD algorithm cut‐off score of 1.63. 
Note 2: 100000 person‐months at risk. 
Note 3: Per 100000 person months. 
Note 4: 95% confidence interval.   
Note 5: Adjusted for date of index prescription and all other variables in this table. 
Note 6: Age categorised into 5 groups due to no events in the 18‐29 yr olds for CPRD 
algorithm score 5 and the multisource algorithm.  
Note 7: Concomitant prescription for drugs considered (common or less common) causes of 
cholestatic liver injury, within 1 month prior to end of follow‐up.  
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5.8 Sensitivity analyses 
Removing people who had a prescription for co-fluampicil from the exposed to 
flucloxacillin group increased all estimated risks and rate ratios, although by a 
negligible amount. For example the 1-45 day risk estimate for the high specificity 
CPRD algorithm for flucloxacillin increased from 6.15 per 100 000 users (95% CI 4.61 
– 8.04) to 6.26 per 100 000 users (95% CI 4.66 – 8.23), while the multivariable rate 
ratio for the same algorithm increased from 3.72 (1.16 – 11.96) to 3.75 (95% CI 1.16 - 
12.06). 
Removing people who were classified as the heaviest drinkers from the analysis (i.e. in 
the over 6 units per day category) resulted in a very small increase in the flucloxacillin 
45-day risk estimate, with a (larger) reduction in the multivariable rate ratio for all 
algorithms. For example, the 1-45 day risk estimate for the low specificity algorithm for 
flucloxacillin increased from 14.15 per 100 000 users (95% CI 11.75 – 16.90) to 14.21 
(95% CI 11.71 – 17.08), while the multivariable rate ratio decreased from 3.70 (95% CI 
1.73 – 7.94) to 3.43 (95% CI 1.60 – 7.36). 
If people were prescribed both oxytetracycline and flucloxacillin in the cohort (with 
either both (i) drugs prescribed on the index date or (ii) oxytetracycline prescribed on 
the index and then flucloxacillin prescribed subsequently before the end of follow-up) 
this was handled by considering these people as exposed to flucloxacillin. Removing 
these people completely did not change the 45-day risk estimates or the relative effect 
estimates.  
In this study, people were excluded during detailed review of those with cholestatic liver 
injury if they had an exclusion code between their date of drug prescription and their 
case assignment date. It is possible that these people could still have been cases of 
cholestatic liver injury caused by one of the study drugs. A sensitivity analysis in which 
these people were considered as cases and not exclusions, resulted in an increased 
45-day risk estimate and a decreased relative effect. For example, the flucloxacillin 45-
day risk estimate for the most specific CPRD algorithm increased from 6.15 per 100 
000 users (95% CI 4.61 – 8.04) to 7.19 per 100 000 users (95% CI 5.51 – 9.22), while 
the multivariable rate ratio decreased from 3.72 (95% CI 1.16 – 11.96) to 3.04 (95% CI 
1.10 - 8.40). 
In summary, there was little differences observed with any of the sensitivity analyses, 
and the number of outcomes is so low that small changes to the number of outcomes 
will inevitably lead to changes to the relative effect (to some extent).  
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5.9 Discussion  
5.9.1 Key results 
In this study, the use of the CPRD cholestatic liver injury algorithm (three cut-off scores 
of low to high specificity) and the multisource cholestatic liver injury algorithm as 
outcomes in a pharmacoepidemiological study were assessed by performing a cohort 
study on the association between cholestatic liver injury and flucloxacillin (compared to 
oxytetracycline).  
The number of cases of cholestatic liver injury identified increased with increasing 
algorithm sensitivity, and the proportion considered to be caused by one of the drugs 
under study was generally higher for the CPRD algorithm(s) than for the multisource 
algorithm. Flucloxacillin risk estimates were 6.15 (95% CI 4.61 – 8.04) per 100 000 
users and increased with increasing CPRD algorithm sensitivity (up to 14.15, 95% CI 
11.75 – 16.90). The multisource algorithm obtained an estimate of cholestatic liver 
injury in the exposed to flucloxacillin group of 8.69 (95% CI 6.34 – 11.63). Multivariable 
adjusted rate ratios for the association (comparing flucloxacillin to oxytetracycline 
exposure) were very similar for the most specific (RR 3.72, 95% CI 1.16 – 11.96) and 
the most sensitive (RR 3.70, 95% CI 1.73 – 7.94) CPRD algorithms. In HES-linked 
practices only, the rate ratio using the most sensitive CPRD algorithm was 8.86 (95% 
CI 2.17 – 36.11), similar to the estimate obtained using the multisource algorithm (RR 
9.26, 95% CI 1.27 – 67.35), although more precise. In risk factor analysis, all 
algorithms demonstrated age to be the most important risk factor after multivariable 
adjustments, with sharp increases in risk over the age of 50 and over the age of 70. 
Number of prescriptions of flucloxacillin was another important risk factor. 
5.9.2 Number of cases identified and case characteristics 
When considering the number of people initially identified as cholestatic liver injury 
cases who were subsequently confirmed as flucloxacillin or oxytetracycline cases 
based upon detailed record review, of interest was the higher proportion of cholestatic 
liver injury cases identified as drug-induced in the HES-linked data for each of the 
CPRD algorithms. This suggests that the prevalence of conditions leading to 
exclusions may be higher in the complete cohort than in the HES-linked cohort, due to 
a higher prevalence in the underlying populations from which the samples are taken.  
Chapter 5 Appendix Table 4 provides an overview of the reasons why individuals who 
were considered as cholestatic liver injury cases were subsequently excluded based 
upon detailed clinician review of records for (i) the complete cohort (ii) the HES-linked 
cohort (used in this study) and (iii) individuals from the complete cohort who were not 
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linked to HES. Of note is the fact that while the HES-linked cohort contained of 60% of 
the individuals from the complete cohort, the proportion of those people excluded was 
only 30% of the total excluded from the complete cohort. Exclusions related to 
alcoholism, cancer and heart failure made up the largest proportion of exclusions in the 
complete cohort (33% of all exclusions). In the subset of practices not linked to HES 
there was a much higher proportion of people excluded due to these three conditions 
(50%) than in the HES-linked subset (19%, with no alcoholics). This comparison is 
effectively comparing practices in England (HES-linked) with those in Scotland, Wales 
and Northern Ireland (not linked to HES), and the differing prevalence of these 
conditions by region (for example, higher alcoholism and ischaemic heart disease rates 
in Scotland [114, 115]) may explain the variation seen here. 
In Chapter 2 of this thesis, a comparison of the proportion (%) of those with a liver-
related diagnostic code of interest who were eventually considered to be cases of 
(drug-induced) cholestatic liver injury in previously published studies is presented 
(Chapter 2 Table 2-6). Proportions range from 4% to 83% (median 8%), with two 
flucloxacillin studies that reported numbers having figures of 7% (for a study that used 
a relatively sensitive initial codelist) and 83% (for the study that used the most specific 
codelist) [53, 55]. In this study, 393 people had a liver-related code in the complete 
cohort, and the comparable % for the CPRD algorithms tested in this study were 
therefore 26%, 38% and 70% (by increasing algorithm specificity, and using numerator 
figures obtained from Table 5-2). For the multisource algorithm 220 people had any of 
the liver-related codes and 43% of these ended up as cases, showing that the 
sensitivity of the codelists used in this study was midway between the two previous 
flucloxacillin studies. In Chapter 2, the suggestion that a sensitive codelist could lead to 
increased manual review of electronic health records was discussed. If applying the 
algorithms used in this study, this becomes less of an issue, because a validated score 
is used to identify non-cases of cholestatic liver injury from potential cases of 
cholestatic liver injury based on an automated search of their electronic health record. 
Subsequent record review is then needed to attribute the cause of the injury to the 
medication under study, but a reduction in the amount of manual review is still likely to 
be conferred. This means that use of a codelist of moderate to high sensitivity becomes 
possible, and it is not necessary to use a restricted codelist (which could potentially 
result in cases being missed).  
A previous cohort study performed in the GPRD (predecessor to the CPRD) between 
1992 – 2002 found that the time from first administration of flucloxacillin until injury was 
25.5 days [53]. In another Swedish analysis of 43 spontaneous reports considered to 
be flucloxacillin, dicloxacillin or cloxacillin-induced cholestatic liver injury between 1981 
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and 1990, it was  reported that 72% of patients suffered reactions within 30 days [116].  
In this study, the median times were slightly longer, ranging from 32 - 36 days 
depending on algorithm (see Table 5-2, median times when considering flucloxacillin 
on its own were no different to those presented in this table).   
It is possible that the latency result in the study performed here is a more precise 
estimate of the median time from flucloxacillin prescription until injury than the 
referenced 1992 - 2002 GPRD cohort, as the study performed here was three times 
larger.  Calculation of the 95% CI around the median using a binomial method (for the 
highly specific CPRD algorithm) provides an estimate of 36 days (95% CI 33 day – 37 
days), which would exclude the median of 25.5 from the earlier cohort study. An 
alternative explanation is that the measurement has been performed differently in the 
previous studies. Generally, for all algorithms in this study, the earliest possible event 
used as a case date is a diagnostic code for jaundice (or similar). In both the other 
studies mentioned here, it is not specified what clinical information is used to determine 
the onset of injury, but this could well have been other less severe symptoms that were 
identified earlier than the onset of (e.g.) jaundice, such as pruritus, or feeling unwell. 
This potentially provides more accurate clinical information, but not specifying clearly 
the information used and timing of case assignment risks introducing bias into cohort 
studies. In any case, the median latency for flucloxacillin-induced liver injury found here 
is consistent with injury occurring up to 45 days from first prescription. 
5.9.3 Absolute and relative effect measures 
5.9.3.1 Comparison across the algorithms used in this study 
The increase in flucloxacillin 45-day risk estimates with increasing CPRD algorithm 
sensitivity is as expected, given the fact that as algorithm specificity decreases the 
sensitivity increases and more individuals are considered to be cases. Of note was the 
fact that while the absolute risk for both drugs increased in a similar way between the 
least and most sensitive CPRD algorithms, the CPRD algorithm with moderate 
sensitivity/specificity estimated a higher flucloxacillin risk than the most specific 
algorithm, but the same oxytetracycline risk. Given the low numbers of oxytetracycline 
users with cholestatic liver injury identified by any of the algorithms (minimum of 1 for 
the multisource algorithm, maximum of 7 for the most sensitive CPRD algorithm), this 
could well be explained by chance, as if one more case had been identified by the 
algorithm with medium specificity, the oxytetracycline and flucloxacillin trends would 
have been similar. Furthermore, the 95% confidence intervals for all of the 
oxytetracycline risk estimates do not exclude the possibility that the true values in the 
underlying population are no different from each other. 
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The slightly higher 45-day risk point estimates obtained for all CPRD algorithms in the 
HES-linked cohort (Table 5-3) are likely to be due to the lower prevalence of exclusion 
conditions in the HES-linked cohort, as described previously (see previous section and 
Chapter 5 Appendix Table 4). Despite this slight difference, the 95% confidence 
intervals for each algorithm do not exclude the point estimates for the corresponding 
algorithm in the HES-linked subset. The fact that the similarity between the multisource 
algorithm measurement for flucloxacillin risk (8.69, 95% CI 6.34 – 11.63) is very similar 
to the most specific CPRD algorithm within the HES-linked subset (7.72, 95% CI 5.52 – 
10.52), shows that the specific CPRD algorithm can be used as a reliable way of 
calculating risk within only the CPRD, and provides estimates with similar precision. 
Despite the difference in the absolute effect estimates (45-day risk), the multivariable 
rate ratios were comparable for each of the CPRD algorithms. The estimates were 
particularly similar when comparing the least sensitive (RR 3.72, 95% CI 1.16 – 11.96) 
with the most sensitive CPRD algorithm (RR 3.70, 95% CI 1.73 – 7.94) and of note was 
that the more sensitive algorithm estimated with greater precision. This suggests that 
although the least specific CPRD algorithm is identifying more false positives, the 
measurement error occurs randomly across the exposure groups and therefore a valid 
rate ratio estimation can be obtained. This could be particularly useful when 
considering situations when low-power is an issue. This point is emphasised by the fact 
that rate ratios could not be estimated within the HES-linked cohort for the two more 
specific CPRD algorithms due to low numbers. In contrast, the most sensitive algorithm 
was able to identify sufficient cases to allow a rate ratio to be calculated (RR 8.86, 95% 
CI 2.17 – 36.11), and the similarity to the multisource algorithm result in this setting 
(RR 9.26, 95% CI 1.27 – 67.35) suggests that a sensitive algorithm with low specificity 
could provide reliable rate ratios when studying drug-induced cholestatic liver injury in a 
pharmacoepidemiological study.  
The different results obtained for the most sensitive algorithm in the two settings 
(complete dataset compare to HES-linked only) could well be explained by chance, as 
the 95% confidence intervals overlap the point estimates, and if only 2 more cases of 
oxytetracycline-induced cholestatic liver injury had been identified in the HES-linked 
cohort, the rate ratios would have been similar.  
5.9.3.2 Comparison with results in the literature 
Table 5-6 shows the risk and risk ratios for the three CPRD algorithm cut-offs and for 
two published studies within CPRD (or its predecessor databases) looking at 
flucloxacillin, oxytetracycline and cholestatic liver injury. Figure 5.2 presents the risk 
ratios as a forest plot. As time-to-event information was not available in the referenced 
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studies [53, 55], risk ratios rather than rate ratios have been presented here to aid the 
comparison of relative effects. The risk ratios for each of the CPRD algorithms are very 
similar to the multivariable rate ratios calculated and discussed previously (see Table 
5-4). 
The risk estimate obtained using the most specific algorithm (6.15, 95% CI 4.61 – 8.04) 
is very similar to the risk estimated in the study by Derby et al (7.57, 95% CI 3.63 – 
13.92), while the slightly less specific CPRD algorithm estimate (8.93, 95% CI 7.05 – 
11.16) is similar to the risk estimated in the study by Russman et al (8.48, 95% CI 5.43 
– 12.61). In terms of relative risk, the crude risk ratio for the most specific CPRD 
algorithm (3.79, 95% CI 1.18 – 12.12) and the least specific CPRD algorithm (3.74, 
95% CI 1.74 – 8.00) are similar to the estimate obtained in the study by Derby et al 
(3.68, 95% CI 1.01 – 13.37). All of these are lower than the estimate from the study by 
Russman et al (RR 11.12, 95% CI 1.50 – 82.23), although this does have wide 
confidence intervals.  
The risk ratio obtained from the Russman study is driven by fewer oxytetracycline 
cases having been identified than might have been expected (based upon the study 
performed here and that performed by Derby et al). As discussed previously, this could 
have been a chance result, given the low numbers that are being dealt with. Another 
possible factor is blinding to exposure status: while the Derby paper specifies that one 
of the reviewers was blinded to exposure status, and all reviewers were blinded in this 
work, there is no mention that reviewers were blinded to exposure status in the 
Russman study. Where the absolute numbers in an exposure group are very small, the 
inclusion or omission of even one case can have a large impact on the relative effect 
measure. When reviewing routinely collected primary care records of potentially drug-
induced liver injury, the experience in this study was that there are likely to be 
numerous instances where it is difficult to decide whether an acute liver symptom or 
test result is due to a drug or to another cause. Knowing that the person was or was 
not exposed to a known cause of liver injury may well tip the case assignment decision 
one way or another.  
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Table 5-6: Comparison of risk and crude risk ratios estimated by the three CPRD algorithm cut-off 
scores and those obtained from previous studies in CPRD (or its preceding database VAMP and 
GPRD) 
Algorithm 
or Reference 
(specificity1) 
Specificity, 
sensitivity 
Exposure 
 
# exposed[cases]  45‐day risk2 (CI3)  Crude Risk Ratio4 
Algorithm       
     CPRD (High)  100%, 81%  Oxytetracycline  184737[3] 1.62 (0.33 – 4.75)  1
    Flucloxacillin  861959[53] 6.15 (4.61 – 8.04)  3.79 (1.18 – 12.12)
     CPRD (Med)  86%, 87%  Oxytetracycline  184737[3] 1.62 (0.33 – 4.75)  1
    Flucloxacillin  861959[77] 8.93 (7.05 – 11.16)  5.50 (1.74 – 17.43)
     CPRD (Low)  48%, 100%  Oxytetracycline  184737[7] 3.79 (1.52 – 7.81)  1
    Flucloxacillin  861959[122] 14.15 (11.75 – 16.90)  3.74 (1.74 – 8.00)
Reference5       
     Russman 2005 
[53] 
N/A  Oxytetracycline  131189[1] 0.76 (0.02 – 4.25)  1
    Flucloxacillin  283097[24] 8.48 (5.43 – 12.61)  11.12 (1.50 – 82.23)
     Derby 1993 [55]  N/A  Oxytetracycline  145844[3] 2.06 (0.42 – 6.01)  1
    Flucloxacillin  132087[10] 7.57 (3.63 – 13.92)  3.68 (1.01 – 13.37)
Note 1: Compared against a gold standard of the multisource algorithm (probable – definite case). High=CPRD algorithm cut‐off score of 5, med=CPRD 
algorithm cut‐off score of 2.29, low=CPRD algorithm cut‐off score of 1.63. 
Note 2: Per 100000 patients prescribed the drug. 
Note 3: 95% confidence interval. 
Note 4: Risk ratios presented (rather than rate ratios) as follow‐up time was not available in published articles. Risk ratios calculated here for the three 
CPRD algorithm cut‐offs are very similar to the multivariable rate ratios presented in Table 5‐4. 
Note 5: Risk ratios for references calculated from number of exposed and number of cases presented in articles. 
 
Figure 5.2: Forest plot of the crude risk ratios estimated by the three CPRD algorithm cut-
off scores and those obtained from previous studies in CPRD (or its preceding database 
VAMP and GPRD) 
Algorithm or reference & exposure category Risk ratio 
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5.9.4 Risk factor analysis 
The results for all algorithms demonstrated increasing age to be the most important risk 
factor for flucloxacillin-induced liver injury, with number of prescriptions another 
important risk factor. Unlike for the comparative analysis with oxytetracycline, power 
was not a particular issue for the most specific algorithm or the multisource algorithm, 
although the age estimations for both of these algorithms did have wide confidence 
intervals. Risk increased sharply over the age of 50, and increased substantially again 
over the age of 70 when measured by all algorithms.  
Previous studies also showed age to be the most important risk factor. One case-
control study reported that people over the age of 55 experienced 18.61 times the odds 
of cholestatic liver injury than those in the under 30 age group (95% CI 5.16 – 67.17 
[56]), while a more recent cohort study reported that people over the age of 60 were 
6.1 times more likely to develop flucloxacillin-induced cholestatic liver injury than those 
under the age of 60 (95% CI 2.9 – 13.0). Neither study provide any absolute effect 
measures stratified by age, as presented here. One of the studies also identified use of 
flucloxacillin for greater than 14 days as a risk factor, with people using the drug for 
more than 14 days having 7.13 times the risk of injury than those using for less than 
this period (95% CI 2.90 – 17.58) [56]. This is comparable with the relative effect 
estimates for number of prescriptions obtained by all of the algorithms in this study (see 
Table 5-5), considering that one prescription for flucloxacillin typically lasts 7 days.   
The results of this study provide further detail of age and duration related effects, and 
include absolute estimates of effect as well as relative. Both the most specific and 
multisource algorithms suggest that the increased risk is very high over the age of 70 
(e.g. multivariable rate ratio of 80.80, 95% CI 10.66 – 612.20 when comparing the 70 – 
79 year olds with those under the age of 50). For the most specific CPRD algorithm 
(requiring that all cases had biochemically confirmed cholestatic liver injury), the 
absolute 45-day risk of cholestatic liver injury in those prescribed flucloxacillin under 
the age of 70 is estimated at 2.16 per 100 000 users (95% CI 1.21 – 3.56), while for 
those over the age of 70, this rises to 2.26 per 10 000 users (95% CI 1.60 – 3.11). 
Within the highest risk group (those over the age of 70 who received three or more 
prescriptions), this risk approaches 1 in every 1000 users (7.27 per 10 000 users, 95% 
CI 1.98 – 18.59).  
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5.9.5 Limitations 
5.9.5.1 Chance 
The study used 95% confidence intervals throughout to assess the role of chance. 
Some of the analyses were underpowered, but these were discussed appropriately 
where they occurred, considering the full range of possible values (and not just whether 
the confidence interval spanned the null). Test of significance were used to test for 
interactions. 
5.9.5.2 Bias 
Misclassification of main exposures 
This study based drug exposure on prescription records from CPRD, which are 
automatically generated and recorded for automated uploading to the database as the 
general practitioner selects the drug for prescription. Therefore, the group assignments 
are very accurate representations of who was prescribed each of the drugs. This does 
not account for whether or not the individual actually took the drug, however, which is a 
problem for all studies that use CPRD prescription records for assigning drug 
exposure. As the two drugs are used for similar indications, and the characteristics of 
patients were shown to be broadly similar (Table 5-1), it is unlikely that one exposure 
group had improved adherence to the drugs prescribed than another, unless one of the 
drugs has a markedly better or worse side-effect profile than the other. A review of the 
prescribing information for each drug suggests comparable side-effect profiles (with the 
exception of serious liver injury) [117, 118], so this non-differential misclassification 
would likely bias results towards the null. Care was taken to ensure that that patients 
initially prescribed oxytetracycline but then prescribed flucloxacillin before their end of 
follow-up were assigned to the flucloxacillin group. Sensitivity analyses testing the 
impact of this decision and that of the decision to include co-fluampicil in the 
flucloxacillin group showed minimal impact on results.   
Misclassification of outcomes 
Clearly there will be patients identified as cases of flucloxacillin or oxytetracycline 
induced liver injury by all of the algorithms who then go on to be diagnosed with 
conditions that were more likely to have been responsible for the detected injury. 
Considering events occurring after the case assignment date was considered to be 
problematic, however, because it is not possible to apply a time window within which 
one could be sure that all study participants would remain available in the database. 
This is in contrast to the application of exclusions for such conditions based on 
information prior to the case date, where all participants had to be included in the 
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database for the same amount of time prior to the case (or matched case) date and 
exclusion conditions were searched for within this time period. Furthermore, there is a 
possibility that case and or exposure status to the drugs under study could influence 
the likelihood of being tested for the conditions in question, which risks biasing the 
study. A count of the number of people identified as cases who then went on to have 
an exclusion code at any time after their case date identified 66 people out of the 277 
cases (24%), 32 of whom were within a 90 day period (12%). It should be noted, 
however, that having a subsequent exclusion code would not necessarily mean that the 
individual’s injury was not due to one of the study drugs. 
As the aim of this study was to assess the performance of a number of outcome 
definitions of varying specificity and sensitivity, there was very likely to be 
misclassification of outcome status for the less specific, more sensitive outcome 
definitions, which assign case status based upon relatively sparse information (for 
example, a CPRD diagnostic code of jaundice only, with no other information). 
Therefore, a degree of non-differential measurement error here is inevitable, which 
would likely increase absolute measures of effect and reduce relative measure of 
effect. This was observed and commented on throughout this study (for example the 
increasing risk measurements with decreasing sensitivity and the reduction in rate 
ratios for the risk factor analysis when comparing the less specific algorithms with the 
more specific ones). Furthermore, where external standards exist (e.g. for liver test 
results), these have been utilised and referenced throughout, and a careful and 
detailed exclusions list was prepared and followed to try and ensure those with other 
underlying causes of cholestatic liver injury would not be included in the study. Finally, 
a systematic and methodological approach to case definition was applied, using 
multiple database sources, and then validating carefully when developing other 
algorithms. 
Differential misclassification of outcome has the potential to bias the results much more 
strongly, and could reduce or increase rate ratios observed. This study is very unlikely 
to have been susceptible to this, due to the fact that drug exposure status was only 
added to the cohort at the last possible time point, and that all review was completely 
blinded to drug exposure status (including the exposure on the index date, and any 
subsequent exposures during follow-up). One point that should be noted is that those 
identified as potential cases by the presence of diagnostic codes had a detailed 
(clinician) review of the electronic record performed in order to identify underlying 
causes for the injury. This review was not performed on the individuals not identified as 
potential cases (due to resource). Given the rarity of the underlying conditions in those 
without liver symptoms, not performing this is unlikely to have biased the results 
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obtained. In the future, application of automated algorithms to this part of the process 
(as has recently been tested elsewhere [77]) might allow a greater proportion of 
records to be reviewed in this way.   
Observer/ascertainment bias 
Ascertainment bias has the potential to impact this study in 2 ways. Firstly, at the level 
of the general practitioners who are responsible for diagnosing patients in the source 
population. All CPRD health records used in this study were routinely collected during 
primary care consultations before the design of this study, meaning that 
prescribing/diagnosing clinicians would not be aware which group particular exposure 
group of this study patients had been assigned to. Clinicians would be aware of 
flucloxacillin as a potential cause of cholestatic liver injury, however. Given this, there is 
a possibility that GPs could be more likely to identify these people as suffering drug-
induced liver injury, which could increase both the absolute and relative effect 
measures obtained. This is unlikely to have affected the study results because the 
endpoints used were clinical symptoms/laboratory test results, and not a diagnosis of 
drug-induced liver injury by the attending clinician. Drug exposure status could have 
made the clinician more or less likely to have requested liver tests for a patient. The 
impact within this study would have been to make those on flucloxacillin with 
cholestatic liver injury more likely to be identified as definite cases than those on 
oxytetracycline with cholestatic liver injury. As diagnostic codes were also used as part 
of the case definition, oxytetracyline users with cholestatic liver injury would still have a 
high likelihood of being identified as (at least probable) cases by their symptoms. At the 
stage of review of electronic record for this study, the use of two exposure groups and 
blinding to exposure status would have greatly minimised the likelihood of observer 
bias contributing to the results.  
Selection bias 
Selection bias would occur if the relationship between exposure (flucl or oxyt) and 
outcome (cholestatic liver injury) is different within those people included in the study, 
compared to those people in the underlying study population. This is unlikely to have 
affected this study, because everybody who was ever prescribed flucl or oxyt in the 
total CPRD database was initially included in the study. 
5.9.5.3 Co-variates, confounding and missing data 
Age, gender, date of index prescription, prescriptions for other causes of liver injury, 
smoking status, BMI, alcohol intake, socioeconomic status and ethnicity were all 
considered as potential confounders, based upon a-priori knowledge and causal 
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modelling. All categories for age, gender, and date of prescription were complete and 
accurate, as these were obtained directly from CPRD. Prescriptions for other causes of 
cholestatic liver injury for use in the concomitant prescriptions variable were obtained 
from a variety of sources, but there are likely to be as yet unknown causes of 
cholestatic liver injury that people were taking. Furthermore, those drugs that are 
known to cause injury are poorly characterised, so the categorisation used here could 
only be a rough approximation.  Of note is that in this study it was not possible to 
monitor the use of over-the-counter or hospital-prescribed drugs, although this is 
unlikely to have had a substantial impact on results. 
The primary method for handling missing data was by including “missing” or “unknown” 
categories, allowing the extent of missing data to be observed for each variable. 
Smoking status, BMI and alcohol intake had missing values (all under 15% of records 
in all cases), as did socioeconomic status (>20% missing) and ethnicity (>30% 
missing). Creating missing categories in this way can be problematic, however, 
because it risks individuals with very dissimilar true values for the variable being placed 
in the same category, and adjustments with the variable may not adjust for 
confounding.   When considering the association of flucloxacillin with cholestatic liver 
injury using each of the algorithms, none of the final multivariable models included 
variables with any missing data. Multiple imputation was therefore not performed. 
Restricting the cohort to only those individuals with complete records for all co-variates 
(not just those included in the final model) left a cohort of 489 367 people (46% of the 
original cohort), within which only the lowest specificity CPRD algorithm was able to 
identify any oxytetracycline cases. The multivariable rate ratio for the CPRD low 
specificity algorithm using only individuals with complete records (analysing the final 
multivariable model) was 7.76 (95% CI 1.91 - 31.62), stronger (but consistent with) that 
obtained in the main analysis (RR 3.70, 95% CI 1.73 – 7.94).   
5.9.6 Generalisability 
The CPRD is a good representation of the geographic distribution, age and sex 
structure of the UK population [119] and has a very large coverage (around 8% of the 
population [120]). In this study we used a total sample of over 1 000 000 people from 
this database, so our results are likely to be as generalisable to the UK population as 
the CPRD database itself. UK population groups not covered might include those not 
registered with a primary care practice which for example may include people who 
have immigrated to the UK and do not trust the health system or the 
homeless/prisoners. Given the rarity of the outcome under study, it is unlikely that 
omission of such groups would occur at a high enough level to impact the results of this 
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study.  Overall, it is likely that our results could be generalised to the UK as a whole 
and other countries with a similar demography to the UK. 
5.9.7 Conclusions and recommendations 
This study has demonstrated that an algorithm for the detection of cholestatic liver 
injury using CPRD data alone can perform similarly to a (multiple source) algorithm 
using CPRD, HES and ONS data in measuring the frequency of drug-induced 
cholestatic liver injury. Furthermore, although increasing the sensitivity and decreasing 
the specificity of the CPRD algorithm (when compared to the multisource algorithm) 
results in an increase in the measured frequency of drug-induced cholestatic liver 
injury, analyses of association (relative effects) between a drug exposure and injury 
produce very similar estimates. When performing a risk-factor type analyses, the 
conclusions that can be drawn from the data are again likely to be similar across 
varying specificity of CPRD algorithm, with the less specific algorithms generating more 
conservative estimates with narrower confidence intervals.  
For studies that are being performed to assess absolute risk (e.g. possibly to inform 
decisions about drug licence suspension or withdrawal), the algorithm versions with 
high sensitivity and high specificity could both play a role. For example, the lower 
specificity more sensitive algorithm could be used initially, possibly run in an automated 
fashion on a database (or databases) in order to obtain early signals of issues related 
to cholestatic liver injury. If cases were detected and further investigation warranted, 
the more specific version of the algorithm could then be run to obtain an accurate 
estimation of absolute risk.  
When considering the results and methods that have been applied in the literature, 
frequency estimates for the two higher specificity CPRD algorithms were comparable 
with those obtained in the literature. Furthermore, relative estimates of effect were 
comparable with published data. It is of particular note that the two previous studies 
(and in fact, all of the studies with cholestatic liver injury as an outcome discussed in 
Chapter 2 of this thesis), performed retrieval and review of actual hard copies of notes 
from health centres in order to assign a case status. In this study, only electronic data 
was used, and the results obtained were very similar. This suggests that for 
pharmacoepidemiological studies of cholestatic liver injury within the databases used, 
hard copies of notes are unlikely to add any additional information above and beyond 
the information provided in the electronic record. The CPRD algorithm tested in this 
study could be used to facilitate the monitoring of CPRD for new case recruitment to 
genetic association studies, or as part of pharmacovigilance activities (as discussed in 
Chapter 4, section 4.4 and in reference [36]). If subsequent verification of case status 
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from a patient’s responsible clinician was required (for example, in the situation where 
recruitment to a genetic association study was being performed using the low 
specificity CPRD algorithm as described in Chapter 4, section 4.4), a targeted, brief 
questionnaire similar to the one contained in Chapter 5, Appendix Table 5 could be 
utilised to verify status. 
Finally, the results of this study have confirmed that the risk of flucloxacillin-induced 
liver injury increases dramatically over the age of 50, but also suggests that those over 
the age of 70 who receive more than one prescription are particularly susceptible. 
Current prescribing information only specifies an increased risk over the age of 50  
[117] and could be updated accordingly with absolute risk figures for different age 
groups  based on the results found here, in the largest study performed to date on the 
association between flucloxacillin and cholestatic liver injury. 
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5.10 Chapter 5 Summary 
• In this chapter, the results were presented for the cohort study of the 
association between flucloxacillin (compared with oxytetracycline) and 
cholestatic liver injury 
 
• Three versions of the CPRD cholestatic liver algorithm (low, medium and high 
specificity) were used  
 
• Although absolute effects were different across the algorithms (low specificity 
algorithm crude rate 9.67 per 100 000 person months 95% CI 8.10 – 11.55, 
high specificity 4.20, 3.21 – 5.50), the lowest specificity algorithm estimated a 
rate ratio that was slightly lower but similar to the highest specificity algorithm 
but with narrower confidence intervals (multivariable adjusted rate ratio low 
specificity 3.70, 1.73 – 7.94; high specificity 3.72, 1.16 – 11.96) 
 
• The 45-day risk estimate for the most specific algorithm (6.15 per 100 000 
users, 95% CI 4.61 – 8.04)  was very similar to estimates obtained by previous 
studies in the literature, which in contrast to this study relied on information 
requested from clinicians (external to the database) 
 
• Risk of cholestatic liver injury is highest within people aged over 70 who receive 
three or more prescriptions (i.e. 45-day risk for those over the age of 70 who 
receive three or more prescriptions was 7.27 per 10 000 users 95% CI 1.98 – 
18.59, compared to a risk of 2.16 per 100 000 users 95% CI 1.21 – 3.56 for 
people under the age of 70) 
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6 Results: applying the algorithm to putative but unknown 
associations - a case control study of the association 
between five drug exposures and cholestatic liver injury  
6.1 Introduction 
In this chapter, the results are presented for the case-control study of the association 
between cholestatic liver injury and the following five drug exposures: 
1. Carbamazepine 
2. Celecoxib 
3. Duloxetine 
4. Ramipril 
5. Risperidone 
As discussed in Section 3.4.2, these drugs were selected because they were (1) 
considered to be prescribed relatively frequently in the UK (2) had a lack of large 
epidemiological studies of their effect on cholestatic liver injury and (3) had been 
included in recent or multiple cholestatic liver injury case reports published in the 
literature and/or had statements in their prescribing information suggesting that they 
caused liver injury at an unknown frequency. 
Details of the number of participants and a description of those included in the final 
case-control analysis are provided, before the following results are presented.  
(5) The association of the study co-variates with cholestatic liver injury 
(6) Crude estimated rate ratios for the association between being a current, recent 
or past user of one of the drugs of interest and experiencing a subsequent 
cholestatic liver injury 
(7) Multivariable adjusted rate ratios of the associations described in (2) 
(8) Frequency (risk) of cholestatic liver injury for those drug exposures shown to be 
strongly associated with cholestatic liver injury by the analysis in (3) 
(9) Adjusted rate ratios presented stratified by important risk factors 
Finally, a discussion of the results is provided, in which the results obtained for each 
drug exposure are discussed (including a comparison with flucloxacillin, included in the 
analysis in order to illustrate validity of the results). 
Throughout this chapter, the CPRD algorithm cut-off scores will be described in terms 
of their specificity (as compared to the multisource case status of definite to probable), 
with cut-off score 5 being “high” specificity (specificity 100%, sensitivity 81%) and score 
1.63 “low” specificity (48%, 100%).  
 170 
 
6.2 Participants 
Between the dates of 1st January 1992 and 31 January 2014 38 529 people aged 18 
years and over were identified in CPRD with a diagnostic code indicating potential liver 
injury (see Chapter 3 Appendix Table 1) who had been registered in the database for at 
least 6 months.  Applying the low specificity CPRD cholestatic liver injury algorithm to 
this cohort resulted in 13 693 individuals being identified as non-cases, while 30 967 
individuals were identified as non-cases by the high specificity CPRD cholestatic liver 
injury algorithm. After applying exclusions to the low specificity cases, matching them 
to controls (by age, gender and practice) and applying the same exclusions to the 
controls, the low specificity algorithm case-control cohort consisted of 19 891 cases 
and 77 476 matched controls. The equivalent final figures for the high specificity 
algorithm were 5 681 cases matched to 22 176 controls. Full details are provided in 
Figure 6.1. 
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Figure 6.1: Flow of number of individuals included in the case-control study of the 
association between five drug exposures and cholestatic liver injury (with cases 
identified using a low-specificity and a high-specificity case identification algorithm) 
1Non‐cases: individuals who were not identified as cases by the high or the low specificity CPRD algorithm 
2Non‐cases (high‐specificity algorithm): individuals who were not identified as cases by the high specificity CPRD algorithm only 
3Excluded potential cases (low‐specificity algorithm): made up of people who (1) had an underlying liver‐related condition (n=4 
095) (2) were pregnant (n=109) (3) had a pre‐follow‐up DILI liver test result (n=662) 
4Excluded potential cases (high‐specificity algorithm): (1) underlying liver‐related condition (n=1 385) (2) pregnant (n=23) (3) pre‐
follow‐up DILI liver test result (n=446) 
5Excluded potential matched controls (low‐specificity algorithm): (1) underlying liver‐related condition (n=955) (2) pregnant 
(n=298) (3) pre‐follow‐up DILI liver test result (n=125) 
6Excluded potential matched controls (high‐specificity algorithm): (1) underlying liver‐related condition (n=257) (2) pregnant 
(n=38) (3) pre‐follow‐up DILI liver test result (n=50) 
7No matches: no potential controls identified as suitable matches, cases not included in final analysis  
Potential cases 
 (n=7 562)
Potential cases
(n=24 836)
Individuals in CPRD over the age of 18 with a liver‐related diagnosis 
between 01/01/1992 and 31/01/2014 with at least 6 months 
registration in CPRD prior to their drug prescription (N=38 529)
   Low‐specificity algorithm                                       High‐specificity algorithm
Non‐cases2 
(n=17 274)
Non‐cases1 
(n=13 693)
Final cases
 (n=5 708)
Final cases 
(n=19 970)
Excluded4 
(n=1 854)
Excluded3 
(n=4 866)
Final matched cases
 (n=5 681)
Final matched cases 
(n=19 891)
Potential matched controls  
(N=78 854)
Final matched controls 
(n=77 476)
Final matched controls 
(n=22 176)
Excluded5 
(n=1 378)
Potential matched controls
(N=22 521)
No matches7 
(n=27)
No matches7 
(n=79)
Excluded6 
(n=345)
      Cases                                                  Cases                                          Controls                                         Controls
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6.3 Descriptive data 
There were 19 891 cases identified by the low-specificity algorithm in the database 
between 1st January 1992 and 31 January 2014 that were matched to 77 476 controls 
(by age, gender and practice). 5 681 of the low-specificity algorithm cases were also 
classified as cases by the high-specificity algorithm, and these were matched to 22 176 
controls. 
Table 6-1 provides an overview of the characteristics of the people included in the 
study, presented by algorithm and case-control status, including percentage 
distributions and odds of association across categories of each co-variate. The 
distribution of cases and controls for the matched variables (age, gender and date of 
cholestatic liver injury) were comparable within each algorithm. Comparing between the 
algorithms, 63% of the cases identified by the low-specificity algorithm were aged 60 or 
over, compared to 75% of those identified by the high-specificity algorithm, and a 
greater proportion of cases were identified after 2005 by the high-specificity algorithm 
(65%) than by the low-specificity algorithm (45%).     
Receiving prescriptions for drugs considered to be causes of cholestatic liver injury (not 
including any of the drugs under study) was the variable associated most strongly with 
the outcome as defined by both algorithms, with an odds ratio of 8.28 (95% CI 7.62 – 
9.00) for prescriptions considered to be the most common causes of liver injury for the 
low specificity algorithm. The estimate of the association for drugs considered to be 
causes of cholestatic liver injury when applying the high specificity algorithm was 
approximately 8-times higher than the low-specificity for both categories (e.g. 68.41, 
52.52 – 89.11 for the more common causes).   
Smoking status was associated with cholestatic liver injury as defined by both 
algorithms, with current smokers 1.48 (1.36 – 1.61) times more likely to experience 
cholestatic liver injury than non-smokers (high-specificity algorithm). BMI was also 
associated with cholestatic liver injury as defined by both algorithms, with people with a 
BMI of less than 20 more likely to suffer the injury when compared to those over this 
weight. People with alcohol status recorded as ex- drinkers and those who reported 
drinking over 6 units per day experienced an increased risk of cholestatic liver injury 
according to both the low and high-specificity algorithms, and both algorithms also 
detected a trend of increasing risk of injury with decreasing socioeconomic status. 
There was a suggestion that people who were any other ethnicity than white had a 
reduced risk of injury for both algorithms. 
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Table 6-1: Descriptive and univariable analysis for the cholestatic liver injury matched case control study, for the low- and high- specificity algorithms 
    Low-specificity algorithm High-specificity algorithm 
  Controls 
(N = 77 476) 
Cases 
(N = 19 891) 
Univariable OR 
(95% CI) 
  Controls 
(N = 22 176) 
Cases 
(N = 5 681) 
Univariable OR 
(95% CI) 
n (%)  n (%)      n (%)  n (%)   
Age at index date1 18 – 29  4209 (5) 1093 (5) ‐  433 (2) 113 (2) ‐
30 – 39  5380 (7) 1386 (7) ‐  807 (4) 209 (4) ‐
40 – 49  7966 (10) 2012 (10) ‐  1634 (7) 414 (7) ‐
50 – 59  11152 (14) 2816 (14) ‐  2819 (13) 711 (13) ‐
60 – 69  15458 (20) 3921 (20) ‐  4719 (21) 1198 (21) ‐
70 – 79  17855 (23) 4553 (23) ‐  5983 (27) 1521 (27) ‐
80+  15456 (20) 4110 (21) ‐  5781 (26) 1515 (27) ‐
median (25 ‐ 75%):  66 (51 – 77)  66 (51 – 78)  ‐  71 (59 – 80) 71 (59 – 80)
 
Gender1  Male  41054 (53) 10503 (53) ‐  11444 (52) 2929 (52) ‐
Female  36422 (47) 9388 (47) ‐  10732 (48) 2752 (48) ‐
 
Date of cholestatic 
liver injury1 
1992 – 1993  3524 (5) 917 (5) ‐  64 (0) 17 (0) ‐
1994 – 1996  5987 (8) 1554 (8) ‐  250 (1) 66 (1) ‐
  1997 – 1999  7955 (10) 2050 (10) ‐  833 (4) 218 (4) ‐
  2000 – 2002  11678 (15) 2993 (15) ‐  2318 (10) 597 (11) ‐
2003 – 2005  13934 (18) 3576 (18) ‐  4513 (20) 1158 (20) ‐
2006 – 2008  13713 (18) 3507 (18) ‐  5287 (24) 1350 (24) ‐
2009 – 2011  12258 (16) 3137 (16) ‐  5215 (24) 1331 (23) ‐
2012 – 2014   8427 (11) 2157 (11) ‐  3696 (17) 944 (17) ‐
 
Prescriptions for 
causes  
of cholestatic injury2 
None  47383 (61) 8526 (43) 1  20022 (90) 2150 (38) 1 
Less common cause 28974 (37) 9834 (49) 2.08 (2.00 ‐ 2.15) 2087 (9) 3007 (53) 16.66 (15.21 ‐ 18.26) 
More common cause 1119 (1) 1531 (8) 8.28 (7.62 ‐ 9.00) 87 (0) 524 (9) 68.41 (52.52 ‐ 89.11) 
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    Low-specificity algorithm High-specificity algorithm 
  Controls 
(N = 77 476) 
Cases 
(N = 19 891) 
Univariable OR 
(95% CI) 
  Controls 
(N = 22 176) 
Cases 
(N = 5 681) 
Univariable OR 
(95% CI) 
n (%)  n (%)      n (%)  n (%)   
Smoking status  Non‐smoker  33408 (43) 8182 (41) 1  9595 (43) 2227 (39) 1 
Ex‐smoker  25726 (33) 6272 (32) 0.99 (0.96 ‐ 1.03) 8521 (38) 2174 (38) 1.11 (1.03 ‐ 1.19) 
Current smoker  14169 (18) 4285 (22) 1.27 (1.21 ‐ 1.32) 3434 (15) 1138 (20) 1.48 (1.36 ‐ 1.61) 
Unknown  4162 (5) 1152 (6) 1.12 (1.04 ‐ 1.21) 621 (3) 142 (2) 0.98 (0.80 ‐ 1.19) 
           
BMI   <20  3993 (5) 1295 (7) 1  1132 (5) 378 (7) 1 
  20 ‐ 25  23042 (30) 5790 (29) 0.77 (0.72 ‐ 0.83) 6576 (30) 1743 (31) 0.78 (0.69 ‐ 0.89) 
25+  38930 (50) 9639 (48) 0.76 (0.71 ‐ 0.82) 11981 (54) 2848 (50) 0.70 (0.62 ‐ 0.80) 
Unknown  11511 (15) 3167 (16) 0.85 (0.78 ‐ 0.91) 2487 (11) 712 (13) 0.85 (0.74 ‐ 0.99) 
Alcohol intake  Non‐drinker  9098 (12) 2394 (12) 1  2364 (11) 586 (10) 1 
  Ex‐drinker  2884 (4) 993 (5) 1.34 (1.23 ‐ 1.46) 1177 (5) 358 (6) 1.24 (1.06 ‐ 1.44) 
  Current NOS  1821 (2) 516 (3) 1.08 (0.97 ‐ 1.21) 577 (3) 157 (3) 1.11 (0.91 ‐ 1.36) 
  2 or less u/d  13621 (18) 3274 (16) 0.92 (0.86 ‐ 0.97) 4240 (19) 1032 (18) 0.99 (0.88 ‐ 1.11) 
  3/6 u/d  33959 (44) 7750 (39) 0.88 (0.84 ‐ 0.93) 10007 (45) 2318 (41) 0.96 (0.86 ‐ 1.06) 
  >6 u/d  5590 (7) 2269 (11) 1.61 (1.50 ‐ 1.73) 1488 (7) 617 (11) 1.76 (1.53 ‐ 2.02) 
  Unknown  10503 (14) 2695 (14) 0.97 (0.91 ‐ 1.03) 2323 (10) 613 (11) 1.07 (0.94 ‐ 1.22) 
   
Socioeconomic status 1 (Highest SES)  13882 (18) 3396 (17) 1  4463 (20) 1075 (19) 1 
  2 13957 (18) 3403 (17) 1.03 (0.96 – 1.10) 4261 (19) 1056 (19) 1.07 (0.96 ‐ 1.21) 
  3 13359 (17) 3458 (17) 1.14 (1.06 – 1.22) 3984 (18) 1033 (18) 1.17 (1.03 ‐ 1.32) 
  4 11193 (14) 2972 (15) 1.21 (1.12 – 1.31) 3258 (15) 871 (15) 1.25 (1.09 ‐ 1.44) 
  5 (Lowest SES)  10199 (13) 2827 (14) 1.36 (1.25 – 1.49) 2594 (12) 713 (13) 1.36 (1.16 ‐ 1.60) 
  Unknown  14886 (19) 3835 (19) ‐3  3636 (16) 933 (16) ‐3 
   
Ethnicity  White  39005 (50) 8544 (43) 1  12607 (57) 2878 (51) 1 
  South Asian  734 (1) 125 (1) 0.75 (0.61 ‐ 0.92) 168 (1) 25 (0) 0.61 (0.39 ‐ 0.94) 
  Black  396 (1) 59 (0) 0.66 (0.50 ‐ 0.88) 99 (0) 11 (0) 0.46 (0.24 ‐ 0.87) 
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    Low-specificity algorithm High-specificity algorithm 
  Controls 
(N = 77 476) 
Cases 
(N = 19 891) 
Univariable OR 
(95% CI) 
  Controls 
(N = 22 176) 
Cases 
(N = 5 681) 
Univariable OR 
(95% CI) 
n (%)  n (%)      n (%)  n (%)   
  Other  337 (0) 75 (0) 1.02 (0.79 ‐ 1.32) 83 (0) 12 (0) 0.62 (0.34 ‐ 1.15) 
  Mixed  88 (0) 11 (0) 0.57 (0.30 ‐ 1.07) 32 (0) 4 (0) 0.53 (0.18 ‐ 1.50) 
  Not Stated  5851 (8) 1799 (9) 1.47 (1.39 ‐ 1.57) 1758 (8) 544 (10) 1.41 (1.26 ‐ 1.58) 
  Unknown  31065 (40) 9278 (47) 1.79 (1.71 ‐ 1.87) 7449 (34) 2207 (39) 1.64 (1.50 ‐ 1.79) 
Note 1: Matched variables 
Note 2: Prescriptions were counted if they occurred anytime from 45 days prior to index date. List of drugs did not include those under study (see Chapter 3 section 3.4.1.5 for 
full list). Less common categories were created using flucloxacillin as a standard (so less than or more common than that caused by flucloxacillin), as reported in the literature 
(see Chapter 3 section 3.4.1.5). Therefore, less common are drugs reported to cause cholestatic liver injury at a frequency of less than approximately 1 per 1000 users, more 
common at a frequency of over 1 per 1000. 
Note 3: Omitted because of no within‐group variance. 
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6.4 Relative effect estimates: associations between each drug and 
cholestatic liver injury  
The results of the crude and multivariable analysis of the association between each 
drug exposure and cholestatic liver injury as detected by the low and high specificity 
algorithms are shown in Table 6-2, and a forest plot of the multivariable results is 
provided in Figure 6.2.  
Risperidone: Of the four putative causes of cholestatic liver injury, risperidone was the 
most strongly associated with the outcome. Current users of risperidone experienced 
2.03 times the rate of liver injury as detected by the low specificity algorithm with a 95% 
confidence interval (CI) of 1.53 to 2.70, after multivariable adjustments. When the same 
analysis was performed with the high specificity algorithm, the rate ratio (RR) for 
current users of risperidone increased but the estimate was less precise (multivariable 
RR 2.59, 95% CI 1.41 – 4.75). Being a recent user of risperidone did not seem to 
increase the rate of liver injury as detected by either algorithm, while there was a 
suggestion that past users had a slightly increased rate (low specificity algorithm 
multivariable RR 1.24 95% CI 0.96 – 1.60, high specificity algorithm multivariable RR 
1.59 95% CI 0.85 – 2.95).  
Celecoxib: Recent users of celecoxib were also shown to have an increased rate of 
cholestatic liver injury, with a multivariable rate ratio of 1.89 (95% CI 1.11 – 3.22) as 
detected by the low specificity algorithm. When applying the high specificity algorithm, 
the estimated rate ratio was consistent with an increased rate for recent users, 
although the association lacked power (RR 1.93 95% CI 0.51 – 7.27). No association 
was observed for current or past users as detected by either algorithm.  
Ramipril: There was a slightly increased rate of cholestatic liver injury for current users 
of ramipril, although the high specificity estimate lacked power (low specificity RR 1.13 
95% CI 1.04 – 1.22, high specificity RR 1.12 95% CI 0.96 – 1.30). When applying the 
low specificity algorithm, recent users of ramipril had a further increased risk of liver 
injury (RR 1.73 95% CI 1.20 – 2.50), but this association was not observed when 
applying the high specificity algorithm. 
Duloxetine: There was a suggestion that current users of duloxetine experience an 
increased rate of liver injury, with similar point estimates across both algorithms but a 
loss of precision with the high specificity algorithm (low specificity multivariable RR 1.56 
95% CI 0.93 – 2.61, high specificity multivariable RR 1.5 to 95% CI 0.55 – 4.25).  
Carbamazepine: Carbamazepine use did not seem to be associated with liver injury, 
while the known cause of cholestatic liver injury flucloxacillin showed strong 
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associations with the outcome for both current and recent users, with the high 
specificity algorithm measuring associations approximately twice the strength of those 
detected by the low specificity (but with wider confidence intervals). 
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Table 6-2: Crude and multivariable association between each drug and cholestatic liver injury as defined by the low and high specificity algorithms in the 
matched case control study (matched on age, gender and date of cholestatic liver injury) 
    Low-specificity algorithm High-specificity algorithm 
    Controls 
(N = 77 476) 
Cases 
(N = 19 891) 
Crude RR 
(95% CI) 
Multivariable1 
RR 
 Controls 
(N = 22 176) 
Cases 
(N = 5 681) 
Crude RR 
(95% CI) 
Multivariable1 RR 
    n (%) n (%)    n (%) n (%)   
Carbamazepine  Never users   75814 (98)    19382 (97)  1  11      21650 (98)     5509 (97)  1  11 
  Current users1     414 (1)      133 (1)  1.27 (1.05 ‐ 1.55)  1.07 (0.87 – 1.32)        103 (0)       36 (1)  1.38 (0.94 ‐ 2.01)  1.46 (0.86 – 2.47) 
  Recent users      30 (0)       11 (0)  1.44 (0.72 ‐ 2.88)  1.40 (0.67 – 2.93)         10 (0)        7 (0)  2.73 (1.04 ‐ 7.17)  1.65 (0.45 – 5.95) 
  Past users    1218 (2)      365 (2)  1.18 (1.04 ‐ 1.32)  1.00 (0.88 – 1.13)        413 (2)      129 (2)  1.23 (1.00 ‐ 1.50)  0.96 (0.72 – 1.27) 
                     
Celecoxib  Never users   74977 (97)    19197 (97)  1  12      21087 (95)     5393 (95)  1  12 
  Current users     270 (0)       58 (0)  0.84 (0.63 – 1.13)  0.92 (0.68 – 1.23)        114 (1)       20 (0)  0.69 (0.43 ‐ 1.10)  1.00 (0.54 – 1.82) 
  Recent users      45 (0)       23 (0)  2.04 (1.23 – 3.39)  1.89 (1.11 – 3.22)         16 (0)        8 (0)  1.95 (0.83 ‐ 4.56)  1.93 (0.51 – 7.27) 
  Past users    2184 (3)      613 (3)  1.11 (1.01 – 1.21)  1.02 (0.93 – 1.13)        959 (4)      260 (5)  1.06 (0.92 ‐ 1.23)  1.01 (0.83 – 1.23) 
                     
Duloxetine  Never users   77300 (100)    19837 (100)  1  13      22089 (100)     5655 (100)  1  13 
  Current users      57 (0)       22 (0)  1.52 (0.93 ‐ 2.49)  1.56 (0.93 – 2.61)         33 (0)       10 (0)  1.20 (0.59 ‐ 2.44)  1.52 (0.55 – 4.25) 
  Recent users       6 (0)        3 (0)  2.00 (0.50 ‐ 8.00)  1.53 (0.36 – 6.56)          1 (0)        3 (0)  11.21 (1.16 ‐ 108.11)  2.11 (0.16 – 27.28) 
  Past users     113 (0)       29 (0)  1.00 (0.66 ‐ 1.50)  0.80 (0.52 – 1.23)         53 (0)       13 (0)  0.96 (0.52 ‐ 1.75)  0.86 (0.34 – 2.15) 
                     
Ramipril   Never users   71231 (92)    18134 (91)  1  14      19348 (87)     4931 (87)  1  14 
  Current users    3728 (5)     1021 (5)  1.09 (1.01 ‐ 1.18)  1.13 (1.04 – 1.22)       1680 (8)      432 (8)  1.01 (0.90 ‐ 1.14)  1.12 (0.96 – 1.30) 
  Recent users     102 (0)       45 (0)  1.78 (1.25 ‐ 2.54)  1.73 (1.20 – 2.50)         54 (0)       17 (0)  1.23 (0.71 ‐ 2.14)  0.79 (0.37 – 1.70) 
  Past users    2415 (3)      691 (3)  1.14 (1.05 ‐ 1.25)  0.99 (0.90 – 1.09)       1094 (5)      301 (5)  1.08 (0.94 ‐ 1.24)  0.83 (0.69 – 1.00) 
                     
Risperidone   Never users   77071 (99)    19700 (99)  1  15      22035 (99)     5615 (99)  1  15 
  Current users     157 (0)       86 (0)  2.13 (1.64 ‐ 2.78)  2.03 (1.53 – 2.70)         53 (0)       33 (1)  2.42 (1.55 ‐ 3.76)  2.59 (1.41 – 4.75) 
  Recent users      10 (0)        5 (0)  2.09 (0.71 ‐ 6.11)  1.34 (0.42 – 4.23)          4 (0)        1 (0)  1.00 (0.11 ‐ 8.95)  0.44 (0.03 – 8.06) 
  Past users     238 (0)      100 (1)  1.66 (1.31 ‐ 2.10)  1.24 (0.96 – 1.60)         84 (0)       32 (1)  1.50 (1.00 ‐ 2.27)  1.59 (0.85 – 2.95) 
                     
Flucloxacillin  Never users   57746 (75)    13965 (70)  1  1      15536 (70)     3687 (65)  1  1 
  Current users     215 (0)      118 (1)  2.30 (1.83 ‐ 2.88)  3.43 (2.71 – 4.35)         70 (0)       36 (1)  2.18 (1.45 ‐ 3.27)  5.46 (3.41 – 8.73) 
  Recent users     392 (1)      333 (2)  3.57 (3.08 ‐ 4.14)  5.51 (4.72 – 6.44)        138 (1)      144 (3)  4.37 (3.45 ‐ 5.54)  13.37 (10.01 – 17.85) 
  Past users   19123 (25)     5475 (28)  1.21 (1.16 ‐ 1.25)  1.12 (1.08 – 1.17)       6432 (29)     1814 (32)  1.21 (1.13 ‐ 1.29)  1.11 (1.02 – 1.22) 
Note 1: Adjusted for all variables in Table 6‐1 except calendar period (low‐specificity algorithm) and age and calendar period (high‐specificity algorithm) as additional stratification on these matched variables was not possible 
 
  
  
 
Figure 6.2: Forest plot of the multivariable association between each drug and cholestatic liver injury as defined by the low and high specificity 
algorithms in the matched case control study (matched on age, gender and date of cholestatic liver injury and adjusted as detailed in Table 6-2) 
Low-specificity algorithm High specificity algorithm 
          Exposure and category                   Rate ratio     Exposure and category                       Rate ratio 
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6.4.1 Interactions/Effect modification 
As discussed in Chapter 3, all co-variates included in the DAG analysis were 
investigated as potential effect modifiers.  Evidence of effect modification was strongest 
for the low-specificity algorithm across all drugs (where there was more power to detect 
interactions), and all results discussed in this section relate to those obtained for the 
low-specificity algorithm. Likelihood ratio tests (LRT) for effect modification showed 
evidence that prescription with other hepatotoxic drugs, age, and ethnicity were 
possible effect modifiers of the association between drug exposure and cholestatic liver 
injury, particularly for risperidone (LRT p-values: other prescriptions – 0.001, age – 
0.017, ethnicity - 0.041). Table 6-3 shows the association between risperidone and 
cholestatic liver injury (low-specificity algorithm) stratified by each of these variables. 
Risperidone users who were not being prescribed another cause of liver injury had an 
increased rate of liver injury when compared to those being prescribed another 
hepatotoxic drug. For example, RR in current risperidone users (compared to never 
users) who were not prescribed another hepatotoxic drug: 3.22 (95% CI 2.20 – 4.73) 
compared with 1.38 (95% CI 0.86 – 2.17) for current risperidone users who were 
prescribed a hepatotoxic drug. This difference between categories of prescriptions for 
another hepatotoxic drug was apparent across all categories of risperidone exposure 
(e.g. within past users of risperidone, those not prescribed another cause of liver injury 
had a RR of 2.24, 95% CI 1.39 – 3.59 while those prescribed a more common cause 
had an RR of 0.67, 95% CI 0.36 – 1.22). A similar pattern of effect modification by 
prescriptions for other hepatotoxic drugs was also observed for celecoxib (Chapter 6 
Appendix Table 1a). 
When considering the effect of age, there was a trend for the effect of risperidone on 
cholestatic liver to be stronger in younger age groups (e.g. RR for current users of 
risperidone in the 18-49 yr old age group 4.79, 95% CI 2.35 – 9.76 compared to 1.38, 
95% CI 0.94 – 2.03 in those aged over 70). A similar clear trend was apparent for 
Celecoxib (Chapter 6 Appendix Table 1b). 
Finally, although there was insufficient power to obtain results for all categories of 
ethnicity, stratification by this variable suggested that the effect of risperidone on 
cholestatic liver injury was particularly marked in South Asian users (RR for current 
users compared to never users 26.06, 95% CI 2.78 – 244.21). 
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Table 6-3: Association between risperidone and cholestatic liver injury (low-specificity algorithm) by prescription with other hepatotoxic drugs, age at 
date of liver injury and ethnicity 
  Multivariable RR1 (95% CI2) by risperidone exposure category
 
  Never users Current users Recent users Past users
Prescription 
with 
Not prescribed another 
cause  1  3.22 (2.20 – 4.73)  3.57 (0.49 – 25.98) 
2.24 (1.39 – 3.59)
other 
hepatotoxic  
Prescribed a less common 
cause  1  1.38 (0.86 – 2.17)  0.55 (0.06 – 4.61) 
1.17 (0.85 – 1.61)
drugs3  Prescribed a more common 
cause  1  1.14 (0.54 – 2.41)  1.54 (0.13 – 17.81) 
0.67 (0.36 – 1.22)
 
     
Age at date of 
liver 
18 ‐ 49 
1  4.79 (2.35 – 9.76)  ‐ 
1.49 (0.87 – 2.54)
Injury4  50 ‐ 69  1 2.91 (1.63 – 5.20) 1.91 (0.17 – 21.57) 1.30 (0.76 – 2.22)
70+ 1 1.38 (0.94 – 2.03) 0.83 (0.20 – 3.52) 1.13 (0.80 – 1.59)
 
Ethnicity5  White 1 1.93 (1.31 – 2.84) ‐ 1.20 (0.84 – 1.71)
  South Asian  1 26.06 (2.78 – 244.21)  ‐ 7.08 (1.02 – 49.02)
  Black 1 7.60 (0.44 – 130.67)  ‐ 1.50 (0.14 – 16.39)
  Other 1 ‐ ‐ ‐
  Mixed  1 ‐ ‐ ‐
  Not stated  1 4.11 (1.72 – 9.81) 0.64 (0.05 – 8.52) 0.88 (0.36 – 2.08)
Unknown  1 1.40 (0.83 – 2.36) 3.01 (0.55 – 16.30) 1.31 (0.87 – 1.98)
1Multivariable rate ratio, with adjustments as described in Table 6‐2 
295% confidence interval 
3p‐value for Likelihood Ratio Test of interaction with prescription with other hepatotoxic drugs: 0.001 
4p‐value for Likelihood Ratio Test of interaction with age at date of liver injury:  0.017 
5p‐value for Likelihood Ratio Test of interaction with ethnicity: 0.041
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6.5 Absolute effect estimates: frequency (risk) of cholestatic liver 
injury  
Following detailed and blinded review of the electronic record 1 year prior to case 
assignment of the 91 current and recent users of risperidone who were identified as 
cases in the case-control analysis, 39 were found to have no other documented cause 
of liver injury (19 of whom were identified as cases by the high specificity algorithm as 
well as the low specificity algorithm). Searching the entire CPRD database for the total 
number of people exposed to risperidone over the age of 18 during the study period 
resulted in a total number of 40 161 people, giving a risk of 97.11 per 100 000 users 
(95% CI 69.06 – 132.73) as estimated by the low specificity algorithm, and 47.31 per 
100 000 users (28.49 – 73.87) as measured by the high specificity algorithm (Table 
6-4).  
Applying a similar review for celecoxib resulted in the identification of 47 people who 
were likely to have experienced their injury as a result of exposure to celecoxib, and 
150 854 total exposed people in the database during the study period. The risk of liver 
injury per 100 000 users was therefore estimated to be 21.88 (15.06 – 30.72) when 
using the low specificity algorithm, and 7.95 (4.11 – 13.89) according to the high 
specificity.  
The absolute effect estimate obtained for flucloxacillin for the high-specificity algorithm 
(included to allow a comparison between this method for estimating absolute effects 
and the cohort study performed in Chapter 5) of 8.52 per 100 00 users (95% CI 7.10 – 
10.15) was slightly higher but consistent with the estimate obtained in Chapter 5 (6.15 
per 100 000 users, 95% CI 4.61 – 8.04).   
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Table 6-4: Absolute effect estimates  
  High specificity algorithm     Low specificity algorithm 
Drug exposure  Total 
exposed 
people1 
Cases2  Risk3 (CI4) 
(per 100 000 people 
prescribed the drug) 
    Cases  Risk (CI) 
(per 100 000 people 
prescribed the drug) 
 
Risperidone  40 161 19 47.31 (28.49 – 73.87)   39 97.11 (69.06 – 132.73)
Celecoxib  150 854 12 7.95 (4.11 – 13.89)   33 21.88 (15.06 – 30.72)
Flucloxacillin5   1 478 303 126 8.52 (7.10 – 10.15)   344 23.27 (20.88 – 25.86)
Note 1: All those over the age of 18 with at least one prescription in CPRD for the drug in question during the study period
Note 2: Cases identified who were current or recent users of the drug in question and had no other cause of their liver injury in the previous year (assessed by 2 
reviewers, including a clinician blinded to exposure status) 
Note 3: Risk amongst those people who were either (1) current users or (2) recent users of the drug (i.e. the prescription ended within 30 days) 
Note 4: 95% confidence interval 
Note 5: Flucloxacillin results included in order to compare how closely this approach for estimating the absolute effect compared to the cohort study performed in 
Chapter 5. Number of cases in this table was obtained by multiplying the number cases identified in Table 6‐2 by the proportion of cases found to be drug‐induced 
following blinded clinician review in Chapter 5 Table 5‐2 (i.e. 0.72 for the high specificity, 0.68 for the low specificity).  
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6.6 Discussion  
In the case control study of the association between 5 drug exposures and cholestatic 
liver injury as detected by a low and a high specificity case definition algorithm, a 
strong association with liver injury was observed for risperidone (high-specificity 
algorithm: current users 2.59 times the risk of never-users, 95% CI 1.41 – 4.75). A 
weaker association was observed for users of celecoxib, but this was only significant 
for recent users (not current users) and was only detected using the low specificity 
algorithm (RR 1.89, 95% CI 1.11 – 3.22). Finally, ramipril use was associated with 
cholestatic liver injury, although this was only detected by the low specificity algorithm 
and was most pronounced in recent users with (RR 1.73, 95% CI 1.20 – 2.50). 
Stratified analysis of variables identified as effect modifiers suggested that for 
risperidone the effect differed by age, ethnicity and concomitant prescriptions. Similar 
(although less pronounced) effect modification by age and concomitant prescriptions 
was observed for celecoxib.  
6.6.1 Comparison of relative effect estimates obtained by each algorithm 
For those drugs that were shown to be associated with cholestatic liver injury, the low-
specificity algorithm generally obtained a more conservative rate ratio (RR) than the 
high specificity algorithm, but with narrower confidence intervals. For example, the low 
specificity celecoxib recent users result was RR 1.89 (95% CI 1.11 – 3.22) compared to 
RR 1.93 (95% CI 0.51 – 7.27) for the high specificity algorithm. Similarly, for 
risperidone, the low specificity algorithm estimate for current users was RR 2.03 (95% 
CI 1.53 – 2.70) compared to a high specificity algorithm estimate of RR 2.59 (95% CI 
1.41 – 4.75). This observation also applied to the results for flucloxacillin obtained here 
and in the study performed in Chapter 5.  
This effect-dilution could be attributed to the non-differential measurement error that is 
being introduced by using a relatively non-specific case definition, with increased false 
positives biasing the estimate towards the null (so underestimating the true effect). One 
might expect though that there would be a degree of non-differential measurement 
error caused by the highly specific algorithm identifying more false negatives. While 
this will also be true, it seems here that identification of people who are not true cases 
as cases (in the unexposed group) causes the relative effect to be reduced when 
applying the more sensitive algorithm.  The increase in precision is a result of the larger 
sample sizes due to the larger number of cases that are classified as cases by a low-
specificity definition. As discussed previously (Chapter 5 Section 5.9), the fact that a 
relatively non-specific case definition for liver injury obtains estimates that are lower 
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than (although still similar to) and more precise than a more specific case definition is 
encouraging for settings where power may be an issue. It supports the idea that 
relatively accurate results can be obtained with good precision in settings where there 
are insufficient numbers of people with complete case records available to apply a 
highly specific case definition. 
The results for ramipril contrasted to this pattern, as the effect estimated by the low 
specificity algorithm for recent users (RR 1.73, 95% CI 1.20 – 2.50) was in a different 
direction to that estimated by the high specificity algorithm (RR 0.79, 0.37 – 1.70). 
Furthermore, the 95% CI for the high specificity algorithm estimate excluded an effect 
as large as the point estimate obtained by the low specificity algorithm. Underlying 
biases that may have contributed to this result are discussed in the following section on 
interpretation of results.   
A final point to note when considering the performance of each of the algorithms within 
this case control study relates to effect modification. Use of a low-specificity algorithm 
allowed a number of effect modifiers to be investigated, as there was sufficient power 
to detect the interaction and subsequently present and interpret the stratified results. 
Use of only a high specificity algorithm would have restricted this analysis. 
6.6.2 Interpretation of relative and absolute effect estimates 
6.6.2.1 Risperidone 
The results suggest that current users of risperidone have over twice the risk of 
cholestatic liver injury, whichever algorithm is applied. Subsequent calculation of the 
risk revealed a frequency of cholestatic liver injury of 4.73 per 10 000 recent or current 
users (95% CI 2.84 – 7.39) or 9.71, 95% CI 6.91 – 13.27 if measured using the high 
specificity algorithm.  Due to the population exposed to risperidone, however, it is 
necessary to consider these results carefully.  
One possibility is that the increased rate of liver injury in the exposed group represents 
confounding by behaviours that may be associated with the potentially chaotic lifestyle 
of people who have (e.g.) schizophrenia. For example, individuals with schizophrenia 
may be users of illegal drugs, something that may not be recorded in electronic medical 
records but could increase the likelihood of liver injury. Furthermore, they may exhibit 
paranoia or be at least suspicious of GPs or medical centres, which could mean they 
consult less, missing vaccinations or other appointments which could mean other 
underlying unrecorded liver pathologies could be causing the liver injury detected in 
this study (such as infection with hepatitis). In an ad-hoc analysis performed to try and 
look at this, characteristics of people exposed to risperidone compared to people not 
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exposed to risperidone in this study were tabulated (Chapter 6 Appendix Table 2). 
Generally, this analysis did not really suggest that people exposed to risperidone had a 
greater proportion of missing data, however. 
Interestingly, although there was a suggestion (in an underpowered analysis) that 
recent users of risperidone had a small increased risk of cholestatic liver injury as 
measured by the low-specificity algorithm, the high specificity algorithm result did not 
suggest an increased risk. The result was underpowered, but it is also possible that 
some people who have recently stopped risperidone prescriptions in primary care are 
being admitted to hospital due to worsening of their condition, which would means that 
although there could still be cholestatic liver test results these are not recorded in 
primary care.   
The effect of risperidone on cholestatic liver injury was shown to be modified by age at 
date of liver injury and use of other hepatotoxic drugs, with the association being 
strongest in the lowest categories (youngest age group and not prescribed other 
drugs). One possible explanation for this pattern is that the liver event associated with 
risperidone is more common towards the beginning of a course of therapy, and those 
starting risperidone therapy are more likely to be younger and prescribed less other 
drugs than those who are someway into their period of therapy. A similar interpretation 
has been applied previously in a study of drug-induced liver injury relating to non-
steroidal anti-inflammatory drugs [64]. An alternative possibility (relating to other 
hepatotoxic drug prescriptions) is that people who are able to tolerate other hepatotoxic 
drugs are also able to tolerate risperidone. Those who are not being prescribed other 
hepatotoxic drugs could therefore represent a subgroup who have had liver-related 
adverse events when prescribed other potentially hepatotoxic drugs, and are therefore 
also more likely to suffer liver injury when prescribed risperidone.  A common genetic 
basis for liver injury in response to drug administration may explain this (for example, 
polymorphisms in genes encoding the cytochrome P450 (CYP) enzymes, which are 
known to be involved in the metabolism of a number of drugs including antipsychotics 
[121]).  
Although the ethnicity data derived from CPRD and HES data suffers from the fact that 
many people do not have ethnicity recorded at all, the results hint at a possible 
interaction between South Asian ethnicity and the association between risperidone and 
cholestatic liver injury.  Despite the confidence intervals for current users of South 
Asian ethnicity obtained being very wide, the lower bound of the 95% confidence 
interval (RR 2.78) excludes the point estimate obtained for White current users (RR 
1.93). As there were only 4 people in the South Asian current user category, this result 
should be considered with caution. If it were true, it would be of interest as it may be 
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that people of South Asian ethnicity are the least likely to be living a chaotic lifestyle 
(for example, drug dependency in England in 2013 was lowest within this ethnic group 
[122]). A strong effect in this group could indicate that the detected liver injury may 
indeed be due to risperidone, and that there could be genetic traits linked to South 
Asian ethnicity that increase susceptibility. The CYP2D6 gene is known to effect the 
metabolism of risperidone [121] and interethnic variation in its expression is well 
established [123]. CYP2D6 poor metabolisers are known to occur more frequently 
amongst the white population than South Asians, however, so an alternative gene may 
be involved in this case. Alternatively, the effect seen could be because the baseline 
incidence of liver injury is lower within South Asians than it is in the White population.  
There are a lack of published epidemiological studies on liver injury associated with 
either risperidone or with other atypical antipsychotics.  Typical antipsychotics are 
known causes of liver injury: chlorpromazine, for example, has had frequent case 
reports of liver-injury published since its launch in 1951 [124-126]  and newer atypical 
antipsychotics such as risperidone are generally assumed to have better side-effect 
profiles [107, 127]. Chlorpromazine has been studied in a number of large 
epidemiological studies, two of which were performed using primary care data stored in 
the VAMP database (a predecessor of the UK CPRD) and obtained estimates of 
cholestatic liver injury incidence of 28.6 per 100 000 users (95% CI 5.9 – 83.5) [66] and 
135.4 per 100 000 users (49.7 – 294.7) [74]. The estimates obtained in this study for 
risperidone (47.31 per 100 000 users, 95% CI 28.49 – 73.87 for the high specificity 
algorithm, 97.11 per 100 000 users, 95% CI 69.06 – 132.73 for the lower specificity) 
suggests that the frequency of cholestatic liver injury may in fact be comparable to that 
of chlorpromazine.  
As mentioned earlier in this section, there are many other factors that could be 
influencing the rate of liver injury observed in this study, but it should be noted that the 
studies on chlorpromazine performed previously will have also been susceptible to the 
same unmeasured confounding. The perception of risperidone (and possibly other 
antipsychotics) as being safer drugs than chlorpromazine could well be due to the fact 
that prescription habits had changed by the time that risperidone was launched (1990) 
such that it was (and is) not prescribed as freely as chlorpromazine was after its 
launch, and therefore a comparable number of cases of jaundice were not observed, 
despite a similar risk.  
Celecoxib 
The results suggest that recent users of celecoxib have around twice the risk of 
cholestatic liver injury than never users. The low-specificity algorithm was sufficiently 
powered to detect the association (RR 1.89, 95% CI 1.11 – 3.22), while the high 
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specificity algorithm result was consistent with a similar increase, although 
underpowered (RR 1.93, 95% CI 0.51 – 7.27). Subsequent calculation of the risk 
revealed a frequency of cholestatic liver injury of 7.95 per 100 000 current or recent 
users (95% CI 4.11 – 13.89) or 21.88 per 100 000 (95% CI 15.06 – 30.72) if applying 
the low specificity algorithm.  
Of note is that while there was an association detected in recent users, this was not 
apparent in current users (for both the high and low specificity algorithms). One 
possibility is that recent celecoxib users represent a group of users who have generally 
been on celecoxib therapy for a longer period of time than those who are still current 
users, and could have reached some kind of threshold of exposure that was needed for 
liver injury to occur. An ad-hoc analysis was performed in order to investigate this 
possibility, but in fact found the opposite: the group of current users of celecoxib had a 
median of 9 prescriptions (spanning a median period of 416 days), while recent users 
had a median exposure of 3 prescriptions (spanning 181 days).  
An alternative possibility, therefore, is that the effect seen in this study is due to the 
characteristics of the people who have had a shorter course of therapy (i.e. recent 
users). For example they could be finishing their prescriptions early due to other health 
issues which could be also lead to jaundice and a cholestatic liver test result  (such as 
congestive heart failure). If this were the case, then one would expect that when the 
cases identified by the algorithm were reviewed for the purpose of calculating the 
absolute effect presented in Table 6-4, then a greater proportion of recent users would 
have been identified as non-cases and removed before calculating the risk. An ad-hoc 
analysis looking at this proportion indicated that it stayed constant, however (28% of 
cases were recent users before and after the review required for the absolute effect 
calculation). Another possibility is that recent users could include current users who 
have taken their prescription irregularly throughout their current use period and 
continue to do so during their recent use period. 
If the effect is real, then it suggests that celecoxib is a rare cause of liver injury, and 
symptoms associated with the reaction may be prolonged before jaundice or a 
cholestatic liver test result. Existing case studies of celecoxib-induced liver injury have 
reported relatively short latencies between drug exposure and jaundice of less than 
one month, which is in contrast to this finding [128, 129]. Single case reports are more 
likely to be generated for occasions where the reaction has occurred very shortly after 
the drug administration (and is relatively straightforward to associated with the drug in 
question), however, which could explain this disparity.  
Effect modification patterns were comparable to risperidone, and as discussed there 
(and in a previous study on NSAIDs [68]) could be due to the lower background level of 
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injury in those who are younger or do not have prescriptions for any other hepatotoxic 
drugs. It could also be due to a shared genetic susceptibility for liver injury in response 
to exposure to a number of drugs [9]. The apparent susceptibility of South Asian users 
to risperidone but not celecoxib could indicate the involvement of distinct genetic loci, 
however. 
Although a number of epidemiological studies have been published looking at the 
hepatotoxicity of conventional NSAIDs (such as ibuprofen, diclofenac and mefenamic 
acid), there is a lack of data on COX-2 inhibitors such as celecoxib. One published 
result estimates a rate ratio for any liver injury associated with celecoxib of 1.0 (95 % 
CI 0.1–7.3) and a risk of 15.1 per 100 000 person years, but has very wide confidence 
intervals (95% CI 0.4 – 84.2) [130, 131]. The result obtained here suggests that the risk 
of cholestatic liver injury (confirmed by biochemical test i.e. the high specificity 
algorithm) is lower than this (assuming that one person is receiving celecoxib therapy 
for approximately 1 year) at 7.95 per 100 000 current or recent users (95% CI 4.11 – 
13.89). If considering those without lab test results available (but still with a diagnosis 
of jaundice in order to qualify as low-specificity cases), the risk is higher, however 
(21.88 per 100 000 current or recent users, 95% CI 15.06 – 30.72). Of note is that both 
the (high and low specificity) estimates obtained in this study suggest that celecoxib 
may be a more common cause of liver injury than the older NSAIDs [68, 74], although 
still a rare cause.   
6.6.2.2 Ramipril 
For ramipril, there was a small increase in the rate of cholestatic liver injury observed in 
current users as detected by the low-specificity algorithm (RR 1.13, 95% CI 1.04 – 
1.22), which was also detected by the high-specificity algorithm, but the analysis lacked 
power (RR 1.12, 95% CI 0.96 – 1.30). As discussed previously, for recent users the low 
specificity algorithm estimated a relatively strong association (RR 1.73, 95% CI 1.20 – 
2.50) that was in a different direction and did not seem to be compatible with the effect 
estimated by the high specificity algorithm (RR 0.79, 0.37 – 1.70).  
Such a discordant result suggests that there is likely to be an underlying bias, because 
if a drug increases the rate of jaundice (required to be a low specificity algorithm case), 
one would normally expect that the rate of biochemically confirmed cholestatic liver 
injury (required to be a high specificity case) would also increase.  For example, this is 
the pattern observed for flucloxacillin (a known cause of cholestatic liver injury) in this 
analysis, and for each of the other drugs analysed. 
Therapy with ramipril is likely to be long term, as once a person is diagnosed with (e.g.) 
hypertension, this requires ongoing management. People who have recently stopped 
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using the drug are either likely to have reacted badly to it, or the disease requiring 
ramipril treatment may have worsened. One indication that ramipril can be used for is 
the treatment of portal hypertension associated with chronic liver disease [132]. People 
who have recently stopped ramipril therapy could represent a group whose condition 
has deteriorated sufficiently that their current prescriptions are stopped and/or they are 
admitted to secondary care (where they may still receive drugs but these prescriptions 
would not be recorded in CPRD). If amongst these people there are individuals with 
(previously well managed) chronic liver disease, a worsening of condition could result 
in jaundice, either prior to admission to hospital (and therefore recorded in CPRD) or 
after being admitted to hospital (and entered retrospectively in CPRD).  
This could explain the increased rate observed in recent users of ramipril detected by 
the low-specificity algorithm. A similar increase is not observed when applying the high-
specificity algorithm because this relies on the presence of cholestatic liver test results, 
and if these tests were performed in hospital, the results would not be available in 
primary care.  Therefore, the observed association detected in recent users by the low-
specificity algorithm likely represents confounding by a condition that is an underlying 
cause of the indication being treated.  
A post-hoc investigation was performed to try and assess whether this could be an 
explanation for the observed results, in which the CPRD records of twenty randomly 
selected ramipril recent user cases were reviewed again. All twenty were low-specificity 
algorithm cases; five were also high-specificity cases.  Although it was not possible to 
determine the presence of portal hypertension and chronic liver disease was not 
documented in any of the cases, more than half of the cases (11/20, 55%) were 
hospitalised around the time of their final ramipril prescription or liver injury date.  4/11 
(37%) of those hospitalised went on to be diagnosed with conditions that were more 
likely to have caused the observed symptoms than a drug exposure. These included 
conditions such as malignant neoplasm of the pancreas and congestive heart failure, 
which are more common in those leading a lifestyle that is likely to also require a 
prescription for ramipril (such as heavy smokers, drinkers and those who are 
overweight). Confounding by indication is therefore a likely explanation for the results 
obtained here.  
6.6.2.3 Carbamazepine, duloxetine and flucloxacillin 
Although the point estimates for carbamazepine and duloxetine were consistent with an 
increased rate of cholestatic liver injury, the analyses were underpowered in this 
setting. Performing a similar analysis in a database where drug utilisation was higher 
(for example, a U.S. database for Duloxetine) could be advisable. Alternatively, 
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combining datasets from multiple databases might be one way of increasing power 
sufficiently for a valid analysis to be performed. 
The results obtained for flucloxacillin provide encouragement that the methods applied 
for the calculation of relative and absolute effects in this case-control study were valid. 
Flucloxacillin is a known cause of cholestatic liver injury, so one would expect that (as 
seen here) decreasing the specificity of a cholestatic liver injury algorithm would result 
in a reduction of the measured rate ratio (as the non-differential measurement error 
dilutes the effect estimate). Furthermore, the absolute effect estimate for the high 
specificity algorithm (8.52, 95% CI 7.10 – 10.15) is very similar to that obtained in 
Chapter 5 (6.15 per 100 000 users, 95% CI 4.61 – 8.04) and in previous studies 
performed in the same setting [53, 55].  
6.6.3 Limitations 
6.6.3.1 Chance 
The same considerations as those detailed in Chapter 5 applied to this study. 
6.6.3.2 Method for absolute effect estimation 
For the calculation of the absolute effect in this analysis, the risk of cholestatic liver 
injury was calculated by dividing (1) the total number of cases identified for the drug by 
(2) the total number of people in CPRD with at least one prescription during the study 
period and the risk of cholestatic liver injury per 100 000 current and recent users was 
presented. This is only provides a crude estimate of the risk, as it does not take into 
account follow-up time or time that each person is on the drug in the analysis. Analysis 
that could allow further characterisation of the absolute effect could involve a cohort-
design that factors in the time that each individual was exposed to the drug prior to 
their injury (allowing estimation of the rate).  
6.6.3.3 Bias 
Misclassification of main exposures 
As discussed in Chapter 5, CPRD records indicating a prescription for a drug do not 
provide any information about how much of the prescription was actually taken by the 
individual. If the compliance to the drug was linked to case or control status, then this 
could bias the result in unexpected ways. Being a case could be related to drug 
compliance because early symptoms of liver injury may lead to a person stopping 
taking the drug during the time that the prescription covers. In this study this is unlikely 
to have led an exposed case to be incorrectly assigned as an unexposed case 
however, because a person was considered exposed from the beginning of their 
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prescription for the entire period that the prescription covered (plus an additional grace 
period). The most likely misclassification is between recent and current users. The 
grace period added on to the end of a prescription period was included to help cope 
with this (providing a period at the end of a prescription during which a person may still 
be taking drugs provided as part of that prescription). Furthermore, if a small number of 
people were still taking the drug but ended up being assigned to the wrong exposure 
group, the impact on the conclusions drawn would be minimal (the person would still be 
considered as exposed to the drug, whether or not they were recent or current users). 
Misclassification of outcomes 
As the case-control analysis performed here included the use of algorithms of varying 
specificity and sensitivity, there was very likely to be misclassification of outcome 
status, as case status was assigned based upon relatively sparse information (for 
example, a CPRD diagnostic code of jaundice only, with no other information). 
Therefore, a degree of non-differential measurement error here is inevitable, which 
would likely increase absolute measures of effect and reduce relative measure of 
effect. This was observed and commented on throughout this study (for example the 
increasing risk measurements with decreasing sensitivity and the reduction in rate 
ratios for the risk factor analysis when comparing the less specific algorithms with the 
more specific ones). A further point that should be noted is that for the absolute risk 
estimate (requiring close review of the electronic record in order to verify whether the 
injury was drug-induced), after review there were often cases identified as “probably” 
due to the drug exposure. These were considered as non-cases and not included in the 
final risk calculations (i.e. a conservative approach was adopted so that if there was 
any doubt, the individual was considered a non-case). This was done so that the 
resulting absolute effect estimates were very unlikely to be overestimated. 
Observer/ascertainment bias and selection bias 
Ascertainment bias has the potential to impact this study in 2 ways. Firstly, at the level 
of the general practitioners who are responsible for diagnosing patients in the source 
population. All CPRD health records used in this study were routinely collected during 
primary care consultations before the design of this study, meaning that 
prescribing/diagnosing clinicians would not be aware which particular exposure group 
of this study patients had been assigned to. Clinicians would also have been unlikely to 
have suspected the drugs under study to be causes of cholestatic liver injury, as none 
were established causes of liver injury. Then at the stage of review of electronic record 
for this study, blinding to exposure status would have greatly minimised the likelihood 
of observer bias contributing to the results.  
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Selection bias was minimised in this study in terms of selection of controls by ensuring 
that the source population that the controls were drawn from was the same as that 
which the cases were drawn. In the past (and as discussed in Chapter 2), case-control 
studies of cholestatic liver injury performed in electronic health records have been 
careless in this respect, and have included a close review and exclusion process on 
potential cases but not potential controls. This effectively makes the source population 
of controls different to that of the cases, and risks selection bias that could alter the 
effect estimate unpredictably. The omission of this type of potential case review 
increases non-differential measurement error in the case control study (as more people 
will be included who may not actually be cases), but this is known to underestimate the 
effect rather than bias it in an unknown direction. Close review of case information was 
then subsequently performed in the study, but only when required to obtain accurate 
risk estimates.  
6.6.3.4 Co-variates, confounding and missing data 
Careful consideration and planning around potential confounders was performed in 
relation to this study, including the use of a causal diagram (or DAG). As many of the 
co-variates identified in the DAG as possible were included in the analysis, but there 
were some that could not be included in the analysis due to the routine nature of the 
data. Where this occurred, the impact on the results was discussed and considered (for 
example, unmeasured confounders such as illicit drug use that may have affected the 
results for risperidone).  
The primary method for handling missing data was by including “missing” or “unknown” 
categories, allowing the extent of missing data to be observed for each variable. 
Smoking status, BMI and alcohol intake had missing values (all under 17% of records 
in all cases), as did socioeconomic status (20% missing) and ethnicity (>40% missing). 
This may not be an ideal approach, as the true distribution of the covariates categories 
within the missing group is unknown and may mean that the confounder has not been 
appropriately adjusted for [133]. Given that that nearly half of the cohort had ethnicity 
data missing, a sensitivity analysis was performed by repeating the analysis with a 
model that included all co-variates apart from ethnicity. The results obtained without 
adjusting for ethnicity were very similar to those obtained with the ethnicity co-variate 
included (the biggest difference across all drugs and algorithms being for ramipril using 
the high specificity algorithm: with ethnicity recent users vs. never users RR 2.11, 95% 
CI 0.16 – 27.28, without ethnicity RR 1.81, 0.16 – 19.91).  
A complete records analysis was also performed for the low specificity algorithm, 
meaning that only records that had values recorded for all variables analysed were 
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included. For risperidone, the results obtained for the complete records analysis were 
consistent with those obtained for the main analysis. Of note was that the magnitude of 
the association between current users of risperidone and cholestatic liver injury was 
increased from an RR of 2.13 (95% CI 1.64 – 2.78) to an RR of 3.10 (2.05 – 4.70). This 
does suggest that the involvement of unmeasured confounders associated with a 
chaotic lifestyle may not be substantial, because people with complete records are 
likely to be those with the least chaotic lifestyles yet the rate ratio increases if they are 
the only people included in the analysis. 
For celecoxib, restricting to those with complete records only altered the point 
estimates by a maximum of 0.08, but the reduction in sample size meant that there was 
a loss of precision such that the 95% CIs crossed the null value for recent users. This 
was predominantly due to the fact that so many people had ethnicity data missing. 
Although ethnicity was included as a covariate in the DAG, whether or not it was 
included as a covariate in the final model of the main analysis had minimal impact on 
the results obtained. If the complete records analysis was performed in those with 
complete records apart from ethnicity, then the results obtained were very similar to 
those in the main analysis.  
Considering missing data more closely, for a complete case analysis to provide 
sensible results, the probability of being a complete case needs to be independent of 
the outcome (conditional on the covariates) [134] [135]. One way that this condition 
could be fulfilled is if the data were missing completely at random (MCAR), where the 
probability of data being missing for a variable is unrelated to the value of the variable 
itself and also unrelated to the value of (an)other fully observed variable(s) [136]. This 
is unlikely to apply to studies using routinely collected data (unless, for example, a file 
system storing the records becomes corrupt and a random sample of those records are 
lost). Although MCAR is unlikely to apply, it could be argued that after adjusting for all 
co-variates in this study, the probability of being a complete case is independent of the 
outcome (suffering acute liver injury), because the outcome is relatively rapid onset, 
severe and of (again, relatively) short duration. In contrast to a chronic outcome that 
could well influence attendance at health clinics over a long period of time and 
therefore the availability of information on co-variates, it is unlikely that the idiosyncratic 
liver injury studied here would influence the availability of information on co-variates. 
Therefore, a complete case analysis could well be valid.   
If one were not convinced that this condition held, one could consider that the 
mechanism for missingness might be missing at random (MAR), where the chance of 
values for a particular variable being missing could depend on the values of a fully 
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observed variable. If this was the case, multiple imputation is one method that could be 
used to allow a valid analysis, by imputing the missing data.  In fact, within this study a 
missing not at random (MNAR) mechanism is possible, meaning that whether an 
individual has missing data for a variable could depend on the underlying value of the 
variable itself. For example, a reason that somebody has missing smoking information 
could be because they are heavy smokers who attend primary care infrequently as 
they don’t want to be told to stop smoking. Additional work could therefore be 
performed where multiple imputation assuming MAR is performed in order to impute 
missing data, with sensitivity analyses included to investigate the plausibility of this 
model.  
6.6.4 Generalisability 
The CPRD is a good representation of the geographic distribution, age and sex 
structure of the UK population [119] and has a very large coverage (around 8% of the 
population [120]). In this study we used a total sample of approximately 100 000 people 
from this database, so our results are likely to be as generalisable to the UK population 
as the CPRD database itself. UK population groups not covered might include those 
not registered with a primary care practice which for example may include people who 
have immigrated to the UK and do not trust the health system or the 
homeless/prisoners. Given the rarity of the outcome under study, it is unlikely that 
omission of such groups would occur at a high enough level to impact the results of this 
study.  Overall, it is likely that our results could be generalised to the UK as a whole 
and other countries with a similar demography to the UK. 
6.7 Conclusions and recommendations 
Use of the cholestatic liver injury algorithm in a case-control study confirmed that it is 
possible for a low specificity algorithm to obtain results that will be smaller in magnitude 
than high specificity algorithm results but with narrower confidence intervals. This 
finding is consistent with a previous study that applied algorithms for identifying acute 
liver injury with varying specificity to the UK CPRD and the Spanish BIFAP database, 
suggesting that it is likely to be generalisable to databases other than just the UK 
CPRD [112].   If results are obtained that do not fit this pattern, this can be an aid to 
identifying possible biases with the underlying data. As described in Chapter 5, both 
low specificity and high specificity algorithms for identifying cholestatic liver injury can 
be of use depending on setting. Low specificity analysis may also allow interactions to 
be studied that might not have otherwise been detected.  
The antipsychotic risperidone and the non-steroidal anti-inflammatory celecoxib were 
both shown to be associated with cholestatic liver injury in this study. The risk 
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associated with celecoxib was low (less than 1 per 10 000 users) than might have been 
expected based on the literature and prescribing information for risperidone (almost 1 
per 1000 users and comparable with the older generation of antipsychotics). 
Independent of whether the increased rate of liver injury in this study is wholly caused 
by risperidone, the finding that those prescribed the drug have a relatively high rate of 
serious liver injury is of concern, as this group are likely to be particularly vulnerable. 
Based on the results obtained in this study additional work is recommended. A cohort 
analysis looking at the risk of cholestatic liver injury in risperidone compared to the use 
of another antipsychotic (such as chlorpromazine) would be advisable. This could help 
deduce how much of the effect is due to risperidone and how much is related to 
characteristics of population who receive risperidone.  Within the study, risk estimates 
by age and other characteristics could be obtained, and further characterisation of the 
nature of the liver injury could be obtained (for example, time between first or last 
prescription and liver injury, occurrence of other symptoms). Similarly, a cohort study 
comparing celecoxib with the older non-steroidal anti-inflammatory drugs could be 
performed. Finally, given the widespread use of ramipril and the public health impact of 
even a small increase risk associated with its use, a further study is recommended to 
help understand the risk that current users of the drug may experience, given that a 
small increased risk was detected by the low specificity algorithm (and was suggested 
by the high specificity). A carefully designed cohort or self-controlled case series 
design could help minimise confounding. 
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6.8 Chapter 6 Summary 
• In this chapter, the results were presented for the case-control study of the 
association between cholestatic liver injury and carbamazepine, celecoxib, 
duloxetine, ramipril and risperidone 
 
• When performing a case control study of cholestatic liver injury, a low specificity 
algorithm generally obtains comparable (although smaller) relative effect 
estimates than a high specificity algorithm and has narrower confidence 
intervals (e.g. risperidone current vs. never users: high specificity multivariable 
RR 2.59, 95% CI 1.41 – 4.75, low specificity 2.03, 1.53 – 2.70; celecoxib recent 
vs. never users: high specificity multivariable RR 1.93, 0.51 – 7.27, low 
specificity 1.89, 1.11 – 3.22). 
 
• Inconsistencies between high and low specificity algorithm results can be used 
to help identify bias – for example, with Ramipril different relative effect 
measures (high specificity recent vs. never users multivariable rate ratio 1.73, 
95% CI 1.20 – 2.50, low specificity 0.79, 95% CI 0.37 – 1.70) were likely to 
have been explained by confounding by a condition that was an underlying 
cause of the treatment indication (hepatic portal hypertension), leading to 
hospitalisation and an associated decreased recording of liver test results in 
primary care 
 
• The anti-inflammatory drug celecoxib and the atypical antipsychotic risperidone 
were associated with cholestatic liver injury (celecoxib low-specificity algorithm 
multivariable RR recent vs. current users 1.89, 95% CI 1.11 – 3.22, high 
specificity risk per 100 000 people prescribed the drug 7.95, 4.11 – 13.89; 
risperidone high specificity multivariable RR 2.59, 95% CI 1.41 – 4.75, high 
specificity risk 47.31, 28.49 – 73.87) 
 
• Absolute effect estimates for risperidone suggest it may be as common a cause 
of liver injury as the older antipsychotics 
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7 Summary and Conclusions 
7.1 Introduction 
The aim of this final chapter is to provide an overarching summary of findings, key 
discussion points, and future directions. Detailed discussion sections are provided at 
the end of each previous chapter of this thesis. 
7.2 Summary of research and main findings 
In this thesis, methods for identifying serious adverse drug reactions for 
epidemiological studies in electronic health records were investigated and developed, 
with a focus on drug-induced cholestatic liver injury.   The concept of rare but serious 
drug reactions was introduced, and a likely genetic predisposition to such reactions 
was discussed. Challenges in detection of these reactions during drug discovery and 
limitations of current methods for post-marketing signal detection were identified. An 
increasing trend for using databases for pharmacoepidemiology studies was 
highlighted, including potential novel uses such as predictive genetic test development 
and adaptive licensing. The specific serious adverse reaction of cholestatic liver injury 
was then described (the cholestatic type of drug induced liver injury), with cholestatic 
liver injury caused by flucloxacillin cited as an important example. 
A systematic literature review of studies with an outcome of cholestatic liver injury 
performed within routinely collected electronic health records then found 16 existing 
studies that had studied this outcome. 14 criteria were assessed, with criteria selected 
based upon existing standards for the reporting of observational studies with a 
particular focus on case-identification methods and their reproducibility. While 10 of the 
studies met the majority of assessed criteria, the following issues were identified as 
problematic: (1) exclusion criteria were often not defined clearly or applied 
appropriately for the study design (2), the availability and specific use of data was 
generally not described in detail (3) there was a potential overreliance on information 
requested from health centres (i.e. requests for data that was not included in the 
database) (4) time intervals that were applied between diagnoses and liver test results 
were not specified (5) measurement of validity was not performed and (6) multiple case 
status levels were not included . Suggested areas for further work included: linking 
existing databases (such as primary and secondary care databases), assessing the 
benefit of requesting notes from clinicians, allowing “real-time” identification and 
reducing reliance upon binary case definitions if at all possible.  
Multiple electronic health records sources (UK CPRD and UK HES and ONS 
databases) were then utilised to construct a multisource algorithm for detection of 
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cholestatic liver injury. The multisource algorithm case status was used to develop and 
validate a CPRD cholestatic liver injury algorithm, using data only from a standard 
CPRD record.  Testing of low, medium and high specificity algorithms in a study of the 
antibiotics oxytetracycline and flucloxacillin demonstrated that while absolute effects 
differed by specificity, relative effects were similar between the highest and lowest 
algorithms. Incidence estimates for the most specific algorithm were very similar to 
those obtained by previous studies in the literature that did rely on external information.    
The algorithms were then implemented within a real-life pharmacoepidemiological 
database research setting by performing a case-control study of cholestatic liver injury 
for a number of putative drug causes. This study showed that a low specificity 
algorithm obtained comparable (although smaller) relative effect estimates to that 
estimated by a high specificity algorithm, with narrower confidence intervals. 
Inconsistencies between high and low specificity algorithm results for the same drug 
were used to help identify likely underlying biases. The anti-inflammatory drug 
celecoxib and the atypical antipsychotic risperidone were associated with cholestatic 
liver injury. Absolute effect estimates for risperidone suggest that it may be as common 
a cause of liver injury as some older antipsychotics. 
7.3 Comparison with existing research 
7.3.1 Comparison of algorithm and study methodology 
The most well-known and well established algorithm for detection of drug-induced liver 
injury (including cholestatic liver injury) was developed in 1990 by CIOMS and is known 
as the RUCAM method [45]. This algorithm provides a system for assigning scores for 
specific characteristics of a potential drug-induced liver injury event, and the total score 
assigned can then be used to indicate the probability of whether a drug suspected of 
causing the liver injury was responsible (i.e. excluded, unlikely, possible, probable and 
definite). With the increasing incidence of non-alcoholic fatty liver disease, the 
threshold for defining DILI based upon biochemical parameters were increased (so, for 
example, DILI based upon raised ALT required ALT to be more than five times the 
upper limit of normal compared to two times the upper limit as was originally suggested 
in the RUCAM method). These up to date parameters were discussed in a paper 
written by a group of international experts in 2011 [46], and these updated parameters 
were used in the CPRD algorithm developed in this thesis.  
Other characteristics that the CPRD algorithm (and subsequent clinician review and 
study analysis steps) have in common with the RUCAM-type method include the 
careful exclusion of non-drug causes, consideration of concomitant therapies when 
assessing drug causes and consideration of time periods between the drug prescription 
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and the event (e.g. 90 days for cholestatic reactions). There were a number of ways in 
which the approaches differed, as detailed in Table 7-1.  
Table 7-1: Contrasting characteristics of the RUCAM-type algorithm approach and the 
CPRD algorithm 
# RUCAM CPRD algorithm*  
1 For use in a range of settings, 
although likely to be difficult to apply 
in a database setting. Not specifically 
for epidemiological studies. 
Designed specifically for use in electronic health 
records (CPRD, although could be amended 
relatively easily for other databases), with a 
particular focus on epidemiology. 
2 Main focus on causality (i.e. how to 
assess whether a drug caused a 
particular injury) 
Focuses on how to identify an event qualifying as 
(cholestatic) liver injury in electronic health records, 
which then allows further investigation into drug 
causes 
3 Includes criteria obtained from (1) 
monitoring patient after injury event 
and (2) drug rechallenge 
Does not include criteria on monitoring after injury 
event or drug rechallenge (difficult generally, but 
particularly in databases) 
4 Considers the presence of risk 
factors as adding to the evidence for 
likelihood of DILI 
Does not consider risk factors as part of causality, 
but allows the effect of these to be investigated as 
part of subsequent analysis 
5 Blinding to drug exposure status not 
specified (in fact, prior knowledge of 
drug hepatotoxicity is a criteria) 
Blinding to drug exposure status required during 
any review step 
*CPRD algorithm: includes the electronic algorithm and the subsequent case review and study analysis 
performed in this thesis 
One reason for these differences relates to the complexity of identifying any outcome 
within (routinely collected) electronic health records. A second reason is that the CPRD 
algorithm is designed for epidemiological studies and not for use in clinical settings, 
where there will certainly be different approaches required. For example, when 
comparing two drugs in an epidemiological study, blinding to exposure status is very 
important in order to prevent observer bias. In contrast, blinding to exposure status is 
unlikely to help a clinician who is trying to establish whether a single patient is suffering 
from drug induced liver injury caused by a drug they have prescribed in a clinic.   
Chapter 2 of this thesis provides an overview of studies that have developed algorithms 
specifically for use in electronic health record database settings. These were a useful 
basis for development of the CPRD algorithm, as they provided lists of diagnostic 
codes used, descriptions of high-level approaches and external standards for 
biochemical criteria. Areas where it was identified that these algorithms could be 
improved or enhanced that were subsequently addressed within the CPRD algorithm 
are as follows: 
1. Reduction in reliance on information other than that found in the routinely collected 
electronic health records for case identification, and assessment of the effect of 
doing this 
2. The use of multiple levels of case status 
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3. Within case control analysis, ensuring equivalent review procedures of electronic 
health record data for potential cases and for potential controls 
4. The use of information from multiple linked electronic health record databases  
5. Specification of a maximum allowable time window between a liver test result and 
an associated diagnostic code 
6. Inclusion of a maximum allowable period between separate liver enzyme tests used 
when calculating the ‘R’ value (used for determining type of liver injury) 
7. Detailing of codelists of exclusion terms (that could then be provided to journals 
when submitting for publication) 
7.3.2 Comparison of research findings (by drug) 
7.3.2.1 Flucloxacillin 
The CPRD algorithm estimated an overall risk of cholestatic liver injury associated with 
flucloxacillin that was comparable to results in the literature. This was despite the fact 
that (in contrast to all previous studies that had estimated the incidence of flucloxacillin-
induced cholestatic liver injury) information external to the database was not used as 
part of the CPRD algorithm. Slight differences could be explained by chance and/or a 
lack of blinding to exposure status (whether or not this was done was not specified in 
previous studies). The median time between first prescription and injury was slightly 
longer than previously reported. 
In previous studies, age (over 55) and duration of use (greater than 14 days) were 
shown to be important risk factors for flucloxacillin-induced liver injury. The results 
obtained here confirmed a substantial increased risk for those over the age of 50, and 
in those receiving more than 2 prescriptions, but also suggested a particular 
susceptibility in the over 70 year aged old group. Absolute effect estimates for 
flucloxacillin-induced liver injury stratified by these important characteristics were also 
presented for the first time. 
7.3.2.2 Risperidone 
This was the first large epidemiological study to assess whether risperidone is 
associated with liver injury. Typical antipsychotics such as chlorpromazine are 
established causes of liver injury, and the study performed here suggests that 
risperidone (one of the newer atypical antipsychotics generally assumed to have an 
improved side-effect profile) may be associated with the injury at a similar frequency.  
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7.3.2.3 Celecoxib 
Although a number of epidemiological studies have been published looking at the 
hepatotoxicity of conventional NSAIDs (such as ibuprofen, diclofenac and mefenamic 
acid), there is a lack of data on COX-2 inhibitors such as celecoxib. The absolute risk 
estimated in this study was low (and was also lower than in another published study of 
the drug), but higher than studies of the older NSAIDs. 
7.3.2.4 Ramipril 
Recent case studies had suggested Ramipril might be associated with liver injury. The 
analyses performed here did not detect that it was associated with liver injury, but 
highlighted difficulties relating to confounding by indication that should be considered in 
any future studies. 
7.3.2.5 Carbamazepine and duloxetine 
This study did not detect that carbamazepine or duloxetine were associated with 
cholestatic liver injury, which contrasts with case reports in the literature. It should be 
noted that the analyses were underpowered, however, and a large association was not 
ruled out by the upper 95% confidence interval boundary. 
7.4 Strengths 
The strengths of the approaches used in this thesis were as follows: 
1. The preparation of a systematic literature review in order to inform the design of 
the case-identification algorithm 
2. The use of clearly defined existing biochemical standards for (cholestatic) liver 
injury as part of the case definition algorithms 
3. The novel use of multiple linked data sources for development of a case 
identification algorithm 
4. The clear description of all diagnostic codes, exclusions, and time windows 
applied in the development of the algorithm 
5. Development of an algorithm that could be implemented into a program to allow 
“real-time” detection of cholestatic liver injury within a single database 
6. Use of multiple versions of the algorithm (varying specificity and sensitivity) to 
allow the effect of clinical uncertainty and/or the impact of data availability to be 
presented 
7. The use of this algorithm in conjunction with detailed medical review of 
electronic records where appropriate for risk estimation (but not for case control 
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analysis to minimise the introduction of bias due to different handling of 
potential case and potential control populations) 
8. Testing of the algorithm on a known cause of cholestatic liver injury 
7.5 Limitations and suggested further work 
7.5.1 Challenges in using routinely-collected electronic health data 
There are likely to be fundamental limitations of using routinely collected electronic 
data alone for the identification of drug-induced liver injury. For example, there may 
always be some degree of misclassification with this approach compared to the “ideal” 
of having all available information, copies of letters/free text, and the ability to query 
treating clinicians. Although this is an acknowledged limitation of this approach, the fact 
that sensible and comparable results have been obtained throughout this thesis without 
the use of such information suggests that this misclassification is unlikely to have as 
much impact as people may often intuitively think that it will. 
7.5.2 Detection of hepatocellular injury 
In this thesis, the primary outcome of interest was a cholestatic liver injury, which 
represents only a subtype of all DILI. A driver for this was the development of an 
algorithm that could be used to further progress genetic work already performed on 
flucloxacillin-induced liver injury (which is primarily cholestatic in nature) [58]. Although 
cholestatic liver injury may represent a significant proportion of all DILI, hepatocellular 
liver injury can be at least if not more serious for the patient – for example, if a patient 
presents with hepatocellular injury and jaundice, case fatality may be between 10 and 
50% [46, 137].  
Updating the algorithm to cover all DILI subtypes would be relatively straightforward. 
For example, the liver test result parameters could be updated to include the criteria for 
hepatocellular injury (i.e. R* ≥ 5, see Chapter 1 Table 1-2). Minor changes to the 
diagnostic lists used based upon review of the literature could be made, and the 
algorithm could then be utilised for pharmacoepidemiological studies of DILI as an 
outcome. It would remain straightforward to analyse results for each subtype 
separately, however. This could be particularly important for any genetic studies, where 
it is possible that the hepatocellular and cholestatic injury subtypes have a distinct 
genetic basis. Having said this, the fact that the biochemical pattern of a single episode 
of a drug-induced liver injury can change from one subtype to another over time may 
suggest a common genetic aetiology [46], and genetic work to date has focused more 
on DILI caused by specific drugs as an outcome, rather than on the injury subtype [57, 
138]). It would be a worthwhile exercise to repeat the analyses performed in this thesis 
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with the algorithm updated in this way, as it is possible that some of the drugs studied 
may be associated with hepatocellular injury (as well as or even instead of cholestatic 
injury).  
7.5.3 Further characterisation of injury  
While working on the flucloxacillin analysis, there were many people found in the 
database who had liver function tests that met the criteria for drug-induced liver injury, 
but did not have symptoms such as jaundice recorded in the database. These people 
did not meet any of the case definitions used in the analyses, but amending the 
algorithm to include them could help improve understanding of the genetic and cellular 
processes underlying DILI. Furthermore, this amendment could allow updated absolute 
effects to be estimated that include those with less severe liver injury (i.e. possibly 
including a group not presenting with jaundice, although the fact that people may have 
had jaundice without it being recorded in the database would also need to be 
considered). An additional (related) change would be to amend the algorithm so that it 
was able to categorise cases into different severity groups, for example based upon 
how far their liver test values deviated from normal and/or the presence or absence of 
specific symptoms. This could also help identify any specific groups of cases with 
different underlying genetic, clinical or environmental characteristics. 
Finally, the algorithm could be amended to make it possible to detect if the cases of 
liver injury identified displayed any clinical or biochemical precursors to their injury. For 
example, did the majority of people have serious liver injury without any signs of illness 
prior to the injury, or were there a common set of clinical and biochemical features 
present in the database that preceded the case date (such as a rash, or perhaps raised 
liver test values prior to the value that met the DILI standard threshold). 
7.5.4 Use of a probabilistic method for case identification 
A potential weakness of the case definition approach used is the requirement to select 
a cut-off for each case definition above which a person is considered a case and below 
which they are considered a non-case. Although the analysis in this thesis did allow the 
use of a cut-off “score” system for defining injury, and multiple score cut-offs were used 
to try and allow the impact of different decisions around case definition to be assessed, 
using such cut-offs is still applying a binary case definition (i.e. a person is either a 
case or a non-case). With such an approach, it could be said that there is some 
“wasted” information, i.e. the presence or absence of other characteristics that could be 
contributing to the overall probability of a person being a case is not considered. For 
example, with a highly specific definition that requires a diagnosis of jaundice and a 
cholestatic liver test result, an individual may or may not have other (perhaps less 
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critical although still contributory) symptoms whose presence could contribute to the 
overall probability that the person has cholestatic liver injury (such as a rash, or general 
malaise). With a binary classification, these characteristics are basically ignored. One 
option could be to include them as part of the case definition, although this may well 
result in far too specific a definition if only a proportion of all cases present with these 
additional symptoms.  
In order to try and handle this issue, it might be possible to adopt a probabilistic system 
of case identification for analysis, where instead of either being a case or not, all cohort 
members have a probability of being a case. Analyses of association could then be 
carried out by performing a regression model directly on that probability. One key 
challenge with this method would be how to obtain the probabilities of being a true case 
(when there is no gold standard to compare against). Latent class analysis is one 
method which could enable probabilities to be obtained based upon observed indicator 
variables [139, 140]. In order for this approach to work, indicator variables for 
membership of each latent class would need to be defined. The indicators identified as 
predictors for multisource algorithm case status from chapter 4 could be used as 
predictors of latent class membership, which would allow conditional properties of 
being in each latent class to be assigned. Application of such an approach would be 
difficult to apply to a real-time case identification model, but it could be of interest to 
apply to a pharmacoepidemiology study and compare with the methods developed 
within this thesis.  
7.5.5 Facilitation of collaboration with other groups 
When a researcher develops an algorithm for case identification within databases of 
electronic health records as part of a study for publication, the reproducibility of that 
algorithm is facilitated by clearly defining the methodology used for case identification 
(as has been highlighted throughout this thesis). Including the codelists themselves in 
published articles is particularly helpful, as is inclusion of any search terms used to 
generate the codelists. Making these codelists and/or search terms available for 
download from dedicated repositories means that sharing with other research teams is 
even simpler. ClinicalCode.org is an example of one such repository [141]. Although 
codelists were not uploaded during the preparation of this thesis, all codelists will be 
uploaded to this site as part of the preparation of any scientific publications. To aid in 
the understanding of how the codelists were generated, the search terms used to 
generate the terms and codes (where appropriate) will also be uploaded.   
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7.6 Context and future applications 
7.6.1 Real-time detection of liver injury for newly licensed drugs 
As discussed in Chapter 1, prior to launch of a new medicine, the relatively low 
numbers of people that a new medicine is tested on and the strict eligibility criteria of 
Phase III clinical trials means that it is difficult to detect (1) rare events (2) events that 
might occur within specific sub groups or (3) events that might occur when a drug is 
used differently than it was by trial participants (for a longer duration, for example). 
Spontaneous reporting systems for pharmacovigilance were also introduced in Chapter 
1.  Such systems (e.g. the UK’s yellow card system) are very prone to inaccuracies and 
bias.  
Large stored databases (such as the CPRD) provide an alternative setting for active 
surveillance of serious adverse drug reactions associated with newly marketed drugs. 
In contrast to a spontaneous reporting system, such databases provide information on 
the number of people exposed to the drug, and not just those who have been exposed 
and might have experienced a reaction (i.e. valid denominator information is provided). 
Furthermore, data that is entered into these databases is standardised, and careful 
development of algorithms such as the ones developed in this thesis allows 
standardised approaches for case definition to be applied. Finally, susceptibility to 
reporting biases are likely to be somewhat reduced, as longitudinal data captured 
routinely during (e.g.) primary and secondary care for an individual can allow a much 
more reliable analysis of whether the drug actually caused the injury to be applied 
(particularly if including clinician review of records).  
Active surveillance of databases such as the UK CPRD could play an important role in 
a move away from all or nothing safety decisions and towards a phased regulatory 
approval approach (as per an adaptive drug licensing system [38]). Here, an initial 
restricted licence could be based upon results from a trial powered for efficacy, but 
then broadening of the licence could be based upon subsequent studies performed in 
real-world settings (for example, pragmatic trials using databases of electronic health 
records). Continued updating of the licence based upon surveillance of large databases 
would then take place throughout the product’s lifecycle.  In order for this approach to 
work, it is likely to require collaboration between pharmaceutical company, regulatory 
agency and possibly an external group who manage the detection algorithm and 
analysis of results. A suggested process is detailed in Table 7-2.  
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Table 7-2: High level outline of process and responsible parties for safety surveillance 
within an adaptive licensing approach 
# Step Responsible 
1 Identify potential safety issues pre-
marketing (based on results of 
animal studies, human safety 
studies, biomarker studies or 
knowledge of similar drugs) 
Pharmaceutical company, regulatory agency 
2 Develop algorithm for identifying the 
likely or possible event in 
association with the newly launched 
drug 
Pharmaceutical company working with external 
partner 
3 Launch drug Pharmaceutical company 
4 Run algorithm on monthly basis External partner 
5 Analyse results Pharmaceutical company with external partner 
6 Update label (restrict or expand as 
appropriate) 
Pharmaceutical company, regulatory agency 
 
7.6.2 Application to genetic and genomic studies 
As discussed in Chapter 1, a genetic susceptibility to Type B reactions is becoming 
well established. For DILI, for example, there are a number of studies of genetic 
associations, including identifying involvement of the HLA-B*5701 genotype in liver 
injury associated with flucloxacillin [58] .  Despite this strong association, translation to 
clinical practice would not yet be feasible, as >13 000 individuals would need to be 
screened to prevent a single case [59]. The algorithms developed here could be used 
to recruit cases on an ongoing basis from the CPRD, in order to increase sample sizes, 
which could help obtain cohorts big enough for more in-depth genetic analysis. An 
alternative (and complimentary) approach would be to utilise newly developed methods 
for investigating cellular processes (functional genomics), which could likely provide 
insights into the mechanism and underlying processes of DILI. Cell lines could be 
developed from gene samples obtained from cases of DILI, and a detailed analysis of 
the underlying cellular mechanism performed [142, 143]. The algorithm developed 
within this thesis would allow for recruitment of both case and control patients for this 
research, and these patients would have detailed historical medical records that could 
be linked to their genetic and genomic profiles.  
Bringing together large databases of electronic health records and genetic/genomic 
research in this way does not necessarily have to be limited to DILI, or adverse drug 
reactions, or even rare outcomes.  Setting up pilot studies and testing the methodology 
for more common outcomes, and/or for outcomes that are considered to be hard to 
identify could represent very important areas of future work. Success in these pilots 
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could allow the potential of using EHR databases in this way to be realised and in 
doing so facilitate real progress in the understanding of disease treatment, prevention 
and aetiology.  
7.6.3 Conclusion 
Although large databases of stored electronic health records have been used as a 
setting for epidemiological and pharmacoepidemiological studies for over 20 years, 
there remain challenges for methods of case identification within such studies. These 
challenges intensify if we start trying to maximise the potential of such databases for 
drug safety and genetic epidemiology. 
Using the cholestatic type of serious drug-induced liver injury as an example, the work 
in this thesis first of all focused on understanding case-identification approaches that 
had been applied in existing epidemiological studies of this reaction. This knowledge 
was then used to help develop an algorithm that could be applied to the UK CPRD 
database, validated against an algorithm that used CPRD data but also data from UK 
HES and ONS data. Testing of the algorithm on a known cause of the injury 
(flucloxacillin) demonstrated that it was able to obtain similar absolute and relative 
effect estimates to previous studies. When subsequently used  to examine a number of 
possible drug-causes of the injury, associations with risperidone and with celecoxib 
were identified. Key features of the new algorithm included the possibility of applying 
different levels of specificity, and the ability to detect cases without the need for 
information external to the database. Both these characteristics could facilitate 
innovative uses of large databases including real-time detection of injury events for 
pharmacovigilance (and adaptive licensing) and rolling recruitment to genetic 
association studies.  
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7.7 Chapter 7 Summary 
• This chapter provided an overarching summary of findings, key discussion 
points, and future directions 
 
• Following a detailed review of the literature, a new algorithm for identifying 
cholestatic liver injury in the UK CPRD was developed, validated using data 
from the UK HES and ONS databases 
 
• The algorithm detected similar absolute and relative effects for flucloxacillin (a 
known cause of cholestatic liver injury) as previous studies, and also detected 
associations with risperidone and celecoxib (suspected causes of the injury for 
which there was a lack of epidemiological data)  
 
• Key characteristics of the new algorithm that could facilitate the use of 
electronic health records for (1) real-time detection for pharmacovigilance and 
(2) rolling recruitment to genetic association studies include the ability to (a) 
apply varying levels of specificity and (b) detect cases without using information 
external to the electronic health record 
 
• Further development of the algorithm could be to allow detection of 
hepatocellular (as well as cholestatic) liver injury, and the development of an 
approach allowing analysis by probability of case status (removing the need for 
binary case assignment) 
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Appendices 
Chapter 2 Appendix 
Chapter 2 Appendix Table A1: alphabetical list of all database diagnostic codes used to 
select potential cases in the retrieved studies of cholestatic liver injury performed in 
databases of stored electronic health records 
Database code Diagnosis 
OXMIS  
9669XX Abnormal drug reactions/effects 
L3264AB Abnormal hepatic function 
L3263AB Abnormal liver enzymes 
L3260AB Abnormal liver function test 
5710HA Alcoholic  hepatitis 
L4720N Alkaline phosphatase level 
L109H ALT raised 
L1002CR Aspartate aminotransferase level raised 
L110H AST raised 
L1151NA Bilirubin serum level abnormal 
L1151 Bilirubin serum level normal 
L3262AB Biochemical liver dysfunction 
574AL Cholelithiasis 
7852JC Cholestatic jaundice 
5719CH Chronic hepatitis 
9779PN Drug-induced jaundice 
7851XX Enlarged liver 
7516JA Familial intrahepatic cholestasis 
070F Fulminant hepatitis 
574XX Gallbladder disorders 
570XX Hepatitis/liver necrosis 
5730D Hepatocellular damage 
57300 Hepatocellular damage 
K5091 Hepatostomy 
070 Infectious hepatitis 
7852XX Jaundice 
7852 Jaundice 
K501 Liver biopsy 
K501XX Liver biopsy 
L3263H Liver enzymes raised 
L3260 Liver function test 
070N Non-A non-B hepatitis 
576A Obstructive jaundice 
575XX Other gallbladder disorders (cholangitis/cholecystisis) 
573XX Other liver disorders 
785CP Pale stools 
ICD-9 
782.4 Jaundice (ICD-9) 
570 Necrosis of the liver (ICD-9) 
573.3 Unspecified hepatitis (ICD-9) 
READ 
J633.00 Hepatitis unspecified (READ) 
1675.11 Jaundice - symptom (READ) 
R024.00 Jaundice (not of newborn) (READ) 
R024111 Jaundice (READ) 
J66y600 Obstructive jaundice nos (READ) 
*XX = category including a range of diagnoses 
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Chapter 2 Appendix Table A2: alphabetical list of all exclusions applied during 
identification of patients with cholestatic liver injury in the sixteen studies performed in 
databases of stored electronic health records that have cholestatic liver injury as the 
outcome 
Exclusion (as described in article)
Alcoholism 
ALT or AST elevations above normal levels during 1 year prior 
Cancer of the gallbladder 
Cancer of the liver 
Cancer of the pancreas 
Cholecystitis 
Cholelithiasis 
Concomitant use of medications associated with hepatotoxicity 
Chronic liver disease 
Crohn’s disease 
Cirrhosis 
Congestive heart failure 
Crohn's disease 
Gallbladder or pancreatic disease 
Hepatitis after blood transfusion 
HIV infection 
Inflammatory bowel disease 
Liver disease 
Liver-related diagnosis 
Malignant neoplasm 
Normal liver function test results 
Not referred to a specialist/not admitted to hospital 
Other co-morbidity associated with liver chemistry elevations 
Other liver disorders 
Other well-defined pathology or disease 
Pancreatic disease 
Rheumatoid arthritis 
Sarcoidosis 
Systemic lupus 
Ulcerative colitis 
Viral hepatitis (based on serology) 
Viral infection (serologically confirmed) 
Well-defined systemic condition affecting the liver 
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Chapter 3 Appendix 
Chapter 3 Appendix Table 1: List of CPRD clinical diagnosis terms and codes used to 
identify patients with potential cholestatic liver injury, with strength of evidence for 
cholestatic liver injury groupings indicated 
Term READ code Strength of evidence 
marker1 
toxic liver disease with cholestasis j635000 Group 1 
 
[d]jaundice (not of newborn) r024.00 Group 2 
hepatitis unspecified j633.00 Group 2 
[d]jaundice r024111 Group 2 
obstructive jaundice nos j66y600 Group 2 
hepatitis unspecified nos j633z00 Group 2 
o/e – jaundiced 2274.11 Group 2 
jaundice – symptom 1675.11 Group 2 
[d]icterus nos r024100 Group 2 
yellow/jaundiced colour 1675.00 Group 2 
o/e - jaundiced colour 2274.00 Group 2 
[d]jaundice (not of newborn) nos r024z00 Group 2 
 
infective hepatitis a701.11 Group 3 
other liver disorders j63..00 Group 3 
chronic hepatitis j614.00 Group 3 
chronic aggressive hepatitis j614200 Group 3 
acute alcoholic hepatitis j611.00 Group 3 
other specified liver disorder nos j63yz00 Group 3 
[d]cholaemia nos r024000 Group 3 
acute hepatic failure j600000 Group 3 
o/e - liver grossly enlarged 25g4.00 Group 3 
alcoholic hepatitis j617.00 Group 3 
open wedge biopsy of lesion of liver 7804200 Group 3 
Cholangitis j661.00 Group 3 
biopsy of liver nec 780b000 Group 3 
liver disorder nos j63z.00 Group 3 
primary sclerosing cholangitis j661700 Group 3 
chronic hepatitis nos j614z00 Group 3 
toxic hepatitis j633000 Group 3 
recurrent cholangitis j661200 Group 3 
acute hepatitis – noninfective j600100 Group 3 
o/e -liver moderately enlarged 25g3.00 Group 3 
hepatic failure j62y.13 Group 3 
needle biopsy of liver nec 780a112 Group 3 
toxic liver disease with chronic persistent 
hepatitis 
j635300 Group 3 
alcoholic hepatic failure j613000 Group 3 
hepatitis non a non b a705400 Group 3 
fh: hepatitis 12e3.11 Group 3 
subacute hepatitis – noninfective j601100 Group 3 
encephalopathy – hepatic j622.11 Group 3 
hepatic coma j622.00 Group 3 
chronic persistent hepatitis j614000 Group 3 
calculus of bile duct with cholangitis j646.00 Group 3 
[x] hepatic failure j625.00 Group 3 
liver abscess due to cholangitis j620100 Group 3 
other specified liver disorder j63y.00 Group 3 
subacute hepatic failure j601000 Group 3 
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Term READ code Strength of evidence 
marker1 
nonspecific reactive hepatitis j63y100 Group 3 
other cholangitis j661y00 Group 3 
other non-alcoholic chronic liver disease nos j61yz00 Group 3 
ascending cholangitis j661400 Group 3 
percutaneous transvascular biopsy of lesion of 
liver 
780a000 Group 3 
toxic liver disease with hepatic necrosis j635100 Group 3 
hepatic failure as a complication of care sp14200 Group 3 
toxic liver disease j635.00 Group 3 
toxic liver disease with chronic active hepatitis j635500 Group 3 
toxic liver disease with acute hepatitis j635200 Group 3 
acute hepatic failure due to drugs j635700 Group 3 
acute necrosis of liver j600.00 Group 3 
toxic liver disease, unspecified j635x00 Group 3 
other non-alcoholic chronic liver disease j61y.00 Group 3 
toxic liver disease with fibrosis and cirrhosis of 
liver 
j635600 Group 3 
sclerosing cholangitis unspecified j661900 Group 3 
other sequelae of chronic liver disease j62y.00 Group 3 
acute and subacute liver necrosis j60..00 Group 3 
chronic cholangitis j661100 Group 3 
recurrent hepatitis j614300 Group 3 
acute yellow atrophy j600200 Group 3 
chronic hepatitis unspecified j614y00 Group 3 
acute necrosis of liver nos j600z00 Group 3 
hepatic failure nos j62y.11 Group 3 
subacute necrosis of liver j601.00 Group 3 
cholangitis nos j661z00 Group 3 
central haemorrhagic necrosis of liver j636.00 Group 3 
toxic liver disease with chronic lobular 
hepatitis 
j635400 Group 3 
menghini needle biopsy of liver 780a111 Group 3 
acute and subacute liver necrosis nos j60z.00 Group 3 
toxoplasma hepatitis ad05.00 Group 3 
cholangitis lenta j661500 Group 3 
chronic lobular hepatitis j614400 Group 3 
subacute yellow atrophy j601200 Group 3 
subacute necrosis of liver nos j601z00 Group 3 
endoscopic ultrasound examination liver 
biopsy lesion liver 
780f000 Group 3 
obliterative cholangitis j661600 Group 3 
sheeba needle biopsy of liver 780a113 Group 3 
Note 1: Group 1=strongest evidence for cholestatic liver injury, Group 2=weaker evidence for cholestatic liver injury, 
Group 3=weakest evidence for cholestatic liver injury  
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Chapter 3 Appendix Table 2: List of HES clinical diagnosis terms and codes used to 
identify individuals with potential cholestatic liver injury, with strength of evidence for 
cholestatic liver injury groupings indicated 
Term ICD code Strength of evidence 
marker1 
toxic liver disease with cholestasis K71.0 Group 1 
 
unspecified jaundice R17 Group 2 
Note 1: Group 1=strongest evidence for cholestatic liver injury, Group 2=weaker evidence for cholestatic liver injury 
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Chapter 3 Appendix Table 3: List of HES liver related procedure terms and codes used to 
identify hospital procedures likely to elucidate the type of liver injury 
Term OPCS code 
laparoscopic ultrasound examination of liver 
nec J093 
other specified diagnostic endoscopic 
examination of liver using laparoscope J098 
unspecified diagnostic endoscopic examination 
of liver using laparoscope J099 
biopsy of liver nec J141 
other specified endoscopic ultrasound 
examination of liver J178 
unspecified endoscopic ultrasound examination 
of liver J179 
computed tomography of abdomen nec U081 
ultrasound of abdomen U082 
magnetic resonance imaging of abdomen U085 
other specified diagnostic imaging of abdomen U088 
unspecified diagnostic imaging of abdomen U089 
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Chapter 3 Appendix Table 4: List of CPRD potential explanatory variables created for the 
CPRD cholestatic liver injury algorithm 
CPRD characteristic type Potential explanatory variables (all binary) 
Liver test Had cholestatic CPRD liver test result 
Specialist referral Had any referrals <30 days from index date 
 Had liver-related referral <30 days from index 
 Top liver referral code (strength of evidence for cholestatic liver 
injury of referral code: Group 1 or Group 2=1, Group 3 or no 
referral=0) ) 
 Referred for liver scan <30 days from index 
Index diagnosis Toxic liver disease with cholestasis (single code) 
 Obstructive jaundice (single code) 
 Jaundice or similar terms 
 Hepatitis or similar terms 
 Chronic hepatitis or similar terms 
 Hepatic failure related 
 Liver-enlargement related 
 Cholangitis related 
 Liver biopsy related 
 Alcohol-related 
 Liver-necrosis related 
 Toxic liver disease (other than cholestasis) 
 Cholaemia 
 Other or non-specific code 
Other liver-related diagnoses Had additional liver-related diagnoses on index date 
 Had additional liver-related diagnoses <30 days from index 
 Evidence grouping for additional liver-related diagnosis <30 days 
from index (strength of evidence for cholestatic liver injury of 
additional liver-related diagnosis: Group 1 or Group 2=1, Group 
3 or no additional diagnosis=0)  
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Chapter 3 Appendix Table 5: List of exclusion terms applied in epidemiological studies 
Term READ code 
[v]contact with and exposure to viral hepatitis zv01b00 
[v]personal history of alcoholism zv11300 
[v]personal history of malignant neoplasm of 
liver zv10015 
[v]screening for alcoholism zv79100 
[v]screening for rheumatoid arthritis zv7y100 
[v]viral hepatitis carrier zv02600 
[x]acute alcoholic drunkenness eu10011 
[x]alcoholic dementia nos eu10711 
[x]alcoholic hallucinosis eu10511 
[x]alcoholic jealousy eu10512 
[x]alcoholic paranoia eu10513 
[x]alcoholic psychosis nos eu10514 
[x]chronic alcoholic brain syndrome eu10712 
[x]chronic alcoholism eu10212 
[x]dementia in human immunodef virus [hiv] 
disease eu02400 
[x]hiv disease 
result/haematological+immunologic 
abnorms,nec ayucb00 
[x]hiv disease resulting in multiple infections ayuc300 
[x]hiv disease resulting in other non-hodgkin's 
lymphoma ayuc600 
[x]hiv disease resulting in other specified 
conditions ayucc00 
[x]hiv disease resulting/other infectious+parasitic 
diseases ayuc400 
[x]other and unspecified cirrhosis of liver jyu7100 
[x]other cholecystitis jyu8100 
[x]other cholelithiasis jyu8000 
[x]other crohn's disease jyu4000 
[x]other forms of systemic lupus erythematosus nyu4300 
[x]other seropositive rheumatoid arthritis nyu1100 
[x]other specified acute viral hepatitis ayub000 
[x]other specified rheumatoid arthritis nyu1200 
[x]other ulcerative colitis jyu4100 
[x]rheumatoid arthritis+involvement/other organs 
or systems nyu1000 
[x]sarcoidosis of other and combined sites cyu0600 
[x]sequelae of viral hepatitis ayuj900 
[x]seropositive rheumatoid arthritis, unspecified nyu1g00 
[x]unspecified human immunodeficiency virus 
[hiv] disease ayucd00 
[x]viral hepatitis ayub.00 
accidental poisoning by alcoholic beverages t900.00 
acute alcoholic hepatitis j611.00 
acute alcoholic intoxication in alcoholism e230.00 
acute alcoholic intoxication in alcoholism nos e230z00 
acute alcoholic intoxication in remission, in 
alcoholism e230300 
acute alcoholic intoxication, unspecified, in 
alcoholism e230000 
acute angiocholecystitis j650100 
acute cholecystitis j650.00 
acute cholecystitis nos j650z00 
acute cholecystitis unspecified j650000 
acute congestive heart failure g580000 
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Term READ code 
acute emphysematous cholecystitis j650200 
acute gangrenous cholecystitis j650400 
acute polyarticular juvenile rheumatoid arthritis n043100 
acute suppurative cholecystitis j650300 
acute viral hepatitis nos a70z100 
alcohol dependence with acute alcoholic 
intoxication e230.11 
alcoholic cardiomyopathy g555.00 
alcoholic cirrhosis of liver j612.00 
alcoholic dementia nos e012.11 
alcoholic encephalopathy f11x011 
alcoholic fatty liver j610.00 
alcoholic fibrosis and sclerosis of liver j612000 
alcoholic gastritis j153.00 
alcoholic hepatic failure j613000 
alcoholic hepatitis j617.00 
alcoholic liver damage unspecified j613.00 
alcoholic myopathy f394100 
alcoholic paranoia e015.00 
alcoholic polyneuropathy f375.00 
alcoholic psychoses e01..00 
alcoholic psychosis nos e01z.00 
alcoholics anonymous 13y8.00 
Alcoholism e23..11 
alcoholism counselling z4b1.00 
arthropathy in crohn's disease n031100 
arthropathy in ulcerative colitis n031000 
aversion therapy - alcoholism 8g32.00 
bacterial portal cirrhosis j615d00 
benign neoplasm of gallbladder b715200 
benign neoplasm of liver b715000 
benign neoplasm of liver and biliary ducts b715.00 
bile duct calculus + acute cholecystitis - obstruct 
nos j643z00 
bile duct calculus + acute cholecystitis and no 
obstruction j643000 
bile duct calculus + acute cholecystitis and 
obstruction j643100 
bile duct calculus + other cholecystitis - 
obstruction nos j644z00 
bile duct calculus + other cholecystitis and 
obstruction j644100 
bile duct calculus with acute cholecystitis j643.00 
bile duct calculus with other cholecystitis j644.00 
bile duct calculus without cholecystitis nos j645z00 
bile duct calculus without cholecystitis with 
obstruction j645100 
bile duct calculus without cholecystitis, no 
obstruction j645000 
bile duct calculus without mention of 
cholecystitis j645.00 
biliary cirrhosis j616.00 
biliary cirrhosis nos j616z00 
biliary cirrhosis of children j616200 
bmast - brief michigan alcoholism screening test zra1111 
brief michigan alcoholism screening test zra1100 
capsular portal cirrhosis j615600 
carcinoma gallbladder b160.11 
 226 
 
Term READ code 
carcinoma in situ of liver b808000 
carcinoma in situ of liver and biliary system b808.00 
carcinoma in situ of liver or biliary system nos b808z00 
carcinoma in situ of pancreas b80z000 
cardiac portal cirrhosis j615700 
cdai - crohn's disease activity index zr3s.11 
cerebellar ataxia due to alcoholism f144000 
cerebral degeneration due to alcoholism f11x000 
cholecystitis nos j651z00 
cholelithiasis j64..00 
cholelithiasis nos j64z.00 
cholelithiasis nos j64zz00 
cholelithiasis with obstruction nos j64z100 
cholelithiasis without obstruction nos j64z000 
chronic alcoholic brain syndrome e012000 
chronic alcoholic hepatitis j617000 
chronic alcoholism e231.00 
chronic alcoholism in remission e231300 
chronic alcoholism nos e231z00 
chronic cholecystitis j651000 
chronic congestive heart failure g580100 
chronic liver disease nos j61z.00 
chronic viral hepatitis a707.00 
chronic viral hepatitis b with delta-agent a707000 
chronic viral hepatitis b without delta-agent a707100 
chronic viral hepatitis c a707200 
chronic viral hepatitis, unspecified a707x00 
cirrhosis - non alcoholic j615.00 
cirrhosis and chronic liver disease j61..00 
cirrhosis of liver nos j615z13 
congenital viral hepatitis q409.00 
congestive heart failure g580.00 
congestive heart failure due to valvular disease g580400 
congestive heart failure monitoring 662t.00 
continuous acute alcoholic intoxication in 
alcoholism e230100 
continuous chronic alcoholism e231100 
crohn's disease j40..11 
crohn's disease activity index zr3s.00 
crohn's disease nos j40z.11 
crohn's disease of the ileum nos j400400 
crohn's disease of the ileum unspecified j400300 
crohn's disease of the large bowel nos j401z00 
crohn's disease of the small bowel nos j400z00 
crohn's disease of the terminal ileum j400200 
cryptogenic cirrhosis of liver j615z12 
cystic fibrosis related cirrhosis c370800 
cytomegaloviral hepatitis a785200 
delivery of rehabilitation for rheumatoid arthritis 7p20300 
diffuse nodular cirrhosis j615300 
disease activity score 28 joint in rheumatoid 
arthritis 38dz000 
disease activity score in rheumatoid arthritis 38dz.00 
drug-induced systemic lupus erythematosus n000200 
episodic acute alcoholic intoxication in 
alcoholism e230200 
episodic chronic alcoholism e231200 
exacerbation of crohn's disease of large j401200 
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Term READ code 
intestine 
exacerbation of crohn's disease of small 
intestine j400500 
exacerbation of ulcerative colitis j410400 
except rheumatoid arthritis qual indicator: 
informed dissent 9hr1.00 
except rheumatoid arthritis quality indicator: pt 
unsuitable 9hr0.00 
exception reporting: rheumatoid arthritis quality 
indicators 9hr..00 
fatty portal cirrhosis j615400 
fh: alcoholism 1282.00 
fh: crohn's disease 12e5.00 
fh: gallbladder disease 12e4.11 
fh: rheumatoid arthritis 12i1.00 
fh: ulcerative colitis 12e2.11 
fibrosing alveolitis associated with rheumatoid 
arthritis n04y012 
flare of rheumatoid arthritis n040t00 
florid cirrhosis j612.11 
gallbladder calculus with acute cholecystitis j640.00 
gallbladder calculus with acute cholecystitis - 
obst nos j640z00 
gallbladder calculus with acute cholecystitis + 
obstruction j640100 
gallbladder calculus with acute cholecystitis +no 
obstruct j640000 
gallbladder calculus with other cholecystitis j641.00 
gallbladder calculus with other cholecystitis - 
obstruct nos j641z00 
gallbladder calculus with other cholecystitis + 
obstruct j641100 
gallbladder calculus with other cholecystitis +no 
obstruct j641000 
gallbladder calculus without cholecystitis and 
obstruct nos j642z00 
gallbladder calculus without mention 
cholecystitis + obstruc j642100 
gallbladder calculus without mention 
cholecystitis +no obstr j642000 
gallbladder calculus without mention of 
cholecystitis j642.11 
gallbladder calculus without mention of 
cholecystitis j642.00 
gallstones j64..15 
glycogenosis with hepatic cirrhosis c310400 
h/o: alcoholism 1462.00 
h/o: gallbladder disease 14c7.11 
h/o: rheumatoid arthritis 14g1.00 
h/o: ulcerative colitis 14c4.11 
hepatic granulomas in sarcoidosis j63a.00 
hepatoblastoma of liver b150100 
history of viral hepatitis 141f.00 
hiv disease complicating pregnancy childbirth 
puerperium l179.00 
hiv disease result/haematological+immunologic 
abnorms,nec a788u00 
hiv disease resulting in burkitt's lymphoma a789600 
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Term READ code 
hiv disease resulting in candidiasis a789200 
hiv disease resulting in cytomegaloviral disease a789100 
hiv disease resulting in kaposi's sarcoma a789500 
hiv disease resulting in lymphoid interstitial 
pneumonitis a789900 
hiv disease resulting in multiple infections a789400 
hiv disease resulting in multiple malignant 
neoplasms a789800 
hiv disease resulting in mycobacterial infection a789000 
hiv disease resulting in pneumocystis carinii 
pneumonia a789300 
hiv disease resulting in pneumocystis jirovecii 
pneumonia a789311 
hiv disease resulting in unspecified malignant 
neoplasm a788w00 
hiv disease resulting in wasting syndrome a789a00 
hiv disease resulting/unspcf infectious+parasitic 
disease a788x00 
hiv infection with persistent generalised 
lymphadenopathy a788200 
hiv positive 43c3.11 
husband alcoholic 13l3.13 
hypertrophic portal cirrhosis j615500 
indian childhood cirrhosis j615812 
infectious cirrhosis nos j615h00 
inflammatory bowel disease j4...12 
juvenile arthritis in crohn's disease n045300 
juvenile arthritis in ulcerative colitis n045400 
juvenile portal cirrhosis j615800 
juvenile rheumatoid arthritis n045500 
juvenile rheumatoid arthritis - still's disease n043.00 
juvenile rheumatoid arthritis nos n043z00 
korsakoff's non-alcoholic psychosis e040.11 
korsakov's alcoholic psychosis e011000 
korsakov's alcoholic psychosis with peripheral 
neuritis e011100 
laennec's cirrhosis j612.12 
liver abscess and sequelae of chronic liver 
disease j62..00 
liver metastases b577.11 
lung disease with systemic lupus erythematosus h57y400 
macronodular cirrhosis of liver j615z11 
malignant neoplasm gallbladder and 
extrahepatic bile ducts b16..00 
malignant neoplasm gallbladder/extrahepatic 
bile ducts nos b16z.00 
malignant neoplasm of body of pancreas b171.00 
malignant neoplasm of gallbladder b160.00 
malignant neoplasm of head of pancreas b170.00 
malignant neoplasm of liver and intrahepatic bile 
ducts b15..00 
malignant neoplasm of liver and intrahepatic bile 
ducts nos b15z.00 
malignant neoplasm of liver unspecified b152.00 
malignant neoplasm of other specified sites of 
pancreas b17y.00 
malignant neoplasm of pancreas b17..00 
malignant neoplasm of pancreas nos b17z.00 
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Term READ code 
malignant neoplasm of specified site of 
pancreas nos b17yz00 
malignant neoplasm of tail of pancreas b172.00 
malignant neoplasm other 
gallbladder/extrahepatic bile duct b16y.00 
mast - michigan alcoholism screening test zra1.11 
meningitis due to sarcoidosis f013.00 
michigan alcoholism screening test zra1.00 
monarticular juvenile rheumatoid arthritis n043300 
multilobular portal cirrhosis j615100 
multiple cranial nerve palsies in sarcoidosis f326300 
munich alcoholism test zrau.00 
myopathy due to rheumatoid arthritis f396400 
myopathy due to sarcoidosis f396500 
myositis in sarcoidosis n233200 
neoplasm of uncertain behaviour of liver b903000 
neoplasm of uncertain behaviour of liver and 
biliary passage b903.00 
nephrotic syndrome in systemic lupus 
erythematosus k01x400 
non-alcoholic cirrhosis nos j615z00 
non-alcoholic fatty liver j61y100 
o/e - alcoholic breath 2577.11 
oesophageal varices in alcoholic cirrhosis of the 
liver g852300 
oesophageal varices in cirrhosis of the liver g852200 
orofacial crohn's disease j08z900 
other alcoholic dementia e012.00 
other alcoholic psychosis e01y.00 
other alcoholic psychosis nos e01yz00 
other cholecystitis j651.00 
other cholecystitis os j651y00 
other non-alcoholic chronic liver disease j61y.00 
other non-alcoholic chronic liver disease nos j61yz00 
other rheumatoid arthritis of spine n040100 
other sequelae of chronic liver disease j62y.00 
other specified viral hepatitis with coma a704.00 
other specified viral hepatitis with hepatic coma 
nos a704z00 
other specified viral hepatitis without coma a705.00 
other specified viral hepatitis without mention of 
coma nos a705z00 
pauciarticular juvenile rheumatoid arthritis n043200 
pigmentary cirrhosis of liver c350012 
polyneuropathy in rheumatoid arthritis f371200 
polyneuropathy in sarcoidosis f374900 
portal cirrhosis j615.11 
portal cirrhosis unspecified j615y00 
portal fibrosis without cirrhosis j61y300 
primary biliary cirrhosis j616000 
primary carcinoma of liver b150000 
primary malignant neoplasm of liver b150.00 
primary malignant neoplasm of liver nos b150z00 
pulmonary sarcoidosis h57y200 
regional enteritis - crohn's disease j40..00 
rheumatoid arthritis n040.00 
rheumatoid arthritis - multiple joint n040s00 
rheumatoid arthritis and other inflammatory n04..00 
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Term READ code 
polyarthropathy 
rheumatoid arthritis annual review 66hb000 
rheumatoid arthritis of 1st mtp joint n040k00 
rheumatoid arthritis of acromioclavicular joint n040400 
rheumatoid arthritis of ankle n040f00 
rheumatoid arthritis of cervical spine n040000 
rheumatoid arthritis of dip joint of finger n040a00 
rheumatoid arthritis of distal radio-ulnar joint n040600 
rheumatoid arthritis of elbow n040500 
rheumatoid arthritis of hip n040b00 
rheumatoid arthritis of knee n040d00 
rheumatoid arthritis of lesser mtp joint n040l00 
rheumatoid arthritis of mcp joint n040800 
rheumatoid arthritis of other tarsal joint n040j00 
rheumatoid arthritis of pip joint of finger n040900 
rheumatoid arthritis of sacro-iliac joint n040c00 
rheumatoid arthritis of shoulder n040200 
rheumatoid arthritis of subtalar joint n040g00 
rheumatoid arthritis of talonavicular joint n040h00 
rheumatoid arthritis of wrist n040700 
rheumatoid arthritis particle agglutination test 43b9.00 
rheumatoid arthritis screen 68f1.00 
rheumatoid arthritis screening test 43c6.00 
sarcoidosis ad5..00 
sarcoidosis of inferior turbinates ad54.00 
sarcoidosis of lung ad50.00 
sarcoidosis of lung with sarcoidosis of lymph 
nodes ad52.00 
sarcoidosis of lymph nodes ad51.00 
sarcoidosis of skin ad53.00 
secondary biliary cirrhosis j616100 
secondary malignant neoplasm of liver b577.00 
secondary malignant neoplasm of liver b153.00 
sequelae of viral hepatitis ae23.00 
seronegative rheumatoid arthritis n040p00 
seropositive errosive rheumatoid arthritis n047.00 
seropositive rheumatoid arthritis, unspecified n04x.00 
slam - systemic lupus activity measure zrq8.11 
suspected gallstones 1j5..00 
systemic lupus activity measure zrq8.00 
systemic lupus erythematosus n000.00 
systemic lupus erythematosus disease activity 
index zrq9.00 
systemic lupus erythematosus nos n000z00 
systemic lupus erythematosus with organ or sys 
involv n000300 
systemic lupus erythematosus with pericarditis n000400 
toxic liver disease with fibrosis and cirrhosis of 
liver j635600 
ulcerative colitis j410100 
ulcerative colitis and/or proctitis j41..12 
unspecified chronic alcoholism e231000 
unspecified viral hepatitis a70z.00 
viral (serum) hepatitis b a703.00 
viral hepatitis a70..00 
viral hepatitis a with coma a700.00 
viral hepatitis b with coma a702.00 
viral hepatitis c with coma a704000 
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Term READ code 
viral hepatitis c without mention of hepatic coma a705000 
viral hepatitis carrier 65q7.00 
viral hepatitis comp pregnancy, childbirth & the 
puerperium l176500 
viral hepatitis screening test 4jrf.00 
viral hepatitis without hepatic coma a709.00 
xanthomatous portal cirrhosis j615c00 
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Chapter 3 Appendix Table 6a: Causal diagram used to assist in the identification of co-variates likely to confound (or be effect 
modifiers of) the association between flucloxacillin and cholestatic liver injury  
 
Note re: Ethnicity: Both social aspects of health related to ethnicity and genetic variation which can influence health are considered relevant [144]
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Chapter 3 Appendix Table 6b: Causal diagram used to assist in the identification of co-variates likely to confound (or be effect 
modifiers of) the association between the drug exposures carbamazepine, celecoxib, duloxetine, ramipril or risperidone and 
cholestatic liver injury 
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Chapter 3 Appendix Table 7: List of drug substances considered as other potential causes 
of cholestatic liver injury, with assignment to co-variate category marked (=less frequent 
cause of cholestastic liver injury vs. more frequent cause of cholestatic liver injury) 
Drug substance Frequency category  
(category=less frequent unless marked) 
acebutolol hydrochloride/hydrochlorothiazide  
allopurinol  
aluminium hydroxide/bismuth 
subnitrate/magnesium carbonate/sodium 
bicarbonate/deglycyrrhizinised liquorice  
amiloride hydrochloride/hydrochlorothiazide  
amiodarone hydrochloride  
amitriptyline hydrochloride  
amitriptyline hydrochloride/perphenazine  
amlodipine  
amlodipine besilate  
amlodipine 
besilate/hydrochlorothiazide/olmesartan 
medoxomil  
amlodipine besilate/olmesartan medoxomil  
amlodipine besilate/valsartan  
amoxicillin sodium  
amoxicillin sodium/potassium clavulanate More frequent 
amoxicillin trihydrate  
amoxicillin trihydrate/potassium clavulanate More frequent 
ampicillin  
ampicillin sodium  
ampicillin trihydrate  
aspirin  
aspirin/aloxiprin/caffeine citrate  
aspirin/caffeine  
aspirin/caffeine/citric acid/sodium 
bicarbonate/paracetamol  
aspirin/codeine phosphate  
aspirin/ethoheptazine citrate/meprobamate  
aspirin/isosorbide mononitrate  
aspirin/papaveretum  
aspirin/paracetamol  
aspirin/paracetamol/caffeine  
atenolol/amiloride 
hydrochloride/hydrochlorothiazide  
atorvastatin calcium  
atorvastatin calcium trihydrate  
auranofin  
azathioprine More frequent 
bacampicillin  
benzoyl peroxide/clindamycin phosphate  
benzoyl peroxide/erythromycin  
betahistine dihydrochloride  
bezafibrate  
bisoprolol fumarate/hydrochlorothiazide  
bupropion hydrochloride  
captopril  
carbamazepine More frequent 
carmustine  
cefalexin  
cefuroxime  
cefuroxime axetil  
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Drug substance Frequency category  
(category=less frequent unless marked) 
cefuroxime sodium  
celecoxib  
cetirizine hydrochloride  
chlorambucil  
chlorothiazide  
chlorpromazine embonate More frequent 
chlorpromazine hydrochloride More frequent 
chlortetracycline hydrochloride  
chlortetracycline hydrochloride/tetracycline 
hydrochloride/demeclocycline hydrochloride  
chlortetracycline hydrochloride/triamcinolone 
acetonide  
cimetidine  
cinnarizine  
ciprofloxacin  
ciprofloxacin hydrochloride  
ciprofloxacin lactate  
clarithromycin  
clindamycin hydrochloride  
clindamycin phosphate  
clobetasone butyrate/oxytetracycline 
calcium/nystatin  
clomethiazole  
clomethiazole edisilate  
clomipramine hydrochloride  
clopidogrel  
clopidogrel hydrogen sulphate  
cloxacillin  
clozapine  
codeine phosphate/aspirin  
cyclophosphamide  
cyclophosphamide monohydrate  
cyproheptadine hydrochloride  
danazol  
desogestrel/ethinylestradiol  
dexibuprofen  
dexketoprofen trometamol  
dextromethorphan hydrobromide  
dextromethorphan hydrobromide/ephedrine 
hydrochloride  
dextromethorphan hydrobromide/menthol  
dextromethorphan 
hydrobromide/pseudoephedrine hydrochloride  
dextromethorphan hydrobromide/terpin 
hydrate/menthol/pumilio pine oil/eucalyptus oil  
dextromethorphan hydrobromide/triprolidine 
hydrochloride  
dextropropoxyphene hydrochloride  
dextropropoxyphene hydrochloride/paracetamol  
dextropropoxyphene napsylate  
diazepam  
diclofenac diethylammonium  
diclofenac epolamine  
diclofenac potassium  
diclofenac sodium  
diclofenac sodium/misoprostol  
diflunisal  
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Drug substance Frequency category  
(category=less frequent unless marked) 
digoxin  
dimenhydrinate/cinnarizine  
diphenhydramine 
hydrochloride/dextromethorphan hydrobromide  
diphenhydramine 
hydrochloride/menthol/dextromethorphan 
hydrobromide  
dipyridamole/aspirin  
disulfiram  
dosulepin hydrochloride  
doxazosin mesilate  
doxycycline hyclate  
doxycycline monohydrate  
drospirenone/estradiol hemihydrate  
drospirenone/ethinylestradiol  
duloxetine hydrochloride  
dydrogesterone/estradiol  
enalapril maleate  
enalapril maleate/hydrochlorothiazide  
erythromycin  
erythromycin ethyl succinate  
erythromycin lactobionate  
erythromycin stearate  
erythromycin/isotretinoin  
erythromycin/tretinoin  
erythromycin/zinc acetate  
escitalopram oxalate  
esomeprazole magnesium  
esomeprazole magnesium dihydrate  
esomeprazole magnesium trihydrate  
esomeprazole sodium  
estradiol  
estradiol acetate  
estradiol hemihydrate  
estradiol valerate  
estradiol valerate/norethisterone  
estradiol/levonorgestrel  
estradiol/norethisterone acetate  
estrone/estriol/estradiol  
ethinylestradiol  
ethinylestradiol/cyproterone acetate  
ethinylestradiol/etonogestrel  
etodolac  
etoricoxib  
ezetimibe/simvastatin  
fenofibrate  
fenofibrate micronised  
fenoprofen calcium  
flucloxacillin magnesium  
flucloxacillin magnesium/ampicillin trihydrate  
flucloxacillin sodium  
flucloxacillin sodium/ampicillin trihydrate  
fluconazole  
fluphenazine decanoate  
fluphenazine enantate  
fluphenazine hydrochloride  
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Drug substance Frequency category  
(category=less frequent unless marked) 
fluphenazine hydrochloride/nortriptyline 
hydrochloride  
flutamide  
fluvastatin sodium  
fosinopril sodium  
fosphenytoin sodium  
gabapentin  
gemcitabine hydrochloride  
gestodene/ethinylestradiol  
glibenclamide  
glimepiride  
griseofulvin  
haloperidol  
haloperidol decanoate  
halothane  
hydrochlorothiazide  
hydrochlorothiazide/amlodipine 
besilate/olmesartan medoxomil  
hydrochlorothiazide/amlodipine/olmesartan 
medoxomil  
hydrochlorothiazide/captopril  
hydrochlorothiazide/irbesartan  
hydrochlorothiazide/losartan potassium  
hydrochlorothiazide/metoprolol tartrate  
hydrochlorothiazide/olmesartan medoxomil  
hydrochlorothiazide/quinapril hydrochloride  
hydrochlorothiazide/telmisartan  
hydrochlorothiazide/valsartan  
hydrocortisone/nystatin/oxytetracycline calcium  
ibuprofen  
ibuprofen lysine  
ibuprofen sodium dihydrate  
ibuprofen/codeine phosphate  
ibuprofen/levomenthol  
ibuprofen/paracetamol  
ibuprofen/phenylephrine hydrochloride  
ibuprofen/pseudoephedrine hydrochloride  
imipramine hydrochloride  
infliximab  
interferon beta-1a  
iproniazide  
irbesartan  
irbesartan/hydrochlorothiazide  
isoflurane  
isoniazid More frequent 
itraconazole  
ketoprofen  
ketoprofen/omeprazole  
ketorolac trometamol  
lamotrigine  
leflunomide  
levocetirizine dihydrochloride  
levofloxacin  
levofloxacin hemihydrate  
levonorgestrel  
levonorgestrel/ethinylestradiol  
 238 
 
Drug substance Frequency category  
(category=less frequent unless marked) 
linagliptin/metformin hydrochloride  
lisinopril  
lisinopril/hydrochlorothiazide  
lithium carbonate  
lithium citrate  
losartan potassium/hydrochlorothiazide  
loxapine succinate  
lysine acetylsalicylate/metoclopramide 
hydrochloride More frequent 
medroxyprogesterone acetate/estradiol valerate  
mefenamic acid  
meloxicam  
mepivacaine 
hydrochloride/nicotinamide/polyestradiol 
phosphate  
mercaptopurine  
metformin  
metformin hydrochloride  
metformin hydrochloride/rosiglitazone maleate  
metformin hydrochloride/saxagliptin 
hydrochloride  
metformin hydrochloride/sitagliptin phosphate  
metformin hydrochloride/vildagliptin  
methyldopa anhydrous  
methyldopate hydrochloride  
methyltestosterone  
methyltestosterone/pemoline/yohimbine 
hydrochloride  
metoclopramide hydrochloride More frequent 
metoclopramide hydrochloride/paracetamol More frequent 
metoprolol tartrate/hydrochlorothiazide  
mianserin hydrochloride  
minocycline hydrochloride  
nabumetone  
nandrolone decanoate  
naproxen  
naproxen sodium  
naproxen/esomeprazole  
nefazodone hydrochloride  
nevirapine  
nevirapine anhydrate  
nevirapine hemihydrate  
nitrofurantoin  
nomegestrol/estradiol hemihydrate  
norelgestromin/ethinylestradiol  
norethisterone acetate/estradiol  
norethisterone acetate/ethinylestradiol  
norethisterone/ethinylestradiol  
norfloxacin  
norgestimate/ethinylestradiol  
olanzapine  
olanzapine embonate monohydrate  
olmesartan medoxomil/amlodipine besilate  
olmesartan medoxomil/hydrochlorothiazide  
omeprazole  
omeprazole magnesium  
omeprazole sodium  
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Drug substance Frequency category  
(category=less frequent unless marked) 
orlistat  
oxandrolone  
oxymetholone  
oxytetracycline dihydrate  
oxytetracycline hydrochloride  
oxytetracycline hydrochloride/hydrocortisone  
paracetamol/caffeine/aspirin  
paracetamol/dextropropoxyphene hydrochloride  
paracetamol/ibuprofen  
paracetamol/metoclopramide hydrochloride More frequent 
paracetamol/promethazine 
hydrochloride/dextromethorphan hydrobromide  
paracetamol/pseudoephedrine 
hydrochloride/doxylamine 
succinate/dextromethorphan hydrobromide  
paroxetine hydrochloride  
perphenazine  
phenoxymethylpenicillin potassium  
phenylbutazone  
phenytoin  
phenytoin sodium  
pimozide  
pioglitazone hydrochloride  
pioglitazone hydrochloride/metformin 
hydrochloride  
piroxicam  
piroxicam betadex  
pivampicillin  
polymyxin b sulphate/trimethoprim  
prochlorperazine maleate  
prochlorperazine mesilate  
propafenone hydrochloride  
pseudoephedrine 
hydrochloride/dextromethorphan hydrobromide  
pseudoephedrine hydrochloride/ibuprofen  
pseudoephedrine 
hydrochloride/levomenthol/diphenhydramine 
hydrochloride/dextromethorphan hydrobromide  
pseudoephedrine hydrochloride/triprolidine 
hydrochloride/dextromethorphan hydrobromide  
pyrazinamide/rifampicin/isoniazid More frequent 
quetiapine fumarate  
racemic camphor/aspirin/methyl 
salicylate/menthol  
ranitidine bismuth citrate  
ranitidine hydrochloride  
repaglinide  
rifampicin  
rifampicin/isoniazid More frequent 
risperidone  
rofecoxib  
rosiglitazone maleate  
rosiglitazone maleate/metformin hydrochloride  
sertraline hydrochloride  
simvastatin  
simvastatin/ezetimibe  
sodium aurothiomalate  
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Drug substance Frequency category  
(category=less frequent unless marked) 
sodium fusidate  
sodium fusidate/hydrocortisone acetate  
sodium valproate More frequent 
spironolactone/chlorothiazide  
stanozolol  
sulfamethoxazole/trimethoprim  
sulindac  
sulpiride More frequent 
talampicillin hydrochloride  
tamoxifen citrate  
telmisartan/hydrochlorothiazide  
tenoxicam  
terbinafine  
terbinafine hydrochloride  
terfenadine  
testosterone  
testosterone enantate  
testosterone phenylpropionate/testosterone 
propionate/testosterone decanoate/testosterone 
isocaproate  
testosterone propionate  
testosterone propionate/testosterone 
phenylpropionate/testosterone isocaproate  
testosterone undecanoate  
tetracycline hydrochloride  
thioridazine  
thioridazine hydrochloride  
ticlopidine hydrochloride  
timolol maleate/hydrochlorothiazide/amiloride 
hydrochloride  
tolbutamide  
tolmetin sodium  
triamterene/hydrochlorothiazide  
trifluoperazine hydrochloride  
trimethoprim  
trimethoprim/sulfamethoxazole  
trimipramine maleate  
valproate semisodium More frequent 
valsartan/amlodipine besilate  
valsartan/hydrochlorothiazide  
vildagliptin/metformin hydrochloride  
zinc sulphate/lithium succinate  
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Chapter 3 Appendix Table 8: Study protocols and approvals  
ISAC PROTOCOL 
Development and testing of new methods for the identification of cases of cholestatic hepatitis 
in GPRD  
Aims and objectives 
Aim 
To develop optimal methods for the accurate identification of cholestatic hepatitis within the 
GPRD.  
Specific objectives   
Develop an algorithm (the chol-hep multisource algorithm) using data sources within and 
external to GPRD that enables cholestatic hepatitis to be accurately identified as an outcome in 
patients. 
Use the chol-hep multisource algorithm to develop a second algorithm (the chol-hep GPRD 
algorithm) that allows patients with cholestatic hepatitis to be accurately identified using data 
only held within GPRD. 
Test the chol-hep GPRD algorithm by utilising it in a comparison of the rate of cholestatic 
hepatitis in people prescribed flucloxacillin with the rate in people prescribed oxytetracycline (an 
antibiotic which has a similar range of indications but is not associated with cholestatic 
hepatitis).   
Study type 
The primary aim of this study is to design new methodologies for the definition of cholestatic 
hepatitis within the General Practice Research Database (described in part 1 of the following 
sections). 
To assist with analysis of the effectiveness of the new methods, a hypothesis testing study will 
be performed, testing the null hypothesis that flucloxacillin is not associated with an increased 
rate of cholestatic hepatitis (described in part 2 of the following sections). 
Study population 
Study population will be selected from patients registered in the GPRD aged 18+ registered with 
a GPRD practice during the study period of 1st January 2000 to April 2012. 
Part 1 – Design of new methodologies  
We will be developing two algorithms for case definition: a chol-hep multisource algorithm and a 
chol-hep GPRD algorithm. 
The chol-hep multisource algorithm 
Data sources 
Our chol-hep multisource algorithm will utilise the following data sources: 
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GPRD READ codes 
HES ICD10 codes 
Other GPRD/HES information (e.g. laboratory test results) 
Hospital discharge letters from GPs 
GPRD freetext 
ONS mortality data 
Development of case definition 
Based upon standard clinical definitions for cholestatic liver injury [45, 46, 145], we have 
developed an algorithm that will allow patients to be classified as definite, probable, possible 
(and non-) cases. To start with, we will use a combination of coded information and laboratory 
test results from GPRD and HES, as defined in the table below. In this table, the groups of 
GPRD/HES codes represent groups according to strength of evidence for cholestatic hepatitis 
(group 1: highest, group 3: lowest) - full details of the codes contained in each group are 
included in the appendices.  
Case status GPRD (READ) codes 
See Appendix 1 
HES (ICD10) codes 
See Appendix 2  
Laboratory test results1 (in 
GPRD) 
Definite Group 1 Group 1 Cholestatic2 
Definite Group 1 Group 2 or 3 Cholestatic 
Definite Group 2 or 3 Group 1 Cholestatic 
Definite Group 1 No HES record  Cholestatic 
 
Probable Group 1 Group 1 Abnormal liver function, 
but not cholestatic 
Probable Group 1  Group 2 or 3 Abnormal liver function, 
but not cholestatic 
Probable Group 2 or 3 Group 1 Abnormal liver function, 
but not cholestatic 
Probable Group 2 or 3 Group 2 or 3 Cholestatic 
Probable Group 2 or 3 No HES record Cholestatic 
Probable Group 1  Group 1 None available 
 
Possible Group 1 Group 2 or 3 Abnormal liver function, 
but not cholestatic 
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Possible Group 1 No HES record  Abnormal liver function, 
but not cholestatic 
Possible Group 2 or 3 Group 1 Abnormal liver function, 
but not cholestatic 
Possible Group 1 No HES record None available 
1Laboratory test results: need to be recorded in the patient’s medical record within two months 
of being diagnosed with a code from one of the groups. 
2Cholestatic: Either (1) an increase of over twice the upper limit of the normal range in alkaline 
phosphatase (AP) alone or (2) when the ratio (R) of serum activity of alanine aminotransferase 
to serum activity of AP is <=2. 
We will then use other information held within the GPRD or HES records (such as abdominal 
ultrasound test results, biopsy results), questionnaires sent to GPs (questionnaire to be 
provided at a later date), GPRD freetext and ONS mortality data to assist with further 
classification of the probable/possible cases. Finally, a sample of all possible/probable/definite 
cases will be reviewed by a physician in the project team. We will then use the probable and 
definite cases to assist in preparation of the chol-hep GPRD algorithm. 
The chol-hep GPRD algorithm 
Data sources 
Our major goal is to develop an algorithm for cholestatic hepatitis case definition in GPRD that 
uses only data available within a standard GPRD record (i.e. without free-text, hospital 
discharge letters from GPs or linkages to HES/ONS data). This ensures that the method would 
be compatible with “real time” identification of  (e.g. flucloxacillin-induced) cholestatic hepatitis 
cases for studies that aim to recruit patients with flucloxacillin-induced cholestatic hepatitis for 
genetic analysis. These would use the recently developed Randomised Controlled Trial IT 
infrastructure at GPRD, which would allow patients to be flagged as potential cases based on 
exposure to flucloxacillin (assessed by daily downloads of GP data into GPRD) and 
subsequently designated as probable/definite cases based upon application of the chol-hep 
GPRD algorithm.  
Development of case definition 
We will use a data-driven approach to develop a chol-hep GPRD algorithm, using the case 
definitions (probable and definite) from the chol-hep multisource algorithm as the outcome, and 
the following information within GPRD as the exposures: 
READ codes  
Other descriptions of the outcome in the GPRD standard record (e.g. laboratory test results, 
information on referrals) 
We will then use cross tabulations and logistic regression to assess the combination of these 
exposures that best predict the probable and definite case definitions obtained from the chol-
hep multisource algorithm. The log Odds Ratios (OR) for exposures in the final model will be 
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used to obtain a cholestatic-hepatitis diagnosis score for (1) each patient classified (by the chol-
hep multisource algorithm) as having cholestatic hepatitis and (2) a 5:1 random sample of those 
without cholestatic hepatitis by assigning the value of the log OR for each of the exposures 
present in their GPRD record and then summing these values to produce an overall score for 
the individual [79]. We will then determine the cut-off score that best separates individuals 
without cholestatic hepatitis  from those with cholestatic hepatitis. STATA version 12 will be 
used for all statistical analysis. 
This cut-off score will be used as the case definition (outcome) under test in part 2. 
Part 2 – Testing the methods using a cohort analysis of the association between flucloxacillin 
and cholestatic hepatitis 
This part describes the study we will perform that will allow us to test the performance of the 
chol-hep GPRD algorithm for case definition versus (1) case definitions used in published data 
(2) cases identified by obtaining hospital discharge notes from GPs  (3) cases identified using 
HES/ONS data only (4) cases identified using the chol-hep multisource algorithm. 
Study design 
A cohort analysis of the association between flucloxacillin and cholestatic hepatitis.  
Exposed group 
Inclusion criteria 
People with at least one prescription for flucloxacillin and at least 12 months of computerised 
prescription history in GPRD prior to their first prescription. 
Exclusion criteria  
Patients who have any of the following in their GPRD record anytime prior to their first 
flucloxacillin prescription and within a 12 month period after the first prescription will be 
excluded: any documented liver disease, alcoholism, malignant neoplasm, cholelithiasis, viral 
hepatitis, chronic liver disease, cirrhosis, congestive heart failure, hepatitis following blood 
transfusion, HIV, RA, sarcoidosis, systemic lupus or inflammatory bowel disease. 
Comparison group 
Inclusion criteria 
People with at least one prescription for oxytetracycline and at least 12 months of computerised 
prescription history in GPRD prior to their first prescription. 
Oxytetracycline users are likely to be more comparable to the exposed group with respect to 
exposures (in e.g. health-seeking behaviour, level of illness) than non-users but not the 
outcome (oxytetracycline has not been shown to be associated with cholestatic hepatitis).  
We will also use the exposed group as their own comparison group for a part of the analysis, 
comparing the number of outcome events within 60 days with the following 60 days. 
Exclusion criteria 
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Same criteria as for the exposed group, in relation to oxytetracycline. 
Sample size/power calculations 
A recent GPRD cohort study [53] demonstrated the risk of cholestatic liver disease to be 8.5 per 
100 000 first time users for flucloxacillin (95% CI 5.4 – 12.6) and 0.8 per 100 000 first time users 
for oxytetracyline (95% CI 0.02 – 4.3), a risk ratio of 8.5/0.8 = 10.63. We performed a power 
calculation using STATA version 12 and in order to detect a difference of this size with 95% 
precision and 90% power, calculated that we would require a sample size of 189892 in each 
exposure group.  
A feasibility count in GPRD was performed by obtaining the number of first time prescriptions for 
flucloxacillin and for oxytetracycline in a sample of 1 million people (extracted from the database 
October 2011) and multiplying this appropriately to reflect the total number of people in GPRD 
in October 2011 (11.6 million). There were 2241712 people with a first time prescription for 
flucloxacillin with records in the database in October 2011 and 618025 people with a first time 
prescription for oxytetracycline, meaning that our study will be adequately powered to detect the 
likely difference, even after applying exclusion criteria. 
Exposures, outcomes and co-variates 
Exposures 
Exposures will be determined from prescription records within GPRD for these antibiotics. A 
person will be considered exposed up to 45 days after a prescription of flucloxacillin or 
oxytetracycline, as flucloxacillin-induced cholestatic hepatitis may occur up  6-8 weeks after 
administration of the drug [53]. 
Outcomes 
The main study will be performed using an outcome definition determined by the chol-hep 
GPRD algorithm. 
As the purpose of this cohort study is to assess the performance of the chol-hep GPRD 
algorithm, we will then repeat the analysis using cases defined by the methods listed below, and 
compare the results obtained with those obtained using the chol-hep GPRD algorithm:  
The chol-hep multisource algorithm 
Requests for hospital discharge notes from GPs 
HES/ONS cases 
Co-variates 
We will consider adjusting for age, gender, smoking, SES, ethnicity, BMI and alcohol intake. 
We will take account of the possible impact of the use of other drugs associated with liver 
toxicity during the exposure period (e.g. chlorpromazine, amoxicillin/clavulanic acid, macrolides, 
tetracyclines, metoclopramide, chlorpheniramine, betahistine, sulphasalazine, azathioprine, 
diclofenac, antiepileptics [74]) by performing sensitivity analyses that exclude patients on these 
drugs from the analysis. 
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If any patients are exposed to both oxytetracycline and flucloxacillin, we will perform a sensitivity 
analysis to assess if there is any impact of excluding these patients. 
Data/statistical analysis and data management 
Bias 
If any assessment of outcome is required separate from using the algorithm prepared in part 1, 
any reviewers will be blinded to drug exposure status. 
Statistical Analysis  
We will use Cox regression to: 
Compare the rate of cholestatic hepatitis during the 45 days after a first prescription of 
flucloxacillin to the rate during the 45 days after a first prescription of oxytetracycline 
Compare the rate of cholestatic hepatitis during the 45 days after a first prescription of 
flucloxacillin to the rate between 46 and 90 days after a first prescription of flucloxacillin  
We will compare the results obtained from applying Cox regression when using the chol-hep 
GPRD algorithm for outcome definition with the results obtained when using the other outcome 
definitions (as defined in the Outcomes section above). We will also compare the results with 
the incidence rates and rate ratios obtained in comparable studies in the literature.   
Handling of missing values 
For variables with missing values, a “missing” category will be included containing the number 
of individuals with the missing data. Sensitivity analysis will be performed to assess the impact 
of changing missing values to the most extreme values. 
Patient or user group involvement 
We do not believe that this research would benefit from patient involvement (or vice versa) at 
this stage. 
Limitations of the study design, data sources, and analytical methods 
As this is an observational study, confounding must be considered a limitation. We have 
included a list of confounders that we will assess, and will also carry out sensitivity analysis to 
assess the role of drugs other than those under study. Our comparison group has been 
selected to also receive an antibiotic, which should further reduce the likelihood that exposures 
other than those under study are causing observed effects.  
Plans for disseminating and communicating study results 
We plan to publish our findings in a peer-reviewed journal and to present them at relevant 
scientific conferences. 
ISAC APPROVAL 
ISAC EVALUATION OF PROTOCOLS FOR RESEARCH INVOLVING GPRD DATA 
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Chapter 4 Appendix 
Chapter 4 Appendix Table 1: CPRD denominator (total number of patients with up-to-
research standard data in the database) from 2000 onwards 
Year  Denominator1 % of current size 
(increase) 
2000 5606488 45% (-) 
2001 6263789 50% (5%) 
2002 7249997 58% (8%) 
2003 7886617 63% (5%) 
2004 8548007 68% (5%) 
2005 9048301 72% (4%) 
2006 9526092 76% (4%) 
2007 10097134 80% (5%) 
2008 10575875 85% (4%) 
2009 11066617 89% (4%) 
2010 11539683 92% (4%) 
2011 12075098 97% (4%) 
2012 12501163 100% (3%) 
1Denominator: Total number of patients registered in the database on 30th June of that year 
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Chapter 4 Appendix Table 2: Characteristics of people included in the CPRD algorithm training 
and validation cohorts (data from CPRD record unless otherwise stated) 
  Training cohort  Validation cohort 
   (N = 8020)   (N = 8020) 
  n (%)  n (%)
Age at index diagnosis date1  18 – 29 474 (6)  474 (6)
  30 – 39 697 (9)  755 (9)
  40 – 49 1096 (14)  1068 (13)
  50 – 59 1350 (17)  1386 (17)
  60 ‐ 69 1494 (19)  1443 (18)
  70 ‐ 79 1555 (19)  1572 (20)
  80+  1354 (17)  1322 (16)
  median (25 ‐ 75%): 62 (47 – 75)  62 (47 – 75)
   
Gender  Male  4201 (52)  4205 (52)
  Female 3819 (48)  3815 (48)
   
Date of index diagnosis 2000 – 2002 1643 (20)  1693 (21)
  2003 – 2005 1982 (25)  1885 (24)
  2006 – 2008 1971 (25)  1991 (25)
  2009 ‐ 2012 2424 (30)  2451 (31)
Note 1: Date of diagnosis with one of the potential cholestatic liver injury codes listed in Chapter 4 Appendix, Table 1   
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Chapter 4 Appendix Table 3: Algorithm score and corresponding sensitivity and 
specificity when comparing the complete CPRD algorithm (stage 1 and stage 2 case 
assignment) against the multisource algorithm case status of definite to possible 
CPRD algorithm score 
(stage 1 and stage 2 case assignment) 
Sensitivity Specificity 
-1.60 100.0% 0.0% 
-1.20 100.0% 3.8% 
-1.20 100.0% 4.7% 
-0.81 100.0% 4.9% 
-0.80 100.0% 5.1% 
-0.47 100.0% 5.1% 
-0.40 100.0% 9.3% 
-0.07 100.0% 9.3% 
-0.07 100.0% 11.9% 
0.00 100.0% 12.0% 
0.33 99.9% 27.1% 
0.34 99.9% 27.4% 
0.39 99.9% 27.5% 
0.40 99.9% 32.3% 
0.64 99.8% 34.0% 
0.68 99.8% 41.5% 
0.74 99.8% 42.0% 
0.79 99.8% 42.0% 
0.81 99.8% 43.3% 
1.03 99.8% 43.6% 
1.04 99.8% 45.6% 
1.07 99.8% 46.3% 
1.08 99.8% 46.8% 
1.21 99.8% 46.8% 
1.43 99.8% 47.0% 
1.44 99.8% 47.4% 
1.47 99.8% 47.4% 
1.49 99.8% 47.5% 
1.63 99.8% 47.6% 
1.84 94.1% 65.2% 
1.89 94.1% 65.2% 
2.02 91.6% 70.7% 
2.03 88.5% 81.5% 
2.29 86.8% 86.1% 
2.29 85.3% 89.7% 
2.42 84.7% 90.9% 
2.43 82.7% 96.4% 
2.69 82.2% 97.1% 
2.70 81.4% 98.4% 
2.83 81.3% 98.6% 
3.02 81.3% 99.6% 
3.10 81.0% 99.7% 
3.42 81.0% 99.9% 
3.42 81.0% 100.0% 
5 81.0% 100.0% 
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Chapter 4 Appendix Table 4: Algorithm score and corresponding sensitivity and 
specificity when comparing algorithm cut-off score (stage 2 case assignment only) 
against the multisource algorithm case status of definite to possible 
CPRD algorithm score 
(stage 2 case assignment only) 
Sensitivity Specificity 
-1.60 100.0% 0.0% 
-1.20 100.0% 3.8% 
-1.20 100.0% 4.7% 
-0.81 100.0% 4.9% 
-0.80 100.0% 5.1% 
-0.47 100.0% 5.1% 
-0.40 100.0% 9.3% 
-0.07 100.0% 9.3% 
-0.07 100.0% 11.9% 
0.00 100.0% 12.1% 
0.33 99.6% 27.1% 
0.34 99.6% 27.4% 
0.39 99.6% 27.5% 
0.40 99.4% 32.3% 
0.64 99.2% 34.0% 
0.68 99.2% 41.5% 
0.74 99.2% 42.0% 
0.79 99.2% 42.0% 
0.81 99.0% 43.3% 
1.03 99.0% 43.6% 
1.04 99.0% 45.6% 
1.07 99.0% 46.3% 
1.08 99.0% 46.8% 
1.21 99.0% 47.0% 
1.43 99.0% 47.4% 
1.44 99.0% 47.4% 
1.47 99.0% 47.5% 
1.49 99.0% 47.6% 
1.63 99.0% 65.2% 
1.84 69.3% 65.2% 
1.89 69.3% 70.7% 
2.02 56.4% 81.5% 
2.03 40.2% 86.1% 
2.29 31.2% 89.7% 
2.29 23.4% 90.9% 
2.42 20.3% 96.4% 
2.43 9.6% 97.1% 
2.69 7.4% 98.4% 
2.70 3.1% 98.6% 
2.83 2.7% 99.6% 
3.02 0.8% 99.7% 
3.10 0.6% 99.9% 
3.42 0.2% 100.0% 
3.42 0.0% 100.0% 
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Chapter 4 Appendix Table 5: Number of people with liver test results recorded in CPRD before 
and after 2007 (=approximate date of automation of transfer of liver test result data between 
pathology laboratory and primary care centres) 
  Pre‐2007 
N=8582 
Post‐2007 
N=7458 
  n (%)  n (%)
No liver test result recorded    4739 (55)  2615 (35)
Liver test result recorded    3843 (45)  4843 (65)
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Chapter 5 Appendix 
Chapter 5 Appendix Table 1: Characteristics of participants included in the cohort analysis of 
the association between flucloxacillin (compared with oxytetracycline) and cholestatic liver 
injury, by exposure status for the HES-linked cohort only 
  Oxytetracycline 
(N = 103,673) 
Flucloxacillin
(N = 517,803) 
  n (%)  n (%)
Age at index date  18 – 29    17669 (17)    87830 (17) 
  30 – 39    17465 (17)    96745 (19) 
  40 – 49    16968 (16)    88110 (17) 
  50 – 59    16764 (16)    77080 (15) 
  60 – 69    15723 (15)    66182 (13) 
  70 – 79    11846 (11)    54925 (11) 
  80+     7238 (7)    46931 (9) 
  median (25 ‐ 75%):  49 (35 – 65)  48 (34 – 65) 
   
Gender  Male    45576 (44)   235721 (46) 
  Female    58097 (56)   282082 (54) 
   
Date of index prescription  2000 – 2001    18810 (18)    68736 (13) 
  2002 ‐ 2003    19759 (19)    86628 (17) 
  2004 ‐ 2005    17567 (17)    91412 (18) 
  2006 ‐ 2007    16504 (16)    95090 (18) 
  2008 ‐ 2009    16721 (16)    93035 (18) 
  2010 ‐ 2011    14312 (14)    82902 (16) 
   
Prescriptions for other causes   None    18924 (18)   254142 (49) 
of cholestatic injury1 Less common cause    81018 (78)   237303 (46) 
  More common cause     3731 (4)    26358 (5) 
   
Smoking status   Non‐smoker    47903 (46)   228867 (44) 
  Ex‐smoker    22274 (21)   129469 (25) 
  Current smoker    31621 (31)   149286 (29) 
  Unknown     1875 (2)    10181 (2) 
   
BMI   <20     6379 (6)    29670 (6) 
  20 ‐ 25    32179 (31)   151247 (29) 
  25+    52439 (51)   266587 (51) 
  Unknown    12676 (12)    70299 (14) 
Alcohol intake  Non‐drinker    10473 (10)    54603 (11) 
  Ex‐drinker     3134 (3)    17249 (3) 
  Current NOS     3385 (3)    17200 (3) 
  2 or less u/d    15980 (15)    80368 (16) 
  3/6 u/d    49201 (47)   236106 (46) 
  >6 u/d     7720 (7)    41191 (8) 
  Unknown    13780 (13)    71086 (14) 
Socioeconomic status2  1 (Highest SES)    26098 (25)   118154 (23) 
  2    25099 (24)   120327 (23) 
  3    20083 (19)   103849 (20) 
  4    18254 (18)    97450 (19) 
  5 (Lowest SES)    14139 (14)    78023 (15) 
   
Ethnicity3  White    70393 (68)   355416 (69) 
  South Asian     2310 (2)    11330 (2) 
  Black     1126 (1)     6710 (1) 
  Other      996 (1)     4643 (1) 
  Mixed      316 (0)     1778 (0) 
  Not Stated    12155 (12)    61973 (12) 
  Unknown    16377 (16)    75953 (15) 
Note 1: Prescription counted if it occurred anytime from 1 month prior to index date or between index date and before end of follow‐up (see  Chapter 3 section 
3.4.1.5). Less or more common in relation to flucloxacillin, as reported in the literature (see Chapter 3 section 3.4.1.5) 
Note 2: Linked data, only available for practices in England, based on index of Multiple Deprivation (individual patient postcode) or otherwise practice level score 
based upon practice postcode (if no individual‐level data) (see Chapter 3 section 3.4.1.5). 
Note 3: Obtained from CPRD, unless none found, in which case from HES if patient from a linked practice (see Chapter 3 section 3.4.1.5). 
 254 
 
Chapter 5 Appendix Table 2 
Chapter 5 Appendix Table 2a: Rates and crude rate ratios of cholestatic liver injury for co-variates of the flucloxacillin and cholestatic liver injury cohort, using the 
highest specificity CPRD algorithm cut-off score (5), within those exposed to flucloxacillin or oxytetracycline during the 1 – 45 day period from first prescription  
    # with outcome  Patients4  45‐day risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio (CI)  p‐value9 
    n=56  N=1046696           
Age at index date1  18 – 49  1  545975  0.18 (0.00 ‐ 1.02)  7.99  0.13 (0.02 ‐ 0.89)  1  <0.001 
  50 – 59  9  159448  5.64 (2.58 ‐ 10.71)  2.34  3.85 (2.00 ‐ 7.39)  31.51 (3.99 ‐ 248.68)   
  60 – 69  5  139597  3.58 (1.16 ‐ 8.36)  2.05  2.44 (1.02 ‐ 5.87)  20.33 (2.37 ‐ 174.00)   
  70 – 79  21  112655  18.64 (11.54 ‐ 28.49)  1.65  13.35  (8.30 ‐ 20.14)  99.17 (13.31 ‐ 738.93)   
  80+  20  89021  22.47 (13.72 ‐ 34.70)  1.29  16.72 (10.56 – 24.44)  108.04 (14.42 ‐ 809.31)   
                 
Gender  Male  22  475441  4.63 (2.90 ‐ 7.01)  6.96  3.16 (2.08 ‐ 4.80)  1  0.366 
  Female  34  571255  5.95 (4.12 ‐ 8.32)  8.35  4.07 (2.91 ‐ 5.70)  1.29 (0.74 ‐ 2.23)   
                 
Date of index prescription  2000 – 2001  2  144627  1.38 (0.17 ‐ 5.00)  2.13  0.94 (0.23 ‐ 3.76)  1  0.255 
  2002 – 2003  8  178582  4.48 (1.93 ‐ 8.83)  2.63  3.04 (1.52 ‐ 6.09)  3.12 (0.66 ‐ 14.70)   
  2004 – 2005  13  189423  6.86 (3.65 ‐ 11.74)  2.79  4.66 (2.71 ‐ 8.03)  4.65 (1.05 ‐ 20.61)   
  2006 – 2007  12  189394  6.34 (3.27 ‐ 11.07)  2.78  4.31 (2.45 ‐ 7.59)  3.88 (0.86 ‐ 17.50)   
  2008 – 2009  9  182896  4.92 (2.25 ‐ 9.34)  2.69  3.35 (1.74 ‐ 6.43)  3.29 (0.71 ‐ 15.23)   
  2010 – 2011  12  161774  7.42 (3.83 ‐ 12.96)  2.30  5.22 (2.96 ‐ 9.19)  4.26 (0.93 ‐ 19.45)   
               
Prescriptions for other causes   None  11  450216  2.44 (1.22 ‐ 4.37)  6.58  1.67 (0.93 ‐ 3.02)  1  <0.001 
of cholestatic injury2  Rare cause  41  543010  7.55 (5.42 ‐ 10.24)  7.95  5.16 (3.80 ‐ 7.00)  3.59 (1.83 ‐ 7.02)   
  More common cause  4  53470  7.48 (2.04 ‐ 19.15)  0.78  5.12 (1.92 ‐ 13.63)  3.26 (1.04 ‐ 10.22)   
               
Smoking status   Non‐smoker  17  467184  3.64 (2.12 ‐ 5.83)  6.84  2.49 (1.55 ‐ 4.00)  1  <0.001 
  Current smoker  8  260101  3.08 (1.33 ‐ 6.06)  3.81  2.101 (1.05 ‐ 4.20)  0.76 (0.31 ‐ 1.85)   
  Ex‐smoker  30  297657  10.08 (6.80 ‐ 14.39)  4.36  6.88 (4.81 ‐ 9.84)  2.86 (1.55 ‐ 5.26)   
  Unknown  1  21754  4.60 (0.12 ‐ 25.61)  0.31  3.18 (0.45 ‐ 22.61)  1.33 (0.18 ‐ 10.04)   
                 
BMI   <20  1  59374  1.68 (0.04 ‐ 9.38)  0.87  1.15 (0.16 ‐ 8.20)  1  0.163 
  20 – 25  23  303272  7.58 (4.81 ‐ 11.38)  4.44  5.18 (3.44 ‐ 7.80)  4.29 (0.58 ‐ 31.82)   
  25+  26  542418  4.79 (3.13 ‐ 7.02)  7.95  3.27 (2.23 ‐ 4.80)  2.59 (0.35 ‐ 19.12)   
  Unknown  6  141632  4.24 (1.55 ‐ 9.22)  2.06  2.91 (1.31 ‐ 6.47)  2.45 (0.30 ‐ 20.36)   
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    # with outcome  Patients4  45‐day risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio (CI)  p‐value9 
    n=56  N=1046696           
               
Alcohol intake  Non‐drinker  4  117896  3.39 (0.92 ‐ 8.69)  1.72  2.32 (0.87 ‐ 6.18)  1  0.16 
  Ex‐drinker  1  33858  2.95 (0.07 ‐ 16.45)  0.49  2.03 (0.29 ‐ 14.38)  1.15 (0.12 ‐ 11.03)   
  Current NOS  4  33304  12.01 (3.27 ‐ 30.75)  0.49  8.23 (3.09 ‐  21.93)  4.72 (1.06 ‐ 21.10)   
  2 or less u/d  15  169724  8.84 (4.95 ‐ 14.58)  2.48  6.04 (3.64 ‐ 10.01)  3.48 (1.01 ‐ 12.02)   
  3/6 u/d  22  465596  4.73 (2.96 ‐ 7.15)  6.82  3.22 (2.12 ‐ 4.90)  1.69 (0.50 ‐ 5.69)   
  >6 u/d  4  79808  5.01 (1.37 ‐ 12.83)  1.16  3.42 (1.28 ‐ 9.12)  1.94 (0.43 ‐ 8.67)   
  Unknown  6  146510  4.10 (1.50 ‐ 8.91)  2.14  2.81 (1.26 ‐ 6.25)  1.60 (0.40 ‐ 6.39)   
               
Socioeconomic status  1 (Highest SES)  11  186791  5.89 (2.94 ‐ 10.54)  2.74  4.02 (2.23 ‐ 7.26)  1  0.443 
  2  9  175505  5.13 (2.34 ‐ 9.73)  2.57  3.50 (1.82 ‐ 6.73)  0.77 (0.31 ‐ 1.91)   
  3  13  167976  7.74 (4.12 ‐ 13.23)  2.46  5.29 (3.07 ‐ 9.11)  1.30 (0.58 ‐ 2.89)   
  4  9  158966  5.66 (2.59 ‐ 10.75)  2.34  3.87 (2.01 ‐ 7.44)  0.96 (0.40 ‐ 2.31)   
  5 (Lowest SES)  5  121845  4.10 (1.33 ‐ 9.58)  1.78  2.81 (1.17 ‐ 6.75)  0.68 (0.24 ‐ 1.96)   
  Unknown  9  235613  3.82 (1.75 ‐ 7.25)  3.45  2.61 (1.36 ‐ 5.01)  0.52 (0.20 ‐ 1.34)   
               
Ethnicity3  White  33  534140  6.18 (4.25 ‐ 8.68)  7.81  4.22 (3.00 ‐ 5.94)  1  0.08 
  South Asian  0  17497  0.00 (0.00 ‐ 21.08)  0.25  ‐  ‐   
  Black  1  10011  9.99 (0.25 ‐ 55.64)  0.15  6.86 (0.97 ‐ 48.73)  1.57 (0.21 ‐ 11.46)   
  Other  0  7672  0.00 (0.00 ‐ 48.07)  0.11  ‐  ‐   
  Mixed  0  2630  0.00 (0.00 ‐ 140.16)  0.04  ‐  ‐   
  Not Stated  8  85336  9.37 (4.05 ‐ 18.47)  1.25  6.41 (3.21 ‐ 12.82)  1.51 (0.70 ‐ 3.26)   
  Unknown  14  389410  3.60 (1.97 ‐ 6.03)  5.70  2.45 (1.45 ‐ 4.14)  0.46 (0.23 ‐ 0.91)   
Note 1: age groups 18‐29, 30‐39, 40‐49 combined due to lack of events in the 18‐29 or 30‐39 age groups
Note 2: prescription counted if it occurred anytime from 1 month prior to index date or between index date and 
before end of follow‐up (see  Chapter 3 section 4.4.1.5) 
Note 3: Obtained from CPRD, unless none found, in which case from HES (see Chapter 4 section 3.4.1.5) 
Note 4: number of patients prescribed the drug 
Note 5: per 100000 patients prescribed the drug
Note 6: 95% confidence interval 
Note 7: 100000 person‐months at risk 
Note 8: per 100000 person months 
Note 9: p‐value results for LRT of an association over all categories of the variable 
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Chapter 5 Appendix Table 2b: Rates and crude rate ratios of cholestatic liver injury for co-variates of the flucloxacillin and cholestatic liver injury cohort, using the 
CPRD algorithm cut-off score with medium specificity (2.29), within those exposed to flucloxacillin or oxytetracycline during the 1 – 45 day period from first 
prescription 
    # with outcome  Patients4  45‐day risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio (CI)  p‐value9 
    n=80  N=1046696           
Age at index date1  18 – 49  3  545975  0.55 (0.11 ‐ 1.61)  7.99  0.38 (0.12 ‐ 1.16)  1  <0.001 
  50 – 59  12  159448  7.53 (3.89 ‐ 13.15)  2.34  5.13 (2.91 ‐ 9.03)  14.00 (3.95 ‐ 49.62)   
  60 – 69  13  139597  9.31 (4.96 ‐ 15.92)  2.05  6.35 (3.68 ‐ 10.94)  17.62 (5.02 ‐ 61.82)   
  70 – 79  25  112655  22.19 (14.36 ‐ 32.76)  1.65  15.16 (10.24 ‐ 22.43)  39.67 (11.94 ‐ 131.73)   
  80+  27  89021  30.33 (19.99 ‐ 44.13)  1.29  20.93 (14.35 ‐  30.52)  50.02 (15.10 ‐ 165.67)   
                 
Gender  Male  30  475441  6.31 (4.26 ‐ 9.01)  6.96  4.31 (3.01 ‐ 6.16)  1  0.15 
  Female  50  571255  8.75 (6.50 ‐ 11.54)  8.35  5.9862   4.5370   7.8982  1.40 (0.88 ‐ 2.22)   
                 
Date of index prescription  2000 – 2001  6  144627  4.15 (1.52 ‐ 9.03)  2.13  2.82 (1.27 ‐ 6.27)  1  0.732 
  2002 – 2003  12  178582  6.72 (3.47 ‐ 11.74)  2.63  4.57 (2.59 ‐ 8.04)  1.56 (0.59 ‐ 4.16)   
  2004 – 2005  17  189423  8.97 (5.23 ‐ 14.37)  2.79  6.10 (3.79 ‐ 9.81)  2.03 (0.80 ‐ 5.14)   
  2006 – 2007  15  189394  7.92 (4.43 ‐ 13.06)  2.78  5.39 (3.25 ‐ 8.94)  1.65 (0.63 ‐ 4.28)   
  2008 – 2009  15  182896  8.20 (4.59 ‐ 13.53)  2.69  5.58 (3.36 ‐ 9.26)  1.83 (0.71 ‐ 4.71)   
  2010 – 2011  15  161774  9.27 (5.19 ‐ 15.29)  2.30  6.52 (3.93 ‐ 10.82)  1.85 (0.70 ‐ 4.86)   
               
Prescriptions for other causes   None  17  450216  3.78 (2.20 ‐ 6.05)  6.58  2.58 (1.61 ‐ 4.15)  1  <0.001 
of cholestatic injury2  Rare cause  56  543010  10.31 (7.79 ‐ 13.39)  7.95  7.04 (5.42 ‐ 9.15)  3.24 (1.87 ‐ 5.59)   
More common cause  7  53470  13.09 (5.26 ‐ 26.97)  0.78  8.95 (4.27 ‐ 18.78)  3.69 (1.53 ‐ 8.89)   
               
Smoking status   Non‐smoker  29  467184  6.21 (4.16 ‐ 8.91)  6.84  4.24 (2.95 ‐ 6.10)  1  <0.001 
  Current smoker  10  260101  3.84 (1.84 ‐ 7.07)  3.81  2.63 (1.41 ‐ 4.88)  0.56 (0.26 ‐ 1.19)   
  Ex‐smoker  40  297657  13.44 (9.60 ‐ 18.30)  4.36  9.18 (6.73 ‐ 12.51)  2.20 (1.35 ‐ 3.57)   
  Unknown  1  21754  4.60 (0.12 ‐ 25.61)  0.31  3.18 (0.45 ‐ 22.61)  0.76 (0.10 ‐ 5.59)   
                 
BMI   <20  2  59374  3.37 (0.41 ‐ 12.17)  0.87  2.31 (0.58 ‐ 9.23)  1  0.03 
  20 – 25  34  303272  11.21 (7.76 ‐ 15.67)  4.44  7.66 (5.47 ‐ 10.72)  3.22 (0.77 ‐ 13.41)   
  25+  38  542418  7.01 (4.96 ‐ 9.62)  7.95  4.78 (3.48 ‐ 6.57)  1.94 (0.47 ‐ 8.06)   
  Unknown  6  141632  4.24 (1.55 ‐ 9.22)  2.06  2.91 (1.31 ‐ 6.47)  1.23 (0.25 ‐ 6.07)   
                 
Alcohol intake  Non‐drinker  6  117896  5.09 (1.87 ‐ 11.08)  1.72  3.48 (1.56 ‐ 7.75)  1  0.1 
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    # with outcome  Patients4  45‐day risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio (CI)  p‐value9 
    n=80  N=1046696           
  Ex‐drinker  2  33858  5.91 (0.72 ‐ 21.34)  0.49  4.05 (1.01 ‐ 16.20)  1.38 (0.27 ‐ 7.09)   
  Current NOS  5  33304  15.01 (4.87 ‐ 35.03)  0.49  10.29 (4.28 ‐ 24.72)  3.54 (1.03 ‐ 12.24)   
  2 or less u/d  21  169724  12.37 (7.66 ‐ 18.91)  2.48  8.45 (5.51 ‐ 12.96)  2.92 (1.10 ‐ 7.75)   
  3/6 u/d  31  465596  6.66 (4.52 ‐ 9.45)  6.82  4.54 (3.19 ‐ 6.46)  1.47 (0.57 ‐ 3.80)   
  >6 u/d  7  79808  8.77 (3.53 ‐ 18.07)  1.16  5.99 (2.86 ‐ 12.56)  2.04 (0.65 ‐ 6.42)   
  Unknown  8  146510  5.46 (2.36 ‐ 10.76)  2.14  3.75 (1.87 ‐ 7.49)  1.28 (0.42 ‐ 3.91)   
                 
Socioeconomic status  1 (Highest SES)  17  186791  9.10 (5.30 ‐ 14.57)  2.74  6.22 (3.86 – 10.00)  1  0.185 
  2  13  175505  7.41 (3.94 ‐ 12.67)  2.57  5.06 (2.94 ‐ 8.71)  0.74 (0.36 ‐ 1.56)   
  3  19  167976  11.31 (6.81 ‐ 17.66)  2.46  7.73 (4.93 ‐ 12.12)  1.23 (0.64 ‐ 2.36)   
  4  12  158966  7.55 (3.90 ‐ 13.19)  2.34  5.16 (2.93 ‐ 9.09)  0.83 (0.39 ‐ 1.73)   
  5 (Lowest SES)  7  121845  5.75 (2.31 ‐ 11.84)  1.78  3.93 (1.87 ‐ 8.25)  0.62 (0.26 ‐ 1.49)   
  Unknown  12  235613  5.09 (2.63 ‐ 8.90)  3.45  3.48 (1.98 ‐ 6.13)  0.48 (0.22 ‐ 1.05)   
                 
Ethnicity3  White  49  534140  9.17 (6.79 ‐ 12.13)  7.81  6.27 (4.74 ‐ 8.30)  1  0.016 
  South Asian  0  17497  0.00 (0.00 ‐ 21.08)  0.25  ‐  ‐   
  Black  1  10011  9.99 (0.25 ‐ 55.64)  0.15  6.86 (0.97 ‐  48.73)  1.06 (0.15 ‐ 7.64)   
  Other  0  7672  0.00 (0.00 ‐ 48.07)  0.11  ‐  ‐   
  Mixed  0  2630  0.00 (0.00 ‐ 140.16)  0.04  ‐  ‐   
  Not Stated  11  85336  12.89 (6.43 ‐ 23.06)  1.25  8.82 (4.88 ‐ 15.92)  1.40 (0.73 ‐ 2.68)   
  Unknown  19  389410  4.88 (2.94 ‐ 7.62)  5.70  3.33 (2.12 ‐ 5.22)  0.45 (0.26 ‐ 0.79)   
Note 1: age groups 18‐29, 30‐39, 40‐49 combined due to lack of events in the 18‐29 or 30‐39 age groups
Note 2: prescription counted if it occurred anytime from 1 month prior to index date or between index date and 
before end of follow‐up (see  Chapter 3 section 3.4.1.5) 
Note 3: Obtained from CPRD, unless none found, in which case from HES (see Chapter 3 section 3.4.1.5) 
Note 4: number of patients prescribed the drug 
Note 5: per 100000 patients prescribed the drug
Note 6: 95% confidence interval 
Note 7: 100000 person‐months at risk 
Note 8: per 100000 person months 
Note 9: p‐value results for LRT of an association over all categories of the variable 
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Chapter 5 Appendix Table 2c: Rates and crude rate ratios of cholestatic liver injury for co-variates of the flucloxacillin and cholestatic liver injury cohort, using the 
most sensitive/least specific CPRD algorithm cut-off score (1.63),  within those exposed to flucloxacillin or oxytetracycline during the 1 – 45 day period from first 
prescription 
    # with outcome  Patients4  45‐day risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio 
(CI) 
p‐value9 
    n=129  N=1046696           
Age at index date1  18 – 49  14  545975  2.56 (1.40 ‐ 4.30)  7.99  1.75 (1.04 ‐ 2.96)  1  <0.001 
  50 – 59  19  159448  11.92 (7.17 ‐ 18.61)  2.34  8.12 (5.18 ‐ 12.73)  5.12 (2.53 ‐ 10.36)   
  60 – 69  16  139597  11.46 (6.55 ‐ 18.61)  2.05  7.82 (4.79 ‐ 12.76)  5.00 (2.41 ‐ 10.40)   
  70 – 79  42  112655  37.28 (26.87 ‐ 50.39)  1.65  25.47 (18.82 ‐ 34.46)  15.26 (8.16 ‐ 28.53)   
  80+  38  89021  42.69 (30.21 ‐ 58.59)  1.29  29.46 (21.43 ‐ 40.48)  15.70 (8.28 ‐ 29.75)   
                 
Gender  Male  47  475441  9.89 (7.26 ‐ 13.15)  6.96  6.75 (5.07 ‐ 8.98)  1  0.03 
  Female  82  571255  14.35 (11.42 ‐ 17.82)  8.35  9.82 (7.91 ‐ 12.19)  1.50 (1.03 ‐ 2.17)   
                 
Date of index prescription  2000 – 2001  11  144627  7.61 (3.80 ‐ 13.61)  2.13  5.17 (2.86 ‐ 9.33)  1  0.671 
  2002 – 2003  20  178582  11.20 (6.84 ‐ 17.30)  2.63  7.61 (4.91 ‐ 11.80)  1.35 (0.64 ‐ 2.83)   
  2004 – 2005  26  189423  13.73 (8.97 ‐ 20.11)  2.79  9.33 (6.35 ‐ 13.70)  1.63 (0.80 ‐ 3.31)   
  2006 – 2007  28  189394  14.78 (9.82 ‐ 21.37)  2.78  10.06 (6.94 ‐ 14.56)  1.73 (0.86 ‐ 3.49)   
  2008 – 2009  21  182896  11.48 (7.11 ‐ 17.55)  2.69  7.81 (5.09 ‐ 11.98)  1.33 (0.64 ‐ 2.77)   
  2010 – 2011  23  161774  14.22 (9.01 ‐ 21.33)  2.30  10.00 (6.65 ‐ 15.05)  1.55 (0.74 ‐ 3.23)   
             
Prescriptions for other causes   None  35  450216  7.77 (5.41 ‐ 10.81)  6.58  5.32 (3.82 ‐ 7.41)  1  <0.001 
of cholestatic injury2  Rare cause  84  543010  15.47 (12.34 ‐ 19.15)  7.95  10.56 (8.53 ‐ 13.08)  2.28 (1.53 ‐ 3.41)   
More common cause  10  53470  18.70 (8.97 ‐ 34.39)  0.78  12.79 (6.88 ‐ 23.77)  2.56 (1.27 ‐ 5.17)   
             
Smoking status   Non‐smoker  49  467184  10.49 (7.76 ‐ 13.87)  6.84  7.17 (5.42 ‐ 9.48)  1  0.001 
  Current smoker  23  260101  8.84 (5.61 ‐ 13.27)  3.81  6.04 (4.01 ‐ 9.09)  0.80 (0.48 ‐ 1.33)   
  Ex‐smoker  56  297657  18.81 (14.21 ‐ 24.43)  4.36  12.85 (9.89 ‐ 16.70)  1.85 (1.25 ‐ 2.74)   
  Unknown  1  21754  4.60 (0.12 ‐ 25.61)  0.31  3.18 (0.45 ‐ 22.61)  0.46 (0.06 ‐ 3.36)   
                 
BMI   <20  8  59374  13.47 (5.82 ‐ 26.55)  0.87  9.24 (4.62 ‐ 18.47)  1  0.002 
  20 – 25  53  303272  17.48 (13.09 ‐ 22.86)  4.44  11.94 (9.13 ‐ 15.63)  1.24 (0.59 ‐ 2.62)   
  25+  60  542418  11.06 (8.44 ‐ 14.24)  7.95  7.55 (5.86 ‐ 9.72)  0.75 (0.36 ‐ 1.58)   
  Unknown  8  141632  5.65 (2.44 ‐ 11.13)  2.06  3.88 (1.94 ‐ 7.75)  0.36 (0.13 ‐ 0.99)   
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    # with outcome  Patients4  45‐day risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio 
(CI) 
p‐value9 
    n=129  N=1046696           
             
Alcohol intake  Non‐drinker  11  117896  9.33 (4.66 ‐ 16.69)  1.72  6.38 (3.53 ‐ 11.53)  1  0.032 
  Ex‐drinker  3  33858  8.86 (1.83 ‐ 25.89)  0.49  6.08 (1.96 ‐ 18.84)  1.15 (0.31 ‐ 4.24)   
  Current NOS  7  33304  21.02 (8.45 ‐ 43.30)  0.49  14.40 (6.87 ‐ 30.21)  2.76 (1.03 ‐ 7.40)   
  2 or less u/d  35  169724  20.62 (14.36 ‐ 28.68)  2.48  14.09 (10.12 ‐ 19.62)  2.55 (1.22 ‐ 5.33)   
  3/6 u/d  52  465596  11.17 (8.34 ‐ 14.65)  6.82  7.62 (5.81 – 10.00)  1.38 (0.68 ‐ 2.81)   
  >6 u/d  9  79808  11.28 (5.16 ‐ 21.41)  1.16  7.70 (4.01 ‐ 14.80)  1.45 (0.58 ‐ 3.67)   
  Unknown  12  146510  8.19 (4.23 ‐ 14.31)  2.14  5.62 (3.19 ‐ 9.90)  1.07 (0.45 ‐ 2.53)   
             
Socioeconomic status  1 (Highest SES)  23  186791  12.31 (7.81 ‐ 18.48)  2.74  8.41 (5.59 ‐ 12.65)  1  0.866 
  2  21  175505  11.97 (7.41 ‐ 18.29)  2.57  8.17 (5.33 ‐ 12.54)  0.87 (0.47 ‐ 1.60)   
  3  25  167976  14.88 (9.63 ‐ 21.97)  2.46  10.17 (6.88 ‐ 15.06)  1.19 (0.68 ‐ 2.10)   
  4  18  158966  11.32 (6.71 ‐ 17.89)  2.34  7.74 (4.88 ‐ 12.29)  0.86 (0.46 ‐ 1.62)   
  5 (Lowest SES)  15  121845  12.31 (6.89 ‐ 20.30)  1.78  8.43 (5.08 ‐ 13.98)  0.91 (0.47 ‐ 1.77)   
  Unknown  27  235613  11.46 (7.55 ‐ 16.67)  3.45  7.83 (5.37 ‐ 11.41)  0.85 (0.48 ‐ 1.51)   
                 
Ethnicity3  White  79  534140  14.79 (11.71 ‐ 18.43)  7.81  10.11 (8.11 ‐ 12.60)  1  0.026 
  South Asian  0  17497  0.00 (0.00 ‐ 21.08)  0.25  ‐  ‐   
  Black  1  10011  9.99 (0.25 ‐ 55.64)  0.15  6.86 (0.97 ‐ 48.73)  0.68 (0.09 ‐ 4.89)   
  Other  0  7672  0.00 (0.00 ‐ 48.07)  0.11  ‐  ‐   
  Mixed  0  2630  0.00 (0.00 ‐ 140.16)  0.04  ‐  ‐   
  Not Stated  13  85336  15.23 (8.11 ‐ 26.05)  1.25  10.42 (6.05 ‐ 17.95)  1.06 (0.59 ‐ 1.92)   
  Unknown  36  389410  9.24 (6.47 ‐ 12.80)  5.70  6.31 (4.55 ‐ 8.75)  0.58 (0.38 ‐ 0.88)   
Note 1: age groups 18‐29, 30‐39, 40‐49 combined due to lack of events in the 18‐29 or 30‐39 age groups
Note 2: prescription counted if it occurred anytime from 1 month prior to index date or between index date and 
before end of follow‐up (see  Chapter 3 section 3.4.1.5) 
Note 3: Obtained from CPRD, unless none found, in which case from HES (see Chapter 3 section 3.4.1.5) 
Note 4: number of patients prescribed the drug 
Note 5: per 100000 patients prescribed the drug
Note 6: 95% confidence interval 
Note 7: 100000 person‐months at risk 
Note 8: per 100000 person months 
Note 9: p‐value results for LRT of an association over all categories of the variable 
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Chapter 5 Appendix Table 2d: Rates and crude rate ratios of cholestatic liver injury for co-variates of the flucloxacillin and cholestatic liver injury cohort, using 
the multisource algorithm (within those exposed to flucloxacillin or oxytetracycline during the 1 – 45 day period from first prescription) 
    # with outcome  Patients4  Risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio (CI)  p‐value9 
    n=46  N=621476           
Age at index date1  18 – 49  2  324787  0.62 (0.07 ‐ 2.22)  4.75  0.42 (0.11 ‐ 1.68)  1  <0.001 
  50 – 59  6  93844  6.39 (2.35 ‐ 13.92)  1.38  4.35 (1.96 ‐ 9.69)  10.35 (2.09 ‐ 51.27)   
  60 – 69  4  81905  4.88 (1.33 ‐ 12.50)  1.20  3.33 (1.25 ‐ 8.88)  7.92 (1.45 ‐ 43.22)   
  70 – 79  16  66771  23.96 (13.70 ‐ 38.91)  0.98  16.36 (10.03 ‐ 26.71)  38.88 (8.94 ‐ 169.12)   
  80+  18  54169  33.23 (19.69 ‐ 52.51)  0.78  22.93 (14.45 ‐ 36.40)  54.49 (12.64 ‐ 234.86)   
                 
Gender  Male  21  281297  7.47 (4.62 ‐ 11.41)  4.12  5.10 (3.32 ‐ 7.82)  1  0.963 
  Female  25  340179  7.35 (4.76 ‐ 10.85)  4.97  5.03 (3.40 ‐ 7.44)  0.99 (0.55 ‐ 1.76)   
                 
Date of index prescription  2000 – 2001  2  87546  2.28 (0.28 ‐ 8.25)  1.28  1.55 (0.39 ‐ 6.20)  1  0.353 
  2002 – 2003  10  106387  9.40 (4.51 ‐ 17.29)  1.56  6.39 (3.44 ‐ 11.88)  4.11 (0.90 ‐ 18.78)   
  2004 – 2005  9  108979  8.26 (3.78 ‐ 15.68)  1.60  5.61 (2.92 ‐ 10.79)  3.62 (0.78 ‐ 16.74)   
  2006 – 2007  10  111594  8.96 (4.30 ‐ 16.48)  1.64  6.09 (3.28 ‐ 11.32)  3.93 (0.86 ‐ 17.92)   
  2008 – 2009  7  109756  6.38 (2.56 ‐ 13.14)  1.61  4.34 (2.07 ‐ 9.10)  2.80 (0.58 ‐ 13.46)   
  2010 – 2011  8  97214  8.23 (3.55 ‐ 16.21)  1.38  5.79 (2.90 ‐ 11.59)  3.73 (0.79 ‐ 17.58)   
             
Prescriptions for other causes   None  9  273066  3.30 (1.51 ‐ 6.26)  3.99  2.25 (1.17 ‐ 4.33)  1  0.002 
of cholestatic injury2  Rare cause  34  318321  10.68 (7.40 ‐ 14.93)  4.66  7.29 (5.21 ‐ 10.21)  3.23 (1.55 ‐ 6.74)   
More common cause  3  30089  9.97 (2.06 ‐ 29.14)  0.43  6.82 (2.20 ‐ 21.16)  3.03 (0.82 ‐ 11.18)   
             
Smoking status   Non‐smoker  13  276770  4.70 (2.50 ‐ 8.03)  4.05    3.21 (1.86 ‐ 5.53)  1  0.003 
  Current smoker  8  151743  5.27 (2.28 ‐ 10.39)  2.22  3.60 (1.80 ‐ 7.20)  1.12 (0.46 ‐ 2.71)   
  Ex‐smoker  25  180907  13.82 (8.94 ‐ 20.40)  2.65  9.44 (6.38 ‐ 13.97)  2.94 (1.50 ‐ 5.75)   
  Unknown  0  12056  0.00 (0.00 ‐ 30.59)  0.17  ‐  ‐   
                 
BMI   <20  3  36049  8.32 (1.72 ‐ 24.32)  5.71  5.71 (1.84 ‐ 17.69)  1  0.024 
  20 – 25  23  183426  12.54 (7.95 ‐ 18.81)  8.56  8.57 (5.69 ‐ 12.89)  1.50 (0.45 ‐ 5.00)   
  25+  17  319026  5.33 (3.10 ‐ 8.53)  3.63  3.64 (2.26 ‐ 5.85)  0.64 (0.19 ‐ 2.17)   
  Unknown  3  82975  3.62 (0.75 ‐ 10.57)  2.48  2.481 (0.80 ‐ 7.69)  0.43 (0.09 ‐ 2.15)   
             
Alcohol intake  Non‐drinker  3  65076  4.61 (0.95 ‐ 13.47)  0.95  3.16 (1.02 ‐ 9.789)  1  0.107 
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    # with outcome  Patients4  Risk5 (CI6)  PMAR7  Rate8 (CI)  Crude Rate Ratio (CI)  p‐value9 
    n=46  N=621476           
  Ex‐drinker  0  20383  0.00 (0.00 ‐ 18.10)  0.30  ‐  ‐   
  Current NOS  4  20585  19.43 (5.29 ‐ 49.75)  0.30  13.32 (4.99 ‐ 35.49)  4.22 (0.94 ‐ 18.85)   
  2 or less u/d  12  96348  12.45 (6.44 ‐ 21.76)  1.41  8.51 (4.83 ‐ 14.99)  2.70 (0.76 ‐ 9.55)   
  3/6 u/d  20  285307  7.01 (4.28 ‐ 10.83)  4.18  4.78 (3.08 ‐ 7.41)  1.51 (0.45 ‐ 5.10)   
  >6 u/d  3  48911  6.13 (1.26 ‐ 17.92)  0.72  4.19 (1.35 ‐ 12.98)  1.33 (0.27 ‐ 6.57)   
  Unknown  4  84866  4.71 (1.28 ‐ 12.07)  1.23  3.23 (1.21 ‐ 8.62)  1.02 (0.23 ‐ 4.58)   
             
Socioeconomic status  1 (Highest SES)  12  144252  8.32 (4.30 ‐ 14.53)  2.11  5.68 (3.23 ‐ 10.00)  1  0.89 
  2  10  145426  6.88 (3.30 ‐ 12.65)  2.13  4.70 (2.53 ‐ 8.73)  0.83 (0.36 ‐ 1.91)   
  3  11  123932  8.88 (4.43 ‐ 15.88)  1.81  6.07 (3.36 ‐ 10.96)  1.07 (0.47 ‐ 2.42)   
  4  8  115704  6.91 (2.99 ‐ 13.62)  1.69  4.73 (2.36 ‐ 9.45)  0.83 (0.34 ‐ 2.04)   
  5 (Lowest SES)  5  92162  5.43 (1.76 ‐ 12.66)  1.35  3.71 (1.54 ‐ 8.92)  0.65 (0.23 ‐ 1.86)   
             
Ethnicity3  White  35  425809  8.22 (5.73 ‐ 11.43)  6.23  5.62 (4.03 – 7.82)  1  0.079 
  South Asian  0  13640  0.00 (0.00 ‐ 27.04)  0.20  ‐  ‐   
  Black  0  7836  0.00 (0.00 ‐ 47.06)  0.11  ‐  ‐   
  Other  0  5639  0.00 (0.00 ‐ 65.40)  0.08  ‐  ‐   
  Mixed  0  2094  0.00 (0.00 ‐ 176.01)  0.03  ‐  ‐   
  Not Stated  9  74128  12.14 (5.55 ‐ 23.05)  1.08  8.30 (4.32 – 15.96)  1.48 (0.71 ‐ 3.08)   
  Unknown  2  92330  2.17 (0.26 ‐ 7.82)  1.35  1.48 (0.37 – 5.90)  0.26 (0.06 ‐ 1.09)   
Note 1: age groups 18‐29, 30‐39, 40‐49 combined due to lack of events in the 18‐29 or 30‐39 age groups
Note 2: prescription counted if it occurred anytime from 1 month prior to index date or between index date and 
before end of follow‐up (see  Chapter 3 section 3.4.1.5) 
Note 3: Obtained from CPRD, unless none found, in which case from HES (see Chapter 3 section 3.4.1.5) 
Note 4: number of patients prescribed the drug 
Note 5: per 100000 patients prescribed the drug
Note 6: 95% confidence interval 
Note 7: 100000 person‐months at risk 
Note 8: per 100000 person months 
Note 9: p‐value results for LRT of an association over all categories of the variable 
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Chapter 5 Appendix Table 3 
Results of classical (Mantel Haenszel) analysis of the association between flucloxacillin and cholestatic liver injury, using three different CPRD algorithm 
outcome definitions and the multisource algorithm 
  CPRD algorithm (score 5)    CPRD algorithm (score 2.29)    CPRD algorithm (score 1.63)    Multisource algorithm 
  Rate Ratio (CI1)  p‐value2    Rate Ratio (CI)  p‐value    Rate Ratio (CI)  p‐value    Rate Ratio (CI)  p‐value 
Crude  3.79 (1.19 – 12.13)  ‐    5.51 (1.74 – 17.46)  ‐    3.74 (1.75 – 8.01)  ‐    9.02 (1.24 – 65.48)  ‐ 
                     
Age at index date3  3.65 (1.16 – 11.51)  0.634    5.35 (1.72 – 16.68)  0.553    3.65 (1.72 – 7.73)  0.201    8.64 (1.20 – 62.42)  <0.001 
18 – 49  ‐    ‐      2.65 (0.35 – 20.26)      0.19 (0.01 – 3.06)   
50 – 59  ‐    ‐      ‐      ‐   
60 – 69  ‐    ‐      ‐      ‐   
70 – 79  4.64 (0.62 – 34.59)    5.57 (0.75 – 41.17)      4.64 (1.12 – 19.21)      ‐   
80+  1.50 (0.35 – 6.47)    2.08 (0.49 – 8.80)      1.42 (0.50 – 3.99)      ‐   
Gender  3.81 (1.19 – 12.20)  0.872    5.54 (1.75 – 17.58)  0.924    3.76 (1.76 – 8.06)  0.651    8.98 (1.25 – 64.69)  0.256 
Male  4.34 (0.58 – 32.24)    5.99 (0.82 – 43.96)      3.03 (0.94 – 9.75)      3.87 (0.52 – 28.84)   
Female  3.54 (0.85 – 14.79)      5.32 (1.29 – 21.87)      4.32 (1.58 – 11.80)         
Date of index prescription  3.57 (1.13 – 11.30)  0.339    5.26 (1.68 – 16.47)  0.221    3.62 (1.70 – 7.71)  0.489    8.94 (1.20 – 66.80)  0.690 
2000 – 2001  ‐    ‐      ‐      ‐   
2002 – 2003  ‐    ‐      4.61 (0.62 – 34.42)      2.06 (0.26 – 16.22)   
2004 – 2005  ‐    ‐      5.21 (0.71 – 38.42)      ‐   
2006 – 2007  2.08 (0.27 – 16.12)    2.65 (0.35 – 20.14)      5.11 (0.69 – 37.59)      ‐   
2008 – 2009  ‐    ‐      3.81 (0.51 – 28.37)      ‐   
2010 – 2011  0.94 (0.20 – 4.27)    1.22 (0.27 – 5.39)      1.25 (0.37 – 4.20)      ‐   
Prescriptions for other causes                      
of cholestatic injury2  5.16 (1.58 – 16.89)  0.844    7.34 (2.27 – 23.80)  0.819    4.72 (2.16 – 10.32)  0.565    12.62 (1.69 – 94.11)  0.952 
None  ‐    ‐      ‐      ‐   
Rare cause  4.54 (1.40 – 14.72)    6.34 (1.98 – 20.28)      3.95 (1.82 – 8.55)      11.29 (1.54 – 82.54)   
More common cause  ‐    ‐      ‐      ‐   
Smoking status   3.87 (1.22 – 12.32)  0.689    6.22 (0.85 – 45.74)  0.631    3.80 (1.78 – 8.12)  0.713    8.98 (1.28 – 63.20)  0.056 
Non‐smoker  3.56 (0.47 – 26.81)    1.69 (0.21 – 13.31)      3.41 (1.06 – 10.96)      ‐   
Current smoker  1.31 (0.16 – 10.66)    8.92 (1.23 – 64.90)      1.97 (0.46 – 8.39)      1.21 (0.15 – 9.82)   
Ex‐smoker  6.63 (0.90 – 48.67)    ‐      6.17 (1.51 – 25.32)      ‐   
Unknown   ‐          ‐      ‐   
 263 
 
  CPRD algorithm (score 5)    CPRD algorithm (score 2.29)    CPRD algorithm (score 1.63)    Multisource algorithm 
  Rate Ratio (CI1)  p‐value2    Rate Ratio (CI)  p‐value    Rate Ratio (CI)  p‐value    Rate Ratio (CI)  p‐value 
BMI   3.82 (1.19 – 12.23)  0.866    5.57 (1.76 – 17.67)  0.888    3.78 (1.77 – 8.09)  0.564    9.29 (1.27 – 67.84)  0.813 
<20  ‐    ‐      ‐      ‐   
20 – 25  4.96 (0.67 – 36.78)    7.44 (1.02 – 54.38)      5.75 (1.40 – 23.61)      5.12 (0.69 – 37.83)   
25+  2.56 (0.60 – 10.82)    3.84 (0.92 – 15.93)      2.98 (1.08 – 8.23)      ‐   
Unknown  ‐    ‐      1.35 (0.17 – 10.99)      ‐   
Alcohol intake  3.81 (1.19 – 12.22)  0.508    5.53 (1.74 – 17.57)  0.544    3.76 (1.76 – 8.07)  0.519    9.11 (1.25 – 66.53)  0.939 
Non‐drinker  0.65 (0.07 – 6.20)      1.08 (0.13 – 9.21)      0.97 (0.21 – 4.48)      ‐   
Ex‐drinker  ‐      ‐      ‐      ‐   
Current unknown  ‐      ‐      ‐      ‐   
2 or less u/d  ‐      ‐      3.61 (0.87 – 15.04)      ‐   
3‐6 u/d  2.21 (0.52 – 9.43)      3.20 (0.76 – 13.40)      3.60 (1.12 – 11.56)      3.96 (0.53 – 29.60)   
Over 6u/d  ‐      ‐      ‐      ‐   
Unknown  ‐      ‐      ‐      ‐   
Socioeconomic status  3.80 (1.17 – 12.32)  0.245    5.52 (1.72 – 17.71)  0.216    3.74 (1.74 – 8.04)  0.461    9.12 (1.25 – 66.57)  0.471 
1 (Least deprived)  ‐    ‐      ‐      ‐   
2  1.65 (0.21 – 13.17)    2.47 (0.32 – 19.00)      1.96 (0.46 – 8.40)      1.88 (0.24 – 14.84)   
3  ‐    ‐      ‐      ‐   
4  ‐    ‐      3.57 (0.48 – 26.86)      ‐   
5 (Most deprived)  ‐    ‐      2.61 (0.34 – 19.87)      ‐   
Unknown  0.88 (0.18 – 4.22)    1.25 (0.27 – 5.72)      2.00 (0.60 – 6.66)      ‐   
Ethnicity  3.78 (1.17 – 12.15)  0.028    5.49 (1.73 – 17.49)  0.023    3.73 (1.74 – 8.01)  0.361    8.94 (1.23 – 64.85)  0.851 
White  ‐      ‐      5.38 (1.70 – 17.05)      6.75(0.92 – 49.28)   
South Asian  ‐      ‐      ‐      ‐   
Black  ‐      ‐      ‐      ‐   
Other  ‐      ‐      ‐      ‐   
Mixed  ‐      ‐      ‐      ‐   
Not Stated  ‐      ‐      ‐      ‐   
Unknown  0.81 (0.23 – 2.91)      1.18 (0.34 – 4.06)      1.77 (0.63 – 5.01)      ‐   
Note 1: 95% confident interval
Note 2: p‐value of test of homogeneity across categories of variable 
Note 3: For this and all subsequent variables in the table, the overall RR controlled for the variable is presented on the first row. Stratum specific estimates are presented in addition to the overall estimate for 2 reasons: (1) 
important differences between strata can be observed (which could indicate effect modification, with p‐value also being considered) (2) to see the effect of the different algorithm score cut‐off on availability of data for each 
strata. Rows with a “‐“ indicate a lack of individuals with the outcome in both or either of the exposure groups for that variable category.
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Chapter 5 Appendix Table 4 
Reasons why people considered as cases of cholestatic liver injury were subsequently considered as exclusions, following close review of electronic health record (from 
two years prior to index until injury date) for (i) the complete CPRD cohort (ii) the subset of the cohort linked to HES (iii) the subset of the cohort not linked to HES 
 
  Complete CPRD cohort  
N total exclusions=89 (100%) 
HES‐linked subset 
N=27 (30%) 
Subset not linked to HES 
N=62 (70%) 
Reason for exclusion1  n (%)    n (%)      n (%) 
Abdominal pain pre‐index2 1 (1) 0  1 (2)
Alcoholic  12 (13) 0  12 (19)
Cancer  18 (20) 4 (15) 14 (23)
Cholangitis  6 (7) 4 (15) 2 (3)
Data entry error 1 (1) 0  1 (2)
Gallstone  2 (2) 2 (7)  0
Heart failure  6 (7) 1 (4)  5 (8)
Hepatitis A  2 (2) 1 (4)  1 (2)
Unwell pre‐index3 17 (19) 7 (26) 10 (16)
Infective hepatitis 4 (4) 2 (7)  2 (3)
Kidney disease 1 (1) 0  1 (2)
Lack of info  4 (4) 0  4 (6)
Pancreatitis  2 (2) 1 (4)  1 (2)
Same day4  13 (15) 5 (19) 8 (13)
Note 1: Reasons may include more than one CPRD diagnostic code that have been grouped under a more general heading in this table 
Note 2: A code of abdominal pain was present leading up to the injury date, and before the index date (prescription with study drug) 
Note 3: Codes indicating that the patient was generally unwell leading up to the injury date and before the index date were present 
Note 4: Liver related diagnosis was on the index date (prescription date), so a cause other than the drug(s) under study considered more likely
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Chapter 5 Appendix Table 5 
Example questionnaire for obtaining verification from a patient’s clinician in relation to their case 
status, when using a relatively non-specific, high sensitivity method for identifying cases of 
cholestatic liver injury in CPRD when recruiting to genetic association studies 
Dear General Practitioner, 
Re: confirmation of [drugsubstancename]‐induced cholestatic liver injury 
The Clinical Practice Research Database (CPRD) research group at the UK MHRA is researching the genetic 
predisposition to adverse drug reactions. 
We are currently using CPRD records to identify individuals who have experienced cholestatic liver injury as a result 
of therapy with [drugsubstancename], so that these individuals might be recruited for genetic analysis of this 
adverse drug reaction. 
Based upon codes in the medical record, the following patient from your practice has been identified as a potential 
case of [drugsubstancename]‐induced liver injury: 
Patient identifier: [whatever patient identifier CPRD use for questionnaires] 
CPRD record of potential [drugsubstancename]‐induced liver injury: 
CPRD record  Description  Date 
Therapy  [drugsubstancename]  20/06/2010 
Clinical diagnosis  Jaundice  02/07/2010 
We would be grateful if you could answer the following questions in order to help us confirm whether these records 
represent a true case of [drugsubstancename]‐induced cholestatic liver injury for this patient. 
1. Has this patient ever been referred to a liver 
specialist? If yes, we would be grateful if you could 
provide any letters from the specialist. 
□  Yes – please provide letters  
□  No      
2. Based upon your knowledge of this patient, do you 
consider the events indicated by the above records to 
represent liver injury caused by [drugsubstancename] 
therapy?  
□  Yes  □   No* 
□  Unsure* 
*If “No or Unsure” to question 2., please indicate which of the following are likely to have led to (or may have 
possibly contributed to) the clinical and test records detailed above: 
□  Alcoholism  □ HIV infection 
□  Cancer of the liver, pancreas or 
gallbladder 
□ Inflammatory bowel disease 
□  Cholecystitis  □ Drug other than [drugsubstancename] (please 
specify):______________________________ 
□  Cholelithiasis  □ Pancreatic disease 
□  Cirrhosis  □ Pregnancy 
□  Congestive heart failure  □ Pre‐existing chronic liver disease 
□  Gallbladder disease  □ Viral hepatitis 
□  Other reason (please specify):   
___________________________________________________________________________
_____________________________________________________________ 
____________________________________________________________________ 
 
Please send the completed questionnaire back using the addressed envelope provided 
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Chapter 6 Appendix 
Chapter 6 Appendix Table 1 
Chapter 6 Appendix Table 1a: Association between drug exposures and cholestatic liver injury 
(low-specificity algorithm) by prescription with other hepatotoxic drugs 
 
    Multivariable RR1 (95% CI2) by prescription with other hepatotoxic drugs 
    Not prescribed 
another cause of 
liver injury 
Prescription for less 
common cause 
Prescription for more 
common cause 
       
Carbamazepine3  Never users  1 1 1 
  Current users  1.66 (1.23 – 2.25) 1.03 (0.75 – 1.41) 0.40 (0.23 – 0.67)
  Recent users  1.35 (0.44 – 4.09) 1.66 (0.60 – 4.61) 0.51 (0.03 – 8.23)
  Past users  1.33 (1.06 – 1.69) 0.95 (0.81 – 1.11) 0.69 (0.48 – 0.98)
       
Celecoxib4  Never users  1 1 1 
  Current users  1.60 (1.07 – 2.38) 0.59 (0.34 – 0.86) 0.84 (0.27 – 2.59)
  Recent users  3.57 (1.48 – 8.77) 1.47 (0.72 – 2.99) 1.14 (0.25 – 5.17)
  Past users  1.22 (1.00 – 1.49) 0.95 (0.84 – 1.06) 1.23 (0.89 – 1.72)
       
       
Ramipril5  Never users  1 1 1 
  Current users  1.59 (1.41 – 1.79) 0.92 (0.83 – 1.02) 1.09 (0.82 – 1.45)
  Recent users  1.15 (0.51 – 2.61) 2.00 (1.30 – 3.07) 1.27 (0.25 – 6.38)
  Past users  1.51 (0.51 – 2.61) 0.91 (0.82 – 1.02) 0.76 (0.56 – 1.05)
         
Risperidone6   Never users  1 1 1 
  Current users  3.22 (2.20 – 4.73) 1.38 (0.86 – 2.17) 1.14 (0.54 – 2.41)
  Recent users  3.57 (0.49 – 25.98) 0.55 (0.06 – 4.61) 1.54 (0.13 – 17.81)
  Past users  2.24 (1.39 – 3.59) 1.17 (0.85 – 1.61) 0.67 (0.36 – 1.22)
       
Flucloxacillin7   Never users  1 1 1 
  Current users  3.73 (2.92 – 4.77) 1.73 (0.56 – 5.28) 1.47 (0.43 – 5.08)
  Recent users  6.25 (5.32 – 7.33) 1.89 (0.88 – 4.08) 0.96 (0.44 – 2.06)
  Past users  1.24 (1.17 – 1.32) 1.08 (1.03 – 1.13) 0.84 (0.71 – 1.00)
1Multivariable rate ratio, with adjustments as described in Table 2 
295% confidence interval 
3p‐value for Likelihood Ratio Test of interaction for carbamazepine: 
4p‐value for Likelihood Ratio Test of interaction for celecoxib: 
5p‐value for Likelihood Ratio Test of interaction for ramipril: 
6p‐value for Likelihood Ratio Test of interaction for risperidone: 
7p‐value for Likelihood Ratio Test of interaction for flucloxacillin:
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Chapter 6 Appendix Table 1b: Association between drug exposures and cholestatic liver 
injury (low-specificity algorithm) by age at date of liver injury  
    Multivariable RR1 (95% CI2)  by age at date of liver injury
    18 ‐ 49 50 ‐ 69 70+
   
Celecoxib1  Never users  1 1 1 
  Current users 3.72 (1.29 – 10.73) 0.74 (0.45 – 1.23)  0.89 (0.59 – 1.33)
  Recent users  18.50 (1.90 –
179.67)  2.13 (0.87 – 5.21)  1.34 (0.64 – 2.79) 
  Past users  0.83 (0.53 – 1.30) 0.90 (0.75 – 1.08)  1.10 (0.98 – 1.24)
 
Duloxetine2  Never users  1 1 1 
  Current users 3.54 (1.18 – 10.60) 1.94 (0.96 – 3.91)  0.37 (0.09 – 1.64)
  Recent users 
1.57 (0.26 – 9.53) 
1.45 (0.12 –
17.16)  1.57 (0.26 – 9.53) 
  Past users  1.18 (0.51 – 2.74) 0.93 (0.46 – 1.90)  0.54 (0.26 – 1.12)
   
Ramipril3  Never users  1 1 1 
  Current users 1.92 (1.32 – 2.79) 1.29 (1.13 – 1.47)  1.01 (0.91 – 1.12)
Recent users  1.99 (0.54 – 7.29) 2.27 (1.19 – 4.34)  1.46 (0.91 – 2.36)
Past users  1.52 (0.96 – 2.41) 1.04 (0.87 – 1.23)  0.94 (0.84 – 1.05)
       
Risperidone4   Never users  1 1 1 
  Current users 4.79 (2.35 – 9.76) 2.91 (1.63 – 5.20)  1.38 (0.94 – 2.03)
Recent users 
‐ 
1.91 (0.17 –
21.57)  0.83 (0.20 – 3.52) 
Past users  1.49 (0.87 – 2.54) 1.30 (0.76 – 2.22)  1.13 (0.80 – 1.59)
   
Flucloxacillin5   Never users  1 1 1 
  Current users 4.20 (2.44 – 7.25) 5.01 (3.31 – 7.60)  2.48 (1.75 – 3.52)
Recent users  2.75 (1.85 – 4.10) 7.07 (5.24 – 9.54)  5.89 (4.80 – 7.22)
Past users  1.21 (1.11 – 1.31) 1.18 (1.11 – 1.26)  1.05 (0.99 – 1.11)
1Multivariable rate ratio, with adjustments as described in Table 2 
295% confidence interval 
3p‐value for Likelihood Ratio Test of interaction for celecoxib: 
4p‐value for Likelihood Ratio Test of interaction for ramipril: 
5p‐value for Likelihood Ratio Test of interaction for risperidone: 
6p‐value for Likelihood Ratio Test of interaction for flucloxacillin:
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Chapter 6 Appendix Table 1c: Association between drug exposures and cholestatic liver injury (low-specificity algorithm) by ethnicity 
  Multivariable RR1 (95% CI2) by ethnicity
  White  South Asian Black Other  Mixed Not stated Unknown
                 
Duloxetine3  Never users  1  1  1  1  1  1  1 
  Current users  1.69 (0.85 – 3.36)  ‐  1.69 (0.85 – 3.36)  1.69 (0.85 – 3.36)  1.69 (0.85 – 3.36)  0.26 (0.03 – 2.30)  1.92 (0.78 – 4.77) 
  Recent users  0.61 (0.06 – 5.94)  0.61 (0.06 – 5.94)  0.61 (0.06 – 5.94)  0.61 (0.06 – 5.94)  0.61 (0.06 – 5.94)  0.61 (0.06 – 5.94)  5.11 (0.45 – 58.14) 
  Past users  0.44 (0.22 – 0.88)  0.44 (0.22 – 0.88)  0.44 (0.22 – 0.88)  ‐  0.44 (0.22 – 0.88)  0.42 (0.04 – 4.03)  1.65 (0.89 – 3.07) 
                 
Ramipril4  Never users  1  1  1  1  1  1  1 
  Current users  1.07 (0.97 – 1.19)  1.15 (0.50 – 2.61)  1.56 (0.57 – 4.27)  0.83 (0.22 – 3.11)  ‐  0.85 (0.64 – 1.11)  1.32 (1.15 – 1.50) 
  Recent users  1.61 (1.01 – 2.55)  4.72 (0.61 – 36.51)  1.61 (1.01 – 2.55)  1.61 (1.01 – 2.55)  1.61 (1.01 – 2.55)  2.86 (0.85 – 9.77)  1.55 (0.74 – 3.24) 
  Past users  0.91 (0.80 – 1.03)  0.67 (0.24 – 1.88)  0.96 (0.20 – 4.51)  ‐  1.30 (0.13 – 13.42)  0.88 (0.64 – 1.21)  1.20 (1.02 – 1.40) 
                 
Risperidone5  Never users  1  1  1  1  1  1  1 
  Current users  1.93 (1.31 – 2.84)  26.06 (2.78 – 244.21)  7.60 (0.44 – 130.67)  1.93 (1.31 – 2.84)  1.93 (1.31 – 2.84)  4.11 (1.72 – 9.81)  1.40 (0.83 – 2.36) 
  Recent users  ‐  ‐  ‐  ‐  ‐  0.64 (0.05 – 8.52)  3.01 (0.55 – 16.30) 
  Past users  1.20 (0.84 – 1.71)  7.08 (1.02 – 49.02)  1.50 (0.14 – 16.39)  ‐  ‐  0.88 (0.36 – 2.08)  1.31 (0.87 – 1.98) 
1Multivariable rate ratio, with adjustments as described in Table 2 
295% confidence interval 
3p‐value for Likelihood Ratio Test of interaction for duloxetine: 
4p‐value for Likelihood Ratio Test of interaction for ramipril: 
5p‐value for Likelihood Ratio Test of interaction for risperidone: 
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Chapter 6 Appendix Table 2 
Chapter 6 Appendix Table 2a Characteristics of participants included in the case-control 
analysis by exposure to risperidone  
  Not exposed to 
risperidone 
(N=96771) 
Exposed to 
risperidone 
(N=596) 
  n (%)  n (%)
Age at index date  18 – 29 5283 (5)  19 (3)
  30 – 39 6738 (7)  28 (5)
  40 – 49 9922 (10)  56 (9)
  50 – 59 13917 (14)  51 (9)
  60 – 69 19300 (20)  79 (13)
  70 – 79 22286 (23)  122 (20)
  80+ 19325 (20)  241 (40)
   
Gender  Male 51298 (53)  259 (43)
  Female 45473 (47)  337 (57) 
   
Date of index prescription  1992‐1993 4441 (5)  0 (0)
  1994‐1996 7540 (8)  1 (0)
  1997‐1999 9995 (10)  10 (2)
  2000‐2002 14598 (15)  73 (12)
  2003‐2005 17328 (18)  182 (31)
  2006‐2008 17101 (18)  119 (20)
  2009‐2011 15278 (16)  117 (20)
  2012‐2014 10490 (11)  94 (16)
   
Prescriptions for other causes   None 55665 (58)  244 (41)
of cholestatic injury Less common cause 38525 (40)  283 (47)
  More common cause 2581 (3)  69 (12)
   
Smoking status   Non‐smoker 41294 (43)  296 (50)
  Ex‐smoker 31836 (33)  162 (27)
  Current smoker 18342 (19)  112 (19)
  Unknown 5288 (5)  26 (4)
   
BMI   <20 5237 (5)  51 (9)
  20 ‐ 25 28682 (30)  150 (25)
  25+ 48295 (50)  274 (46)
  Unknown 14557 (15)  121 (20)
   
Alcohol intake  Non‐drinker 11372 (12)  120 (20)
  Ex‐drinker 3805 (4)  72 (12)
  Current NOS 2316 (2)  21 (4)
  2 or less u/d 16785 (17)  110 (18)
  3/6 u/d 41581 (43)  128 (21)
  >6 u/d 7819 (8)  40 (7)
  Unknown 13093 (14)  105 (18)
   
Socioeconomic status 1 (Highest SES) 17205 (18)  73 (12)
  2  17259 (18)  101 (17)
  3  16732 (17)  85 (14)
  4  14072 (15)  93 (16)
  5 (Lowest SES) 12924 (13)  102 (17)
  Unknown 18579 (19)  142 (24)
   
Ethnicity  White 47229 (49)  320 (54)
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  Not exposed to 
risperidone 
(N=96771) 
Exposed to 
risperidone 
(N=596) 
  n (%)  n (%)
  South Asian 849 (1)  10 (2)
  Black 448 (0)  7 (1)
  Other 410 (0)  2 (0)
  Mixed 98 (0)  1 (0)
  Not Stated 7598 (8)  52 (9)
  Unknown 40139 (41)  204 (34)
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Chapter 6 Appendix Table 2b Characteristics of participants included in the case-control 
analysis by exposure to celecoxib 
  Not exposed to 
celecoxib 
(N=94174) 
Exposed to 
celecoxib 
(N=3193) 
  n (%)  n (%)
Age at index date  18 – 29 5297 (6)  5 (0)
  30 – 39 6730 (7)  36 (1)
  40 – 49 9859 (10)  119 (4)
  50 – 59 13674 (15)  294 (9)
  60 – 69 18698 (20)  681 (21)
  70 – 79 21405 (23)  1003 (31)
  80+ 18511 (20)  1055 (33)
   
Gender  Male 50253 (53)  1304 (41)
  Female 43921 (47)  1889 (59) 
   
Date of index prescription  1992‐1993 4440 (5)  1 (0)
  1994‐1996 7538 (8)  3 (0)
  1997‐1999 9999 (11)  6 (0)
  2000‐2002 14554 (15)  117 (4)
  2003‐2005 16672 (18)  838 (26)
  2006‐2008 16301 (17)  919 (29)
  2009‐2011 14569 (15)  826 (26)
  2012‐2014 10101 (11)  483 (15)
   
Prescriptions for other causes   None 54757 (58)  1152 (36)
of cholestatic injury Less common cause 36889 (39)  1919 (60)
  More common cause 2528 (3)  122 (4)
   
Smoking status   Non‐smoker 40269 (43)  1321 (41)
  Ex‐smoker 30596 (32)  1402 (44)
  Current smoker 18001 (19)  453 (14)
  Unknown 5297 (6)  17 (1)
   
BMI   <20 5100 (5)  188 (6)
  20 ‐ 25 27950 (30)  882 (28)
  25+ 46656 (50)  1913 (60)
  Unknown 14468 (15)  210 (7)
   
Alcohol intake  Non‐drinker 11097 (12)  395 (12)
  Ex‐drinker 3641 (4)  236 (7)
  Current NOS 2250 (2)  87 (3)
  2 or less u/d 16168 (17)  727 (23)
  3/6 u/d 40361 (43)  1348 (42)
  >6 u/d 7646 (8)  213 (7)
  Unknown 13011 (14)  187 (6)
   
Socioeconomic status 1 (Highest SES) 16726 (18)  552 (17)
  2  16800 (18)  560 (18)
  3  16316 (17)  501 (16)
  4  13665 (15)  500 (16)
  5 (Lowest SES) 12674 (13)  352 (11)
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  Not exposed to 
celecoxib 
(N=94174) 
Exposed to 
celecoxib 
(N=3193) 
  n (%)  n (%)
  Unknown 17993 (19)  728 (23)
   
Ethnicity  White 45639 (48)  1910 (60)
  South Asian 827 (1)  32 (1)
  Black 448 (0)  7 (0)
  Other 401 (0)  11 (0)
  Mixed 98 (0)  1 (0)
  Not Stated 7432 (8)  218 (7)
  Unknown 39329 (42)  1014 (32)
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Chapter 6 Appendix Table 2c Characteristics of participants included in the case-control 
analysis by exposure to ramipril 
  Not exposed to 
ramipril 
(N=89365) 
Exposed to 
ramipril 
(N=8002) 
  n (%)  n (%)
Age at index date  18 – 29   5297 (6)        5 (0)
  30 – 39   6730 (8)       36 (0)
  40 – 49   9768 (11)      210 (3)
  50 – 59  13239 (15)      729 (9)
  60 – 69  17715 (20)     1664 (21)
  70 – 79  19686 (22)     2722 (34)
  80+  16930 (19)     2636 (33)
     
Gender  Male  46973 (53)     4584 (57)
  Female   42392 (47)     3418 (43) 
   
Date of index prescription  1992‐1993   4433 (5)        8 (0)
  1994‐1996   7516 (8)       25 (0)
  1997‐1999   9876 (11)      129 (2)
  2000‐2002  14190 (16)      481 (6)
  2003‐2005  16276 (18)     1234 (15)
  2006‐2008  15219 (17)     2001 (25)
  2009‐2011  13034 (15)     2361 (30)
  2012‐2014   8821 (10)     1763 (22)
     
Prescriptions for other causes   None  52904 (59)     3005 (38)
of cholestatic injury Less common cause  34083 (38)     4725 (59)
  More common cause   2378 (3)      272 (3)
     
Smoking status   Non‐smoker  38659 (43)     2931 (37)
  Ex‐smoker  27850 (31)     4148 (52)
  Current smoker  17562 (20)      892 (11)
  Unknown   5283 (6)       31 (0)
     
BMI   <20   4938 (6)      350 (4)
  20 ‐ 25  26801 (30)     2031 (25)
  25+  43323 (48)     5246 (66)
  Unknown  14303 (16)      375 (5)
     
Alcohol intake  Non‐drinker  10656 (12)      836 (10)
  Ex‐drinker   3134 (4)      743 (9)
  Current NOS   2188 (2)      149 (2)
  2 or less u/d  15011 (17)     1884 (24)
  3/6 u/d  38297 (43)     3412 (43)
  >6 u/d   7266 (8)      593 (7)
  Unknown  12813 (14)      385 (5)
     
Socioeconomic status 1 (Highest SES)  15919 (18)     1359 (17)
  2   15963 (18)     1397 (17)
  3   15429 (17)     1388 (17)
  4   12894 (14)     1271 (16)
  5 (Lowest SES)  12011 (13)     1015 (13)
  Unknown  17149 (19)     1572 (20)
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  Not exposed to 
ramipril 
(N=89365) 
Exposed to 
ramipril 
(N=8002) 
  n (%)  n (%)
     
Ethnicity  White  42689 (48)     4860 (61)
  South Asian    774 (1)       85 (1)
  Black    414 (0)       41 (1)
  Other    385 (0)       27 (0)
  Mixed     90 (0)        9 (0)
  Not Stated   7039 (8)      611 (8)
  Unknown  37974 (42)     2369 (30)
 275 
 
 
 
Chapter 6 Appendix Table 2d Characteristics of participants included in the case-control 
analysis by exposure to flucloxacillin 
  Not exposed to 
flucloxacillin 
(N=89365) 
Exposed to 
flucloxacillin 
(N=8002) 
  n (%)  n (%)
Age at index date  18 – 29 5297 (6)  5 (0)
  30 – 39 6730 (8)  36 (0)
  40 – 49 9768 (11)  210 (3)
  50 – 59 13239 (15)  729 (9)
  60 – 69 17715 (20)  1664 (21)
  70 – 79 19686 (22)  2722 (34)
  80+ 16930 (19)  2636 (33)
   
Gender  Male 46973 (53)  4584 (57)
  Female 42392 (47)  3418 (43) 
   
Date of index prescription  1992‐1993 4433 (5)  8 (0)
  1994‐1996 7516 (8)  25 (0)
  1997‐1999 9876 (11)  129 (2)
  2000‐2002 14190 (16)  481 (6)
  2003‐2005 16276 (18)  1234 (15)
  2006‐2008 15219 (17)  2001 (25)
  2009‐2011 13034 (15)  2361 (30)
  2012‐2014 8821 (10)  1763 (22)
   
Prescriptions for other causes   None 52904 (59)  3005 (38)
of cholestatic injury Less common cause 34083 (38)  4725 (59)
  More common cause 2378 (3)  272 (3)
   
Smoking status   Non‐smoker 38659 (43)  2931 (37)
  Ex‐smoker 27850 (31)  4148 (52)
  Current smoker 17562 (20)  892 (11)
  Unknown 5283 (6)  31 (0)
   
BMI   <20 4938 (6)  350 (4)
  20 ‐ 25 26801 (30)  2031 (25)
  25+ 43323 (48)  5246 (66)
  Unknown 14303 (16)  375 (5)
   
Alcohol intake  Non‐drinker 10656 (12)  836 (10)
  Ex‐drinker 3134 (4)  743 (9)
  Current NOS 2188 (2)  149 (2)
  2 or less u/d 15011 (17)  1884 (24)
  3/6 u/d 38297 (43)  3412 (43)
  >6 u/d 7266 (8)  593 (7)
  Unknown 12813 (14)  385 (5)
   
Socioeconomic status 1 (Highest SES) 15919 (18)  1359 (17)
  2  15963 (18)  1397 (17)
  3  15429 (17)  1388 (17)
  4  12894 (14)  1271 (16)
  5 (Lowest SES) 12011 (13)  1015 (13)
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  Not exposed to 
flucloxacillin 
(N=89365) 
Exposed to 
flucloxacillin 
(N=8002) 
  n (%)  n (%)
  Unknown 17149 (19)  1572 (20)
   
Ethnicity  White 42689 (48)  4860 (61)
  South Asian 774 (1)  85 (1)
  Black 414 (0)  41 (1)
  Other 385 (0)  27 (0)
  Mixed 90 (0)  9 (0)
  Not Stated 7039 (8)  611 (8)
  Unknown 37974 (42)  2369 (30)
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